<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD005566.pub2" GROUP_ID="VASC" ID="422104091918095426" MERGED_FROM="" MODIFIED="2011-04-06 09:15:17 +0200" MODIFIED_BY="Joey Kwong" REVIEW_NO="0420" REVMAN_SUB_VERSION="5.1.1" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="4.0">
<COVER_SHEET MODIFIED="2011-04-06 09:15:17 +0200" MODIFIED_BY="Joey Kwong">
<TITLE>Prophylactic corticosteroids for cardiopulmonary bypass in adults</TITLE>
<CONTACT MODIFIED="2011-04-06 09:15:17 +0200" MODIFIED_BY="Joey Kwong"><PERSON ID="050E1EAD82E26AA2004A583DA0682F2A" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Jan</FIRST_NAME><MIDDLE_INITIALS>M</MIDDLE_INITIALS><LAST_NAME>Dieleman</LAST_NAME><POSITION>Anesthesiology Resident</POSITION><EMAIL_1>s.dieleman@umcutrecht.nl</EMAIL_1><MOBILE_PHONE>+31624234488</MOBILE_PHONE><ADDRESS><DEPARTMENT>Division of Anesthesiology, Intensive Care and Emergency Medicine</DEPARTMENT><ORGANISATION>University Medical Center Utrecht</ORGANISATION><ADDRESS_1>PO Box 85500</ADDRESS_1><ADDRESS_2>mailstop: Q04.2.313</ADDRESS_2><CITY>Utrecht</CITY><ZIP>3508 GA</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31887559677</PHONE_1><FAX_1>+31302541828</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2011-04-06 09:15:17 +0200" MODIFIED_BY="Joey Kwong"><PERSON ID="050E1EAD82E26AA2004A583DA0682F2A" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Jan</FIRST_NAME><MIDDLE_INITIALS>M</MIDDLE_INITIALS><LAST_NAME>Dieleman</LAST_NAME><POSITION>Anesthesiology Resident</POSITION><EMAIL_1>s.dieleman@umcutrecht.nl</EMAIL_1><MOBILE_PHONE>+31624234488</MOBILE_PHONE><ADDRESS><DEPARTMENT>Division of Anesthesiology, Intensive Care and Emergency Medicine</DEPARTMENT><ORGANISATION>University Medical Center Utrecht</ORGANISATION><ADDRESS_1>PO Box 85500</ADDRESS_1><ADDRESS_2>mailstop: Q04.2.313</ADDRESS_2><CITY>Utrecht</CITY><ZIP>3508 GA</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31887559677</PHONE_1><FAX_1>+31302541828</FAX_1></ADDRESS></PERSON><PERSON ID="50505ED782E26AA2017F61BB5191B3AF" ROLE="AUTHOR"><FIRST_NAME>Judith</FIRST_NAME><LAST_NAME>van Paassen</LAST_NAME><EMAIL_1>j.van_paassen@lumc.nl</EMAIL_1><ADDRESS><DEPARTMENT>Department of Intensive Care</DEPARTMENT><ORGANISATION>Leiden University Medical Center</ORGANISATION><ADDRESS_1>PO Box 9600</ADDRESS_1><CITY>Leiden</CITY><ZIP>2300 RC</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY></ADDRESS></PERSON><PERSON ID="17845" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Diederik</FIRST_NAME><LAST_NAME>van Dijk</LAST_NAME><EMAIL_1>ddijk@azu.nl</EMAIL_1><ADDRESS><DEPARTMENT>Division of Anesthesiology, Intensive Care and Emergency Medicine</DEPARTMENT><ORGANISATION>University Medical Center Utrecht</ORGANISATION><ADDRESS_1>PO Box 85500</ADDRESS_1><CITY>Utrecht</CITY><ZIP>3508 GA</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31-30-2509677</PHONE_1><FAX_1>+31-30-2541828</FAX_1></ADDRESS></PERSON><PERSON ID="50515B8682E26AA2017F61BB6D08DD50" ROLE="AUTHOR"><FIRST_NAME>M.</FIRST_NAME><MIDDLE_INITIALS>Sesmu</MIDDLE_INITIALS><LAST_NAME>Arbous</LAST_NAME><EMAIL_1>m.s.arbous@lumc.nl</EMAIL_1><ADDRESS><DEPARTMENT>Department of Intensive Care</DEPARTMENT><ORGANISATION>Leiden University Medical Center</ORGANISATION><ADDRESS_1>PO Box 9600</ADDRESS_1><CITY>Leiden</CITY><ZIP>2300 RC</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY></ADDRESS></PERSON><PERSON ID="050E1AC582E26AA2004A583D2C190A8F" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Cor</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>Kalkman</LAST_NAME><POSITION>Professor Anaesthesiology</POSITION><EMAIL_1>c.j.kalkman@azu.nl</EMAIL_1><ADDRESS><DEPARTMENT>Department of Perioperative Care and Emergency Medicine</DEPARTMENT><ORGANISATION>University Medical Center Utrecht</ORGANISATION><ADDRESS_1>PO Box 85500</ADDRESS_1><ADDRESS_2>Mailstop: E 03.511</ADDRESS_2><CITY>Utrecht</CITY><ZIP>3508 GA</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31302509677</PHONE_1><FAX_1>+31302541828</FAX_1></ADDRESS></PERSON><PERSON ID="139E421782E26AA201B4268BC2E8FDFA" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Jan</FIRST_NAME><MIDDLE_INITIALS>P</MIDDLE_INITIALS><LAST_NAME>Vandenbroucke</LAST_NAME><EMAIL_1>j.p.vandenbroucke@lumc.nl</EMAIL_1><ADDRESS><DEPARTMENT>Department of Clinical Epidemiology</DEPARTMENT><ORGANISATION>Leiden University Medical Center</ORGANISATION><ADDRESS_1>PO Box 9600</ADDRESS_1><CITY>Leiden</CITY><ZIP>2300 RC</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31 71 526 4037</PHONE_1><FAX_1>+31 71 524 6994</FAX_1></ADDRESS></PERSON><PERSON ID="6E9F1EEB82E26AA201AFF01290272DA6" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Geert</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>van der Heijden</LAST_NAME><SUFFIX>PhD</SUFFIX><POSITION>Associate Professor of Clinical Epidemiology</POSITION><EMAIL_1>g.vanderheijden@umcutrecht.nl</EMAIL_1><EMAIL_2>g.vanderheijden@irv.nl</EMAIL_2><MOBILE_PHONE>+31 6 83224640</MOBILE_PHONE><ADDRESS><DEPARTMENT>Julius Center for Health Sciences and Primary Care</DEPARTMENT><ORGANISATION>University Medical Center Utrecht (STR 6.131)</ORGANISATION><ADDRESS_1>PO Box 85500</ADDRESS_1><CITY>Utrecht</CITY><ZIP>3508 GA</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31 88 7559377</PHONE_1></ADDRESS></PERSON><PERSON ID="5054915D82E26AA2017F61BB8B6E2799" ROLE="AUTHOR"><FIRST_NAME>Olaf</FIRST_NAME><MIDDLE_INITIALS>M</MIDDLE_INITIALS><LAST_NAME>Dekkers</LAST_NAME><EMAIL_1>o.m.dekkers@lumc.nl</EMAIL_1><ADDRESS><DEPARTMENT>Department of Clinical Epidemiology</DEPARTMENT><ORGANISATION>Leiden University Medical Center</ORGANISATION><ADDRESS_1>PO Box 9600</ADDRESS_1><CITY>Leiden</CITY><ZIP>2300 RC</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2011-03-04 21:43:08 +0530" MODIFIED_BY="Joey Kwong">
<UP_TO_DATE>
<DATE DAY="1" MONTH="6" YEAR="2010"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="31" MONTH="12" YEAR="2009"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="31" MONTH="12" YEAR="2011"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2006"/>
<REVIEW_PUBLISHED ISSUE="" YEAR=""/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2010"/>
</DATES>
<WHATS_NEW MODIFIED="2011-01-12 08:48:22 +0530" MODIFIED_BY="Joey Kwong"/>
<HISTORY MODIFIED="2010-06-01 19:55:22 +0530" MODIFIED_BY="Joey Kwong"/>
<SOURCES_OF_SUPPORT MODIFIED="2010-06-01 19:54:21 +0530" MODIFIED_BY="Joey Kwong">
<INTERNAL_SOURCES MODIFIED="2010-06-01 19:54:21 +0530" MODIFIED_BY="Joey Kwong">
<SOURCE>
<NAME>Department of Perioperative Care and Emergency Medicine, University Medical Center Utrecht</NAME>
<COUNTRY CODE="NL">Netherlands</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2010-06-01 19:54:21 +0530" MODIFIED_BY="Joey Kwong">
<NAME>Department of Intensive Care Medicine, University Medical Center, Leiden</NAME>
<COUNTRY CODE="NL">Netherlands</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2011-04-06 12:40:56 +0530" MODIFIED_BY="Joey Kwong">
<SUMMARY MODIFIED="2011-03-04 19:52:58 +0530" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2010-05-23 08:17:27 +0530" MODIFIED_BY="[Empty name]">High-dose corticosteroids in heart surgery</TITLE>
<SUMMARY_BODY MODIFIED="2011-03-04 19:52:58 +0530" MODIFIED_BY="[Empty name]">
<P>During heart surgery, high doses of corticosteroids aiming to reduce inflammation are often administered. This practice, however, is controversial since there is no evidence available to show clear benefits. Moreover, corticosteroids have the potential of important side-effects. The aim of this meta-analysis was to summarize (pool) data from studies on this subject and to estimate the effect of corticosteroid administration on the risk of major complications (death, heart infarction, lung problems) following heart surgery.</P>
<P>Major databases of medical literature were searched for publications of studies that randomly assigned adult patient undergoing heart surgery to receive either corticosteroid treatment compared to no treatment or placebo. A total of 54 publications were selected for the analysis. The quality of most of these publications was rather poor, thereby limiting the value of the pooled risk estimate. For none of the major complications (death, heart infarction, lung problems), a change of risk by corticosteroid administration could be demonstrated. Only the risk of (often encountered) heart rhythm disturbances (atrial fibrillation) was clearly shown to be reduced (around 40% less).</P>
<P>The authors therefore conclude that no beneficial effects of high-dose corticosteroids could be shown on the risk of major complications following heart surgery, although this conclusion is limited to low quality of the data available. For a more definitive conclusion, studies with much larger numbers of patients need to be performed.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2011-04-06 12:34:01 +0530" MODIFIED_BY="Joey Kwong">
<ABS_BACKGROUND MODIFIED="2010-05-14 13:12:55 +0530" MODIFIED_BY="[Empty name]">
<P>High-dose prophylactic corticosteroids are often administered during cardiac surgery. Their use, however, remains controversial, as no trials are available that have been sufficiently powered to draw conclusions on their effect on major clinical outcomes.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2009-12-08 16:43:15 +0530" MODIFIED_BY="[Empty name]">
<P>The objective of this meta-analysis was to estimate the effect of prophylactic corticosteroids in cardiac surgery on mortality, cardiac and pulmonary complications.<BR/>
</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2011-02-22 16:20:11 +0530" MODIFIED_BY="Nicole Ackermann">
<P>Major medical databases (CENTRAL, MEDLINE, EMBASE, CINAHL and Web of Science) were systematically searched for randomised studies assessing the effect of corticosteroids in adult cardiac surgery. Database were searched for the full period covered, up to December 2009. No language restrictions were applied.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2010-06-01 19:54:17 +0530" MODIFIED_BY="Joey Kwong">
<P>Randomised controlled trials comparing corticosteroid treatment to either placebo treatment or no treatment in adult cardiac surgery were selected. There were no restrictions with respect to length of the follow-up period. All selected studies qualified for pooling of results for one or more end-points.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2010-09-24 15:52:23 +0530" MODIFIED_BY="Joey Kwong">
<P>The processes of searching and selection for inclusion eligibility were performed independently by two authors. Also, quality assessment and data-extraction of selected studies were independently performed by two authors. The primary endpoints were mortality, cardiac and pulmonary complications. The main effect measure was the Peto odds ratio comparing corticosteroids to no treatment/placebo.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2011-04-06 12:34:01 +0530" MODIFIED_BY="Joey Kwong">
<P>Fifty-four randomised studies, mostly of limited quality, were included. Altogether, 3615 patients were included in these studies. The pooled odds ratio for mortality was 1.12 (95% CI 0.65 to 1.92), showing no mortality reduction in patients treated with corticosteroids. The odds ratios for myocardial and pulmonary complications were 0.95, (95% CI 0.57 to 1.60) and 0.83 (95% CI 0.49 to 1.40), respectively. The use of a random effects model did not substantially influence study results. Analyses of secondary endpoints showed a reduction of atrial fibrillation and an increase in gastrointestinal bleeding in the corticosteroids group.<BR/>
</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2010-05-14 13:23:18 +0530" MODIFIED_BY="[Empty name]">
<P>This meta-analysis showed no beneficial effect of corticosteroid use on mortality, cardiac and pulmonary complications in cardiac surgery patients.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2011-04-06 12:40:56 +0530" MODIFIED_BY="Joey Kwong">
<BACKGROUND MODIFIED="2011-04-06 12:34:29 +0530" MODIFIED_BY="Joey Kwong">
<CONDITION MODIFIED="2011-03-02 22:16:11 +0530" MODIFIED_BY="[Empty name]">
<P>Cardiovascular diseases have a high incidence in western society, affecting one in every three persons (<LINK REF="REF-Lloyd_x002d_Jones-1999" TYPE="REFERENCE">Lloyd-Jones 1999</LINK>) and are currently the leading cause of death, with coronary heart disease being responsible for around 20% of annual deaths in the United States (<LINK REF="REF-AHA-2009" TYPE="REFERENCE">AHA 2009</LINK>). Millions of cardiac interventions are performed every year worldwide (<LINK REF="REF-AHA-2009" TYPE="REFERENCE">AHA 2009</LINK>). Currently, 30-40% of these procedures comprise cardiac surgery, mainly for revascularization or treatment of valve defects (<LINK REF="REF-AHA-2009" TYPE="REFERENCE">AHA 2009</LINK>) .</P>
<P>The development of cardiopulmonary bypass in the early 1950's has been a breakthrough in cardiac surgery (<LINK REF="REF-Hill-1982" TYPE="REFERENCE">Hill 1982</LINK>; <LINK REF="REF-Pastuszko-2004" TYPE="REFERENCE">Pastuszko 2004</LINK>). The possibility of temporary suppression of cardiac activity while maintaining systemic circulation with a heart-lung machine, made surgery on a non-beating heart possible (<LINK REF="REF-Gibbon-1954" TYPE="REFERENCE">Gibbon 1954</LINK>). Patients with coronary vessel or heart valve disease could from then on be treated with an effective relief of symptoms and prolonged life expectancy (<LINK REF="REF-Lee-1976" TYPE="REFERENCE">Lee 1976</LINK>; <LINK REF="REF-Hunt-2000" TYPE="REFERENCE">Hunt 2000</LINK>; <LINK REF="REF-Rahimtoola-1993" TYPE="REFERENCE">Rahimtoola 1993</LINK>; <LINK REF="REF-Thompson-1999" TYPE="REFERENCE">Thompson 1999</LINK>). However, extracorporeal circulation often induces a systemic inflammatory response syndrome, a sepsis like condition (<LINK REF="REF-Asimakopoulos-1999" TYPE="REFERENCE">Asimakopoulos 1999</LINK>; <LINK REF="REF-Chaney-2002" TYPE="REFERENCE">Chaney 2002</LINK>; <LINK REF="REF-Kirklin-1983" TYPE="REFERENCE">Kirklin 1983</LINK>; <LINK REF="REF-McGuinness-2008" TYPE="REFERENCE">McGuinness 2008</LINK>; <LINK REF="REF-Wan-1997a" TYPE="REFERENCE">Wan 1997a</LINK>). This response involves complement activation, along with activation of platelets, neutrophils, monocytes, and macrophages (<LINK REF="REF-Chaney-2002" TYPE="REFERENCE">Chaney 2002</LINK>; <LINK REF="STD-Loef-2004" TYPE="STUDY">Loef 2004</LINK>). As a result, coagulation and fibrinolytic cascades are initiated (<LINK REF="REF-Kirklin-1983" TYPE="REFERENCE">Kirklin 1983</LINK>; <LINK REF="STD-Loef-2004" TYPE="STUDY">Loef 2004</LINK>; <LINK REF="STD-Whitlock-2005" TYPE="STUDY">Whitlock 2005</LINK>). The ensuing systemic inflammatory response syndrome is associated with fever, impaired alveolar gas exchange, vasodilatation, myocardial stunning, renal insufficiency and even multiorgan dysfunction (<LINK REF="REF-Asimakopoulos-1999" TYPE="REFERENCE">Asimakopoulos 1999</LINK>; <LINK REF="REF-Moat-1993" TYPE="REFERENCE">Moat 1993</LINK>; <LINK REF="REF-Roach-1996" TYPE="REFERENCE">Roach 1996</LINK>; <LINK REF="REF-Zanardo-1994" TYPE="REFERENCE">Zanardo 1994</LINK>). It is conceivable that the systemic inflammatory response syndrome contributes to the incidence of major complications after heart surgery, including death, myocardial infarction, pulmonary dysfunction and loss of renal function (<LINK REF="STD-Hill-1995b" TYPE="STUDY">Hill 1995b</LINK>; <LINK REF="REF-Ho-2009" TYPE="REFERENCE">Ho 2009</LINK>; <LINK REF="REF-Talmor-1999" TYPE="REFERENCE">Talmor 1999</LINK>; <LINK REF="REF-Whitlock-2008" TYPE="REFERENCE">Whitlock 2008</LINK>). In the past decades, several studies have explored the association between the systemic inflammatory response syndrome and major complications after heart surgery. These studies have shown very variable results, with often conflicting conclusions. However, generally due to a lack of statistical power, no clear associations with important clinical outcomes have been established so far (<LINK REF="STD-Fillinger-2002" TYPE="STUDY">Fillinger 2002</LINK>; <LINK REF="STD-Kilger-2003a" TYPE="STUDY">Kilger 2003a</LINK>; <LINK REF="STD-McBride-2004" TYPE="STUDY">McBride 2004</LINK>; <LINK REF="STD-Tassani-1999" TYPE="STUDY">Tassani 1999</LINK>; <LINK REF="STD-Toft-1997" TYPE="STUDY">Toft 1997</LINK>; <LINK REF="STD-Turkoz-2001" TYPE="STUDY">Turkoz 2001</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2011-03-30 16:00:56 +0530" MODIFIED_BY="Nicole Ackermann">
<P>Due to the potential associations between the systemic inflammatory response syndrome and a variety of ensuing clinical symptoms, it may appear beneficial to attenuate this response with anti-inflammatory agents (<LINK REF="REF-Hall-1997" TYPE="REFERENCE">Hall 1997</LINK>; <LINK REF="REF-Whitlock-2008" TYPE="REFERENCE">Whitlock 2008</LINK>). The proper timing and duration of administration of corticosteroids are incompletely resolved; there is evidence that early corticosteroid prophylaxis in advance of an insult is more efficacious (<LINK REF="REF-Lasser-1987" TYPE="REFERENCE">Lasser 1987</LINK>). The guidelines of the American Heart Association advocate liberal prophylactic use (<LINK REF="REF-AHA-2004" TYPE="REFERENCE">AHA 2004</LINK>; <LINK REF="REF-Hall-1997" TYPE="REFERENCE">Hall 1997</LINK>), and frequently, one or two doses of dexamethasone or methylprednisolone are injected intravenously before commencing cardiopulmonary bypass (<LINK REF="REF-Chaney-2002" TYPE="REFERENCE">Chaney 2002</LINK>; <LINK REF="REF-Ho-2009" TYPE="REFERENCE">Ho 2009</LINK>; <LINK REF="REF-Whitlock-2008" TYPE="REFERENCE">Whitlock 2008</LINK>). Corticosteroids are potent anti-inflammatory agents that possess multi-inhibitory effects on numerous components of the inflammatory response (<LINK REF="REF-Chaney-2002" TYPE="REFERENCE">Chaney 2002</LINK>; <LINK REF="REF-Hill-1998" TYPE="REFERENCE">Hill 1998</LINK>; <LINK REF="REF-Wan-1997a" TYPE="REFERENCE">Wan 1997a</LINK>). Moreover, corticosteroids are low-cost, generic drugs, and potentially cost-effective if any reduction in major complications (and a subsequent improvement of quality of life) can be achieved by their administration.</P>
<P>However, the use of corticosteroids has important potential disadvantages. Almost all patients experience higher mean and peak blood-glucose levels (<LINK REF="REF-Chaney-2002" TYPE="REFERENCE">Chaney 2002</LINK>; <LINK REF="STD-Mayumi-1997" TYPE="STUDY">Mayumi 1997</LINK>; <LINK REF="STD-Tassani-1999" TYPE="STUDY">Tassani 1999</LINK>), which is associated with increased morbidity and mortality (<LINK REF="REF-Van-den-Berghe-2001" TYPE="REFERENCE">Van den Berghe 2001</LINK>). Furthermore, it has been demonstrated that the use of corticosteroids is associated with higher lactate levels, a higher sensitivity to infectious agents, impaired wound healing and gastrointestinal blood loss (<LINK REF="REF-Chaney-2002" TYPE="REFERENCE">Chaney 2002</LINK>; <LINK REF="STD-Mayumi-1997" TYPE="STUDY">Mayumi 1997</LINK>), but all studies were too small to demonstrate significant effects. More-over corticosteroids-use has been associated with a prolonged ventilation time (longer than twelve hours) in some studies (<LINK REF="STD-Chaney-1998" TYPE="STUDY">Chaney 1998</LINK>; <LINK REF="STD-Chaney-1999" TYPE="STUDY">Chaney 1999</LINK>; <LINK REF="STD-Chaney-2001" TYPE="STUDY">Chaney 2001</LINK>). Some of these complications could lead to prolonged intensive care stay and increased morbidity and mortality (<LINK REF="REF-Chaney-2002" TYPE="REFERENCE">Chaney 2002</LINK>; <LINK REF="REF-Van-den-Berghe-2001" TYPE="REFERENCE">Van den Berghe 2001</LINK>).</P>
</INTERVENTION>
<IMPORTANCE MODIFIED="2011-04-06 12:34:29 +0530" MODIFIED_BY="Joey Kwong">
<P>To date, the use of corticosteroids in heart surgery is almost standard care in several European countries (<LINK REF="REF-Van-Dijk-2005" TYPE="REFERENCE">Van Dijk 2005</LINK>), while in the United States very few centres for cardiac surgery use corticosteroids in the perioperative period (personal communications, data not published). However, there is no convincing evidence that potential benefits of corticosteroid use outweigh their possible disadvantages in adult cardiac surgery (<LINK REF="REF-Chaney-2002" TYPE="REFERENCE">Chaney 2002</LINK>).</P>
<P>A substantial number of trials have been conducted comparing outcome following heart surgery with and without corticosteroid use. Most trials focused on intermediate, non-clinical end-points like serum markers and pulmonary water content, demonstrating a significant suppression of inflammation (<LINK REF="STD-Andersen-1989" TYPE="STUDY">Andersen 1989</LINK>; <LINK REF="STD-Anic-2004" TYPE="STUDY">Anic 2004</LINK>; <LINK REF="STD-Boldt-1986" TYPE="STUDY">Boldt 1986</LINK>; <LINK REF="STD-Boscoe-1983" TYPE="STUDY">Boscoe 1983</LINK>; <LINK REF="STD-Celik-2004" TYPE="STUDY">Celik 2004</LINK>; <LINK REF="STD-Corbi-2001" TYPE="STUDY">Corbi 2001</LINK>; <LINK REF="STD-El-Busto-Osacar-1979" TYPE="STUDY">El Busto Osacar 1979</LINK>; <LINK REF="STD-Engelman-1995" TYPE="STUDY">Engelman 1995</LINK>; <LINK REF="STD-Ferries-1984" TYPE="STUDY">Ferries 1984</LINK>; <LINK REF="STD-Fosse-1987" TYPE="STUDY">Fosse 1987</LINK>; <LINK REF="STD-Harig-1999" TYPE="STUDY">Harig 1999</LINK>; <LINK REF="STD-Hill-1994" TYPE="STUDY">Hill 1994</LINK>; <LINK REF="STD-Jansen-1991a" TYPE="STUDY">Jansen 1991a</LINK>; <LINK REF="STD-Jorens-1993" TYPE="STUDY">Jorens 1993</LINK>; <LINK REF="STD-Karlstad-1993" TYPE="STUDY">Karlstad 1993</LINK>; <LINK REF="STD-Kawamura-1995" TYPE="STUDY">Kawamura 1995</LINK>; <LINK REF="STD-Kawamura-1999" TYPE="STUDY">Kawamura 1999</LINK>; <LINK REF="STD-Loubser-1997" TYPE="STUDY">Loubser 1997</LINK>; <LINK REF="STD-Mayumi-1997" TYPE="STUDY">Mayumi 1997</LINK>; <LINK REF="REF-Nuutinen-1976" TYPE="REFERENCE">Nuutinen 1976</LINK>; <LINK REF="STD-Tabardel-1996" TYPE="STUDY">Tabardel 1996</LINK>; <LINK REF="STD-Tassani-1999" TYPE="STUDY">Tassani 1999</LINK>; <LINK REF="REF-Tennenberg-1986" TYPE="REFERENCE">Tennenberg 1986</LINK>; <LINK REF="STD-Toft-1997" TYPE="STUDY">Toft 1997</LINK>; <LINK REF="STD-Wan-1997b" TYPE="STUDY">Wan 1997b</LINK>; <LINK REF="STD-Wan-1999" TYPE="STUDY">Wan 1999</LINK>). Of the trials which evaluated clinical end-points after corticosteroid administration, the results were unequivocal (<LINK REF="STD-Chaney-1998" TYPE="STUDY">Chaney 1998</LINK>; <LINK REF="STD-Chaney-1999" TYPE="STUDY">Chaney 1999</LINK>; <LINK REF="STD-Chaney-2001" TYPE="STUDY">Chaney 2001</LINK>; <LINK REF="STD-Coffin-1975" TYPE="STUDY">Coffin 1975</LINK>; <LINK REF="STD-Fecht-1978" TYPE="STUDY">Fecht 1978</LINK>; <LINK REF="STD-Fillinger-2002" TYPE="STUDY">Fillinger 2002</LINK>; <LINK REF="REF-Heikkinen-1985" TYPE="REFERENCE">Heikkinen 1985</LINK>; <LINK REF="STD-Kilger-2003a" TYPE="STUDY">Kilger 2003a</LINK>; <LINK REF="STD-Loef-2004" TYPE="STUDY">Loef 2004</LINK>; <LINK REF="REF-Mangos-1995" TYPE="REFERENCE">Mangos 1995</LINK>; <LINK REF="STD-Miranda-1982" TYPE="STUDY">Miranda 1982</LINK>; <LINK REF="STD-Morton-1976" TYPE="STUDY">Morton 1976</LINK>; <LINK REF="STD-Niazi-1979" TYPE="STUDY">Niazi 1979</LINK>; <LINK REF="STD-Oliver-2004" TYPE="STUDY">Oliver 2004</LINK>; <LINK REF="STD-Rao-1977" TYPE="STUDY">Rao 1977</LINK>; <LINK REF="STD-Toft-1997" TYPE="STUDY">Toft 1997</LINK>; <LINK REF="STD-Toledo_x002d_Pereyra-1980" TYPE="STUDY">Toledo-Pereyra 1980</LINK>; <LINK REF="STD-von-Spiegel-2001" TYPE="STUDY">von Spiegel 2001</LINK>; <LINK REF="STD-Yared-1998" TYPE="STUDY">Yared 1998</LINK>).</P>
<P>Two meta-analyses have been conducted recently in the last three years (<LINK REF="REF-Ho-2009" TYPE="REFERENCE">Ho 2009</LINK>; <LINK REF="REF-Whitlock-2008" TYPE="REFERENCE">Whitlock 2008</LINK>). Both meta-analyses claimed positive effects in cardiac surgery patients treated with corticosteroids. However, the conclusions of these meta-analyses are not completely convincing for reasons outlined below:</P>
<P>Firstly, <LINK REF="REF-Whitlock-2008" TYPE="REFERENCE">Whitlock 2008</LINK> showed a non-significant reduction of in hospital mortality (RR 0.73, 95% CI 0.45 to 1.18), but overall no increased number of adverse effects. Importantly, the positive effect on mortality was largely accounted for by the study from <LINK REF="STD-Vallejo-1977" TYPE="STUDY">Vallejo 1977</LINK>. This study showed a reduction in mortality (relative risk 0.55) in patients given corticosteroids and accounted for 27% of the weight in the meta-analysis. <LINK REF="STD-Vallejo-1977" TYPE="STUDY">Vallejo 1977</LINK> was designated by <LINK REF="REF-Whitlock-2008" TYPE="REFERENCE">Whitlock 2008</LINK> as &#8220;low quality&#8221;. It is also uncertain whether the randomisation was truly concealed. More substantially, mortality in the non-steroid group was 22%. Even considering the state of the art for cardiac surgical care 30 years ago, this is a surprisingly high mortality. We therefore conclude that the possible mortality benefit in steroids that was reported by <LINK REF="REF-Whitlock-2008" TYPE="REFERENCE">Whitlock 2008</LINK> is mainly due to the inclusion of one single low quality trial in which the mortality in the non-steroid group was an outlier.</P>
<P>Secondly, the meta-analysis from <LINK REF="REF-Ho-2009" TYPE="REFERENCE">Ho 2009</LINK> did not include outcomes on cardiac and pulmonary outcomes and focused on the effects of corticosteroids on atrial fibrillation (RR 0.74, 95 % CI 0.63 to 0.86). The interpretation of this positive effect must not be overstretched, mainly because atrial fibrillation post-operative is self-limiting (<LINK REF="REF-Banach-2010" TYPE="REFERENCE">Banach 2010</LINK>) and because drugs with less potential side effects than corticosteroids, such as amiodarone and beta-blockers, have shown to be effective in the prevention and treatment of atrial fibrillation (<LINK REF="REF-Crystal-2004" TYPE="REFERENCE">Crystal 2004</LINK>).</P>
<P>A new meta-analysis on corticosteroids in adult cardiac surgery could overcome the outlined limitations. Firstly, the study from <LINK REF="STD-Vallejo-1977" TYPE="STUDY">Vallejo 1977</LINK> will be excluded from our analysis since children were included. Secondly, the aim of a meta-analysis should be on mortality, cardiac ischemia and pulmonary complications in stead of self-limiting conditions as atrial fibrillation. A third advantage is that the search strategy is more up-to-date, with two respectively three additional years of inclusion. Finally, it is expected that in the next few years this review can be updated with data from several ongoing studies (<LINK REF="STD-DECS-trial" TYPE="STUDY">DECS trial</LINK>; <LINK REF="STD-SIRS-trial" TYPE="STUDY">SIRS trial</LINK>) that will, based on their large size, probably importantly impact the results of this meta-analysis.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2010-09-07 01:15:14 +0530" MODIFIED_BY="[Empty name]">
<P>To estimate the effect of corticosteroid use for cardiopulmonary bypass on:</P>
<P>a) a composite end-point of mortality, myocardial infarction and pulmonary complications (including pulmonary edema and/or infection);</P>
<P>b) other relevant outcomes such as other complications, including prolonged mechanical ventilation and stroke.</P>
</OBJECTIVES>
<METHODS MODIFIED="2011-04-06 12:36:29 +0530" MODIFIED_BY="Joey Kwong">
<SELECTION_CRITERIA MODIFIED="2011-03-04 19:59:06 +0530" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2011-01-12 08:48:58 +0530" MODIFIED_BY="Joey Kwong">
<P>Randomised controlled trials in human adults, complying with the Participants-Interventions-Comparisons-Outcomes (PICO) parameters described below (<LINK REF="REF-Moher-2009" TYPE="REFERENCE">Moher 2009</LINK>). There were no restrictions with respect to length of the follow-up period.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2011-01-12 08:48:58 +0530" MODIFIED_BY="Joey Kwong">
<P>Adults (18 years or older):<BR/>
</P>
<UL>
<LI>diagnosed with coronary artery disease or coronary valve disease;</LI>
<LI>undergoing cardiac surgery with the use of cardiopulmonary bypass.</LI>
</UL>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2011-02-22 16:25:56 +0530" MODIFIED_BY="Nicole Ackermann">
<P>Cardiac surgery with cardiopulmonary bypass with or without prophylactic corticosteroid administration. For comparator study arms, trials with concomitant study arms on other interventions were not excluded, as long as patients in the comparator arm received the same treatment as the corticosteroid arm except for corticosteroid administration.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2011-03-04 19:59:06 +0530" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2011-03-04 19:58:42 +0530" MODIFIED_BY="[Empty name]">
<P>Composite end-point, consisting of the following:<BR/>
</P>
<UL>
<LI>all-cause mortality (in-hospital);</LI>
<LI>fatal and non-fatal myocardial infarction (defined as: ECG changes, echocardiological changes, disproportionate elevation of troponines);</LI>
<LI>pulmonary complications (including pulmonary edema and/or infection).</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2011-03-04 19:59:06 +0530" MODIFIED_BY="[Empty name]">
<UL>
<LI>infectious complications</LI>
<LI>gastro-intestinal bleeding</LI>
<LI>occurrence of atrial fibrillation</LI>
<LI>re-thoracotomy</LI>
<LI>neurological complications</LI>
<LI>renal failure</LI>
<LI>inotropic use</LI>
<LI>blood transfusion</LI>
<LI>time to extubation</LI>
<LI>length of ICU stay</LI>
<LI>length of hospital stay</LI>
</UL>
<P>Although in the published protocol an analysis of the secondary outcomes "Quality of life" and "Cost effectiveness" was initially planned, these outcomes have not been included in this final review due to a lack of available data.</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2011-04-06 12:36:29 +0530" MODIFIED_BY="Joey Kwong">
<P>The Cochrane Central Register of Controlled Trials (CENTRAL) (1898 to 31 December 2009; Issue 4, 2009) on <I>The Cochrane Library</I>, MEDLINE (PubMed) (1809 to 31 December 2009), EMBASE (1980 to 31 December 2009), CINAHL (1982 to 31 December 2009) and Web of Science (Science Citations Index (SCI) and Social Science Citations Index (SSCI)) (1945 to 31 December 2009) were all searched on 14 February 2010. Furthermore, trial registers were also searched to identify unpublished and ongoing studies (metaRegister of Controlled trials on <A HREF="http://www.controlled-trials.com/mrct/">www.controlled-trials.com/mrct/</A>, WHO ICTRP (<A HREF="http://apps.who.int/trialsearch/">http://apps.who.int/trialsearch/</A>). Search strategies are displayed in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>. No language restrictions were applied; native speakers were contacted for translation of articles in languages other than English, Dutch, German, French, Spanish or Italian.</P>
<P>Reference lists from retrieved randomised trials, meta-analyses and systematic reviews were screened to identify additional trials. 'Related Articles' identified by PubMed were screened.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2011-04-06 12:36:11 +0530" MODIFIED_BY="Joey Kwong">
<STUDY_SELECTION MODIFIED="2011-03-02 21:57:42 +0530" MODIFIED_BY="[Empty name]">
<P>The selection of studies was done in three different phases:</P>
<UL>
<LI>First phase: judging of each title found by two independent authors (JMD, JvP). If both were certain that a study was unsuitable, based on the title, this study was excluded. The abstracts of all studies that were considered suitable based on the title by at least one author, were printed.</LI>
<LI>Second phase: judging of the remaining studies based on the abstract by the two independent authors (JMD and JvP) If both were certain that a study was unsuitable, based on its abstract, this study was excluded. The complete text of all other studies that were considered suitable based on the abstract by at least one author, was printed.</LI>
<LI>Third phase: judging of the remaining studies based on the complete article by two independent authors (JMD and JvP). If both were certain that a study was unsuitable, this study was excluded. The exclusion was motivated briefly on the selection form. If their opinion was split, the article was discussed until consensus was achieved, if necessary with help of a third author (DvD).</LI>
</UL>
<P>After completion of retrieval and selection of full-text articles, results from both search strategies were combined. Discrepancies were discussed by both authors (JMD and JvP); selection of articles was based on consensus between the reviewers. When disagreement persisted, a third author (DvD) decided on selection of articles.</P>
<P>For each title, abstract or full-text article a standardised selection form was used to assess study eligibility (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>) The authors were not blinded to authors' names or journal names.</P>
<P>The flow of studies was reported according the PRISMA guidelines (<LINK REF="REF-Moher-2009" TYPE="REFERENCE">Moher 2009</LINK>).</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2011-01-12 08:48:58 +0530" MODIFIED_BY="Joey Kwong">
<P>Data was extracted from the full-text article of every included study by two authors independently (JMD and JvP) using a standardised data-extraction form (<LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>). Additional data on major events, if missing in the published studies data, was requested from corresponding authors. The primary outcomes for both the intervention and placebo groups of the present analysis were mortality, cardiac and pulmonary complications. Cardiac complications were defined as evidence for myocardial infarction (ECG changes, echocardiographic changes, disproportionate elevation of cardiac enzymes). Pulmonary complications were defined more variably, including edema and pulmonary infection. When authors stated explicitly "no major complications" occurred in the study, this was interpreted as no deaths, and no cardiac or pulmonary complications for that specific study.</P>
<P>We aimed to perform a pooled analysis for a composite endpoint consisting of the three major endpoints: death, cardiac and pulmonary complications, as well as on each of these outcomes separately. Furthermore, data on infectious complications, gastro-intestinal bleeding, atrial fibrillation, re-thoracotomy, neurological complications, renal failure, inotropic use, blood transfusion, time to extubation, length of intensive care stay and length of hospital stay was extracted and analysed. We did not perform subgroup analyses according to age and sex, since effect measure modification was not a priori expected for these variables.<BR/>
</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2011-04-06 12:36:11 +0530" MODIFIED_BY="Joey Kwong">
<P>The following criteria were used to assess the risk of bias of the included studies (see <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>, items 2, 3, 5, 7, 8 and 10) according to the Cochrane Handbook for Systematic Reviews of Interventions (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>):</P>
<UL>
<LI>concealed allocation,</LI>
<LI>Intention to treat analysis</LI>
<LI>blinding during pre-, peri- and postoperative care,</LI>
<LI>blinded data-collection and analysis,</LI>
<LI>blinded adjudication of endpoints,</LI>
<LI>standardised pre-, peri- and post-surgical care,</LI>
<LI>completeness of (follow-up) data.</LI>
</UL>
<P>Quality score adjusted analysis were not performed, because they are known to be of limited added value (<LINK REF="REF-Juni-1999" TYPE="REFERENCE">Juni 1999</LINK>).</P>
</QUALITY_ASSESSMENT>
<UNIT_OF_ANALYSIS MODIFIED="2010-05-14 14:12:40 +0530" MODIFIED_BY="[Empty name]">
<P>The odds were calculated per treatment group for all binary outcomes. The Peto odds ratio was used as the pooled measure of effect. For continuous variables, weighted means were calculated according to the inverse of the squared standard error.</P>
<P>We expected the meta-analysis to be on sparse outcome data. The best model as well as the appropriate continuity correction for sparse outcome meta-analysis is still under debate (<LINK REF="REF-Shuster-2007" TYPE="REFERENCE">Shuster 2007</LINK>; <LINK REF="REF-Sweeting-2004" TYPE="REFERENCE">Sweeting 2004</LINK>). The use of the Peto odds ratio has two advantages: at first, no continuity correction is needed when one study arm has zero events, and secondly, the Peto odds ratio has been shown to be a robust model for sparse outcome meta-analysis without extreme group imbalances (<LINK REF="REF-Sweeting-2004" TYPE="REFERENCE">Sweeting 2004</LINK>), as was the case in the present meta-analysis. Trials with zero events in both arms do not contribute to the weighted average of the Peto odds ratio, as they do not contribute to the treatment effect of ratio measures in general.</P>
</UNIT_OF_ANALYSIS>
<HETEROGENEITY_ASSESSMENT MODIFIED="2011-03-04 20:01:54 +0530" MODIFIED_BY="[Empty name]">
<P>Due to variations in study-patient groups, clinical settings, concomitant care, and differences in treatment, clinical heterogeneity was to be expected. However, the power from conventional statistical methods to detect heterogeneity is low in case of a small number of included studies or in case of sparse outcome data (<LINK REF="REF-Ioannidis-2007" TYPE="REFERENCE">Ioannidis 2007</LINK>). To deal with expected heterogeneity, we performed a random effects model, besides the Peto odds ratio, for all outcomes. We added 0.5 events to each cell for trials with zero events in one treatment arm. The disadvantage of this continuity correction is that the added 0.5 &#8216;events&#8217; can bias the results, especially when treatment groups are imbalanced. To check the robustness of this correction we also calculated the pooled estimate of the primary outcomes by adding the reciprocal of the opposite treatment arm size (<LINK REF="REF-Sweeting-2004" TYPE="REFERENCE">Sweeting 2004</LINK>). This calculation of the odds ratio enabled inclusion of trials with zero events in both arms. Moreover, we planned to perform sensitivity analyses to explore heterogeneity for the primary outcomes in case of considerable heterogeneity (I<SUP>2</SUP>&gt;40%). Since the included trials were published over a period of four decades, we decided to perform a sensitivity analysis according to the publication date. Stratified analyses were performed for the primary endpoints, using the year 1995 as a cut off between "old" and "new" studies. The choice of this cut off date was rather arbitrary. The year 1995 is in the middle of our study period and mainly based on the "natural gap" in publications, that was present in the mid 1990's. After a period of a very low frequency of publications on the subject of this review, we observed that a renewed interest seems to be present in the second half of that century, given the sharp increase in the number of new publications on the subject.<I>
<BR/>
</I>
</P>
<P>Publication bias was assessed for the three primary outcomes by both graphical inspection of the funnel plot and statistical testing of plot asymmetry, using a 95% confidence interval. We assessed statistical heterogeneity of trial data by using the I-square test (<LINK REF="REF-Higgins-2002" TYPE="REFERENCE">Higgins 2002</LINK>).</P>
</HETEROGENEITY_ASSESSMENT>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2011-04-06 12:40:56 +0530" MODIFIED_BY="Joey Kwong">
<STUDY_DESCRIPTION MODIFIED="2011-03-30 15:48:35 +0530" MODIFIED_BY="Nicole Ackermann">
<SEARCH_RESULTS MODIFIED="2011-03-30 15:48:35 +0530" MODIFIED_BY="Nicole Ackermann">
<P>By search of CENTRAL, MEDLINE (PubMed), EMBASE, CINAHL and Web of Science (SCI/SSCI) 6522 studies were identified in the two separate search arms; 3226 studies in the Utrecht group and 3296 studies the Leiden group (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). After screening of title and abstracts 116 potentially relevant articles were retrieved for detailed assessment by the Utrecht group and 114 articles by the Leiden group. Of these 230 articles, 94 articles were duplicates, which left 136 articles for assessment based on the full-text paper. Of these resulting 136 potentially relevant articles, 75 were excluded because they reported the results of animal experiments, did not report relevant endpoints, or because of lack of randomisation. Thus, a total of 54 studies (60 references) were finally included for the present meta-analysis.</P>
<P>Searching the clinical trials registers identified five relevant ongoing studies (<LINK TAG="CHARACTERISTICS_OF_ONGOING_STUDIES" TYPE="SECTION">Characteristics of ongoing studies</LINK>).</P>
<P>Of the included studies, 36/54 were published in the last 10 years (2000 or later), 11/54 in the 1990s, 4/54 in the 1980s and 3/54 in the 1970s. The majority of studies were conducted in Europe (35/54) and North America (14/54). Altogether, 3615 patients were included in these 54 trials, with a mean age of 60 years and a predominance of male patients (71.9%). Only five studies included high risk surgery patients (<LINK REF="STD-Ferries-1984" TYPE="STUDY">Ferries 1984</LINK>; <LINK REF="STD-Kilger-2003a" TYPE="STUDY">Kilger 2003a</LINK>; <LINK REF="STD-Weis-2006" TYPE="STUDY">Weis 2006</LINK>; <LINK REF="STD-Weis-2009" TYPE="STUDY">Weis 2009</LINK>; <LINK REF="STD-Whitlock-2006" TYPE="STUDY">Whitlock 2006</LINK>). All other study-populations consisted of low risk CABG or valve surgery. Follow-up time was relatively short in most of the studies (duration of hospital stay or shorter in 47 of the 54 studies) (<LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>). None of the studies reported industry funding.</P>
</SEARCH_RESULTS>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2011-04-06 12:32:57 +0530" MODIFIED_BY="Joey Kwong">
<P>The study demographics are shown in <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> and <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>. For all the studies a low risk of bias was unlikely, since no study scored positively on all items of the risk of bias criteria (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>; <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>). In addition some general remarks regarding the quality of studies can be made. The type, frequency and dosage of corticosteroids administered varied largely between studies. In the majority of the studies, the study population was relatively small (median number of patients: 40 per group). Significant heterogeneity was present in the duration of the postoperative stay in both the intensive care and the hospital. This heterogeneity was apparently dictated by a great variation in 'routine' duration of stay both over time (i.e. much longer in the earlier studies) and between hospitals.</P>
<ALLOCATION MODIFIED="2011-04-06 12:32:57 +0530" MODIFIED_BY="Joey Kwong">
<P>Adequate concealment of allocation was present in only 31% of the trials (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>). Out of all the fifty-five randomized trials, only seventeen studies reported concealment of allocation. In six trials concealment of allocation was inadequate, and in the remainder of twenty-one studies randomization or allocation procedures were not specified.</P>
</ALLOCATION>
<BLINDING MODIFIED="2011-03-04 21:45:21 +0530" MODIFIED_BY="Joey Kwong">
<P>Overall, only 34 studies could be classified as blinded. We judged these studies on blinding in several stages: pre- peri- and postoperative care, data-collection. adjudication to endpoints. Besides blinded care and data-collection, only four studies carried out triple blinding and blinded data-analyses (<LINK REF="STD-Mayumi-1997" TYPE="STUDY">Mayumi 1997</LINK>; <LINK REF="STD-Morton-1976" TYPE="STUDY">Morton 1976</LINK>; <LINK REF="STD-Prasongsukarn-2005" TYPE="STUDY">Prasongsukarn 2005</LINK>, <LINK REF="STD-Whitlock-2006" TYPE="STUDY">Whitlock 2006</LINK>)</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2011-03-04 20:06:47 +0530" MODIFIED_BY="[Empty name]">
<P>The follow-up period was variable (ranging from only a few hours to six months), but was mostly short and restricted to hospital stay or ICU stay.A mean follow up period could not be calculated due to the unspecified reporting of follow up period in 33 of the 54 studies (intensive care stay, or hospital stay)<I> (</I>
<LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>
<I>).</I> Most primary endpoints were standardized and complete. In ten studies patients were excluded from analyses when major complications occurred (<LINK REF="STD-Chaney-1998" TYPE="STUDY">Chaney 1998</LINK>; <LINK REF="STD-Chaney-2001" TYPE="STUDY">Chaney 2001</LINK>; <LINK REF="STD-Jansen-1991a" TYPE="STUDY">Jansen 1991a</LINK>; <LINK REF="STD-Mayumi-1997" TYPE="STUDY">Mayumi 1997</LINK>; <LINK REF="STD-Rubens-2005" TYPE="STUDY">Rubens 2005</LINK>; <LINK REF="STD-von-Spiegel-2001" TYPE="STUDY">von Spiegel 2001</LINK>; <LINK REF="STD-Wan-1999" TYPE="STUDY">Wan 1999</LINK>; <LINK REF="STD-Weis-2006" TYPE="STUDY">Weis 2006</LINK>; <LINK REF="STD-Yared-1998" TYPE="STUDY">Yared 1998</LINK>; <LINK REF="STD-Yilmaz-1999" TYPE="STUDY">Yilmaz 1999</LINK>). More importantly, data regarding serious complications, such as mortality, cardiac and pulmonary complications, often appeared to be reported only incidentally, instead of having been subject to a proper follow-up and blinded adjudication for these outcomes according to a study protocol.</P>
</EXCLUSIONS>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2011-04-06 12:40:56 +0530" MODIFIED_BY="Joey Kwong">
<SUBSECTION>
<HEADING LEVEL="3">Mortality, cardiac and pulmonary complications</HEADING>
<P>Only five studies reported all three elements of a composite endpoint: mortality, cardiac complications and pulmonary complications (<LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>) (<LINK REF="STD-Giomarelli-2003" TYPE="STUDY">Giomarelli 2003</LINK>; <LINK REF="STD-Halvorsen-2003" TYPE="STUDY">Halvorsen 2003</LINK>; <LINK REF="STD-Rao-1977" TYPE="STUDY">Rao 1977</LINK>; <LINK REF="STD-Whitlock-2006" TYPE="STUDY">Whitlock 2006</LINK>; <LINK REF="STD-Yared-2007" TYPE="STUDY">Yared 2007</LINK>). In order to prevent double counting of patients and consequently overestimation of the actual number of events, the three accounting endpoints need to be reported on an individual patient-level. Since none of these five studies reported outcome on the individual patient level, we did not perform a pooled analysis of the composite endpoint.</P>
<P>Separate analyses of mortality, myocardial complications and pulmonary complications were performed using the Peto odds ratio. For these separate analyses, all fifty-four studies were taken into account when at least data regarding one of the primary endpoints were available. Data on the number of included studies, as well as on the number of included patients for each of the primary endpoints, are shown in <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>. The use of corticosteroids in coronary bypass surgery did not reduce mortality (odds ratio = 1.12, 95% CI 0.65 to 1.92; 17 studies, 2012 patients, <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>), nor cardiac complications (odds ratio = 0.95, 95% CI 0.57 to 1.60; 16 studies, 1778 patients, <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>), nor pulmonary complications (odds ratio = 0.83, 95% 0.49 to 1.49); 12 studies, 1076 patients, <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>) significantly.<BR/>The I<SUP>2 </SUP>for the primary endpoints were 0% (mortality), 4% (cardiac complications) and 5% (pulmonary complications). Comparing the older studies (published before 1995) with the recent ones (published after 1995) in stratified sensitivity analyse (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>; <LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>; <LINK REF="CMP-004.03" TYPE="ANALYSIS">Analysis 4.3</LINK>; <LINK REF="CMP-004.04" TYPE="ANALYSIS">Analysis 4.4</LINK>; <LINK REF="CMP-004.05" TYPE="ANALYSIS">Analysis 4.5</LINK>; <LINK REF="CMP-004.06" TYPE="ANALYSIS">Analysis 4.6</LINK>) did not reveal differences in Peto odds ratio for mortality, cardiac complications or pulmonary complications over the years. The funnel plots for mortality, cardiac and pulmonary complications did not reveal important asymmetry (<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>, <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>, <LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>, respectively). The use of a random effects model did not materially influence the results and showed odds ratios similar to the Peto odds ratio and confidence intervals including 1 (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).The use of a continuity correction according to the reciprocal of the opposite treatment arm size did also show similar results (data not shown).</P>
<P> </P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Secondary outcomes</HEADING>
<P>We analysed potential complications of the use of corticosteroids: gastro-intestinal ulceration or bleeding and (wound) infections. Also, other outcomes that were reported in two or more studies were analysed, including some outcomes that were not planned for analysis in the review protocol. For all secondary outcomes, the number of included studies, the number of patients, the Peto odds ratios, the random effects odds ratios and the I<SUP>2</SUP> are shown in the <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>.</P>
<P>Hyperglycaemia is a well known side-effect of corticosteroids administration (because of insulin resistance). Glucose regulation reports (regarding levels of serum glucose and insulin administration) were available in as many as 21 studies. Eight studies reported on insulin therapy, without clear definitions with respect to glucose levels that would dictate administration of insulin (<LINK REF="STD-Amr-2009" TYPE="STUDY">Amr 2009</LINK>; <LINK REF="STD-Loef-2004" TYPE="STUDY">Loef 2004</LINK>; <LINK REF="STD-McBride-2004" TYPE="STUDY">McBride 2004</LINK>; <LINK REF="STD-Rubens-2005" TYPE="STUDY">Rubens 2005</LINK>; <LINK REF="STD-Tassani-1999" TYPE="STUDY">Tassani 1999</LINK>; <LINK REF="STD-Toft-1997" TYPE="STUDY">Toft 1997</LINK>; <LINK REF="STD-Yared-1998" TYPE="STUDY">Yared 1998</LINK>; <LINK REF="STD-Yared-2007" TYPE="STUDY">Yared 2007</LINK>). Two studies mentioned the insulin dose necessary to maintain "normal" glucose levels (<LINK REF="STD-Liakopoulos-2007" TYPE="STUDY">Liakopoulos 2007</LINK>; <LINK REF="STD-Sano-2006" TYPE="STUDY">Sano 2006</LINK>). Finally, in fourteen studies, glucose levels after corticosteroid administration were reported. In four of these studies quantitative data were shown (<LINK REF="STD-Amr-2009" TYPE="STUDY">Amr 2009</LINK>; <LINK REF="STD-Chaney-2001" TYPE="STUDY">Chaney 2001</LINK>; <LINK REF="STD-Tassani-1999" TYPE="STUDY">Tassani 1999</LINK>; <LINK REF="STD-Yared-1998" TYPE="STUDY">Yared 1998</LINK>) while in the other ten studies only qualitative data were available ("higher levels or no significantly different levels") (<LINK REF="STD-Celik-2004" TYPE="STUDY">Celik 2004</LINK>; <LINK REF="STD-Fillinger-2002" TYPE="STUDY">Fillinger 2002</LINK>; <LINK REF="STD-Giomarelli-2003" TYPE="STUDY">Giomarelli 2003</LINK>; <LINK REF="STD-Halvorsen-2003" TYPE="STUDY">Halvorsen 2003</LINK>; <LINK REF="STD-Jansen-1991a" TYPE="STUDY">Jansen 1991a</LINK>; <LINK REF="STD-Kilger-2003a" TYPE="STUDY">Kilger 2003a</LINK>; <LINK REF="STD-Mayumi-1997" TYPE="STUDY">Mayumi 1997</LINK>; <LINK REF="STD-Oliver-2004" TYPE="STUDY">Oliver 2004</LINK>; <LINK REF="STD-Sano-2006" TYPE="STUDY">Sano 2006</LINK>; <LINK REF="STD-Toft-1997" TYPE="STUDY">Toft 1997</LINK>). Overall, sixteen out of 21 studies reported either more often insulin therapy or higher glucose levels in the corticosteroids group (<LINK REF="STD-Amr-2009" TYPE="STUDY">Amr 2009</LINK>; <LINK REF="STD-Amr-2009" TYPE="STUDY">Amr 2009</LINK>; <LINK REF="STD-Chaney-2001" TYPE="STUDY">Chaney 2001</LINK>; <LINK REF="STD-Fillinger-2002" TYPE="STUDY">Fillinger 2002</LINK>; <LINK REF="STD-Jansen-1991a" TYPE="STUDY">Jansen 1991a</LINK>; <LINK REF="STD-Liakopoulos-2007" TYPE="STUDY">Liakopoulos 2007</LINK>; <LINK REF="STD-Loef-2004" TYPE="STUDY">Loef 2004</LINK>; <LINK REF="STD-Mayumi-1997" TYPE="STUDY">Mayumi 1997</LINK>; <LINK REF="STD-McBride-2004" TYPE="STUDY">McBride 2004</LINK>; <LINK REF="STD-Oliver-2004" TYPE="STUDY">Oliver 2004</LINK>; <LINK REF="STD-Rubens-2005" TYPE="STUDY">Rubens 2005</LINK>; <LINK REF="STD-Sano-2006" TYPE="STUDY">Sano 2006</LINK>; <LINK REF="STD-Tassani-1999" TYPE="STUDY">Tassani 1999</LINK>; <LINK REF="STD-Yared-1998" TYPE="STUDY">Yared 1998</LINK>; <LINK REF="STD-Yared-1998" TYPE="STUDY">Yared 1998</LINK>; <LINK REF="STD-Yared-2007" TYPE="STUDY">Yared 2007</LINK>). The remaining five studies could not show any difference in insulin therapy or glucose levels (<LINK REF="STD-Celik-2004" TYPE="STUDY">Celik 2004</LINK>; <LINK REF="STD-Giomarelli-2003" TYPE="STUDY">Giomarelli 2003</LINK>; <LINK REF="STD-Halvorsen-2003" TYPE="STUDY">Halvorsen 2003</LINK>; <LINK REF="STD-Kilger-2003a" TYPE="STUDY">Kilger 2003a</LINK>; <LINK REF="STD-Toft-1997" TYPE="STUDY">Toft 1997</LINK>). Due to the heterogeneity of the available data, no further analyses could be performed for the association between glucocorticosteroids and hyperglycaemia.</P>
<P>Another well known side effect of corticosteroids administration is the occurrence of gastrointestinal complications. Only four studies, comprising a total of 304 patients, explicitly reported on gastrointestinal complications (both bleeding and ulceration). The odds ratio was 2.84 (95% CI 0.40 to 20.36) <LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>.</P>
<P>Moreover, the incidence of atrial fibrillation was reduced in the corticosteroids group (odds ratio 0.60, 95% CI 0.46 to 0.78,17 studies, 1389 patients, <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>). The length of intensive care stay was slightly shorter in the corticosteroids group (2.32 hours, 95 % CI -2.84 to -1.81; 25 studies, 1215 patients, <LINK REF="CMP-002.05" TYPE="ANALYSIS">Analysis 2.5</LINK>).</P>
<P>For all other secondary endpoints neither advantage nor disadvantage could be demonstrated for the use of corticosteroids in cardiac surgery. (Infectious complications (Odds ratio 0.89, 95% CI 0.89 to 1.38; 15 studies, 1487 patients, <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>). Time to extubation (hours) (Odds ratio -1.81, 95% CI -11.46 to 7.83; 23 studies, 1351 patients, <LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>). Length of hospital stay (days) (Odds ratio -0.40, 95% CI -0.65 to -0.15; 15 studies, 625 patients, <LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK>). Renal failure (Odds ratio1.00, 95% CI 0.45 to 2.19; 9 studies, 677 patients, <LINK REF="CMP-002.07" TYPE="ANALYSIS">Analysis 2.7</LINK>). Re-thoracotomy [Odds ratio 1.12, 95% CI 0.47 to 2.65; 7 studies, 818 patients, <LINK REF="CMP-002.08" TYPE="ANALYSIS">Analysis 2.8</LINK>). Neurological complications (Odds ratio 0.7, 95% CI 0.33 to 1.48; 10 studies, 1052 patients, <LINK REF="CMP-002.10" TYPE="ANALYSIS">Analysis 2.10</LINK>). Vasoactive medication (Odds ratio 0.91, 95% CI 0.67 to 1.23; 17 studies, 1237 patients, <LINK REF="CMP-002.11" TYPE="ANALYSIS">Analysis 2.11</LINK>). Blood transfusion (yes/no) (Odds ratio 0.87, 95% CI 0.54 to 1.39; 5 studies, 511 patients, <LINK REF="CMP-002.12" TYPE="ANALYSIS">Analysis 2.12</LINK>])</P>
<P>
<I> </I>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Analysis according to corticosteroid dose</HEADING>
<P>We categorized the included studies into high-dose (total administered dose &gt; 1000 mg hydrocortisone equivalents) and low-dose (total administered dose (<U>&lt;</U> 1000 mg hydrocortisone equivalents) studies and performed a stratified meta analysis (<LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>). More detailed stratification and/or dose-response analyses were limited due to sparsity of data. In only nine studies, a hydrocortisone equivalent of 1000 mg or lower was administered (<LINK REF="STD-Halonen-2007" TYPE="STUDY">Halonen 2007</LINK>; <LINK REF="STD-Halvorsen-2003" TYPE="STUDY">Halvorsen 2003</LINK>; <LINK REF="STD-Harig-1999" TYPE="STUDY">Harig 1999</LINK>; <LINK REF="STD-Kilger-2003a" TYPE="STUDY">Kilger 2003a</LINK>; <LINK REF="STD-Kilger-2003b" TYPE="STUDY">Kilger 2003b</LINK>; <LINK REF="STD-Starobin-2007" TYPE="STUDY">Starobin 2007</LINK>; <LINK REF="STD-Weis-2006" TYPE="STUDY">Weis 2006</LINK>; <LINK REF="STD-Weis-2009" TYPE="STUDY">Weis 2009</LINK>; <LINK REF="STD-Yilmaz-1999" TYPE="STUDY">Yilmaz 1999</LINK>). Eight of these &#8220;low-dose&#8221; studies reported on mortality, two on cardiac complications, three on pulmonary complications and none reported on gastrointestinal bleeding. No statistically significant dose dependent difference in major outcomes could be demonstrated, but concomitant confidence intervals were wide (<LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>). The only one exception was atrial fibrillation, which was reduced in both the low- and high-dose groups. </P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2011-03-04 21:46:01 +0530" MODIFIED_BY="Joey Kwong">
<SUMMARY_OF_RESULTS MODIFIED="2010-05-14 14:57:06 +0530" MODIFIED_BY="[Empty name]">
<P>In this meta-analysis on the effects of prophylactic corticosteroid use in adult cardiac surgical patients, there was no beneficial effect on mortality, cardiac and pulmonary complications. Also, an increased risk of potential side effects of corticosteroids, such as infection, impaired wound healing, gastro-intestinal ulceration or bleeding, could not be demonstrated. Of other, secondary endpoints, only the risk for atrial fibrillation and length of ICU stay were found to be reduced. Moreover, no dose dependent effects of corticosteroids for any outcome could be demonstrated, although this conclusion is limited due to the imprecise estimation of the effects.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2011-03-04 20:45:38 +0530" MODIFIED_BY="[Empty name]">
<P>Both the quality and the completeness of this review have, in our view, been improved by combining the efforts of two research groups in the Netherlands, that were coincidently working on very similar systematic review projects. Although the search results with the two different (but robust) search strings reached quite comparable results with respect to the most important studies, as many as 4229 references were part of the results of only one of both strategies. Thus, parallel but separate searching can be a valuable method to improve at least the completeness of future systematic reviews.</P>
<P>The data presented in this systematic review provide no convincing evidence for a beneficial effect of the use of corticosteroids on important outcomes in patients undergoing cardiac surgery with cardiopulmonary bypass, with odds ratios for mortality, cardiac and pulmonary complications that were all close to unity. However, while drawing this conclusion, one should keep in mind the study's important qualitative limitations which are discussed in detail below. Moreover, applicability of the results may be limited because most studies included in this meta-analysis were performed in low-risk patient populations (<LINK REF="REF-Dekkers-2010" TYPE="REFERENCE">Dekkers 2010</LINK>).</P>
<P>A risk-reduction for postoperative atrial fibrillation seems to be one of the few clinical advantages of corticosteroid administration that has been demonstrated repeatedly (<LINK REF="STD-Halonen-2007" TYPE="STUDY">Halonen 2007</LINK>; <LINK REF="STD-Whitlock-2006" TYPE="STUDY">Whitlock 2006</LINK>). The mechanism of this effect is not entirely clear, although several studies have shown an association between higher levels of inflammatory markers and the incidence of atrial fibrillation (<LINK REF="STD-Halonen-2007" TYPE="STUDY">Halonen 2007</LINK>; <LINK REF="STD-Whitlock-2006" TYPE="STUDY">Whitlock 2006</LINK>). Atrial fibrillation following cardiac surgery is associated with an increased hospital length of stay, increased rate of post-operative stroke and increased surgical costs, which can be prevented effectively with anti-arrhythmic drugs, such as beta-blockers or amiodarone (<LINK REF="REF-Crystal-2004" TYPE="REFERENCE">Crystal 2004</LINK>). However, based on the data of the meta-analysis the reduced risk for atrial fibrillation did not translate into a mortality reduction. Moreover, since especially beta-blockers are associated with fewer side-effects than corticosteroids, the sole reduction of atrial fibrillation is not an indication for the use of corticosteroids.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2011-03-04 20:48:04 +0530" MODIFIED_BY="[Empty name]">
<P>There are several important qualitative limitations for this set of published randomised studies on corticosteroids in adult cardiac surgery. These limitations may influence the quality of the evidence and must lead to caution in the interpretation of the results.</P>
<P>First, based on well-established criteria for conduction and reporting of clinical trials, the quality of the included studies was mostly scored as being low. Secondly, in many of the included studies the primary focus was on intermediate endpoints such as markers of inflammation and ventilatory parameters, while reporting of clinical endpoints was not part of the study protocol. Non-standardized collection of clinical outcomes carries a high risk of observer bias, particularly when the endpoint adjudication is not blinded. Furthermore, due to the short follow-up period in the majority of studies, the risk of underreporting of endpoints is also present. Third, the individual studies included in this meta-analysis appeared clinically very heterogeneous. They range over three decades, from the mid 1970s until 2009, a period over which the quality of the surgical, anaesthesiological and postoperative care has dramatically improved. Moreover, the use of perioperative medication has changed over time (aspirin, beta-blockers, aprotinin). Finally, the definitions of cardiac and pulmonary complications that were used across the studies were not uniform (<LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>). Although in many studies cardiac complications were defined as ischaemic events, the definitions that were employed for pulmonary complications were far more variable.</P>
</QUALITY_OF_EVIDENCE>
<AGREEMENT MODIFIED="2011-03-04 21:46:01 +0530" MODIFIED_BY="Joey Kwong">
<P>Recently, two other meta-analyses were published on the same topic by <LINK REF="REF-Whitlock-2008" TYPE="REFERENCE">Whitlock 2008</LINK> and <LINK REF="REF-Ho-2009" TYPE="REFERENCE">Ho 2009</LINK>. The meta-analysis from <LINK REF="REF-Whitlock-2008" TYPE="REFERENCE">Whitlock 2008</LINK> included 44 trials, 41 of which identical to those in our meta-analysis. We did not include three studies that were included in this particular review, for reasons of inclusion of children (<LINK REF="STD-Vallejo-1977" TYPE="STUDY">Vallejo 1977</LINK>), no randomisation (<LINK REF="STD-Fecht-1978" TYPE="STUDY">Fecht 1978</LINK>) and no information regarding randomisation (<LINK REF="STD-Niazi-1979" TYPE="STUDY">Niazi 1979</LINK>). Moreover, we retrieved and included 14 more studies (<LINK REF="STD-Abd.-El_x002d_Hakeem-2003a" TYPE="STUDY">Abd. El-Hakeem 2003a</LINK>; <LINK REF="STD-Amr-2009" TYPE="STUDY">Amr 2009</LINK>; <LINK REF="STD-Bingol-2005" TYPE="STUDY">Bingol 2005</LINK>; <LINK REF="STD-Boscoe-1983" TYPE="STUDY">Boscoe 1983</LINK>; <LINK REF="STD-Cavarocchi-1986" TYPE="STUDY">Cavarocchi 1986</LINK>; <LINK REF="STD-Demir-2009" TYPE="STUDY">Demir 2009</LINK>; <LINK REF="STD-Engelman-1995" TYPE="STUDY">Engelman 1995</LINK>; <LINK REF="STD-Kilger-2003b" TYPE="STUDY">Kilger 2003b</LINK>; <LINK REF="STD-Sano-2003" TYPE="STUDY">Sano 2003</LINK>; <LINK REF="STD-von-Spiegel-2001" TYPE="STUDY">von Spiegel 2001</LINK>; <LINK REF="STD-Weis-2009" TYPE="STUDY">Weis 2009</LINK>; <LINK REF="STD-Sobieski-2008" TYPE="STUDY">Sobieski 2008</LINK>; <LINK REF="STD-Starobin-2007" TYPE="STUDY">Starobin 2007</LINK>). Our results differ in particular with respect to mortality. Whereas <LINK REF="REF-Whitlock-2008" TYPE="REFERENCE">Whitlock 2008</LINK> found a trend towards a reduction in mortality (relative risk 0.73, 95% CI 0.45 to 1.18), no clear mortality benefit was found in our study (Peto odds ratio 1.12, 95% CI 0.65 to 1.92, <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). This difference in point estimates is largely accounted for by the study from <LINK REF="STD-Vallejo-1977" TYPE="STUDY">Vallejo 1977</LINK>. This study showed a reduction in mortality (relative risk 0.55) in patients receiving steroids and accounted for 27% of the weight of the mortality point estimate in the meta-analysis by <LINK REF="REF-Whitlock-2008" TYPE="REFERENCE">Whitlock 2008</LINK>. However, the study from <LINK REF="STD-Vallejo-1977" TYPE="STUDY">Vallejo 1977</LINK> was published in 1977 and was designated by <LINK REF="REF-Whitlock-2008" TYPE="REFERENCE">Whitlock 2008</LINK> as &#8220;low quality&#8221;. It is also uncertain whether the randomisation was truly concealed. We decided not to include this particular study because of the inclusion of patients under the age of 18 years in the study population. However, and even more importantly, the mortality rate in the non-steroid group was 22%: by far the highest mortality rate of all included studies. Even considering the state of the art for cardiac surgical care 30 years ago, this rate is surprisingly high. We therefore conclude that the possible mortality benefit in steroids that was reported by Whitlock <I>et al</I>. is mainly due to the inclusion of one single low quality trial, in which the mortality in the non-steroid group was an outlier. Similar to <LINK REF="REF-Whitlock-2008" TYPE="REFERENCE">Whitlock 2008</LINK> (relative risk 0.99, 95% CI 0.57-1.72), we found no reduction in cardiac complications (Peto odds ratio 0.95, 95% CI 0.57 to 1.60, <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>). Pulmonary complications were not studied by <LINK REF="REF-Whitlock-2008" TYPE="REFERENCE">Whitlock 2008</LINK>.</P>
<P>The meta-analysis from <LINK REF="REF-Ho-2009" TYPE="REFERENCE">Ho 2009</LINK> included 50 trials, 45 of which are identical to those in our meta-analysis. Besides <LINK REF="STD-Vallejo-1977" TYPE="STUDY">Vallejo 1977</LINK>, <LINK REF="STD-Niazi-1979" TYPE="STUDY">Niazi 1979</LINK> and <LINK REF="STD-Fecht-1978" TYPE="STUDY">Fecht 1978</LINK>, as discussed here above, we excluded both <LINK REF="STD-Teoh-1995" TYPE="STUDY">Teoh 1995</LINK> (missing description of randomisation procedure) and <LINK REF="STD-Kilickan-2008" TYPE="STUDY">Kilickan 2008</LINK> (deficient data on primary outcome measures). Moreover, twelve more studies were included in our meta-analysis (<LINK REF="STD-Amr-2009" TYPE="STUDY">Amr 2009</LINK>; <LINK REF="STD-Boscoe-1983" TYPE="STUDY">Boscoe 1983</LINK>; <LINK REF="STD-Cavarocchi-1986" TYPE="STUDY">Cavarocchi 1986</LINK>; <LINK REF="STD-Demir-2009" TYPE="STUDY">Demir 2009</LINK>; <LINK REF="STD-Kilger-2003b" TYPE="STUDY">Kilger 2003b</LINK>; <LINK REF="STD-Liakopoulos-2007" TYPE="STUDY">Liakopoulos 2007</LINK>; <LINK REF="STD-Morton-1976" TYPE="STUDY">Morton 1976</LINK>; <LINK REF="STD-Sano-2003" TYPE="STUDY">Sano 2003</LINK>; <LINK REF="STD-Starobin-2007" TYPE="STUDY">Starobin 2007</LINK>; <LINK REF="STD-von-Spiegel-2001" TYPE="STUDY">von Spiegel 2001</LINK>; <LINK REF="STD-Yared-1998" TYPE="STUDY">Yared 1998</LINK>; <LINK REF="STD-Weis-2009" TYPE="STUDY">Weis 2009</LINK>), accounting for 680 patients. The inclusion of the study of <LINK REF="STD-Vallejo-1977" TYPE="STUDY">Vallejo 1977</LINK> in this review resulted in a relative risk estimate for mortality that was similar to that in the study of <LINK REF="REF-Whitlock-2008" TYPE="REFERENCE">Whitlock 2008</LINK>, with the limitations that have been addressed in the previous paragraph. Apart from the difference in the relative risk for mortality, the results of the meta-analysis of <LINK REF="REF-Ho-2009" TYPE="REFERENCE">Ho 2009</LINK> were largely similar to our results with respect to the effect on other major clinical endpoints, atrial fibrillation and length of intensive care stay.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2011-03-31 16:13:18 +0530" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2011-03-04 21:04:05 +0530" MODIFIED_BY="[Empty name]">
<P>The use of corticosteroids in cardiac surgery has been advocated because of the ability of corticosteroids to inhibit the systemic inflammatory response (<LINK REF="REF-Chaney-2002" TYPE="REFERENCE">Chaney 2002</LINK>; <LINK REF="STD-Whitlock-2005" TYPE="STUDY">Whitlock 2005</LINK>). In the present meta-analysis, we were not able to demonstrate that this concept results in important clinical benefits, as there was no positive effect on major clinical outcomes in cardiac surgical patients receiving corticosteroids. Only a beneficial effect on the occurrence of postoperative atrial fibrillation could be demonstrated.</P>
<P>In the absence of substantial beneficial effects, also other possible adverse effects of corticosteroids, such as gastrointestinal complications, glucose imbalance, and possibly an increased number of (wound) infections, must be taken into account when considering the use of corticosteroids in cardiopulmonary bypass. However, no increased risk on these side effects could be demonstrated.</P>
<P>Therefore, the liberal use of corticosteroids, as advocated by the guidelines of the American Heart Association <LINK REF="REF-AHA-2009" TYPE="REFERENCE">AHA 2009</LINK>, cannot be supported by this meta-analysis as a potentially effective treatment to reduce major complications following cardiac surgery.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2011-03-31 16:13:18 +0530" MODIFIED_BY="[Empty name]">
<P>The studies included in this systematic review were clinically heterogeneous and carried a high risk of bias. Moreover, the confidence intervals of the point estimates of the meta-analysis were broad. Given these important limitations, larger clinical trials are required to determine a precise estimate of the effect sizes. Ideally, these trials would be randomized, blinded, placebo controlled trials of frequently used corticosteroid treatment protocols (i.e. high dose methylprednisolone or dexamethasone). These studies should focus on serious complications (mortality, myocardial infarction and organ failure) as the primary endpoint, which will require a very large number of patients (several thousands) for sufficient statistical power.</P>
<P>As far as we are informed, two major randomized clinical trials evaluating corticosteroid administration in cardiac surgery are currently underway: the <LINK REF="STD-SIRS-trial" TYPE="STUDY">SIRS trial</LINK> (NCT00427388) and the <LINK REF="STD-DECS-trial" TYPE="STUDY">DECS trial</LINK> (NCT00293592), including 10,000 and 4,500 patients, respectively. The results from these trials are expected in the period 2011-2013.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2011-03-31 16:13:02 +0530" MODIFIED_BY="[Empty name]">
<P>We thank J.W. Schoones, library consultant in the Leiden university centre, for his major contribution in developing our search strategy. We further acknowledge Dr. Scoletta for providing additional data for the analysis of his article <LINK REF="STD-Giomarelli-2003" TYPE="STUDY">Giomarelli 2003</LINK>
.
</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2009-09-09 19:15:40 +0530" MODIFIED_BY="[Empty name]">
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2011-01-12 08:48:58 +0530" MODIFIED_BY="Joey Kwong">
<P>Drs Dieleman<BR/>Participated in writing and amending of the protocol. He will participate screening of search results, retrieving papers, data collection, analysis and interpretation, and in writing of the main text. Together with Drs Van Paassen, Drs Dieleman will be the guarantor of the review.</P>
<P>Drs van Paassen<BR/>Participated in writing and amending of the protocol. She will participate in screening of search results, retrieving papers, data collection, analysis and interpretation, and in writing of the main text. Together with Drs Dieleman, Drs Van Paassen will be the guarantor of the review.</P>
<P>Dr Van Dijk<BR/>Participated in the coordination and writing of the protocol. He has participated in screening of search results, and assisted in data collection, analysis and interpretation, and in writing of the main text.</P>
<P>Dr Arbous<BR/>Participated in amending of the protocol. She assisted in analysis and interpretation of the data and participated in writing of the main text.</P>
<P>Prof Dr Kalkman<BR/>Participated in the coordination, writing and amending of the protocol. He assisted in data collection, analysis and interpretation, and coordinated writing of the main text.</P>
<P>Prof Dr Vandenbroucke<BR/>Participated in amending the protocol. He assisted in analysis and interpretation of data, and coordinated writing of the main text.</P>
<P>Dr Van der Heijden<BR/>Participated in the coordination, writing and amending of the protocol. He assisted in data collection, analysis and interpretation, and in writing of the main text.</P>
<P>Dr Dekkers<BR/>Participated in amending the protocol. He assisted in data collection, analysis and interpretation, and in writing of the main text.<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2011-02-22 16:33:04 +0530" MODIFIED_BY="Nicole Ackermann">
<P>Many of the selected studies reported clinical outcomes sparsely. Most often, the reported clinical outcomes were only secondary endpoints in studies looking primarily at intermediate endpoints like, for example, cytokine levels or parameters of mechanical ventilation. As a result, we have not been able to extract data for every outcome listed in the 'Objectives' section. This has lead to a discrepancy between the outcomes that were described in the protocol of this review and the outcomes that we have been able to analyse. More specifically, this applies to the secondary outcomes "Quality of life" and "Cost effectiveness".</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2011-03-04 21:46:46 +0530" MODIFIED_BY="Joey Kwong"/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2011-04-06 12:36:11 +0530" MODIFIED_BY="Joey Kwong">
<STUDIES MODIFIED="2011-03-30 15:43:02 +0530" MODIFIED_BY="Nicole Ackermann">
<INCLUDED_STUDIES MODIFIED="2011-02-22 19:09:11 +0530" MODIFIED_BY="Nicole Ackermann">
<STUDY DATA_SOURCE="PUB" ID="STD-Abd.-El_x002d_Hakeem-2003a" MODIFIED="2011-02-22 17:00:38 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Abd. El-Hakeem 2003a" YEAR="2003">
<REFERENCE MODIFIED="2011-02-22 17:00:38 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Abd. El-Hakeem JJ, Zareh ZE</AU>
<TI>Effects of dexamethasone on the incidence of shivering and recovery in patients undergoing valve replacement surgery</TI>
<SO>Egyptian Journal of Anaesthesia</SO>
<YR>2003</YR>
<VL>19</VL>
<PG>361-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Abd.-El_x002d_Hakeem-2003b" MODIFIED="2011-02-22 17:01:37 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Abd. El-Hakeem 2003b" YEAR="2003">
<REFERENCE MODIFIED="2011-02-22 17:01:37 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Abd. El-Hakeem EE, Ashry MA, El-Minshawy A, Maghraby EA</AU>
<TI>Influence of dexamethasone on cytokine balance in patients undergoing valve replacement surgery</TI>
<SO>Egyptian Journal of Anaesthesia</SO>
<YR>2003</YR>
<VL>3</VL>
<PG>205-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Amr-2009" MODIFIED="2011-02-22 17:01:58 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Amr 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-02-22 17:01:58 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Amr YM, Elmisekawy E, El-serogy H</AU>
<TI>Effects of dexamethasone on pulmonary and renal functions in patients undergoing CABG with cardiopulmonary bypass</TI>
<SO>Seminars in Cardiothoracic and Vascular Anesthesia</SO>
<YR>2009</YR>
<VL>13</VL>
<NO>4</NO>
<PG>231-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Andersen-1989" MODIFIED="2011-02-22 17:02:20 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Andersen 1989" YEAR="1989">
<REFERENCE MODIFIED="2011-02-22 17:02:20 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Andersen LW, Baek L, Thomsen BS, Rasmussen JP</AU>
<TI>Effect of methylprednisolone on endotoxemia and complement activation during cardiac surgery</TI>
<SO>Journal of Cardiothoracic Anesthesia</SO>
<YR>1989</YR>
<VL>3</VL>
<NO>5</NO>
<PG>544-9</PG>
<IDENTIFIERS MODIFIED="2009-12-08 20:00:33 +0530" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="2520931"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bingol-2005" MODIFIED="2011-02-22 17:04:08 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Bingol 2005" YEAR="2005">
<REFERENCE MODIFIED="2011-02-22 17:04:08 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bingol H, Cingoz F, Balkan A, Kilic S, Bolcal C, Demirkilic U, et al</AU>
<TI>The effect of oral prednisolone with chronic obstructive pulmonary disease undergoing coronary artery bypass surgery</TI>
<SO>Journal of Cardiac Surgery</SO>
<YR>2005</YR>
<VL>20</VL>
<PG>252-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boscoe-1983" MODIFIED="2011-02-22 17:05:09 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Boscoe 1983" YEAR="1983">
<REFERENCE MODIFIED="2011-02-22 17:05:09 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boscoe MJ, Yewdall VM, Thompson MA, Cameron JS</AU>
<TI>Complement activation during cardiopulmonary bypass: quantitative study of effects of methylprednisolone and pulsatile flow</TI>
<SO>British Medical Journal (Clinical research ed.)</SO>
<YR>1983</YR>
<VL>287</VL>
<NO>6407</NO>
<PG>1747-50</PG>
<IDENTIFIERS MODIFIED="2010-09-03 23:56:27 +0530" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-09-03 23:56:27 +0530" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="6416575"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bourbon-2004" MODIFIED="2011-02-22 17:05:49 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Bourbon 2004" YEAR="2004">
<REFERENCE MODIFIED="2011-02-22 17:05:49 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bourbon A, Vionnet M, Leprince P, Vaissier E, Copeland J, McDonagh P, et al</AU>
<TI>The effect of methylprednisolone treatment on the cardiopulmonary bypass-induced systemic inflammatory response</TI>
<SO>European Journal of Cardio-Thoracic Surgery</SO>
<YR>2004</YR>
<VL>26</VL>
<NO>5</NO>
<PG>932-8</PG>
<IDENTIFIERS MODIFIED="2009-12-08 20:00:33 +0530" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="15519185"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cavarocchi-1986" MODIFIED="2011-02-22 17:06:45 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Cavarocchi 1986" YEAR="1986">
<REFERENCE MODIFIED="2011-02-22 17:06:45 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cavarocchi NC, Pluth JR, Schaff HV, Orszulak TA, Homburger HA, Solis E, et al</AU>
<TI>Complement activation during cardiopulmonary bypass: comparison of bubble and membrane oxygenators</TI>
<SO>Journal of Thoracic and Cardiovascular Surgery</SO>
<YR>1986</YR>
<VL>91</VL>
<NO>2</NO>
<PG>252-8</PG>
<IDENTIFIERS MODIFIED="2009-12-08 20:00:33 +0530" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="3511328"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Celik-2004" MODIFIED="2009-12-08 20:00:46 +0530" MODIFIED_BY="[Empty name]" NAME="Celik 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-12-08 20:00:46 +0530" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Celik JB, Gormus N, Okesli S, Gormus ZI, Solak H</AU>
<TI>Methylprednisolone prevents inflammatory reaction occurring during cardiopulmonary bypass: effects on TNF-alpha, IL-6, IL-8, IL-10</TI>
<SO>Perfusion</SO>
<YR>2004</YR>
<VL>19</VL>
<NO>3</NO>
<PG>185-91</PG>
<IDENTIFIERS MODIFIED="2009-12-08 20:00:33 +0530" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="15298427"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chaney-1998" MODIFIED="2011-02-22 17:08:09 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Chaney 1998" YEAR="1998">
<REFERENCE MODIFIED="2011-02-22 17:07:27 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chaney MA, Nikolov MP, Blakeman B, Bakhos M, Slogoff S</AU>
<TI>Pulmonary effects of methylprednisolone in patients undergoing coronary artery bypass grafting and early tracheal extubation</TI>
<SO>Anesthesia and Analgesia</SO>
<YR>1998</YR>
<VL>87</VL>
<NO>1</NO>
<PG>27-33</PG>
<IDENTIFIERS MODIFIED="2009-12-08 20:00:33 +0530" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="9661540"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-02-22 17:08:09 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chaney MA, Nikolov MP, Blakeman BP, Bakhos M, Slogoff S</AU>
<TI>Hemodynamic effects of methylprednisolone in patients undergoing cardiac operation and early extubation</TI>
<SO>Annals of Thoracic Surgery</SO>
<YR>1999</YR>
<VL>67</VL>
<NO>4</NO>
<PG>1006-11</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="10320243"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chaney-2001" MODIFIED="2011-02-22 17:08:47 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Chaney 2001" YEAR="2001">
<REFERENCE MODIFIED="2011-02-22 17:08:47 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chaney MA, Durazo-Arvizu RA, Nikolov MP, Blakeman BP, Bakhos M</AU>
<TI>Methylprednisolone does not benefit patients undergoing coronary artery bypass grafting and early tracheal extubation</TI>
<SO>Journal of Thoracic and Cardiovascular Surgery</SO>
<YR>2001</YR>
<VL>121</VL>
<NO>3</NO>
<PG>561-9</PG>
<IDENTIFIERS MODIFIED="2009-12-08 20:00:33 +0530" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="11241092"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Codd-1977" MODIFIED="2011-02-22 17:09:27 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Codd 1977" YEAR="1977">
<REFERENCE MODIFIED="2011-02-22 17:09:27 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Codd JE, Wiens RD, Barner HB, Kaiser GC, Willman VL</AU>
<TI>Steroids and myocardial preservation</TI>
<SO>Journal of Thoracic and Cardiovascular Surgery</SO>
<YR>1977</YR>
<VL>74</VL>
<NO>3</NO>
<PG>418-22</PG>
<IDENTIFIERS MODIFIED="2010-09-03 23:57:01 +0530" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-09-03 23:57:01 +0530" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="302373"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Coetzer-1996" MODIFIED="2011-02-22 17:09:47 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Coetzer 1996" YEAR="1996">
<REFERENCE MODIFIED="2011-02-22 17:09:47 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Coetzer M, Coetzee A, Rossouw G</AU>
<TI>The effect of methylprednisolone, given prior to cardiopulmonary bypass, on indices of gas exchange</TI>
<SO>Cardiovascular Journal of South Africa</SO>
<YR>1996</YR>
<VL>86</VL>
<PG>C188-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Demir-2009" MODIFIED="2011-02-22 17:10:00 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Demir 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-02-22 17:10:00 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Demir T, Demir H, Tansel T, Kalko Y, Tireli E, Dayioglu E, et al</AU>
<TI>Influence of methylprednisolone on levels of neuron-specific enolase in cardiac surgery: a corticosteroid derivative to decrease possible neuronal damage</TI>
<SO>Journal of Cardiac Surgery</SO>
<YR>2009</YR>
<VL>24</VL>
<PG>397-403</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-El-Azab-2002" MODIFIED="2011-02-22 17:10:32 +0530" MODIFIED_BY="Nicole Ackermann" NAME="El Azab 2002" YEAR="2002">
<REFERENCE MODIFIED="2011-02-22 17:10:32 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>El Azab SR, Rosseel PM, de Lange JJ, Groeneveld AB, van Strik R, van Wijk EM, et al</AU>
<TI>Dexamethasone decreases the pro- to anti-inflammatory cytokine ratio during cardiac surgery</TI>
<SO>British Journal of Anaesthesia</SO>
<YR>2002</YR>
<VL>88</VL>
<NO>4</NO>
<PG>496-501</PG>
<IDENTIFIERS MODIFIED="2009-12-08 20:00:33 +0530" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="12066724"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Enc-2006" MODIFIED="2011-02-22 17:10:45 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Enc 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-02-22 17:10:45 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Enc Y, Karaca P, Ayoglu U, Camur G, Kurc E, Cicek S</AU>
<TI>The acute cardioprotective effect of glucocorticoid in myocardial ischemia-reperfusion injury occurring during cardiopulmonary bypass</TI>
<SO>Heart and Vessels</SO>
<YR>2006</YR>
<VL>21</VL>
<NO>3</NO>
<PG>152-6</PG>
<IDENTIFIERS MODIFIED="2009-12-08 20:00:33 +0530" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="16715189"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Engelman-1995" MODIFIED="2011-02-22 17:11:14 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Engelman 1995" YEAR="1995">
<REFERENCE MODIFIED="2011-02-22 17:11:14 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Engelman RM, Rousou JA, Flack JE 3rd, Deaton DW, Kalfin R, Das DK</AU>
<TI>Influence of steroids on complement and cytokine generation after cardiopulmonary bypass</TI>
<SO>The Annals of Thoracic Surgery</SO>
<YR>1995</YR>
<VL>60</VL>
<NO>3</NO>
<PG>801-4</PG>
<IDENTIFIERS MODIFIED="2010-09-03 23:58:07 +0530" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-09-03 23:58:07 +0530" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="7677537"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ferries-1984" MODIFIED="2011-02-22 17:12:33 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Ferries 1984" YEAR="1984">
<REFERENCE MODIFIED="2011-02-22 17:12:33 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ferries LH, Marx JJ, Ray JF</AU>
<TI>The effect of methylprednisolone on complement activation during cardiopulmonary bypass</TI>
<SO>Journal of Extracorporeal Technology</SO>
<YR>1984</YR>
<VL>16</VL>
<PG>83-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-12-08 20:03:04 +0530" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fillinger-2002" MODIFIED="2011-02-22 17:12:56 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Fillinger 2002" YEAR="2002">
<REFERENCE MODIFIED="2011-02-22 17:12:56 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fillinger MP, Rassias AJ, Guyre PM, Sanders JH, Beach M, Pahl J, et al</AU>
<TI>Glucocorticoid effects on the inflammatory and clinical responses to cardiac surgery</TI>
<SO>Journal of Cardiothoracic and Vascular Anesthesia</SO>
<YR>2002</YR>
<VL>16</VL>
<NO>2</NO>
<PG>163-9</PG>
<IDENTIFIERS MODIFIED="2009-12-08 20:00:33 +0530" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="11957164"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Giomarelli-2003" MODIFIED="2011-02-22 17:19:47 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Giomarelli 2003" YEAR="2003">
<REFERENCE MODIFIED="2011-02-22 17:19:47 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Giomarelli P, Scolletta S, Borrelli E, Biagioli B</AU>
<TI>Myocardial and lung injury after cardiopulmonary bypass: role of interleukin (IL)-10</TI>
<SO>The Annals of Thoracic Surgery</SO>
<YR>2003</YR>
<VL>76</VL>
<NO>1</NO>
<PG>117-23</PG>
<IDENTIFIERS MODIFIED="2009-12-08 20:00:33 +0530" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="12842524"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Halonen-2007" MODIFIED="2011-02-22 17:20:02 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Halonen 2007" YEAR="2007">
<REFERENCE MODIFIED="2011-02-22 17:20:02 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Halonen J, Halonen P, Jarvinen O, Taskinen P, Auvinen T, Tarkka M, et al</AU>
<TI>Corticosteroids for the prevention of atrial fibrillation after cardiac surgery: a randomized controlled trial</TI>
<SO>JAMA</SO>
<YR>2007</YR>
<VL>297</VL>
<NO>14</NO>
<PG>1562-7</PG>
<IDENTIFIERS MODIFIED="2009-12-08 20:00:33 +0530" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="17426275"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Halvorsen-2003" MODIFIED="2011-02-22 17:20:29 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Halvorsen 2003" YEAR="2003">
<REFERENCE MODIFIED="2011-02-22 17:20:29 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Halvorsen P, Raeder J, White PF, Almdahl SM, Nordstrand K, Saatvedt K, et al</AU>
<TI>The effect of dexamethasone on side effects after coronary revascularization procedures</TI>
<SO>Anesthesia and Analgesia</SO>
<YR>2003</YR>
<VL>96</VL>
<NO>6</NO>
<PG>1578-83</PG>
<IDENTIFIERS MODIFIED="2009-12-08 20:00:33 +0530" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="12760978"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harig-1999" MODIFIED="2011-02-22 17:20:49 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Harig 1999" YEAR="1999">
<REFERENCE MODIFIED="2011-02-22 17:20:49 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harig F, Feyrer R, Mahmoud FO, Blum U, von der Emde J</AU>
<TI>Reducing the post-pump syndrome by using heparin-coated circuits, steroids, or aprotinin</TI>
<SO>The Thoracic and Cardiovascular Surgeon</SO>
<YR>1999</YR>
<VL>47</VL>
<NO>2</NO>
<PG>111-8</PG>
<IDENTIFIERS MODIFIED="2009-12-08 20:00:33 +0530" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="10363611"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-12-10 02:15:49 +0530" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harig F, Hohenstein B, von der Emde J, Weyand M</AU>
<TI>Modulating IL-6 and IL-10 levels by pharmacologic strategies and the impact of different extracorporeal circulation parameters during cardiac surgery</TI>
<SO>Shock (Augusta, Ga.)</SO>
<YR>2001</YR>
<VL>16 Suppl 1</VL>
<PG>33-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="11770031"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jansen-1991a" MODIFIED="2011-02-22 17:21:22 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Jansen 1991a" YEAR="1991">
<REFERENCE MODIFIED="2011-02-22 17:21:22 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jansen NJ, van Oeveren W, van den Broek L, Oudemans-van Straaten HM, Stoutenbeek CP, Joen MC, et al</AU>
<TI>Inhibition by dexamethasone of the reperfusion phenomena in cardiopulmonary bypass</TI>
<SO>The Journal of Thoracic and Cardiovascular Surgery</SO>
<YR>1991</YR>
<VL>102</VL>
<NO>4</NO>
<PG>515-25</PG>
<IDENTIFIERS MODIFIED="2009-12-08 20:00:33 +0530" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="1656149"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kilger-2003a" MODIFIED="2011-02-22 17:21:56 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Kilger 2003a" YEAR="2003">
<REFERENCE MODIFIED="2011-02-22 17:21:38 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kilger E, Weis F, Briegel J, Frey L, Goetz AE, Reuter D, et al</AU>
<TI>Stress doses of hydrocortisone reduce severe systemic inflammatory response syndrome and improve early outcome in a risk group of patients after cardiac surgery</TI>
<SO>Critical Care Medicine</SO>
<YR>2003</YR>
<VL>31</VL>
<NO>4</NO>
<PG>1068-74</PG>
<IDENTIFIERS MODIFIED="2009-12-08 20:00:33 +0530" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="12682474"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-02-22 17:21:56 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schelling G, Kilger E, Roozendaal B, de Quervain DJ, Briegel J, Dagge A, et al</AU>
<TI>Stress doses of hydrocortisone, traumatic memories, and symptoms of posttraumatic stress disorder in patients after cardiac surgery: a randomized study</TI>
<SO>Biological Psychiatry</SO>
<YR>2004</YR>
<VL>55</VL>
<NO>6</NO>
<PG>627-33</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="15013832"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kilger-2003b" MODIFIED="2011-02-22 17:22:30 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Kilger 2003b" YEAR="2003">
<REFERENCE MODIFIED="2011-02-22 17:22:30 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kilger E, Weis F, Briegel J</AU>
<TI>Einfluss von Hydrocortison auf die Klinische Entwicklung bei Operationen mit Herz-Lung-Maschine</TI>
<SO>Journal für Anästhesie</SO>
<YR>2003</YR>
<PG>135-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liakopoulos-2007" MODIFIED="2011-02-22 17:22:46 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Liakopoulos 2007" YEAR="2007">
<REFERENCE MODIFIED="2011-02-22 17:22:46 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liakopoulos OJ, Schmitto JD, Kazmaier S, Brauer A, Quintel M, Schoendube FA, et al</AU>
<TI>Cardiopulmonary and systemic effects of methylprednisolone in patients undergoing cardiac surgery</TI>
<SO>The Annals of Thoracic Surgery</SO>
<YR>2007</YR>
<VL>84</VL>
<NO>1</NO>
<PG>110-8; discussion 118-9</PG>
<IDENTIFIERS MODIFIED="2010-09-03 23:58:52 +0530" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-09-03 23:58:52 +0530" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="17588396"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Loef-2004" MODIFIED="2011-02-22 17:23:30 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Loef 2004" YEAR="2004">
<REFERENCE MODIFIED="2011-02-22 17:23:30 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Loef BG, Henning RH, Epema AH, Rietman GW, van Oeveren W, Navis GJ, et al</AU>
<TI>Effect of dexamethasone on perioperative renal function impairment during cardiac surgery with cardiopulmonary bypass</TI>
<SO>British Journal of Anaesthesia</SO>
<YR>2004</YR>
<VL>93</VL>
<NO>6</NO>
<PG>793-8</PG>
<IDENTIFIERS MODIFIED="2009-12-08 20:00:33 +0530" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="15377582"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-12-10 02:16:46 +0530" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morariu AM, Loef BG, Aarts LP, Rietman GW, Rakhorst G, van Oeveren W, et al</AU>
<TI>Dexamethasone: benefit and prejudice for patients undergoing on-pump coronary artery bypass grafting: a study on myocardial, pulmonary, renal, intestinal, and hepatic injury</TI>
<SO>Chest</SO>
<YR>2005</YR>
<VL>128</VL>
<NO>4</NO>
<PG>2677-87</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="16236942"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mayumi-1997" MODIFIED="2011-02-22 17:23:59 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Mayumi 1997" YEAR="1997">
<REFERENCE MODIFIED="2011-02-22 17:23:59 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mayumi H, Zhang QW, Nakashima A, Masuda M, Kohno H, Kawachi Y, et al</AU>
<TI>Synergistic immunosuppression caused by high-dose methylprednisolone and cardiopulmonary bypass</TI>
<SO>The Annals of Thoracic Surgery</SO>
<YR>1997</YR>
<VL>63</VL>
<NO>1</NO>
<PG>129-37</PG>
<IDENTIFIERS MODIFIED="2009-12-08 20:00:33 +0530" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="8993254"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McBride-2004" MODIFIED="2010-09-03 23:59:46 +0530" MODIFIED_BY="[Empty name]" NAME="McBride 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-09-03 23:59:46 +0530" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McBride WT, Allen S, Gormley SM, Young IS, McClean E, MacGowan SW, et al</AU>
<TI>Methylprednisolone favourably alters plasma and urinary cytokine homeostasis and subclinical renal injury at cardiac surgery</TI>
<SO>Cytokine</SO>
<YR>2004</YR>
<VL>27</VL>
<NO>2-3</NO>
<PG>81-9</PG>
<IDENTIFIERS MODIFIED="2010-09-03 23:59:46 +0530" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-09-03 23:59:46 +0530" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="15242697"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morton-1976" MODIFIED="2011-02-22 17:24:26 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Morton 1976" YEAR="1976">
<REFERENCE MODIFIED="2011-02-22 17:24:26 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morton JR, Hiebert CA, Lutes CA, White RL</AU>
<TI>Effect of methylprednisolone on myocardial preservation during coronary artery surgery</TI>
<SO>American Journal of Surgery</SO>
<YR>1976</YR>
<VL>131</VL>
<NO>4</NO>
<PG>419-22</PG>
<IDENTIFIERS MODIFIED="2010-09-04 00:00:25 +0530" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-09-04 00:00:25 +0530" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="773198"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oliver-2004" MODIFIED="2009-12-08 20:00:46 +0530" MODIFIED_BY="[Empty name]" NAME="Oliver 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-12-08 20:00:46 +0530" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oliver WC Jr, Nuttall GA, Orszulak TA, Bamlet WR, Abel MD, Ereth MH, et al</AU>
<TI>Hemofiltration but not steroids results in earlier tracheal extubation following cardiopulmonary bypass: a prospective, randomized double-blind trial</TI>
<SO>Anesthesiology</SO>
<YR>2004</YR>
<VL>101</VL>
<NO>2</NO>
<PG>327-39</PG>
<IDENTIFIERS MODIFIED="2009-12-08 20:00:33 +0530" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="15277915"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Prasongsukarn-2005" MODIFIED="2011-02-22 17:24:55 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Prasongsukarn 2005" YEAR="2005">
<REFERENCE MODIFIED="2011-02-22 17:24:55 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Prasongsukarn K, Abel JG, Jamieson WR, Cheung A, Russell JA, Walley KR, et al</AU>
<TI>The effects of steroids on the occurrence of postoperative atrial fibrillation after coronary artery bypass grafting surgery: a prospective randomized trial</TI>
<SO>The Journal of Thoracic and Cardiovascular Surgery</SO>
<YR>2005</YR>
<VL>130</VL>
<NO>1</NO>
<PG>93-8</PG>
<IDENTIFIERS MODIFIED="2009-12-08 20:00:33 +0530" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="15999046"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rao-1977" MODIFIED="2011-02-22 17:25:03 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Rao 1977" YEAR="1977">
<REFERENCE MODIFIED="2011-02-22 17:25:03 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rao G, King J, Ford W, King G</AU>
<TI>The effects of methylprednisolone on the complications of coronary artery surgery</TI>
<SO>Vascular Surgery</SO>
<YR>1977</YR>
<VL>11</VL>
<NO>1</NO>
<PG>1-7</PG>
<IDENTIFIERS MODIFIED="2009-12-08 20:00:33 +0530" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="308283"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rubens-2005" MODIFIED="2011-02-22 17:25:19 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Rubens 2005" YEAR="2005">
<REFERENCE MODIFIED="2011-02-22 17:25:19 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rubens FD, Nathan H, Labow R, Williams KS, Wozny D, Karsh J, et al</AU>
<TI>Effects of methylprednisolone and a biocompatible copolymer circuit on blood activation during cardiopulmonary bypass</TI>
<SO>The Annals of Thoracic Surgery</SO>
<YR>2005</YR>
<VL>79</VL>
<NO>2</NO>
<PG>655-65</PG>
<IDENTIFIERS MODIFIED="2009-12-08 20:00:33 +0530" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="15680854"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rumalla-2001" MODIFIED="2011-02-22 17:25:42 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Rumalla 2001" YEAR="2001">
<REFERENCE MODIFIED="2011-02-22 17:25:42 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rumalla V, Calvano SE, Spotnitz AJ, Krause TJ, Lin E, Lowry SF</AU>
<TI>The effects of glucocorticoid therapy on inflammatory responses to coronary artery bypass graft surgery</TI>
<SO>Archives of Surgery (Chicago, Ill.: 1960)</SO>
<YR>2001</YR>
<VL>136</VL>
<NO>9</NO>
<PG>1039-44</PG>
<IDENTIFIERS MODIFIED="2009-12-08 20:00:33 +0530" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="11529827"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sano-2003" MODIFIED="2011-02-22 17:26:05 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Sano 2003" YEAR="2003">
<REFERENCE MODIFIED="2011-02-22 17:26:05 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sano T, Morita S, Masuda M, Tomita Y, Nishida T, Tatewaki H, et al</AU>
<TI>Cardiopulmonary bypass, steroid administration, and surgical injury synergistically impair memory T cell function and antigen presentation</TI>
<SO>Interactive Cardiovascular and Thoracic Surgery</SO>
<YR>2003</YR>
<VL>2</VL>
<NO>4</NO>
<PG>598-602</PG>
<IDENTIFIERS MODIFIED="2009-12-08 20:00:33 +0530" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="17670133"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sano-2006" MODIFIED="2011-02-22 17:26:21 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Sano 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-02-22 17:26:21 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sano T, Morita S, Masuda M, Yasui H</AU>
<TI>Minor infection encouraged by steroid administration during cardiac surgery</TI>
<SO>Asian Cardiovascular &amp; Thoracic Annals</SO>
<YR>2006</YR>
<VL>14</VL>
<NO>6</NO>
<PG>505-10</PG>
<IDENTIFIERS MODIFIED="2009-12-08 20:00:33 +0530" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="17130328"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schurr-2001" MODIFIED="2011-02-22 17:26:40 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Schurr 2001" YEAR="2001">
<REFERENCE MODIFIED="2011-02-22 17:26:40 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schurr UP, Zund G, Hoerstrup SP, Grunenfelder J, Maly FE, Vogt PR, et al</AU>
<TI>Preoperative administration of steroids: influence on adhesion molecules and cytokines after cardiopulmonary bypass</TI>
<SO>The Annals of Thoracic Surgery</SO>
<YR>2001</YR>
<VL>72</VL>
<NO>4</NO>
<PG>1316-20</PG>
<IDENTIFIERS MODIFIED="2009-12-08 20:00:33 +0530" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="11603453"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sobieski-2008" MODIFIED="2011-02-22 17:26:56 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Sobieski 2008" YEAR="2008">
<REFERENCE MODIFIED="2011-02-22 17:26:56 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sobieski MA, Graham JD, Pappas PS, Tatooles AJ, Slaughter MS</AU>
<TI>Reducing the effects of the systemic inflammatory response to cardiopulmonary bypass: can single dose steroids blunt systemic inflammatory response syndrome?</TI>
<SO>ASAIO Journal</SO>
<YR>2008</YR>
<VL>54</VL>
<PG>203-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Starobin-2007" MODIFIED="2011-02-22 17:27:14 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Starobin 2007" YEAR="2007">
<REFERENCE MODIFIED="2011-02-22 17:27:14 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Starobin D, Rehuven Kramer M, Garty M, Shitirt D</AU>
<TI>Morbidity associated with systemic corticosteroid preparation for coronary artery bypass grafting in patients with chronic obstructive pulmonary disease: a case control study</TI>
<SO>Journal of Cardiothoracic Surgery</SO>
<YR>2007</YR>
<VL>2</VL>
<PG>25</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tassani-1999" MODIFIED="2011-02-22 17:27:34 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Tassani 1999" YEAR="1999">
<REFERENCE MODIFIED="2011-02-22 17:27:34 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tassani P, Richter JA, Barankay A, Braun SL, Haehnel C, Spaeth P, et al</AU>
<TI>Does high-dose methylprednisolone in aprotinin-treated patients attenuate the systemic inflammatory response during coronary artery bypass grafting procedures?</TI>
<SO>Journal of Cardiothoracic and Vascular Anesthesia</SO>
<YR>1999</YR>
<VL>13</VL>
<NO>2</NO>
<PG>165-72</PG>
<IDENTIFIERS MODIFIED="2009-12-08 20:00:33 +0530" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="10230950"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Toft-1997" MODIFIED="2011-02-22 19:00:04 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Toft 1997" YEAR="1997">
<REFERENCE MODIFIED="2011-02-22 19:00:04 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Toft P, Christiansen K, Tonnesen E, Nielsen CH, Lillevang S</AU>
<TI>Effect of methylprednisolone on the oxidative burst activity, adhesion molecules and clinical outcome following open heart surgery</TI>
<SO>Scandinavian Cardiovascular Journal</SO>
<YR>1997</YR>
<VL>31</VL>
<NO>5</NO>
<PG>283-8</PG>
<IDENTIFIERS MODIFIED="2009-12-08 20:00:33 +0530" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="9406295"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Turkoz-2001" MODIFIED="2011-02-22 19:00:24 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Turkoz 2001" YEAR="2001">
<REFERENCE MODIFIED="2011-02-22 19:00:24 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Turkoz A, Cigli A, But K, Sezgin N, Turkoz R, Gulcan O, et al</AU>
<TI>The effects of aprotinin and steroids on generation of cytokines during coronary artery surgery</TI>
<SO>Journal of Cardiothoracic and Vascular Anesthesia</SO>
<YR>2001</YR>
<VL>15</VL>
<NO>5</NO>
<PG>603-10</PG>
<IDENTIFIERS MODIFIED="2009-12-08 20:00:33 +0530" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="11688002"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Volk-2001" MODIFIED="2011-02-22 19:00:38 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Volk 2001" YEAR="2001">
<REFERENCE MODIFIED="2011-02-22 19:00:38 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Volk T, Schmutzler M, Engelhardt L, Docke WD, Volk HD, Konertz W, et al</AU>
<TI>Influence of aminosteroid and glucocorticoid treatment on inflammation and immune function during cardiopulmonary bypass</TI>
<SO>Critical Care Medicine</SO>
<YR>2001</YR>
<VL>29</VL>
<NO>11</NO>
<PG>2137-42</PG>
<IDENTIFIERS MODIFIED="2009-12-08 20:00:33 +0530" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="11700410"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Volk-2003" MODIFIED="2011-02-22 19:00:58 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Volk 2003" YEAR="2003">
<REFERENCE MODIFIED="2011-02-22 19:00:58 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Volk T, Schmutzler M, Engelhardt L, Pantke U, Laule M, Stangl K, et al</AU>
<TI>Effects of different steroid treatment on reperfusion-associated production of reactive oxygen species and arrhythmias during coronary surgery</TI>
<SO>Acta Anaesthesiologica Scandinavica</SO>
<YR>2003</YR>
<VL>47</VL>
<NO>6</NO>
<PG>667-74</PG>
<IDENTIFIERS MODIFIED="2009-12-08 20:00:33 +0530" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="12803583"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-von-Spiegel-2001" MODIFIED="2011-02-22 19:01:53 +0530" MODIFIED_BY="Nicole Ackermann" NAME="von Spiegel 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-12-10 02:18:36 +0530" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>von Spiegel T, Giannaris S, Wietasch GJ, Schroeder S, Buhre W, Schorn B, et al</AU>
<TI>Effects of dexamethasone on intravascular and extravascular fluid balance in patients undergoing coronary bypass surgery with cardiopulmonary bypass</TI>
<SO>Anesthesiology</SO>
<YR>2002</YR>
<VL>96</VL>
<NO>4</NO>
<PG>827-34</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="11964588"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-02-22 19:01:53 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>von Spiegel T, Giannaris S, Wrigge H, Schorn B, Hoeft A</AU>
<TI>Effects of dexamethasone on extravascular lung water and pulmonary haemodynamics in patients undergoing coronary artery bypass surgery</TI>
<TO>Einfluss einer präoperativen Dexamethasongabe auf das extravaskulare Lungenwasser und die pulmonale Hämodynamik bei koronarchirurgischen Patienten</TO>
<SO>Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie</SO>
<YR>2001</YR>
<VL>36</VL>
<NO>9</NO>
<PG>545-51</PG>
<IDENTIFIERS MODIFIED="2009-12-08 20:00:33 +0530" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="11577353"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wan-1999" MODIFIED="2011-02-22 19:02:18 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Wan 1999" YEAR="1999">
<REFERENCE MODIFIED="2011-02-22 19:02:18 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wan S, LeClerc JL, Huynh CH, Schmartz D, DeSmet JM, Yim AP, et al</AU>
<TI>Does steroid pretreatment increase endotoxin release during clinical cardiopulmonary bypass?</TI>
<SO>The Journal of Thoracic and Cardiovascular Surgery</SO>
<YR>1999</YR>
<VL>117</VL>
<NO>5</NO>
<PG>1004-8</PG>
<IDENTIFIERS MODIFIED="2009-12-08 20:00:33 +0530" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="10220696"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weis-2006" MODIFIED="2011-02-22 19:05:06 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Weis 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-02-22 19:05:06 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weis F, Kilger E, Roozendaal B, de Quervain DJ, Lamm P, Schmidt M, et al</AU>
<TI>Stress doses of hydrocortisone reduce chronic stress symptoms and improve health-related quality of life in high-risk patients after cardiac surgery: a randomized study</TI>
<SO>The Journal of Thoracic and Cardiovascular Surgery</SO>
<YR>2006</YR>
<VL>131</VL>
<NO>2</NO>
<PG>277-82</PG>
<IDENTIFIERS MODIFIED="2009-12-08 20:00:33 +0530" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="16434254"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weis-2009" MODIFIED="2010-01-20 16:52:25 +0530" MODIFIED_BY="[Empty name]" NAME="Weis 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-01-20 16:52:25 +0530" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weis F, Beiras-Fernandez A, Schelling G, Briegel J, Lang P, Hauer D, Kreth S, Kaufmann IK, Lamm P, Kilger E</AU>
<TI>Stress doses of hydrocortisone in high-risk patients undergoing cardiac surgery: Effects on interleukin-6 to interleukin-10 ratio and early outcome</TI>
<SO>Critical Care Medicine</SO>
<YR>2009</YR>
<VL>37</VL>
<NO>5</NO>
<PG>1685-1690</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-01-20 16:51:53 +0530" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Whitlock-2006" MODIFIED="2011-02-22 19:08:23 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Whitlock 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-02-22 19:08:23 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Whitlock RP, Young E, Noora J, Farrokhyar F, Blackall M, Teoh KH</AU>
<TI>Pulse low dose steroids attenuate post-cardiopulmonary bypass SIRS; SIRS I</TI>
<SO>The Journal of Surgical Research</SO>
<YR>2006</YR>
<VL>132</VL>
<NO>2</NO>
<PG>188-94</PG>
<IDENTIFIERS MODIFIED="2009-12-08 20:00:33 +0530" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="16566943"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yared-1998" MODIFIED="2011-02-22 19:09:11 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Yared 1998" YEAR="1998">
<REFERENCE MODIFIED="2011-02-22 19:08:34 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yared JP, Starr NJ, Hoffmann-Hogg L, Bashour CA, Insler SR, O'Connor M, et al</AU>
<TI>Dexamethasone decreases the incidence of shivering after cardiac surgery: a randomized, double-blind, placebo-controlled study</TI>
<SO>Anesthesia and Analgesia</SO>
<YR>1998</YR>
<VL>87</VL>
<NO>4</NO>
<PG>795-9</PG>
<IDENTIFIERS MODIFIED="2009-12-08 20:00:33 +0530" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="9768772"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-02-22 19:09:11 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yared JP, Starr NJ, Torres FK, Bashour CA, Bourdakos G, Piedmonte M, et al</AU>
<TI>Effects of single dose, postinduction dexamethasone on recovery after cardiac surgery</TI>
<SO>The Annals of Thoracic Surgery</SO>
<YR>2000</YR>
<VL>69</VL>
<NO>5</NO>
<PG>1420-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="10881816"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yared-2007" MODIFIED="2011-02-22 19:08:48 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Yared 2007" YEAR="2007">
<REFERENCE MODIFIED="2011-02-22 19:08:48 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yared JP, Bakri MH, Erzurum SC, Moravec CS, Laskowski DM, Van Wagoner DR, et al</AU>
<TI>Effect of dexamethasone on atrial fibrillation after cardiac surgery: prospective, randomized, double-blind, placebo-controlled trial</TI>
<SO>Journal of Cardiothoracic and Vascular Anesthesia</SO>
<YR>2007</YR>
<VL>21</VL>
<NO>1</NO>
<PG>68-75</PG>
<IDENTIFIERS MODIFIED="2009-12-08 20:00:33 +0530" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="17289483"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yilmaz-1999" MODIFIED="2009-12-08 20:00:46 +0530" MODIFIED_BY="[Empty name]" NAME="Yilmaz 1999" YEAR="1999">
<REFERENCE MODIFIED="2009-12-08 20:00:46 +0530" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yilmaz M, Ener S, Akalin H, Sagdic K, Serdar OA, Cengiz M</AU>
<TI>Effect of low-dose methyl prednisolone on serum cytokine levels following extracorporeal circulation</TI>
<SO>Perfusion</SO>
<YR>1999</YR>
<VL>14</VL>
<NO>3</NO>
<PG>201-6</PG>
<IDENTIFIERS MODIFIED="2009-12-08 20:00:33 +0530" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="10411250"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2011-03-30 15:40:04 +0530" MODIFIED_BY="Nicole Ackermann">
<STUDY DATA_SOURCE="PUB" ID="STD-Anic-2004" MODIFIED="2011-02-22 19:10:30 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Anic 2004" YEAR="2004">
<REFERENCE MODIFIED="2011-02-22 19:10:30 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anic D, Ga&#353;parovic H, Ivanèan H, Batinic D</AU>
<TI>Effects of corticosteroids on inflammatory response following cardiopulmonary bypass</TI>
<SO>Croatian Medical Journal</SO>
<YR>2004</YR>
<VL>45</VL>
<PG>158-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Augoustides-2007" MODIFIED="2011-02-22 19:10:49 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Augoustides 2007" YEAR="2007">
<REFERENCE MODIFIED="2011-02-22 19:10:49 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Augoustides JGT</AU>
<TI>Use of corticosteroids to prevent atrial fibrillation after cardiac surgery</TI>
<SO>Journal of the American Medical Association</SO>
<YR>2007</YR>
<VL>298</VL>
<NO>3</NO>
<PG>283</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Baker-2007" MODIFIED="2010-08-30 16:33:18 +0530" MODIFIED_BY="[Empty name]" NAME="Baker 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-08-30 16:33:17 +0530" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baker WL, White CM</AU>
<TI>Effect of perioperative corticosteroid use on the incidence of postcardiothoracic surgery atrial fibrillation and length of stay</TI>
<SO>Heart Rhythm</SO>
<YR>2007</YR>
<VL>4</VL>
<NO>4</NO>
<PG>461-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Baraka-1995" MODIFIED="2011-02-22 19:12:50 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Baraka 1995" YEAR="1995">
<REFERENCE MODIFIED="2011-02-22 19:12:50 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baraka A, Choueiry P, Taha S, Yazbeck V, Chidiac G, Azar IA, et al</AU>
<TI>Hydrocortisone pretreatment for attenuation of protamine-induced adverse hemodynamic reactions</TI>
<SO>Journal of Cardiothoracic and Vascular Anesthesia</SO>
<YR>1995</YR>
<VL>9</VL>
<NO>4</NO>
<PG>481-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Biagioli-1981" MODIFIED="2011-02-22 19:14:58 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Biagioli 1981" YEAR="1981">
<REFERENCE MODIFIED="2011-02-22 19:14:58 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Biagioli B, Rossi C, Giomarelli PP, Pescatori G, Barbini P, Grossi A</AU>
<TI>Correlations between membrane and bubble oxygenators in patients treated with or without methylprednisolone. Haemodynamic and metabolic parameters</TI>
<SO>Giornale Italiano di Cardiologia</SO>
<YR>1981</YR>
<VL>11</VL>
<NO>9</NO>
<PG>1288-300</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boldt-1986" MODIFIED="2010-08-27 02:00:17 +0530" MODIFIED_BY="[Empty name]" NAME="Boldt 1986" YEAR="1986">
<REFERENCE MODIFIED="2010-08-27 02:00:16 +0530" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boldt J, von Bormann B, Kling D, Jooss D, Moosdorf R, Hempelmann G</AU>
<TI>Effect of glucocorticoids on extravascular lung water following extra-corporeal circulation</TI>
<SO>Anaesthesist</SO>
<YR>1986</YR>
<VL>35</VL>
<NO>4</NO>
<PG>238-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chaney-1999" MODIFIED="2011-01-05 19:16:06 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Chaney 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-08-30 18:51:15 +0530" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chaney MA, Nikolov MP</AU>
<TI>Methylprednisolone and the systemic inflammatory response syndrome</TI>
<SO>Anesthesia &amp; Analgesia</SO>
<YR>1999</YR>
<VL>89</VL>
<NO>5</NO>
<PG>1333</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Coffin-1975" MODIFIED="2010-08-30 15:34:02 +0530" MODIFIED_BY="[Empty name]" NAME="Coffin 1975" YEAR="1975">
<REFERENCE MODIFIED="2010-08-30 15:34:02 +0530" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Coffin LH, Shinozaki T, DeMeules JE, Browdie DA, Deane RS, Morgan JG</AU>
<TI>Ineffectiveness of methylprednisolone in the treatment of pulmonary dysfunction after cardiopulmonary bypass</TI>
<SO>American Journal of Surgery</SO>
<YR>1975</YR>
<VL>130</VL>
<NO>5</NO>
<PG>555-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Coraim-1987" MODIFIED="2010-08-27 01:56:21 +0530" MODIFIED_BY="[Empty name]" NAME="Coraim 1987" YEAR="1987">
<REFERENCE MODIFIED="2010-08-27 01:56:21 +0530" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Coraim FI, Laufer G, Ilias W, Wollenek G, Wolner E</AU>
<TI>Release of myocardial depressant factor (MDF) during cardiopulmonary bypass (CPB): influence of corticosteroids (methylprednisolone) and protease inhibitor (aprotinin)</TI>
<SO>First Vienna Shock Forum</SO>
<YR>1987</YR>
<VL>Part A</VL>
<PG>611-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Corbi-2001" MODIFIED="2010-08-30 18:50:09 +0530" MODIFIED_BY="[Empty name]" NAME="Corbi 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-08-30 18:50:09 +0530" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Corbi PJ, Rahmati M, Lecron JC</AU>
<TI>Inflammatory response associated with cardiopulmonary bypass and effect of methylprednisolone</TI>
<SO>Journal of Thoracic &amp; Cardiovascular Surgery</SO>
<YR>2001</YR>
<VL>122</VL>
<NO>5</NO>
<PG>1052-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dernek-1999" MODIFIED="2011-02-22 19:16:15 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Dernek 1999" YEAR="1999">
<REFERENCE MODIFIED="2011-02-22 19:16:15 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dernek S, Tunerir B, Sevin B, Aslan R, Uyguc O, Kural T</AU>
<TI>The effects of methylprednisolone on complement, immunoglobulins and pulmonary neutrophil sequestration during cardiopulmonary bypass</TI>
<SO>Cardiovascular Surgery</SO>
<YR>1999</YR>
<VL>7</VL>
<NO>4</NO>
<PG>414-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Diego-1997" MODIFIED="2011-02-22 19:17:19 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Diego 1997" YEAR="1997">
<REFERENCE MODIFIED="2011-02-22 19:17:19 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Diego RP, Mihalakakos PJ, Hexum TD, Hill GE</AU>
<TI>Methylprednisolone and full-dose aprotinin reduces reperfusion injury after cardiopulmonary bypass</TI>
<SO>Journal of Cardiothoracic and Vascular Anesthesia</SO>
<YR>1997</YR>
<VL>11</VL>
<NO>1</NO>
<PG>29-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-El-Busto-Osacar-1977" MODIFIED="2011-02-22 19:19:18 +0530" MODIFIED_BY="Nicole Ackermann" NAME="El Busto Osacar 1977" YEAR="1977">
<REFERENCE MODIFIED="2011-02-22 19:19:18 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>El Busto Osacar JJ, Toran Monserrat I, Perez Reiner R, Gonzalez Esparza L, Arroyo Carreras JL</AU>
<TI>Sympathetic-suprarenal response in extracorporeal circulation. Effects of high-dose corticotherapy</TI>
<SO>Revista Espanola de Anestesiologia y Reanimacion</SO>
<YR>1977</YR>
<VL>24</VL>
<NO>3</NO>
<PG>223-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-El-Busto-Osacar-1979" MODIFIED="2010-08-30 18:49:12 +0530" MODIFIED_BY="[Empty name]" NAME="El Busto Osacar 1979" YEAR="1979">
<REFERENCE MODIFIED="2010-08-30 18:49:12 +0530" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Busto Osacar JJ, Toran M, I, Carrascosa MF, Gonzalez EL, Medina EJ, Pezonaga PL et al</AU>
<TI>Evolution of renal function in open heart surgery with glucosaline hypertonic hemodilution. Effect of methylprednisolone administration</TI>
<SO>Revista Espanola de Anestesiologia y Reanimacion</SO>
<YR>1979</YR>
<VL>26</VL>
<NO>4</NO>
<PG>367-78</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Enderby-1987" MODIFIED="2010-08-27 02:15:22 +0530" MODIFIED_BY="[Empty name]" NAME="Enderby 1987" YEAR="1987">
<REFERENCE MODIFIED="2010-08-27 02:15:21 +0530" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Enderby DH, Boylett A, Parker DJ</AU>
<TI>Methyl prednisolone and lung function after cardiopulmonary bypass</TI>
<SO>Thorax</SO>
<YR>1979</YR>
<VL>34</VL>
<NO>6</NO>
<PG>720-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Erel-1994" MODIFIED="2011-03-30 15:39:27 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Erel 1994" YEAR="1994">
<REFERENCE MODIFIED="2011-03-30 15:39:27 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Erel L, Askar FZ, Certug A, Okur F, Sebik F</AU>
<TI>Complement activation during cardiopulmonary bypass and effect of preoperative corticosteroid administration</TI>
<SO>Türk Anesteziyoloji ve Reanimasyon Cemiyeti mecmuasi</SO>
<YR>1994</YR>
<VL>22</VL>
<PG>265-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fecht-1978" MODIFIED="2010-08-30 16:10:38 +0530" MODIFIED_BY="[Empty name]" NAME="Fecht 1978" YEAR="1978">
<REFERENCE MODIFIED="2010-08-30 15:30:15 +0530" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fecht DC, Magovern GJ, Park SB, Merkow LP, Dixon CM, Dosios T et al</AU>
<TI>Beneficial effects of methylprednisolone in patients on cardiopulmonary bypass</TI>
<SO>Circulatory Shock</SO>
<YR>1978</YR>
<VL>5</VL>
<NO>4</NO>
<PG>415-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fosse-1987" MODIFIED="2011-02-22 19:28:10 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Fosse 1987" YEAR="1987">
<REFERENCE MODIFIED="2011-02-22 19:28:10 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fosse E, Mollnes TE, Osterud A, Aasen AO</AU>
<TI>Effects of methylprednisolone on complement activation and leukocyte counts during cardiopulmonary bypass</TI>
<SO>Scandinavian Journal of Thoracic and Cardiovascular Surgery</SO>
<YR>1987</YR>
<VL>21</VL>
<NO>3</NO>
<PG>255-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Giannaris-1997" MODIFIED="2011-02-22 19:31:33 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Giannaris 1997" YEAR="1997">
<REFERENCE MODIFIED="2011-02-22 19:31:33 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Giannaris S, Schorn B, Wietasch G, Scholtz M, Buhre W, Weyland A, et al</AU>
<TI>Effects of dexamethasone on oedema formation in patients undergoing coronary bypass surgery</TI>
<SO>British Journal of Anaesthesia</SO>
<YR>1997</YR>
<VL>78</VL>
<PG>A23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gott-1998" MODIFIED="2011-02-22 19:32:10 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Gott 1998" YEAR="1998">
<REFERENCE MODIFIED="2011-02-22 19:32:10 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gott JP, Cooper WA, Schmidt FE, Brown III WM, Wright CE, Merlino JD, et al</AU>
<TI>Modifying risk for extracorporeal circulation: trial of four antiinflammatory strategies</TI>
<SO>Annals of Thoracic Surgery</SO>
<YR>1998</YR>
<VL>66</VL>
<PG>747-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gupta-1998" MODIFIED="2011-02-22 19:33:34 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Gupta 1998" YEAR="1998">
<REFERENCE MODIFIED="2011-02-22 19:33:34 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gupta R, Tandon R, Thrall R, Lahiri B, Chawla S</AU>
<TI>Methylprednisolone suppresses upregulation of neutrophil adhesion molecule expression in cardiopulmonary bypass patients</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>1998</YR>
<VL>157</VL>
<NO>3 Suppl</NO>
<PG>A690</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Halonen-2008" MODIFIED="2010-08-30 16:54:51 +0530" MODIFIED_BY="[Empty name]" NAME="Halonen 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-08-30 16:54:49 +0530" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Halonen J, Hakala T, Hartikainen J</AU>
<TI>Can corticosteroids prevent atrial fibrillation after cardiac surgery?</TI>
<SO>Cardiology Review</SO>
<YR>2008</YR>
<VL>25</VL>
<NO>3</NO>
<PG>37-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hill-1994" MODIFIED="2011-02-22 19:34:13 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Hill 1994" YEAR="1994">
<REFERENCE MODIFIED="2011-02-22 19:34:13 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hill GE, Alonso A, Thiele GM, Robbins RA</AU>
<TI>Glucocorticoids blunt neutrophil CD11b surface glycoprotein upregulation during cardiopulmonary bypass in humans</TI>
<SO>Anesthesia and Analgesia</SO>
<YR>1994</YR>
<VL>79</VL>
<NO>1</NO>
<PG>23-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hill-1995a" MODIFIED="2011-02-22 19:34:37 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Hill 1995a" YEAR="1995">
<REFERENCE MODIFIED="2011-02-22 19:34:37 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hill GE, Alonso A, Spurzem JR, Stammers AH, Robbins RA</AU>
<TI>Aprotinin and methylprednisolone equally blunt cardiopulmonary bypass-induced inflammation in humans</TI>
<SO>Journal of Thoracic and Cardiovascular Surgery</SO>
<YR>1995</YR>
<VL>110</VL>
<PG>1658-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hill-1995b" MODIFIED="2011-02-22 19:36:03 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Hill 1995b" YEAR="">
<REFERENCE MODIFIED="2011-02-22 19:36:03 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hill GE, Snider S, Galbraith TA, Forst F, Robbins RA</AU>
<TI>Glucocorticoid reduction of bronchial epithelial inflammation during cardiopulmonary bypass</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>1995</YR>
<VL>152</VL>
<PG>1791-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hoche-1995" MODIFIED="2011-02-22 19:36:41 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Hoche 1995" YEAR="1995">
<REFERENCE MODIFIED="2011-02-22 19:36:41 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hoche A, Schlapp U, Riedel W, Klovekorn WP, Karliczek G</AU>
<TI>Effects of dexamethasone on release of endotoxin, ACTH and cortisol during hypothermic cardiopulmonary bypass</TI>
<SO>British Journal of Anaesthesia</SO>
<YR>1995</YR>
<VL>74</VL>
<PG>A75</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hoche-1997" MODIFIED="2011-02-22 19:37:00 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Hoche 1997" YEAR="1997">
<REFERENCE MODIFIED="2011-02-22 19:37:00 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hoche A, Phillipp E, Riedel W, Karliczek G</AU>
<TI>Effects of dexamethasone on release of endotoxin and cytokines during hypothermic cardiopulmonary bypass</TI>
<SO>British Journal of Anaesthesia</SO>
<YR>1997</YR>
<VL>78</VL>
<PG>A24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Husedzinovic-1998" MODIFIED="2011-02-22 19:37:19 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Husedzinovic 1998" YEAR="1998">
<REFERENCE MODIFIED="2011-02-22 19:37:19 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Husedzinovic I, Tonkovic D, Kurosic A, Romic Z, Biocina B, Poljak-Blazi M</AU>
<TI>Free iron and transport protein values during administration of dexamethasone in cardiac surgery patients</TI>
<SO>British Journal of Anaesthesia</SO>
<YR>1998</YR>
<VL>80</VL>
<PG>A12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Inaba-1994" MODIFIED="2011-02-22 19:37:37 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Inaba 1994" YEAR="1994">
<REFERENCE MODIFIED="2011-02-22 19:37:37 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Inaba H, Kochi A, Yorozu S</AU>
<TI>Suppression by methylprednisolone of augmented plasma endotoxin-like activity and interleukin-6 during cardiopulmonary bypass</TI>
<SO>British Journal of Anaesthesia</SO>
<YR>1994</YR>
<VL>72</VL>
<NO>3</NO>
<PG>348-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jahangiri-2008" MODIFIED="2011-02-22 19:38:14 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Jahangiri 2008" YEAR="2008">
<REFERENCE MODIFIED="2011-02-22 19:38:14 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jahangiri M, Camm AJ</AU>
<TI>Do corticosteroids prevent atrial fibrillation after cardiac surgery?</TI>
<SO>Nature Clinical Practice. Cardiovascular Medicine</SO>
<YR>2007</YR>
<VL>4</VL>
<NO>11</NO>
<PG>592-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Janower-2007" MODIFIED="2011-02-22 19:38:47 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Janower 2007" YEAR="2007">
<REFERENCE MODIFIED="2011-02-22 19:38:47 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Janower S</AU>
<TI>Corticosteroids for the prevention of atrial fibrillation after cardiac surgery</TI>
<SO>Medecine Therapeutique Cardio</SO>
<YR>2007</YR>
<VL>3</VL>
<NO>4</NO>
<PG>279-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jansen-1991b" MODIFIED="2011-02-22 19:39:30 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Jansen 1991b" YEAR="">
<REFERENCE MODIFIED="2011-02-22 19:39:30 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jansen NJ, van Oeveren W, van Vliet M, Stoutenbeek CP, Eysman L, Wildevuur CR</AU>
<TI>The role of different types of corticosteroids on the inflammatory mediators in cardiopulmonary bypass</TI>
<SO>European Journal of Cardio-thoracic Surgery</SO>
<YR>1991</YR>
<VL>5</VL>
<NO>4</NO>
<PG>211-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jorens-1993" MODIFIED="2011-02-22 19:40:21 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Jorens 1993" YEAR="1993">
<REFERENCE MODIFIED="2011-02-22 19:40:21 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jorens PG, De Jongh R, De Backer W, Van Damme J, Van Overveld F, Bossaert L, et al</AU>
<TI>Interleukin-8 production in patients undergoing cardiopulmonary bypass. The influence of pretreatment with methylprednisolone</TI>
<SO>American Review of Respiratory Disease</SO>
<YR>1993</YR>
<VL>148</VL>
<NO>4 Pt 1</NO>
<PG>890-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Juneja-2000" MODIFIED="2011-02-22 19:40:36 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Juneja 2000" YEAR="2000">
<REFERENCE MODIFIED="2011-02-22 19:40:36 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Juneja R, Dhar A, Raizada A, Mehta Y, Trehan N</AU>
<TI>Methylprednisolone-immunomodulation and outcome following CPB</TI>
<SO>British Journal of Anaesthesia</SO>
<YR>2000</YR>
<VL>84</VL>
<PG>A18</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Karlstad-1993" MODIFIED="2011-02-22 19:41:11 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Karlstad 1993" YEAR="1993">
<REFERENCE MODIFIED="2011-02-22 19:41:11 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Karlstad MD, Patteson SK, Guszcza JA, Langdon R, Chesney JT</AU>
<TI>Methylprednisolone does not influence endotoxin translocation during cardiopulmonary bypass</TI>
<SO>Journal of Cardiothoracic and Vascular Anesthesia</SO>
<YR>1993</YR>
<VL>7</VL>
<NO>1</NO>
<PG>23-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kawamura-1995" MODIFIED="2011-02-22 19:41:44 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Kawamura 1995" YEAR="1995">
<REFERENCE MODIFIED="2011-02-22 19:41:44 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kawamura T, Inada K, Okada H, Okada K, Wakusawa R</AU>
<TI>Methylprednisolone inhibits increase of interleukin 8 and 6 during open heart surgery</TI>
<SO>Canadian Journal of Anaesthesia</SO>
<YR>1995</YR>
<VL>42</VL>
<NO>5 pt 1</NO>
<PG>399-403</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kawamura-1999" MODIFIED="2011-02-22 19:41:57 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Kawamura 1999" YEAR="1999">
<REFERENCE MODIFIED="2011-02-22 19:41:57 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kawamura T, Inada K, Nara N, Wakusawa R, Endo S</AU>
<TI>Influence of methylprednisolone on cytokine balance during cardiac surgery</TI>
<SO>Critical Care Medicine</SO>
<YR>1999</YR>
<VL>27</VL>
<NO>3</NO>
<PG>545-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kilger-2007" MODIFIED="2010-08-30 17:19:41 +0530" MODIFIED_BY="[Empty name]" NAME="Kilger 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-08-30 17:19:40 +0530" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kilger E, Weis F, Briegel J</AU>
<TI>Why are corticosteroids still considered controversial in the setting of cardiopulmonary bypass?</TI>
<SO>Applied Cardiopulmonary Pathophysiology</SO>
<YR>2007</YR>
<VL>11</VL>
<NO>2</NO>
<PG>14-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kilickan-2008" MODIFIED="2011-02-22 19:42:25 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Kilickan 2008" YEAR="2008">
<REFERENCE MODIFIED="2011-02-22 19:42:25 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kilickan L, Yumuk Z, Bayindir O</AU>
<TI>The effect of combined preinduction thoracic epidural anaesthesia and glucocorticoid administration on perioperative interleukin-10 levels and hyperglycemia. A randomized controlled trial</TI>
<SO>The Journal of Cardiovascular Surgery</SO>
<YR>2008</YR>
<VL>49</VL>
<NO>1</NO>
<PG>87-93</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="18212693"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kirsh-1979" MODIFIED="2011-02-22 19:43:08 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Kirsh 1979" YEAR="1979">
<REFERENCE MODIFIED="2011-02-22 19:43:08 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kirsh MM, Behrendt DM, Jochim KE</AU>
<TI>Effects of methylprednisolone in cardioplegic solution during coronary bypass grafting</TI>
<SO>Journal of Thoracic and Cardiovascular Surgery</SO>
<YR>1979</YR>
<VL>77</VL>
<NO>6</NO>
<PG>896-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kito-1980" MODIFIED="2011-02-22 19:43:19 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Kito 1980" YEAR="1980">
<REFERENCE MODIFIED="2011-02-22 19:43:19 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kito Y, Fujita T, Naito Y, Koyanagi H, Obara K, Kosakai Y, et al</AU>
<TI>The effects of methylprednisolone on myocardial protection during open heart surgery</TI>
<SO>Kyobu Geka</SO>
<YR>1980</YR>
<VL>33</VL>
<NO>8</NO>
<PG>587-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kobayashi-1996" MODIFIED="2010-08-30 16:00:03 +0530" MODIFIED_BY="[Empty name]" NAME="Kobayashi 1996" YEAR="1996">
<REFERENCE MODIFIED="2010-08-30 16:00:02 +0530" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kobayashi N</AU>
<TI>The circulatory and respiratory effects of methylprednisolone associated with catecholamine undergoing open heart surgery</TI>
<SO>Tokyo Joshi Ikadaigaku Zasshi</SO>
<YR>1996</YR>
<VL>66</VL>
<PG>1-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Launo-1990" MODIFIED="2011-02-22 19:43:54 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Launo 1990" YEAR="1990">
<REFERENCE MODIFIED="2011-02-22 19:43:54 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Launo C, Palermo S, Gobbi GC, Fumagalli C, Federici E, Moroni G</AU>
<TI>Methylprednisolone sodium succinate in the profile of respiratory complications after thoracic surgical intervention</TI>
<SO>Minerva Anestesiologica</SO>
<YR>1990</YR>
<VL>56</VL>
<NO>6</NO>
<PG>219-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lee-2005" MODIFIED="2011-02-22 19:44:39 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Lee 2005" YEAR="2005">
<REFERENCE MODIFIED="2011-02-22 19:44:39 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lee HS, Lee JM, Kim MS, Kim HY, Hwangbo B, Zo JI</AU>
<TI>Low-dose steroid therapy at an early phase of postoperative acute respiratory distress syndrome</TI>
<SO>Annals of Thoracic Surgery</SO>
<YR>2005</YR>
<VL>79</VL>
<PG>405-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Levinsky-1979" MODIFIED="2011-02-22 19:45:10 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Levinsky 1979" YEAR="1979">
<REFERENCE MODIFIED="2011-02-22 19:45:10 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Levinsky L, Schimert G, Lajos TZ, Lee AB Jr, Korenyi-Both A, Vladutiu A, et al</AU>
<TI>The use of steroids as a potentiator of hypothermic myocardial preservation in man</TI>
<SO>Journal of Surgical Research</SO>
<YR>1979</YR>
<VL>26</VL>
<NO>6</NO>
<PG>629-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Loubser-1997" MODIFIED="2011-02-22 19:45:41 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Loubser 1997" YEAR="1997">
<REFERENCE MODIFIED="2011-02-22 19:45:41 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Loubser PG</AU>
<TI>Effect of methylprednisolone on complement activation during heparin neutralization</TI>
<SO>Journal of Cardiovascular Pharmacology</SO>
<YR>1997</YR>
<VL>29</VL>
<NO>1</NO>
<PG>23-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Medonca_x002d_Filho-2004" MODIFIED="2011-02-22 19:45:58 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Medonca-Filho 2004" YEAR="2004">
<REFERENCE MODIFIED="2011-02-22 19:45:58 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mendonca-Filho HT, Gomes RV, Almeida Campos LA, Tura B, Nunes EM, Gomes R, Bozza F, et al</AU>
<TI>Circulating levels of macrophage migration inhibitory factor are associated with mild pulmonary dysfunction after cardiopulmonary bypass</TI>
<SO>Shock</SO>
<YR>2004</YR>
<VL>22</VL>
<NO>6</NO>
<PG>533-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ming-2001" MODIFIED="2011-02-22 19:48:06 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Ming 2001" YEAR="2001">
<REFERENCE MODIFIED="2011-02-22 19:48:06 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ming W, Yun-Bi L, Bo Y, Shi-Wei X, Ru-Kun C, Han-Liang Z</AU>
<TI>Effects of methylprednisolone and aprotinin on phospholipase D activity of leukocytes in systemic inflammatory response induced by cardiopulmonary bypass</TI>
<SO>Acta Pharmacologica Sinica</SO>
<YR>2001</YR>
<VL>22</VL>
<PG>913-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Miranda-1982" MODIFIED="2010-08-30 15:37:20 +0530" MODIFIED_BY="[Empty name]" NAME="Miranda 1982" YEAR="1982">
<REFERENCE MODIFIED="2010-08-30 15:37:20 +0530" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miranda DR, Stoutenbeek C, Karliczek G, Rating W</AU>
<TI>Effects of dexamethason on the early postoperative course after coronary artery bypass surgery</TI>
<SO>Thoracic &amp; Cardiovascular Surgeon</SO>
<YR>1982</YR>
<VL>30</VL>
<NO>1</NO>
<PG>21-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Niazi-1979" MODIFIED="2010-08-30 16:11:20 +0530" MODIFIED_BY="[Empty name]" NAME="Niazi 1979" YEAR="1979">
<REFERENCE MODIFIED="2010-08-30 15:28:52 +0530" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Niazi Z, Flodin P, Joyce L, Smith J, Mauer H, Lillehei RC</AU>
<TI>Effects of glucocorticosteroids in patients undergoing coronary artery bypass surgery</TI>
<SO>Chest</SO>
<YR>1979</YR>
<VL>76</VL>
<NO>3</NO>
<PG>262-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oh-2007" MODIFIED="2010-08-30 17:30:33 +0530" MODIFIED_BY="[Empty name]" NAME="Oh 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-08-30 17:30:31 +0530" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oh J, Chung JH, Kang SM</AU>
<TI>Use of corticosteroids to prevent atrial fibrillation after cardiac surgery</TI>
<SO>JAMA</SO>
<YR>2007</YR>
<VL>298</VL>
<NO>3</NO>
<PG>283</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ohe-1993" MODIFIED="2010-08-27 01:11:13 +0530" MODIFIED_BY="[Empty name]" NAME="Ohe 1993" YEAR="1993">
<REFERENCE MODIFIED="2010-08-27 01:11:12 +0530" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ohe Y, Satoh K, Hashimoto N, Tachibana C, Fukada T, Furuya Y</AU>
<TI>The circulatory and respiratory effects of methylprednisolone associated with catecholamine administration of a few hours</TI>
<SO>Masui</SO>
<YR>1993</YR>
<VL>42</VL>
<NO>5</NO>
<PG>683-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Raff-1987" MODIFIED="2011-02-22 19:49:09 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Raff 1987" YEAR="1987">
<REFERENCE MODIFIED="2011-02-22 19:49:09 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Raff H, Norton AJ, Flemma RJ, Findling JW</AU>
<TI>Inhibition of the adrenocorticotropin response to surgery in humans: interaction between dexamethasone and fentanyl</TI>
<SO>Journal of Clinical Endocrinology and Metabolism</SO>
<YR>1987</YR>
<VL>65</VL>
<NO>2</NO>
<PG>295-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ranucci-1994" MODIFIED="2011-02-22 19:49:49 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Ranucci 1994" YEAR="1994">
<REFERENCE MODIFIED="2011-02-22 19:49:49 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ranucci M, Pavesi M, Conti D, Soro G, Ceocopieri M, Ghanem G, et al</AU>
<TI>High - dose steroids during cardiopulmonary bypass: comparison between two therapeutic approaches</TI>
<SO>Journal of Cardiothoracic and Vascular Anesthesia</SO>
<YR>1994</YR>
<VL>8</VL>
<NO>3</NO>
<PG>134</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Santarpino-2009a" MODIFIED="2011-02-22 19:50:06 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Santarpino 2009a" YEAR="">
<REFERENCE MODIFIED="2011-02-22 19:50:06 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Santarpino G, Caroleo S, Onorati F, Rubino AD, Dardano A, Gulletta E, Santangelo E, Amantea B, Renzulli A</AU>
<TI>Inflammatory response after cardiopulmonary bypass: a randomized comparison between conventional hemofiltration and steroids</TI>
<SO>Journal of Cardiovascular Surgery (Torino)</SO>
<YR>2009</YR>
<VL>50</VL>
<NO>4</NO>
<PG>555-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Santarpino-2009b" MODIFIED="2011-02-22 19:50:50 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Santarpino 2009b" YEAR="">
<REFERENCE MODIFIED="2011-02-22 19:50:50 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Santarpino G, Caroleo S, Onorati F, Dimastromatteo G, Abdalla K, Amantea B, Santangelo E, Gulletta E, Renzulli A</AU>
<TI>Inflammatory response to cardiopulmonary bypass with enoximone or steroids in patients undergoing myocardial revascularization: a preliminary report study</TI>
<SO>International Journal of Clinical Pharmacology and Therapeutics</SO>
<YR>2009</YR>
<VL>47</VL>
<NO>2</NO>
<PG>78-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schelling-2006" MODIFIED="2011-02-22 19:51:38 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Schelling 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-02-22 19:51:38 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schelling G, Roozendaal B, Krauseneck T, Schmoelz M, De Quervain D, Briegel J</AU>
<TI>Efficacy of hydrocortisone in preventing posttraumatic stress disorder following critical illness and major surgery</TI>
<SO>Annals of the New York Academy of Sciences</SO>
<YR>2006</YR>
<VL>1071</VL>
<PG>46-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schmartz-1996" MODIFIED="2011-02-22 19:51:55 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Schmartz 1996" YEAR="1996">
<REFERENCE MODIFIED="2011-02-22 19:51:55 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schmartz D, Tabardel Y, Duchateau J, Barvais L, dHollander A</AU>
<TI>Corticosteroid effects on cytokine production in cardiac surgery: Dose-effect relationship</TI>
<SO>British Journal of Anaesthesia</SO>
<YR>1996</YR>
<VL>76</VL>
<PG>A167</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tabardel-1996" MODIFIED="2011-02-22 19:52:06 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Tabardel 1996" YEAR="1996">
<REFERENCE MODIFIED="2011-02-22 19:52:06 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Taberdel Y, Duchateau J, Schmartz D, Marecaux G, Shahla M, Barvais L, et al</AU>
<TI>Corticosteroids increase blood interleukin-10 levels during cardiopulmonary bypass in men</TI>
<SO>Surgery</SO>
<YR>1996</YR>
<VL>119</VL>
<PG>76-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Teoh-1995" MODIFIED="2011-02-22 19:52:33 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Teoh 1995" YEAR="1995">
<REFERENCE MODIFIED="2011-02-22 19:52:33 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Teoh KHT, Bradley CA, Gauldie J, Burrows H</AU>
<TI>Steroid inhibition of cytokine-mediated vasodilation after warm heart surgery</TI>
<SO>Circulation</SO>
<YR>1995</YR>
<VL>92</VL>
<NO>suppl9</NO>
<PG>II347-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thompson-1980" MODIFIED="2010-08-27 02:09:36 +0530" MODIFIED_BY="[Empty name]" NAME="Thompson 1980" YEAR="1980">
<REFERENCE MODIFIED="2010-08-27 02:09:35 +0530" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thompson MA, Broadbent MP</AU>
<TI>Methylprednisolone prior to cardiopulmonary bypass</TI>
<SO>Anaesthesia</SO>
<YR>1980</YR>
<VL>35</VL>
<NO>4</NO>
<PG>345-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thompson-1982" MODIFIED="2010-08-27 02:02:01 +0530" MODIFIED_BY="[Empty name]" NAME="Thompson 1982" YEAR="1982">
<REFERENCE MODIFIED="2010-08-27 02:02:00 +0530" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thompson MA, Broadbent MP, English J</AU>
<TI>Plasma levels of methylprednisolone following administration during cardiac surgery</TI>
<SO>Anaesthesia</SO>
<YR>1982</YR>
<VL>37</VL>
<NO>4</NO>
<PG>405-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Toledo_x002d_Pereyra-1980" MODIFIED="2011-02-22 19:52:59 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Toledo-Pereyra 1980" YEAR="1980">
<REFERENCE MODIFIED="2011-02-22 19:52:59 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Toledo-Pereyra LH, Lin CY, Kundler H, Replogle RL</AU>
<TI>Steroids in heart surgery: a clinical double-blind and randomized study</TI>
<SO>American Surgeon</SO>
<YR>1980</YR>
<VL>46</VL>
<NO>3</NO>
<PG>155-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Turkoz-2000" MODIFIED="2011-03-30 15:40:04 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Turkoz 2000" YEAR="2000">
<REFERENCE MODIFIED="2011-03-30 15:40:04 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Turkoz A, Cigli A, But K, Sezgin N,  Turkoz R, Gulcan O, et al</AU>
<TI>The effect of aprotinin and methylprednisolone during coronary artery surgery induced cytokines</TI>
<SO>Türk Anesteziyoloji ve Reanimasyon Cemiyeti mecmuasi</SO>
<YR>2000</YR>
<VL>28</VL>
<PG>247-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Us-2001" MODIFIED="2010-08-30 16:08:45 +0530" MODIFIED_BY="[Empty name]" NAME="Us 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-08-30 16:08:43 +0530" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Us MH, Ege T, Cakir O, Ozkan S, Duran E, Ozturk OY</AU>
<TI>Effect of methylprednisolone in post-pump syndrome</TI>
<SO>Gulhane Tip Dergisi</SO>
<YR>2001</YR>
<VL>43</VL>
<NO>2</NO>
<PG>197-203</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vallejo-1977" MODIFIED="2010-08-30 15:36:28 +0530" MODIFIED_BY="[Empty name]" NAME="Vallejo 1977" YEAR="1977">
<REFERENCE MODIFIED="2010-08-30 15:33:46 +0530" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vallejo JL, Gemenez-Fernandez R, Mainer JL,Rivera R</AU>
<TI>Clinical analysis of the protective effect of methylprednisolone on the heart in anoxic arrest (random study)</TI>
<SO>Revista Espanola de Cardiologia</SO>
<YR>1977</YR>
<VL>30</VL>
<PG>705-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Overveld-1994" MODIFIED="2011-02-22 19:54:49 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Van Overveld 1994" YEAR="1994">
<REFERENCE MODIFIED="2011-02-22 19:54:49 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van Overveld FJ, De Jongh RF, Jorens PG, Walter P, Bossaert L, De Backer WA</AU>
<TI>Pretreatment with methylprednisolone in coronary artery bypass grafting influences the levels of histamine and tryptase in serum but not in bronchoalveolar lavage fluid</TI>
<SO>Clinical Science (London)</SO>
<YR>1994</YR>
<VL>86</VL>
<NO>1</NO>
<PG>49-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vogelzang-2007" MODIFIED="2011-02-22 19:55:27 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Vogelzang 2007" YEAR="2007">
<REFERENCE MODIFIED="2011-02-22 19:55:27 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vogelzang M, Hoekstra M, Drost JT, Janse M, van der Horst IC, Boonstra PW, et al</AU>
<TI>The impact of a reduced dose of dexamethasone on glucose control after coronary artery bypass surgery</TI>
<SO>Cardiovascular Diabetology</SO>
<YR>2007</YR>
<VL>17</VL>
<NO>6</NO>
<PG>39</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wan-1997b" MODIFIED="2010-08-30 18:44:48 +0530" MODIFIED_BY="[Empty name]" NAME="Wan 1997b" YEAR="1997">
<REFERENCE MODIFIED="2010-08-30 18:44:48 +0530" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wan S, LeClerc JL, Schmartz D, Barvais L, Huynh CH, Deviere J et al</AU>
<TI>Hepatic release of interleukin-10 during cardiopulmonary bypass in steroid-pretreated patients</TI>
<SO>American Heart Journal</SO>
<YR>1997</YR>
<VL>133</VL>
<NO>3</NO>
<PG>335-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weis-2007" MODIFIED="2011-02-22 19:55:49 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Weis 2007" YEAR="2007">
<REFERENCE MODIFIED="2011-02-22 19:55:49 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weis JJ</AU>
<TI>Heart surgery: hydrocortisone lowers the incidence of atrial fibrillation</TI>
<SO>Deutsche Medizinische Wochenschrift</SO>
<YR>2007</YR>
<VL>132</VL>
<NO>21</NO>
<PG>1145</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Whitlock-2005" MODIFIED="2011-02-22 19:56:10 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Whitlock 2005" YEAR="2005">
<REFERENCE MODIFIED="2011-02-22 19:56:10 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Whitlock RP, Rubens FD, Young E, Teoh KH</AU>
<TI>Pro: steroids should be used for cardiopulmonary bypass</TI>
<SO>Journal of Cardothoracic and Vascular Anesthesia</SO>
<YR>2005</YR>
<VL>19</VL>
<PG>250-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wu-2001" MODIFIED="2011-02-22 19:56:41 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Wu 2001" YEAR="2001">
<REFERENCE MODIFIED="2011-02-22 19:56:41 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wu M, Lu YB, Jiang B, Xu SW, Chen RK, Zhou HL</AU>
<TI>Effects of methylprednisolone and aprotinin on phospholipase D activity of leukocytes in systemic inflammatory response induced by cardiopulmonary bypass</TI>
<SO>Acta Pharmacologica Sinica</SO>
<YR>2001</YR>
<VL>22</VL>
<NO>10</NO>
<PG>913-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yaeger-2005" MODIFIED="2011-02-22 19:57:02 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Yaeger 2005" YEAR="2005">
<REFERENCE MODIFIED="2011-02-22 19:57:02 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yeager MP, Rassias AJ, Fillinger MP, DiScipio AW, Gloor KE, Gregory JA, et al</AU>
<TI>Cortisol antiinflammatory effects are maximal at postoperative plasma concentrations</TI>
<SO>Critical Care Medicine</SO>
<YR>2005</YR>
<VL>33</VL>
<PG>1507-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yasser-2009" MODIFIED="2011-02-22 19:58:04 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Yasser 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-02-22 19:58:04 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yasser Mohamed Amr, Elmistekawy E, El-Serogy H</AU>
<TI>Effects of dexamethasone on pulmonary and renal functions in patients undergoing CABG with cardiopulmonary bypass</TI>
<SO>Seminars in Cardiothoracic and Vascular Anesthesia</SO>
<YR>2009</YR>
<VL>13</VL>
<NO>4</NO>
<PG>231-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yasuura-1977" MODIFIED="2010-08-30 15:31:25 +0530" MODIFIED_BY="[Empty name]" NAME="Yasuura 1977" YEAR="1977">
<REFERENCE MODIFIED="2010-08-30 15:31:24 +0530" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yasuura K, Nishitani Y, Tanimoto K, Hashimoto A, Hayashi H</AU>
<TI>Administration of steroid during open-heart surgery</TI>
<SO>Nippon Kyobu Geka Gakkai Zasshi</SO>
<YR>1977</YR>
<VL>25</VL>
<NO>12</NO>
<PG>1587-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2011-03-30 15:41:54 +0530" MODIFIED_BY="Nicole Ackermann">
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT00490828" MODIFIED="2011-03-30 15:41:54 +0530" MODIFIED_BY="Nicole Ackermann" NAME="NCT00490828" YEAR="2008">
<REFERENCE MODIFIED="2011-03-30 15:41:54 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>NCT00490828</AU>
<TI>Influence of hydrocortisone on immunologic markers and health care related quality of life in patients after cardiac surgery</TI>
<SO>http://clinicaltrials.gov/ct2/show/NCT00490828</SO>
<YR>(accessed 30 August 2010)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES MODIFIED="2011-03-30 15:43:02 +0530" MODIFIED_BY="Nicole Ackermann">
<STUDY DATA_SOURCE="UNPUB" ID="STD-DECS-trial" MODIFIED="2011-03-30 15:41:33 +0530" MODIFIED_BY="Nicole Ackermann" NAME="DECS trial" YEAR="">
<REFERENCE MODIFIED="2011-03-30 15:41:33 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>NCT00293592</AU>
<TI>Dexamethasone for Cardiac Surgery Trial</TI>
<SO>http://clinicaltrials.gov/ct2/show/NCT00293592</SO>
<YR>(accessed 30 August 2010)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT00879931" MODIFIED="2011-03-30 15:42:10 +0530" MODIFIED_BY="Nicole Ackermann" NAME="NCT00879931" YEAR="9931">
<REFERENCE MODIFIED="2011-03-30 15:42:10 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>NCT00879931</AU>
<TI>Influence of corticoids on renal function in cardiac surgery</TI>
<SO>http://clinicaltrials.gov/ct2/show/NCT00879931</SO>
<YR>(accessed 30 August 2010)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-SIRS-trial" MODIFIED="2011-03-30 15:42:21 +0530" MODIFIED_BY="Nicole Ackermann" NAME="SIRS trial" YEAR="">
<REFERENCE MODIFIED="2011-03-30 15:42:21 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>NCT00427388</AU>
<TI>Phase 3 study of perioperative steroid's effects on death or MI in patients undergoing cardiac surgery requiring cardiopulmonary bypass</TI>
<SO>http://clinicaltrials.gov/ct2/show/NCT00427388</SO>
<YR>(accessed 30 August 2010)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-STRESS-trial" MODIFIED="2011-03-30 15:43:02 +0530" MODIFIED_BY="Nicole Ackermann" NAME="STRESS trial" YEAR="">
<REFERENCE MODIFIED="2011-03-30 15:43:02 +0530" MODIFIED_BY="Nicole Ackermann" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Boer C</AU>
<TI>Reduction of the cardiac proapoptotic stress response by dexamethasone in patients undergoing coronary artery bypass grafting</TI>
<SO>http://clinicaltrials.gov/ct2/show/NCT00807521</SO>
<YR>(accessed 30 August 2010)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2011-04-06 12:36:11 +0530" MODIFIED_BY="Joey Kwong">
<ADDITIONAL_REFERENCES MODIFIED="2011-04-06 12:36:11 +0530" MODIFIED_BY="Joey Kwong">
<REFERENCE ID="REF-AHA-2004" MODIFIED="2011-03-30 15:44:04 +0530" MODIFIED_BY="Nicole Ackermann" NAME="AHA 2004" TYPE="JOURNAL_ARTICLE">
<AU>American Heart Association</AU>
<TI>ACC/AHA 2004 Guideline Update for Coronary Artery Bypass Graft Surgery</TI>
<SO>http://circ.ahajournals.org/cgi/reprint/110/14/e340</SO>
<YR>2004 (accessed 16 August 2010)
</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-AHA-2009" MODIFIED="2011-03-30 15:44:38 +0530" MODIFIED_BY="Nicole Ackermann" NAME="AHA 2009" TYPE="OTHER">
<AU>American Heart Association</AU>
<TI>Heart Disease &amp; Stroke Statistics 2009</TI>
<SO>http://circ.ahajournals.org/cgi/content/full/119/3/e21</SO>
<YR>2009 (accessed 10 September 2009)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Asimakopoulos-1999" MODIFIED="2009-11-02 19:35:50 +0530" MODIFIED_BY="[Empty name]" NAME="Asimakopoulos 1999" TYPE="JOURNAL_ARTICLE">
<AU>Asimakopoulos G, Smith PL, Ratnatunga CP, Taylor KM</AU>
<TI>Lung injury and acute respiratory distress syndrome after cardiopulmonary bypass</TI>
<SO>Annals of Thoracic Surgery</SO>
<YR>1999</YR>
<VL>68</VL>
<NO>3</NO>
<PG>1107-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Banach-2010" MODIFIED="2011-02-22 20:41:45 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Banach 2010" TYPE="JOURNAL_ARTICLE">
<AU>Banach M, Kourliouros A, Reinhart KM, Benussi S, Mikhailidis DP, Jahangiri M, et al</AU>
<TI>Postoperative atrial fibrillation - what do we really know?</TI>
<SO>Current Vascular Pharmacology</SO>
<YR>2010</YR>
<VL>1</VL>
<PG>[Epub ahead of print]</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chaney-2002" MODIFIED="2009-11-02 19:42:39 +0530" MODIFIED_BY="[Empty name]" NAME="Chaney 2002" TYPE="JOURNAL_ARTICLE">
<AU>Chaney MA</AU>
<TI>Corticosteroids and cardiopulmonary bypass : a review of clinical investigations</TI>
<SO>Chest</SO>
<YR>2002</YR>
<VL>121</VL>
<NO>3</NO>
<PG>921-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Crystal-2004" MODIFIED="2011-02-22 20:42:38 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Crystal 2004" TYPE="COCHRANE_REVIEW">
<AU>Crystal E, Garfinckle MS, Conolly S, Ginger T, Sleik K, Ysyf S</AU>
<TI>Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2011-02-22 20:42:38 +0530" MODIFIED_BY="Nicole Ackermann">
<IDENTIFIER MODIFIED="2011-02-22 20:42:38 +0530" MODIFIED_BY="Nicole Ackermann" TYPE="DOI" VALUE="10.1002/14651858.CD003611.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Dekkers-2010" MODIFIED="2010-05-14 15:01:40 +0530" MODIFIED_BY="[Empty name]" NAME="Dekkers 2010" TYPE="JOURNAL_ARTICLE">
<AU>Dekkers OM, v Elm E, Algra A, Romijn JA, Vandenbroucke JP</AU>
<TI>How to assess the external validity of therapeutic trials; a conceptual approach</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2010</YR>
<VL>39</VL>
<NO>1</NO>
<PG>89-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gibbon-1954" MODIFIED="2011-02-22 20:43:01 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Gibbon 1954" TYPE="JOURNAL_ARTICLE">
<AU>Gibbon JH, Jr</AU>
<TI>Application of a mechanical heart and lung apparatus to cardiac surgery</TI>
<SO>Minnesota Medical Journal</SO>
<YR>1954</YR>
<VL>37</VL>
<PG>171-180</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hall-1997" MODIFIED="2011-02-22 20:43:12 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Hall 1997" TYPE="JOURNAL_ARTICLE">
<AU>Hall RI, Smith MS, Rocker G</AU>
<TI>The systemic inflammatory response to cardiopulmonary bypass: pathophysiological, therapeutic,and pharmacological considerations</TI>
<SO>Anaesthesia Analgesia</SO>
<YR>1997</YR>
<VL>85</VL>
<PG>766-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Heikkinen-1985" MODIFIED="2009-11-02 19:44:00 +0530" MODIFIED_BY="[Empty name]" NAME="Heikkinen 1985" TYPE="JOURNAL_ARTICLE">
<AU>Heikkinen L, Harjula A, Merikallio E</AU>
<TI>Acute renal failure related to open-heart surgery</TI>
<SO>Annales Chirurgiae et Gynaecologiae</SO>
<YR>1985</YR>
<VL>74</VL>
<NO>5</NO>
<PG>203-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2002" MODIFIED="2011-02-22 20:43:36 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Higgins 2002" TYPE="JOURNAL_ARTICLE">
<AU>Higgings JP, Thompson SG</AU>
<TI>Quantifying heterogeneity in a meta-analysis</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<PG>1539-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2011-04-06 12:36:11 +0530" MODIFIED_BY="Joey Kwong" NAME="Higgins 2011" TYPE="OTHER">
<TI>Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). <I>Cochrane Handbook for Systematic Reviews of Interventions </I>Version 5.1.0 (updated March 2011).<I> </I>The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hill-1982" MODIFIED="2011-02-22 20:44:30 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Hill 1982" TYPE="JOURNAL_ARTICLE">
<AU>Hill JD, Gibbon, JH Jr</AU>
<TI>The development of the first successful heart-lung machine</TI>
<SO>Annals of Thoracic surgery</SO>
<YR>1982</YR>
<VL>34</VL>
<NO>3</NO>
<PG>337-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hill-1998" MODIFIED="2009-11-02 19:24:36 +0530" MODIFIED_BY="[Empty name]" NAME="Hill 1998" TYPE="JOURNAL_ARTICLE">
<AU>Hill GE</AU>
<TI>Cardiopulmonary bypass-induced inflammation: is it important?</TI>
<SO>Journal of Cardiothoracic &amp; Vascular Anesthesia</SO>
<YR>1998</YR>
<VL>12</VL>
<NO>2 Suppl 1</NO>
<PG>21-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ho-2009" MODIFIED="2011-02-22 20:44:46 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Ho 2009" TYPE="JOURNAL_ARTICLE">
<AU>Ho KM, Tan JA</AU>
<TI>Benefits and risks of corticosteroids prophylaxis in adult cardiac surgery; a dose-response meta-analysis</TI>
<SO>Circulation</SO>
<YR>2009</YR>
<VL>119</VL>
<PG>1853-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hunt-2000" MODIFIED="2011-02-22 20:45:37 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Hunt 2000" TYPE="JOURNAL_ARTICLE">
<AU>Hunt JO, Hendrata M, Myles PS</AU>
<TI>Quality of life after cardiac surgery</TI>
<SO>Heart &amp; Lung</SO>
<YR>2000</YR>
<VL>29</VL>
<PG>401-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ioannidis-2007" MODIFIED="2009-11-02 19:25:00 +0530" MODIFIED_BY="[Empty name]" NAME="Ioannidis 2007" TYPE="JOURNAL_ARTICLE">
<AU>Ioannidis JP, Patsopoulos NA, Evangelou E</AU>
<TI>Uncertainty in heterogeneity estimates in meta-analysis</TI>
<SO>BMJ</SO>
<YR>2007</YR>
<VL>335</VL>
<PG>914-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Juni-1999" MODIFIED="2009-11-02 19:25:28 +0530" MODIFIED_BY="[Empty name]" NAME="Juni 1999" TYPE="JOURNAL_ARTICLE">
<AU>Juni P, Witschi A, Block R, Egger M</AU>
<TI>The hazards of scoring the quality of clinical trials for meta-analysis</TI>
<SO>Journal of American Medical Association</SO>
<YR>1999</YR>
<VL>282</VL>
<PG>1054-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kirklin-1983" MODIFIED="2009-11-02 19:26:44 +0530" MODIFIED_BY="[Empty name]" NAME="Kirklin 1983" TYPE="JOURNAL_ARTICLE">
<AU>Kirklin JK, Westaby S, Blackstone EH, Kirklin JW, Chenowerh DE, Pacifico AD</AU>
<TI>Complement and damaging effects of cardiopulmonary bypass</TI>
<SO>Journal of Thoracic &amp; Cardiovascular Surgery</SO>
<YR>1983</YR>
<VL>86</VL>
<NO>6</NO>
<PG>845-57</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lasser-1987" MODIFIED="2011-02-22 21:02:35 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Lasser 1987" TYPE="JOURNAL_ARTICLE">
<AU>Lasser EC, Berry CC, Talner LB, Santini LC, Lang EK, Gerber FH et al</AU>
<TI>Pretreatment with corticosteroids to alleviate reactions to intravenous contrast material</TI>
<SO>New England Journal of Medicine</SO>
<YR>1987</YR>
<VL>317</VL>
<PG>845-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lee-1976" MODIFIED="2011-02-22 20:47:30 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Lee 1976" TYPE="JOURNAL_ARTICLE">
<AU>Lee SJ, Barr C, Callaghan JC, Rossall RE, Fraser RS</AU>
<TI>Long-term survival after isolated replacement of mitral valve with ball-valve prosthesis</TI>
<SO>Canadian Medical Association Journal</SO>
<YR>1976</YR>
<VL>114</VL>
<NO>5</NO>
<PG>422-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lloyd_x002d_Jones-1999" MODIFIED="2009-09-21 18:29:04 +0530" MODIFIED_BY="[Empty name]" NAME="Lloyd-Jones 1999" TYPE="JOURNAL_ARTICLE">
<AU>Lloyd-Jones DM, Larson MG, Beiser A, Levy D</AU>
<TI>Lifetime risk of developing coronary heart disease</TI>
<SO>Lancet</SO>
<YR>1999</YR>
<VL>353</VL>
<PG>89-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mangos-1995" MODIFIED="2009-11-02 19:27:28 +0530" MODIFIED_BY="[Empty name]" NAME="Mangos 1995" TYPE="JOURNAL_ARTICLE">
<AU>Mangos GJ, Brown MA, Chan WY, Horton D, Trew P, Whitworth JA</AU>
<TI>Acute renal failure following cardiac surgery: incidence, outcomes and risk factors</TI>
<SO>Australian &amp; New Zealand Journal of Medicine</SO>
<YR>1995</YR>
<VL>25</VL>
<NO>4</NO>
<PG>284-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McGuinness-2008" MODIFIED="2011-03-02 22:12:57 +0530" MODIFIED_BY="[Empty name]" NAME="McGuinness 2008" TYPE="JOURNAL_ARTICLE">
<AU>McGuinness J, Bouchier-Hayes D, Redmond JM</AU>
<TI>Understanding the inflammatory response to cardiac surgery</TI>
<SO>Surgeon</SO>
<YR>2008</YR>
<VL>6</VL>
<NO>3</NO>
<PG>162-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moat-1993" MODIFIED="2009-11-02 19:28:35 +0530" MODIFIED_BY="[Empty name]" NAME="Moat 1993" TYPE="JOURNAL_ARTICLE">
<AU>Moat NE, Shore DF, Evans TW</AU>
<TI>Organ dysfunction and cardiopulmonary bypass: the role of complement and complement regulatory proteins</TI>
<SO>European Journal of Cardiothoracic Surgery</SO>
<YR>1993</YR>
<VL>7</VL>
<NO>11</NO>
<PG>563-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-2009" MODIFIED="2011-02-22 20:48:33 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Moher 2009" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Liberati A, Tetzlaff J, Altman DG</AU>
<TI>Methods of systematic reviews and meta-analysis. Preferred reporting Items for systematic reviews and meta-Analyses: The PRISMA Statement</TI>
<SO>The Journal of Clinical Epidemiology</SO>
<YR>2009</YR>
<VL>62</VL>
<PG>1006-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nuutinen-1976" MODIFIED="2009-11-02 19:29:17 +0530" MODIFIED_BY="[Empty name]" NAME="Nuutinen 1976" TYPE="JOURNAL_ARTICLE">
<AU>Nuutinen L, Hollmen A</AU>
<TI>Cardiopulmonary bypass time and renal function</TI>
<SO>Annales Chirurgiae et Gynaecologiae</SO>
<YR>1976</YR>
<VL>65</VL>
<NO>3</NO>
<PG>191-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pastuszko-2004" MODIFIED="2011-02-22 20:49:22 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Pastuszko 2004" TYPE="JOURNAL_ARTICLE">
<AU>Pastuszko JH, Edie RN, Gibbon JH Jr</AU>
<TI>The inventor of the first successful heart-lung machine</TI>
<SO>Journal of Cardiac Surgery</SO>
<YR>2004</YR>
<VL>19</VL>
<NO>1</NO>
<PG>65-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rahimtoola-1993" MODIFIED="2011-02-22 20:49:33 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Rahimtoola 1993" TYPE="JOURNAL_ARTICLE">
<AU>Rahimtoola SH, Fessler CL, Grunkemeier GL, Starr A</AU>
<TI>Survival 15 to 20 years after coronary bypass surgery for angina</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>1993</YR>
<VL>21</VL>
<NO>1</NO>
<PG>151-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Roach-1996" MODIFIED="2011-02-22 20:50:27 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Roach 1996" TYPE="JOURNAL_ARTICLE">
<AU>Roach GW, Kanchuger M, Mangano CM, Newman M, Nussmeier N, Wolman R et al</AU>
<TI>Adverse cerebral outcomes after coronary bypass surgery: multicenter study of Perioperative Ischemia Research Group and the Ischemia Research and Education Foundation Investigators</TI>
<SO>New England Journal of Medicine</SO>
<YR>1996</YR>
<VL>335</VL>
<NO>25</NO>
<PG>1857-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shuster-2007" MODIFIED="2011-02-22 20:51:48 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Shuster 2007" TYPE="JOURNAL_ARTICLE">
<AU>Shuster JJ, Jones LS, Salmon DA</AU>
<TI>Fixed vs random effect meta-analysis in rare event studies: the rosiglitazone link with myocardial infarction and cardiac death</TI>
<SO>Statistics in Medicine</SO>
<YR>2007</YR>
<VL>26</VL>
<PG>4375-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sweeting-2004" MODIFIED="2011-02-22 20:51:58 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Sweeting 2004" TYPE="JOURNAL_ARTICLE">
<AU>Sweeting MJ, Sutton AJ, Lambert PC</AU>
<TI>What to add nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data</TI>
<SO>Statistics in Medicine</SO>
<YR>2004</YR>
<VL>23</VL>
<PG>1351-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Talmor-1999" MODIFIED="2009-11-02 19:32:47 +0530" MODIFIED_BY="[Empty name]" NAME="Talmor 1999" TYPE="JOURNAL_ARTICLE">
<AU>Talmor M, Hydo L, Barie PS</AU>
<TI>Relationship of systemic inflammatory response syndrome to organ dysfunction, length of stay, and mortality in critical surgical illness: effect of intensive care unit resuscitation</TI>
<SO>Archives of Surgery</SO>
<YR>1999</YR>
<VL>134</VL>
<PG>81-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tennenberg-1986" MODIFIED="2009-11-02 19:33:13 +0530" MODIFIED_BY="[Empty name]" NAME="Tennenberg 1986" TYPE="JOURNAL_ARTICLE">
<AU>Tennenberg SD, Bailey WW, Cotta LA, Brodt JK, Solomkin JS</AU>
<TI>The effects of methylprednisolone on complement-mediated neutrophil activation during cardiopulmonary bypass</TI>
<SO>Surgery</SO>
<YR>1986</YR>
<VL>100</VL>
<NO>2</NO>
<PG>134-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thompson-1999" MODIFIED="2011-02-22 20:52:34 +0530" MODIFIED_BY="Nicole Ackermann" NAME="Thompson 1999" TYPE="JOURNAL_ARTICLE">
<AU>Thompson R, Ahmed M, Ilsey C, Seabra-Gomes R, Rickards A, Yacoub M</AU>
<TI>Evaluation of combined homograft replacement of aortic valve and coronary bypass grafting in patients with aortic stenosis</TI>
<SO>British Heart Journal</SO>
<YR>1979</YR>
<VL>42</VL>
<PG>447-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Van-den-Berghe-2001" MODIFIED="2009-11-02 19:34:07 +0530" MODIFIED_BY="[Empty name]" NAME="Van den Berghe 2001" TYPE="JOURNAL_ARTICLE">
<AU>Van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M et al</AU>
<TI>Intensive insulin therapy in the critically ill patients</TI>
<SO>New England Journal of Medicine</SO>
<YR>2001</YR>
<VL>345</VL>
<NO>19</NO>
<PG>1359-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Van-Dijk-2005" MODIFIED="2011-01-12 08:48:58 +0530" MODIFIED_BY="Joey Kwong" NAME="Van Dijk 2005" TYPE="OTHER">
<AU>Van Dijk I, Van Dijk D, Van Klarenbosch J, Kalkman CJ</AU>
<TI>The use of corticosteroids by Dutch cardiac anesthesiologists</TI>
<SO>Dutch Society of Anesthesiologists Annual Meeting abstract 2005</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wan-1997a" MODIFIED="2009-11-02 19:34:28 +0530" MODIFIED_BY="[Empty name]" NAME="Wan 1997a" TYPE="JOURNAL_ARTICLE">
<AU>Wan S, LeClerc JL, Vincent JL</AU>
<TI>Inflammatory response to cardiopulmonary bypass: mechanisms involved and possible therapeutic strategies</TI>
<SO>Chest</SO>
<YR>1997</YR>
<VL>112</VL>
<NO>3</NO>
<PG>676-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Whitlock-2008" MODIFIED="2009-11-02 19:34:49 +0530" MODIFIED_BY="[Empty name]" NAME="Whitlock 2008" TYPE="JOURNAL_ARTICLE">
<AU>Whitlock RP, Chan S, Devereaux PJ, Sun J, Rubens FD, Thorlund K et al</AU>
<TI>Clinical benefit of steroids use in patients undergoing cardiopulmonary bypass: a meta-analysis of randomized trials</TI>
<SO>European Heart Journal</SO>
<YR>2008</YR>
<VL>29</VL>
<PG>2592-600</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zanardo-1994" MODIFIED="2009-11-02 19:35:25 +0530" MODIFIED_BY="[Empty name]" NAME="Zanardo 1994" TYPE="JOURNAL_ARTICLE">
<AU>Zanardo G, Michielon P, Paccagnella A, Rosi P, Calo M, Salandin V, et al</AU>
<TI>Acute renal failure in the patient undergoing cardiac operation. Prevalence, mortality rate, and main risk factors</TI>
<SO>Journal of Thoracic &amp; Cardiovascular Surgery</SO>
<YR>1994</YR>
<VL>107</VL>
<NO>6</NO>
<PG>1489-95</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2011-03-31 16:08:37 +0530" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2011-03-31 16:04:17 +0530" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2011-02-22 16:33:16 +0530" MODIFIED_BY="Nicole Ackermann" STUDY_ID="STD-Abd.-El_x002d_Hakeem-2003a">
<CHAR_METHODS MODIFIED="2009-12-15 16:51:02 +0530" MODIFIED_BY="[Empty name]">
<P>Randomized placebo-controlled, double blinded trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 16:14:28 +0530" MODIFIED_BY="[Empty name]">
<P>46 elective valve surgery (aortic or mitral)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 16:30:55 +0530" MODIFIED_BY="[Empty name]">
<P>100 mg Dexamethasone, pre-CPB</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-02-22 16:33:16 +0530" MODIFIED_BY="Nicole Ackermann">
<P>mortality, time to extubation, ICU-stay, vaso-active medication, blood transfusions y/n<BR/>"no major complications"</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-12-15 15:54:25 +0530" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-02-22 16:33:56 +0530" MODIFIED_BY="Nicole Ackermann" STUDY_ID="STD-Abd.-El_x002d_Hakeem-2003b">
<CHAR_METHODS MODIFIED="2009-12-15 16:50:57 +0530" MODIFIED_BY="[Empty name]">
<P>Randomized placebo-controlled, double blinded trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 16:14:50 +0530" MODIFIED_BY="[Empty name]">
<P>20 elective valve surgery (aortic or mitral)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 16:30:48 +0530" MODIFIED_BY="[Empty name]">
<P>100 mg Dexamethasone, pre-CPB</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-02-22 16:33:56 +0530" MODIFIED_BY="Nicole Ackermann">
<P>mortality, time to extubation, ICU-stay, atrial fibrillation, vaso-active medication, number of blood transfusion, biomarker</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-02-22 16:34:25 +0530" MODIFIED_BY="Nicole Ackermann" STUDY_ID="STD-Amr-2009">
<CHAR_METHODS MODIFIED="2010-01-20 17:11:06 +0530" MODIFIED_BY="[Empty name]">
<P>Randomized placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-20 17:11:25 +0530" MODIFIED_BY="[Empty name]">
<P>100 elective CABG</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-20 17:13:05 +0530" MODIFIED_BY="[Empty name]">
<P>dexamethasone 1 mg/kg pre-CPB, 0,5 mg/kg after 8 hr</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-02-22 16:34:25 +0530" MODIFIED_BY="Nicole Ackermann">
<P>mortality, cardiac complications, ICU-stay, hospital stay, atrial fibrillation, gastro-intestinal complications, infections</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-12-15 16:58:48 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Andersen-1989">
<CHAR_METHODS MODIFIED="2009-12-15 15:55:31 +0530" MODIFIED_BY="[Empty name]">
<P>Randomized, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 16:15:35 +0530" MODIFIED_BY="[Empty name]">
<P>16 elective CABG</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 16:30:36 +0530" MODIFIED_BY="[Empty name]">
<P>30 mg/kg Methylprednisolone, pre-CPB</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-15 16:58:48 +0530" MODIFIED_BY="[Empty name]">
<P>mortality, cardiac complications, infections, biomarker<BR/>"no major complications"</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-03-02 21:59:24 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bingol-2005">
<CHAR_METHODS MODIFIED="2010-02-01 20:08:59 +0530" MODIFIED_BY="[Empty name]">
<P>Randomized, placebo-controlled, double-blind trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-01 20:07:23 +0530" MODIFIED_BY="[Empty name]">
<P>40 elective CABG-patients with a history of COPD</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-03-02 21:59:24 +0530" MODIFIED_BY="[Empty name]">
<P>17 days (10 pre op, 7 postop) oral prednisolon (20 mg/day in a single dose) or placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-02-01 20:08:21 +0530" MODIFIED_BY="[Empty name]">
<P>Postoperative pulmonary function and pulmonary complications</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-12-15 16:30:39 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Boscoe-1983">
<CHAR_METHODS MODIFIED="2009-12-15 15:58:44 +0530" MODIFIED_BY="[Empty name]">
<P>Randomized, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 16:17:15 +0530" MODIFIED_BY="[Empty name]">
<P>44 elective CABG and/or valve surgery<BR/>(17 steroids, 17 placebo, 10 pulsatile flow) - 34 included in meta-analysis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 16:30:39 +0530" MODIFIED_BY="[Empty name]">
<P>2 x 30 mg/kg Methylprednisolone, pre-CPB</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-15 16:01:08 +0530" MODIFIED_BY="[Empty name]">
<P>mortality, biomarker</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-12-15 16:59:07 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bourbon-2004">
<CHAR_METHODS MODIFIED="2009-12-15 16:01:49 +0530" MODIFIED_BY="[Empty name]">
<P>Randomized, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 16:18:43 +0530" MODIFIED_BY="[Empty name]">
<P>36 elective CABG</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 16:31:21 +0530" MODIFIED_BY="[Empty name]">
<P>high dose (10 mg/kg), low dose (5 mg/kg) Methylprednisolone, pre-CPB</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-15 16:59:07 +0530" MODIFIED_BY="[Empty name]">
<P>mortality, time to extubation (not included in meta-analyses; separate outcomes in high- and low dose group), biomarker<BR/>"no major complications"</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-12-15 16:12:05 +0530" MODIFIED_BY="[Empty name]">
<P>no dose dependant analyses</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-02-22 16:36:04 +0530" MODIFIED_BY="Nicole Ackermann" STUDY_ID="STD-Cavarocchi-1986">
<CHAR_METHODS MODIFIED="2009-12-15 16:19:33 +0530" MODIFIED_BY="[Empty name]">
<P>Randomized, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-02-22 16:36:04 +0530" MODIFIED_BY="Nicole Ackermann">
<P>91 elective CABG and/or valve surgery<BR/>30 excluded: different type of oxygenator (membrane in stead of bubble)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 16:53:39 +0530" MODIFIED_BY="[Empty name]">
<P>30 mg/kg Solumedrol, pre-CPB<BR/>different types of oxygenators</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-15 16:59:16 +0530" MODIFIED_BY="[Empty name]">
<P>mortality, time to extubation (not included in meta-analysis; stratified analyses), vaso-active medication, biomarker<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-02-22 16:36:26 +0530" MODIFIED_BY="Nicole Ackermann" STUDY_ID="STD-Celik-2004">
<CHAR_METHODS MODIFIED="2009-12-15 16:50:48 +0530" MODIFIED_BY="[Empty name]">
<P>Randomized placebo-controlled, double blinded trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 16:28:44 +0530" MODIFIED_BY="[Empty name]">
<P>60 elective CABG</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 16:31:10 +0530" MODIFIED_BY="[Empty name]">
<P>6 x 30 mg/kg Methylprednisolone, peri-operatively</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-02-22 16:36:26 +0530" MODIFIED_BY="Nicole Ackermann">
<P>mortality, cardiac complications, re-intubation, time to extubation, ICU-stay, atrial fibrillation, vaso-active medication, number of blood transfusions, biomarker</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-01-05 19:15:27 +0530" MODIFIED_BY="Nicole Ackermann" STUDY_ID="STD-Chaney-1998">
<CHAR_METHODS MODIFIED="2009-12-15 16:50:45 +0530" MODIFIED_BY="[Empty name]">
<P>Randomized placebo-controlled, double blinded trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 16:34:02 +0530" MODIFIED_BY="[Empty name]">
<P>60 elective CABG</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 16:35:03 +0530" MODIFIED_BY="[Empty name]">
<P>2 x 30 mg/kg Methylprednisolone, sternotomy and at initiation of CPB</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-15 16:36:39 +0530" MODIFIED_BY="[Empty name]">
<P>mortality, cardiac complications, time to extubation, hospital stay, neurological complications, atrial fibrillation, gastro-intestinal complications, vaso-active medication, biomarker</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-01-05 19:15:27 +0530" MODIFIED_BY="Nicole Ackermann"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-02-22 16:37:35 +0530" MODIFIED_BY="Nicole Ackermann" STUDY_ID="STD-Chaney-2001">
<CHAR_METHODS MODIFIED="2009-12-15 16:50:38 +0530" MODIFIED_BY="[Empty name]">
<P>Randomized placebo-controlled, double blinded trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 16:39:14 +0530" MODIFIED_BY="[Empty name]">
<P>90 elective CABG</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 16:40:50 +0530" MODIFIED_BY="[Empty name]">
<P>high dose (2 x 30 mg/kg), low dose (2 x 15 mg/kg) Methylprednisolone, sternotomy and at initiation of CPB </P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-15 16:59:48 +0530" MODIFIED_BY="[Empty name]">
<P>mortality, cardiac complications, time to extubation, neurological complications, vaso-active medication<BR/>"no major complications"</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-02-22 16:37:35 +0530" MODIFIED_BY="Nicole Ackermann">
<P>2 patients excluded; study-violation</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-12-15 16:59:57 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Codd-1977">
<CHAR_METHODS MODIFIED="2009-12-15 16:43:06 +0530" MODIFIED_BY="[Empty name]">
<P>Randomized placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 16:43:24 +0530" MODIFIED_BY="[Empty name]">
<P>150 elective CABG</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 16:45:21 +0530" MODIFIED_BY="[Empty name]">
<P>1000 mg Methylprednisolone, half an hour before initiation of CPB</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-15 16:59:57 +0530" MODIFIED_BY="[Empty name]">
<P>mortality, cardiac complications, vasoactive medication<BR/>"no major complications"</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-12-15 16:52:21 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Coetzer-1996">
<CHAR_METHODS MODIFIED="2009-12-15 16:47:23 +0530" MODIFIED_BY="[Empty name]">
<P>Randomized placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 16:52:21 +0530" MODIFIED_BY="[Empty name]">
<P>295 cardiac surgery, not further specified</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 16:48:52 +0530" MODIFIED_BY="[Empty name]">
<P>30 mg/kg Methylprednisolone, before initiation of CPB</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-15 16:49:07 +0530" MODIFIED_BY="[Empty name]">
<P>mortality</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-20 18:35:41 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Demir-2009">
<CHAR_METHODS MODIFIED="2010-01-20 18:32:00 +0530" MODIFIED_BY="[Empty name]">
<P>Randomized placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-20 18:32:43 +0530" MODIFIED_BY="[Empty name]">
<P>30 elective CABG</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-20 18:33:13 +0530" MODIFIED_BY="[Empty name]">
<P>1000 mg methylprednisolone before CPB</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-20 18:35:41 +0530" MODIFIED_BY="[Empty name]">
<P>mortality, time to extubation, ICU-stay, hospital stay, renal failure, neurological complications, infections, vasoactive medication, number of blood-transfusions, "no major complications"</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-12-15 17:00:15 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-El-Azab-2002">
<CHAR_METHODS MODIFIED="2009-12-15 16:50:31 +0530" MODIFIED_BY="[Empty name]">
<P>Randomized placebo-controlled, double blinded trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 16:52:07 +0530" MODIFIED_BY="[Empty name]">
<P>18 elective CABG</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 16:52:43 +0530" MODIFIED_BY="[Empty name]">
<P>100 mg Dexamethasone, pre-surgery</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-15 17:00:15 +0530" MODIFIED_BY="[Empty name]">
<P>mortality, time to extubation, ICU-stay, vaso-active medication, biomarker<BR/>"no major complications"</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-12-15 16:57:54 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Enc-2006">
<CHAR_METHODS MODIFIED="2009-12-15 16:55:16 +0530" MODIFIED_BY="[Empty name]">
<P>Randomized placebo-controlled, double blinded trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 16:55:55 +0530" MODIFIED_BY="[Empty name]">
<P>40, elective CABG</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 16:56:53 +0530" MODIFIED_BY="[Empty name]">
<P>25 mg/kg Methylprednisolone, 1 hour before initiation of CPB</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-15 16:57:54 +0530" MODIFIED_BY="[Empty name]">
<P>hospital-stay, renal failure, neurological complications, atrial fibrillation<BR/>"no major complications"</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-12-15 17:04:20 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Engelman-1995">
<CHAR_METHODS MODIFIED="2009-12-15 17:01:41 +0530" MODIFIED_BY="[Empty name]">
<P>Randomized placebo-controlled, double blinded trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 17:02:03 +0530" MODIFIED_BY="[Empty name]">
<P>19 elective CABG</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 17:03:33 +0530" MODIFIED_BY="[Empty name]">
<P>1 x 1000 mg Methylprednisolone before CPB, 4 x 4 mg Dexamethasone after surgery</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-15 17:04:20 +0530" MODIFIED_BY="[Empty name]">
<P>mortality, time to extubation, ICU-stay, Hospital-stay, biomarker</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-01 18:23:01 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ferries-1984">
<CHAR_METHODS MODIFIED="2009-12-15 17:05:47 +0530" MODIFIED_BY="[Empty name]">
<P>Randomized placebo-controlled, double blinded trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 17:07:22 +0530" MODIFIED_BY="[Empty name]">
<P>80 CABG and/or valve surgery and/or ASD surgery</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 17:07:52 +0530" MODIFIED_BY="[Empty name]">
<P>30 mg/kg Methylprednisolone<BR/>Membrane versus bubble oxygenator</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-15 17:08:30 +0530" MODIFIED_BY="[Empty name]">
<P>mortality, biomarker<BR/>"no major complications"</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-02-01 18:23:01 +0530" MODIFIED_BY="[Empty name]">
<P>same study-population as Ferries 1987</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-02-22 16:38:46 +0530" MODIFIED_BY="Nicole Ackermann" STUDY_ID="STD-Fillinger-2002">
<CHAR_METHODS MODIFIED="2009-12-15 17:12:25 +0530" MODIFIED_BY="[Empty name]">
<P>Randomized placebo-controlled, double blinded trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-02-22 16:38:46 +0530" MODIFIED_BY="Nicole Ackermann">
<P>50 elective CABG<BR/>(15 steroids, 15 placebo, 14 etomidate, 6 healthy volunteered) - 30 included in meta-analysis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 17:15:12 +0530" MODIFIED_BY="[Empty name]">
<P>15 mg/kg Methylprednisolone 60 minutes before surgical incision, 4 x 0,3 mg/kg Methylprednisolone after surgery.<BR/>Etomidate</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-15 17:17:11 +0530" MODIFIED_BY="[Empty name]">
<P>time to extubation, ICU-stay, hospital-stay, biomarker</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-12-15 17:16:30 +0530" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-02-22 16:39:05 +0530" MODIFIED_BY="Nicole Ackermann" STUDY_ID="STD-Giomarelli-2003">
<CHAR_METHODS MODIFIED="2009-12-15 17:18:39 +0530" MODIFIED_BY="[Empty name]">
<P>Randomized placebo-controlled, double blinded trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 17:19:32 +0530" MODIFIED_BY="[Empty name]">
<P>20 elective CABG</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 17:21:24 +0530" MODIFIED_BY="[Empty name]">
<P>1000 mg Methylprednisolon pre-operatively, 5 x 125 mg Methylprednisolone after CPB and at ICU</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-02-22 16:39:05 +0530" MODIFIED_BY="Nicole Ackermann">
<P>mortality, cardiac complications, pulmonary complications, time to extubation, ICU-stay, hospital-stay, renal failure, neurological complications, atrial fibrillation, vasoactive medication, blood transfusion Y/N, biomarker</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-12-15 17:23:22 +0530" MODIFIED_BY="[Empty name]">
<P>outcome retrieved after correspondence with author</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-03-02 22:01:23 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Halonen-2007">
<CHAR_METHODS MODIFIED="2009-12-15 17:23:32 +0530" MODIFIED_BY="[Empty name]">
<P>Randomized placebo-controlled, double blinded trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 17:25:01 +0530" MODIFIED_BY="[Empty name]">
<P>241 CABG and/or aortic valve surgery</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 17:28:11 +0530" MODIFIED_BY="[Empty name]">
<P>10 x 100 mg Hydrocortisone; first in the evening pre-surgery, repeated eight hourly </P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-03-02 22:01:23 +0530" MODIFIED_BY="[Empty name]">
<P>mortality, cardiac complications, neurological complications, atrial fibrillation, infections, re-thoracotomy<BR/>"no major complications"</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-12-15 17:29:34 +0530" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-02-22 16:39:30 +0530" MODIFIED_BY="Nicole Ackermann" STUDY_ID="STD-Halvorsen-2003">
<CHAR_METHODS MODIFIED="2009-12-15 17:30:47 +0530" MODIFIED_BY="[Empty name]">
<P>Randomized, placebo-controlled, double blinded trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-02-22 16:39:28 +0530" MODIFIED_BY="Nicole Ackermann">
<P>300 elective CABG<BR/>6 excluded from analysis (abdominal complications, anaphylaxis, study violation)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 17:32:59 +0530" MODIFIED_BY="[Empty name]">
<P>8 mg/kg Dexamethasone after induction</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-02-22 16:39:29 +0530" MODIFIED_BY="Nicole Ackermann">
<P>mortality, cardiac complications, pulmonary complications, time to extubation, ICU-stay, atrial fibrillation, gastro-intestinal complications, infections, vasoactive medication, blood transfusion Y/N, re-thoracotomy</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-02-22 16:39:30 +0530" MODIFIED_BY="Nicole Ackermann">
<P>6 excluded from analysis (abdominal complications, anaphylaxis, study violation)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-01-05 19:16:54 +0530" MODIFIED_BY="Nicole Ackermann" STUDY_ID="STD-Harig-1999">
<CHAR_METHODS MODIFIED="2009-12-15 17:45:04 +0530" MODIFIED_BY="[Empty name]">
<P>Randomized, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 17:46:31 +0530" MODIFIED_BY="[Empty name]">
<P>40 elective CABG<BR/>(10 steroids, 10 placebo, 10 aprotinine, 10 heparine coated system), 20 included in meta-analysis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 17:46:58 +0530" MODIFIED_BY="[Empty name]">
<P>2 x 250 mg Prednisolone pre-and postoperatively</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-15 18:01:56 +0530" MODIFIED_BY="[Empty name]">
<P>mortality, time to extubation, ICU-stay, re-thoracotomy, biomarker</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-01-05 19:16:54 +0530" MODIFIED_BY="Nicole Ackermann"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-12-15 18:03:21 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jansen-1991a">
<CHAR_METHODS MODIFIED="2009-12-15 18:00:04 +0530" MODIFIED_BY="[Empty name]">
<P>Randomized, placebo-controlled, double-blinded trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 18:00:28 +0530" MODIFIED_BY="[Empty name]">
<P>25 elective CABG</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 18:02:44 +0530" MODIFIED_BY="[Empty name]">
<P>1 mg/kg Dexamethasone</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-15 18:03:21 +0530" MODIFIED_BY="[Empty name]">
<P>mortality, ICU-stay, infections, biomarker</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-12-15 18:01:35 +0530" MODIFIED_BY="[Empty name]">
<P>3 excluded, study-violation</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-02-22 16:40:40 +0530" MODIFIED_BY="Nicole Ackermann" STUDY_ID="STD-Kilger-2003a">
<CHAR_METHODS MODIFIED="2009-12-15 18:04:29 +0530" MODIFIED_BY="[Empty name]">
<P>Randomized, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 18:13:20 +0530" MODIFIED_BY="[Empty name]">
<P>91 high risk cardiac surgery</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 18:08:50 +0530" MODIFIED_BY="[Empty name]">
<P>Hydrocortisone, 1x 100 mg before induction, followed by 240 mg/day, 120 mg/day, 60 mg/day, 30 mg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-02-22 16:40:40 +0530" MODIFIED_BY="Nicole Ackermann">
<P>mortality, time to extubation, ICU-stay, hospital-stay, number of blood transfusions, biomarker</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-01-05 19:17:40 +0530" MODIFIED_BY="Nicole Ackermann"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-02-22 16:40:46 +0530" MODIFIED_BY="Nicole Ackermann" STUDY_ID="STD-Kilger-2003b">
<CHAR_METHODS MODIFIED="2009-12-15 18:14:35 +0530" MODIFIED_BY="[Empty name]">
<P>Randomized, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 18:15:56 +0530" MODIFIED_BY="[Empty name]">
<P>80 high risk cardiac surgery</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 18:14:35 +0530" MODIFIED_BY="[Empty name]">
<P>Hydrocortisone, 1x 100 mg before induction, followed by 240 mg/day, 120 mg/day, 60 mg/day, 30 mg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-02-22 16:40:46 +0530" MODIFIED_BY="Nicole Ackermann">
<P>time to extubation, ICU-stay, hospital-stay, number of blood transfusions, biomarker</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-12-15 18:16:19 +0530" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-12-15 18:20:07 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liakopoulos-2007">
<CHAR_METHODS MODIFIED="2009-12-15 18:18:39 +0530" MODIFIED_BY="[Empty name]">
<P>Randomized, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 18:18:54 +0530" MODIFIED_BY="[Empty name]">
<P>80 elective CABG</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 18:19:13 +0530" MODIFIED_BY="[Empty name]">
<P>15 mg/kg Methylprednisolone pre-CPB</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-15 18:20:07 +0530" MODIFIED_BY="[Empty name]">
<P>mortality, pulmonary complications, re-intubation, time to extubation, ICU-stay, hospital-stay, renal failure, infections, biomarker</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-12-15 18:19:24 +0530" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-02-22 16:41:12 +0530" MODIFIED_BY="Nicole Ackermann" STUDY_ID="STD-Loef-2004">
<CHAR_METHODS MODIFIED="2009-12-15 18:21:10 +0530" MODIFIED_BY="[Empty name]">
<P>Randomized, placebo-controlled, double-blinded trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 18:25:24 +0530" MODIFIED_BY="[Empty name]">
<P>20 elective CABG</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 18:26:32 +0530" MODIFIED_BY="[Empty name]">
<P>Dexamethasone, 1 mg/kg before induction, 0,5 mg/kg after 8 hours</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-02-22 16:41:12 +0530" MODIFIED_BY="Nicole Ackermann">
<P>mortality, time to extubation, ICU-stay, vasoactive medication, number of blood transfusions, biomarker</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-01-05 19:17:15 +0530" MODIFIED_BY="Nicole Ackermann"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-02-22 16:41:21 +0530" MODIFIED_BY="Nicole Ackermann" STUDY_ID="STD-Mayumi-1997">
<CHAR_METHODS MODIFIED="2009-12-15 18:29:47 +0530" MODIFIED_BY="[Empty name]">
<P>Randomized, placebo-controlled, double-blinded trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 18:30:06 +0530" MODIFIED_BY="[Empty name]">
<P>24 elective valve replacement surgery</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 18:31:45 +0530" MODIFIED_BY="[Empty name]">
<P>2 x 20 mg/kg Methylprednisolone, before and after bypass</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-02-22 16:41:21 +0530" MODIFIED_BY="Nicole Ackermann">
<P>mortality, time to extubation, infection, transfusion Y/N, biomarker</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-12-15 18:29:28 +0530" MODIFIED_BY="[Empty name]">
<P>3 patients excluded; 1x IABP - 2x Bloodtransfusion</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-12-15 18:40:54 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McBride-2004">
<CHAR_METHODS MODIFIED="2009-12-15 18:36:38 +0530" MODIFIED_BY="[Empty name]">
<P>Randomized, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 18:37:35 +0530" MODIFIED_BY="[Empty name]">
<P>36 elective CABG</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 18:38:57 +0530" MODIFIED_BY="[Empty name]">
<P>30 mg/kg Methylprednisolone, before induction</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-15 18:40:54 +0530" MODIFIED_BY="[Empty name]">
<P>mortality, cardiac complications, time to extubation, hospital-stay, vasoactive medication, re-thoracotomy, biomarker</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-12-15 18:36:44 +0530" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-12-15 18:44:30 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Morton-1976">
<CHAR_METHODS MODIFIED="2009-12-15 18:41:44 +0530" MODIFIED_BY="[Empty name]">
<P>Randomized, placebo-controlled, double-blinded trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 18:42:27 +0530" MODIFIED_BY="[Empty name]">
<P>95 elective CABG</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 18:43:41 +0530" MODIFIED_BY="[Empty name]">
<P>30 mg/kg or 2000 mg Methylprednisolone, before induction</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-15 18:44:20 +0530" MODIFIED_BY="[Empty name]">
<P>mortality, cardiac complications, pulmonary complications</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-12-15 18:44:30 +0530" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-02-22 16:42:02 +0530" MODIFIED_BY="Nicole Ackermann" STUDY_ID="STD-Oliver-2004">
<CHAR_METHODS MODIFIED="2010-08-26 01:41:32 +0530" MODIFIED_BY="[Empty name]">
<P>Randomized, placebo-controlled, double-blinded trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 18:49:49 +0530" MODIFIED_BY="[Empty name]">
<P>189 cardiac surgery requiring CPB<BR/>(62 steroids, 63 placebo, 64 hemofiltration), 125 included in meta-analysis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 19:01:10 +0530" MODIFIED_BY="[Empty name]">
<P>1000 mg Methylprednisolone, before induction, 4 x 4 mg Dexamethasone 6 hourly</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-02-22 16:42:02 +0530" MODIFIED_BY="Nicole Ackermann">
<P>mortality, cardiac complications, pulmonary complications, time to extubation, ICU-stay, neurological complications, transfusion Y/N, re-thoracotomy</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-12-15 18:59:57 +0530" MODIFIED_BY="[Empty name]">
<P>3 exclusions; study-violation (lateral thoracotomy, retrosternal mass, surgery cancelled)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-12-15 19:04:36 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Prasongsukarn-2005">
<CHAR_METHODS MODIFIED="2009-12-15 19:00:20 +0530" MODIFIED_BY="[Empty name]">
<P>Randomized, placebo-controlled, double-blinded trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 19:00:45 +0530" MODIFIED_BY="[Empty name]">
<P>86 elective CABG<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 19:01:38 +0530" MODIFIED_BY="[Empty name]">
<P>1000 mg Methylprednisolone, before induction, 4 x 4 mg Dexamethasone 6 hourly</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-15 19:02:55 +0530" MODIFIED_BY="[Empty name]">
<P>mortality, renal failure, neurological complications, atrial fibrillation, gastro-intestinal complications, infections, biomarker</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-12-15 19:04:36 +0530" MODIFIED_BY="[Empty name]">
<P>2 patients excluded; off pump</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-12-15 19:05:41 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rao-1977">
<CHAR_METHODS MODIFIED="2009-12-15 19:04:03 +0530" MODIFIED_BY="[Empty name]">
<P>Randomized, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 19:04:13 +0530" MODIFIED_BY="[Empty name]">
<P>150 elective CABG</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 19:05:18 +0530" MODIFIED_BY="[Empty name]">
<P>1000 mg Methylprednisolone before CPB</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-15 19:05:41 +0530" MODIFIED_BY="[Empty name]">
<P>mortality, cardiac complications, pulmonary complications, neurological complications, infections, </P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-12-15 19:03:59 +0530" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-12-15 19:10:09 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rubens-2005">
<CHAR_METHODS MODIFIED="2009-12-15 19:06:09 +0530" MODIFIED_BY="[Empty name]">
<P>Randomized, placebo-controlled, double-blinded trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 19:07:20 +0530" MODIFIED_BY="[Empty name]">
<P>68 elective CABG</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 19:09:06 +0530" MODIFIED_BY="[Empty name]">
<P>1000 mg Methylprednisolone, before CPB<BR/>Surface Modifiing additive - CPB</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-15 19:09:53 +0530" MODIFIED_BY="[Empty name]">
<P>mortality, cardiac complications, ICU-stay, hospital-stay, atrial fibrillation, infections, biomarker</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-12-15 19:10:09 +0530" MODIFIED_BY="[Empty name]">
<P>3 excluded before surgery started</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-12-15 19:12:39 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rumalla-2001">
<CHAR_METHODS MODIFIED="2009-12-15 19:10:32 +0530" MODIFIED_BY="[Empty name]">
<P>Randomized, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 19:11:06 +0530" MODIFIED_BY="[Empty name]">
<P>13 elective CABG</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 19:11:22 +0530" MODIFIED_BY="[Empty name]">
<P>1000 mg Methylprednisolone, at induction</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-15 19:12:39 +0530" MODIFIED_BY="[Empty name]">
<P>mortality, neurological complications, infections, re-thoracotomy, biomarker</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-12-15 19:10:26 +0530" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-02-22 16:44:05 +0530" MODIFIED_BY="Nicole Ackermann" STUDY_ID="STD-Sano-2003">
<CHAR_METHODS MODIFIED="2009-12-15 19:13:22 +0530" MODIFIED_BY="[Empty name]">
<P>Randomized, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 19:14:30 +0530" MODIFIED_BY="[Empty name]">
<P>28 elective CABG<BR/>(10 steroids, 10 placebo, 10 off pump), 20 included in meta-analysis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 19:15:05 +0530" MODIFIED_BY="[Empty name]">
<P>2 x 50 mg/kg Hydrocortisone, before and after CPB</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-02-22 16:44:05 +0530" MODIFIED_BY="Nicole Ackermann">
<P>mortality, pulmonary complications, blood transfusion Y/N, biomarker<BR/>"no major complications"</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-12-15 19:13:18 +0530" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-12-15 19:19:52 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sano-2006">
<CHAR_METHODS MODIFIED="2009-12-15 19:16:37 +0530" MODIFIED_BY="[Empty name]">
<P>Randomized, placebo-controlled, double-blinded trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 19:16:46 +0530" MODIFIED_BY="[Empty name]">
<P>60 elective CABG</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 19:17:23 +0530" MODIFIED_BY="[Empty name]">
<P>50 mg/kg Hydrocortisone, before and after CPB</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-15 19:19:52 +0530" MODIFIED_BY="[Empty name]">
<P>pulmonary complications, time to extubation, ICU-stay, renal failure, atrial fibrillation, infections<BR/>"no major complications"</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-12-15 19:16:38 +0530" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-12-15 19:23:13 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schurr-2001">
<CHAR_METHODS MODIFIED="2009-12-15 19:20:57 +0530" MODIFIED_BY="[Empty name]">
<P>Randomized, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 19:21:04 +0530" MODIFIED_BY="[Empty name]">
<P>50 elective CABG</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 19:21:35 +0530" MODIFIED_BY="[Empty name]">
<P>10 mg/kg Methylprednisolone, 4 hours before surgery</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-15 19:23:13 +0530" MODIFIED_BY="[Empty name]">
<P>time to extubation, ICU-stay, hospital-stay, atrial fibrillation, vasoactive medication, re-thoracotomy, biomarker<BR/>"no major complications"</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-12-15 19:20:52 +0530" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-20 18:39:25 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sobieski-2008">
<CHAR_METHODS MODIFIED="2010-01-20 18:36:33 +0530" MODIFIED_BY="[Empty name]">
<P>Randomized placebo-controlled double-blinded trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-20 18:39:25 +0530" MODIFIED_BY="[Empty name]">
<P>28 elective CABG</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-20 18:39:00 +0530" MODIFIED_BY="[Empty name]">
<P>100 mg dexamethasone pre-CPB</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-20 18:37:51 +0530" MODIFIED_BY="[Empty name]">
<P>mortality, time to extubation, ICU-stay, hospital stay, renal failure, neurological complications, atrial fibrillation, re-thoracotomy</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-20 18:42:35 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Starobin-2007">
<CHAR_METHODS MODIFIED="2010-01-20 18:38:26 +0530" MODIFIED_BY="[Empty name]">
<P>Randomized placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-20 18:39:45 +0530" MODIFIED_BY="[Empty name]">
<P>60 elective CABG</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-20 18:40:52 +0530" MODIFIED_BY="[Empty name]">
<P>5 mg betamethasone slow release, 2 mg betamethasone rapid-release 2-3 weeks prior to surgery</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-20 18:42:35 +0530" MODIFIED_BY="[Empty name]">
<P>mortality, pulmonary complications, time to extubation, ICU-stay, hospital stay, renal failure, neurological complications, atrial fibrillation, infections, re-thoracotomy</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-02-22 16:44:58 +0530" MODIFIED_BY="Nicole Ackermann" STUDY_ID="STD-Tassani-1999">
<CHAR_METHODS MODIFIED="2009-12-15 19:24:09 +0530" MODIFIED_BY="[Empty name]">
<P>Randomized, placebo-controlled, double-blinded trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 19:24:14 +0530" MODIFIED_BY="[Empty name]">
<P>52 elective CABG</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 19:38:28 +0530" MODIFIED_BY="[Empty name]">
<P>1000 mg Methylprednisolone, half an hour before CPB</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-02-22 16:44:58 +0530" MODIFIED_BY="Nicole Ackermann">
<P>time to extubation, ICU-stay, hospital-stay, blood transfusion Y/N, biomarker<BR/>"no major complications"</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-12-15 19:24:09 +0530" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-02-22 16:45:07 +0530" MODIFIED_BY="Nicole Ackermann" STUDY_ID="STD-Toft-1997">
<CHAR_METHODS MODIFIED="2009-12-15 19:34:45 +0530" MODIFIED_BY="[Empty name]">
<P>Randomized, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 19:35:35 +0530" MODIFIED_BY="[Empty name]">
<P>16 low risk cardiac surgery with CPB</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 19:36:02 +0530" MODIFIED_BY="[Empty name]">
<P>30 mg/kg Methylprednisolone at induction</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-02-22 16:45:07 +0530" MODIFIED_BY="Nicole Ackermann">
<P>mortality, pulmonary complications, renal failure, infections, biomarker</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-12-15 19:34:38 +0530" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-12-15 19:40:00 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Turkoz-2001">
<CHAR_METHODS MODIFIED="2009-12-15 19:37:26 +0530" MODIFIED_BY="[Empty name]">
<P>Randomized, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 19:37:55 +0530" MODIFIED_BY="[Empty name]">
<P>30 elective CABG<BR/>(10 steroids, 10 placebo, 10 aprotinine), 20 included in meta-analysis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 19:39:28 +0530" MODIFIED_BY="[Empty name]">
<P>30 mg/kg Methylprednisolone, before CPB</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-15 19:40:00 +0530" MODIFIED_BY="[Empty name]">
<P>number of transfusions, biomarker<BR/>"no major complications"</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-12-15 19:37:23 +0530" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-12-15 19:43:29 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Volk-2001">
<CHAR_METHODS MODIFIED="2009-12-15 19:41:14 +0530" MODIFIED_BY="[Empty name]">
<P>Randomized, placebo-controlled, double-blinded trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 19:42:20 +0530" MODIFIED_BY="[Empty name]">
<P>39 elective CABG (13 steroids, 13 placebo, 13 tirilazad mesylate) <BR/>26 included in meta-analysis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 19:42:57 +0530" MODIFIED_BY="[Empty name]">
<P>15 mg/kg Methylprednisolone, one and a half hour before CPB</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-15 19:43:29 +0530" MODIFIED_BY="[Empty name]">
<P>mortality, ICU-stay, hospital-stay, biomarker</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-12-15 19:41:15 +0530" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-02-22 16:45:33 +0530" MODIFIED_BY="Nicole Ackermann" STUDY_ID="STD-Volk-2003">
<CHAR_METHODS MODIFIED="2009-12-15 19:45:05 +0530" MODIFIED_BY="[Empty name]">
<P>Randomized, placebo-controlled, double-blinded trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 19:45:23 +0530" MODIFIED_BY="[Empty name]">
<P>36 elective CABG (12 steroids, 12 placebo, 12 tirilazad mesylate)<BR/>24 included in meta-analysis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 19:45:05 +0530" MODIFIED_BY="[Empty name]">
<P>15 mg/kg Methylprednisolone, one and a half hour before CPB</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-02-22 16:45:33 +0530" MODIFIED_BY="Nicole Ackermann">
<P>mortality, cardiac complications, ICU-stay, number of blood transfusions</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-12-15 19:45:05 +0530" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-12-15 19:48:43 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-von-Spiegel-2001">
<CHAR_METHODS MODIFIED="2009-12-15 19:46:56 +0530" MODIFIED_BY="[Empty name]">
<P>Randomized, placebo-controlled, double-blinded trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 19:47:19 +0530" MODIFIED_BY="[Empty name]">
<P>20 elective CABG</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 19:48:18 +0530" MODIFIED_BY="[Empty name]">
<P>1 mg/kg Dexamethasone, after induction</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-15 19:48:43 +0530" MODIFIED_BY="[Empty name]">
<P>mortality, vasoactive medication</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-12-15 19:46:56 +0530" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-12-15 19:53:45 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wan-1999">
<CHAR_METHODS MODIFIED="2009-12-15 19:49:46 +0530" MODIFIED_BY="[Empty name]">
<P>Randomized, placebo-controlled, double-blinded trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 19:50:18 +0530" MODIFIED_BY="[Empty name]">
<P>20 elective CABG or valve</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 19:51:06 +0530" MODIFIED_BY="[Empty name]">
<P>30 mg/kg Methylprednisolone, during induction</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-15 19:51:29 +0530" MODIFIED_BY="[Empty name]">
<P>mortality, time to extubation, ICU-stay, biomarker</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-12-15 19:53:45 +0530" MODIFIED_BY="[Empty name]">
<P>77 eligible patients were excluded from the final study because they didn't met inclusion criteria</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-29 00:09:43 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Weis-2006">
<CHAR_METHODS MODIFIED="2009-12-15 19:54:01 +0530" MODIFIED_BY="[Empty name]">
<P>Randomized, placebo-controlled, double-blinded trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 19:56:01 +0530" MODIFIED_BY="[Empty name]">
<P>36 high risk CPB-patients (8 lost to follow up)<BR/>28 included in meta-analysis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 19:56:41 +0530" MODIFIED_BY="[Empty name]">
<P>Hydrocortisone, 1x 100 mg before induction, followed by 240 mg/day, 120 mg/day, 60 mg/day, 30 mg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-29 00:09:43 +0530" MODIFIED_BY="[Empty name]">
<P>mortality, time to intubation, ICU-stay, hospital stay, post-traumatic stress, health related quality of life</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-12-15 19:54:58 +0530" MODIFIED_BY="[Empty name]">
<P>8 patients lost to follow up</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-20 18:45:04 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Weis-2009">
<CHAR_METHODS MODIFIED="2010-01-20 18:43:21 +0530" MODIFIED_BY="[Empty name]">
<P>Randomized, placebo-controlled, double-blinded trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-20 18:43:38 +0530" MODIFIED_BY="[Empty name]">
<P>36 high-risk CPB patients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-20 18:44:09 +0530" MODIFIED_BY="[Empty name]">
<P>Hydrocortisone, 1x 100 mg before induction, followed by 240 mg/day, 120 mg/day, 60 mg/day, 30 mg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-20 18:45:04 +0530" MODIFIED_BY="[Empty name]">
<P>mortality, pulmonary complications, intubation time, ICU-stay, hospital stay, renal failure, atrial fibrillation, infections, number of blood-transfusions, biomarker</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-02-22 16:46:32 +0530" MODIFIED_BY="Nicole Ackermann" STUDY_ID="STD-Whitlock-2006">
<CHAR_METHODS MODIFIED="2009-12-15 19:58:16 +0530" MODIFIED_BY="[Empty name]">
<P>Randomized, placebo-controlled, double-blinded trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 20:01:16 +0530" MODIFIED_BY="[Empty name]">
<P>60 all types of cardiac surgery with CPB</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 19:59:06 +0530" MODIFIED_BY="[Empty name]">
<P>2 x 150 mg Methylprednisolone, at induction and at start CPB</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-02-22 16:46:32 +0530" MODIFIED_BY="Nicole Ackermann">
<P>mortality, cardiac complications, pulmonary complications, time to extubation, ICU stay, hospital stay, renal failure, neurological complications, atrial fibrillation, gastro-intestinal complications, infections, vasoactive medication, number of blood transfusions, biomarker</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-12-15 19:59:19 +0530" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-01-05 19:19:37 +0530" MODIFIED_BY="Nicole Ackermann" STUDY_ID="STD-Yared-1998">
<CHAR_METHODS MODIFIED="2009-12-15 20:01:57 +0530" MODIFIED_BY="[Empty name]">
<P>Randomized, placebo-controlled, double-blinded trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 20:02:42 +0530" MODIFIED_BY="[Empty name]">
<P>236 elective CABG or valve surgery</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 20:03:12 +0530" MODIFIED_BY="[Empty name]">
<P>0,6 mg/kg Dexamethasone, after induction</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-29 00:41:41 +0530" MODIFIED_BY="[Empty name]">
<P>mortality, cardiac complications, time to extubation, ICU-stay, renal failure, neurological complications, infections, vasoactive medication, shivering</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-01-05 19:19:37 +0530" MODIFIED_BY="Nicole Ackermann">
<P>
<BR/>20 exclusions (no study-medication (10), bleeding (3), aprotinine (1), Additive steroids (6))</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-03-31 16:04:17 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yared-2007">
<CHAR_METHODS MODIFIED="2009-12-15 20:07:10 +0530" MODIFIED_BY="[Empty name]">
<P>Randomized, placebo-controlled, double-blinded trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 20:09:37 +0530" MODIFIED_BY="[Empty name]">
<P>78 elective combined CABG and valve surgery (7 excluded)<BR/>71 included in meta-analysis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 20:07:10 +0530" MODIFIED_BY="[Empty name]">
<P>0,6 mg/kg Dexamethasone, after induction</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-15 20:10:53 +0530" MODIFIED_BY="[Empty name]">
<P>mortality, cardiac complications, pulmonary complications, time to extubation, ICU-stay, renal failure, neurological complications, atrial fibrillation, infections, biomarker<BR/>"no major complications"</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-31 16:04:17 +0530" MODIFIED_BY="[Empty name]">
<P>7 exclusions (change in surgical plan (5), aprotinine (1), additives steroids (1))</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-09 16:50:22 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yilmaz-1999">
<CHAR_METHODS MODIFIED="2009-12-15 20:11:31 +0530" MODIFIED_BY="[Empty name]">
<P>Randomized, placebo-controlled, double-blinded trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 20:11:45 +0530" MODIFIED_BY="[Empty name]">
<P>20 elective CABG</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 20:12:57 +0530" MODIFIED_BY="[Empty name]">
<P>1 mg/kg Methylprednisolone in pump prime solution</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-15 20:13:47 +0530" MODIFIED_BY="[Empty name]">
<P>time to extubation, ICU-stay, hospital stay, infections, vasoactive medication, biomarker</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-02-09 16:50:22 +0530" MODIFIED_BY="[Empty name]">
<P>pump-prime solution!!<BR/>5 patients excluded: (2x glucose dysregulation, transfusion need 3x) </P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>Abbreviations are explained in full in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2011-03-31 16:08:37 +0530" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2010-09-21 15:57:11 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Anic-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-21 15:57:11 +0530" MODIFIED_BY="[Empty name]">
<P>No clinical endpoints reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-01-12 08:48:57 +0530" MODIFIED_BY="Joey Kwong" STUDY_ID="STD-Augoustides-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-01-12 08:48:57 +0530" MODIFIED_BY="Joey Kwong">
<P>Comment on another study in letter to the editor. No randomized controlled trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-21 15:57:11 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Baker-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-21 15:57:11 +0530" MODIFIED_BY="[Empty name]">
<P>Review article</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-21 15:57:11 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Baraka-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-21 15:57:11 +0530" MODIFIED_BY="[Empty name]">
<P>No clinical endpoints reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-21 15:57:11 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Biagioli-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-21 15:57:11 +0530" MODIFIED_BY="[Empty name]">
<P>No clinical endpoints reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-21 15:57:11 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Boldt-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-21 15:57:11 +0530" MODIFIED_BY="[Empty name]">
<P>No clinical endpoints reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-21 15:57:11 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chaney-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-21 15:57:11 +0530" MODIFIED_BY="[Empty name]">
<P>Review article</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-21 15:57:11 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Coffin-1975">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-21 15:57:11 +0530" MODIFIED_BY="[Empty name]">
<P>No randomization (consecutive patients)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-21 15:57:11 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Coraim-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-21 15:57:11 +0530" MODIFIED_BY="[Empty name]">
<P>No clinical endpoints reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-03-31 16:08:37 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Corbi-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-03-31 16:08:37 +0530" MODIFIED_BY="[Empty name]">
<P>Comment on another study in letter to the editor. No randomized controlled trial. </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-21 15:57:12 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dernek-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-21 15:57:12 +0530" MODIFIED_BY="[Empty name]">
<P>No randomization</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-21 15:57:12 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Diego-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-21 15:57:12 +0530" MODIFIED_BY="[Empty name]">
<P>No clinical endpoints reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-21 15:57:12 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-El-Busto-Osacar-1977">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-21 15:57:12 +0530" MODIFIED_BY="[Empty name]">
<P>No randomization</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-21 15:57:12 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-El-Busto-Osacar-1979">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-21 15:57:12 +0530" MODIFIED_BY="[Empty name]">
<P>No clinical outcomes reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-21 15:57:12 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Enderby-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-21 15:57:12 +0530" MODIFIED_BY="[Empty name]">
<P>No randomization</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-21 15:57:12 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Erel-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-21 15:57:12 +0530" MODIFIED_BY="[Empty name]">
<P>No clinical endpoints reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-21 15:57:12 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fecht-1978">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-21 15:57:12 +0530" MODIFIED_BY="[Empty name]">
<P>No randomization </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-21 15:57:12 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fosse-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-21 15:57:12 +0530" MODIFIED_BY="[Empty name]">
<P>No randomization</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-21 15:57:12 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Giannaris-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-21 15:57:12 +0530" MODIFIED_BY="[Empty name]">
<P>No clinical endpoints reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-21 15:57:12 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gott-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-21 15:57:12 +0530" MODIFIED_BY="[Empty name]">
<P>No untreated control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-21 15:57:12 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gupta-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-21 15:57:12 +0530" MODIFIED_BY="[Empty name]">
<P>No clinical endpoints reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-21 15:57:12 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Halonen-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-21 15:57:12 +0530" MODIFIED_BY="[Empty name]">
<P>Review article</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-21 15:57:12 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hill-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-21 15:57:12 +0530" MODIFIED_BY="[Empty name]">
<P>No clinical endpoints reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-21 15:57:12 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hill-1995a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-21 15:57:12 +0530" MODIFIED_BY="[Empty name]">
<P>No clinical endpoints reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-21 15:57:12 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hill-1995b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-21 15:57:12 +0530" MODIFIED_BY="[Empty name]">
<P>No clinical endpoints reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-21 15:57:12 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hoche-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-21 15:57:12 +0530" MODIFIED_BY="[Empty name]">
<P>No clinical endpoints reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-21 15:57:12 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hoche-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-21 15:57:12 +0530" MODIFIED_BY="[Empty name]">
<P>No clinical endpoints reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-21 15:57:13 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Husedzinovic-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-21 15:57:13 +0530" MODIFIED_BY="[Empty name]">
<P>No clinical endpoints reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-21 15:57:13 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Inaba-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-21 15:57:13 +0530" MODIFIED_BY="[Empty name]">
<P>No randomization reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-21 15:57:13 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jahangiri-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-21 15:57:13 +0530" MODIFIED_BY="[Empty name]">
<P>Review article</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-21 15:57:13 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Janower-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-21 15:57:13 +0530" MODIFIED_BY="[Empty name]">
<P>Review article</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-21 15:57:13 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jansen-1991b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-21 15:57:13 +0530" MODIFIED_BY="[Empty name]">
<P>No clinical endpoints reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-21 15:57:13 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jorens-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-21 15:57:13 +0530" MODIFIED_BY="[Empty name]">
<P>No clinical endpoints reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-03-31 16:08:28 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Juneja-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-03-31 16:08:28 +0530" MODIFIED_BY="[Empty name]">
<P>Unsufficient data in abstract (only publication about this study); no additional data received upon request. </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-21 15:57:13 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Karlstad-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-21 15:57:13 +0530" MODIFIED_BY="[Empty name]">
<P>No clinical endpoints reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-21 15:57:13 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kawamura-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-21 15:57:13 +0530" MODIFIED_BY="[Empty name]">
<P>No clinical endpoints reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-21 15:57:13 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kawamura-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-21 15:57:13 +0530" MODIFIED_BY="[Empty name]">
<P>No clinical endpoints reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-21 15:57:13 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kilger-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-21 15:57:13 +0530" MODIFIED_BY="[Empty name]">
<P>Review article</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-22 18:02:33 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kilickan-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-22 18:02:33 +0530" MODIFIED_BY="[Empty name]">
<P>No data regarding major clinical outcomes available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-21 15:57:13 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kirsh-1979">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-21 15:57:13 +0530" MODIFIED_BY="[Empty name]">
<P>Steroids in cardioplegic solution only</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-21 15:57:13 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kito-1980">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-21 15:57:13 +0530" MODIFIED_BY="[Empty name]">
<P>No clinical endpoints reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-21 15:57:13 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kobayashi-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-21 15:57:13 +0530" MODIFIED_BY="[Empty name]">
<P>No clinical endpoints reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-21 15:57:13 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Launo-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-21 15:57:13 +0530" MODIFIED_BY="[Empty name]">
<P>No cardiac surgical patient (general thoracic surgery)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-21 15:57:13 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lee-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-21 15:57:13 +0530" MODIFIED_BY="[Empty name]">
<P>Administration only postoperatively (not prophylactic)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-21 15:57:13 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Levinsky-1979">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-21 15:57:13 +0530" MODIFIED_BY="[Empty name]">
<P>Steroids in cardioplegic solution only</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-21 15:57:13 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Loubser-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-21 15:57:13 +0530" MODIFIED_BY="[Empty name]">
<P>No clinical endpoints reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-03-31 16:08:04 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Medonca_x002d_Filho-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-03-31 16:08:04 +0530" MODIFIED_BY="[Empty name]">
<P>Observational prospective study. It was listed two times in our database under names Medonca 2004 and Filho 2004.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-21 15:57:14 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ming-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-21 15:57:14 +0530" MODIFIED_BY="[Empty name]">
<P>No clinical endpoints reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-21 15:57:14 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Miranda-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-21 15:57:14 +0530" MODIFIED_BY="[Empty name]">
<P>No clinical endpoints reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-21 15:57:14 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Niazi-1979">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-21 15:57:14 +0530" MODIFIED_BY="[Empty name]">
<P>Not randomized (consecutive patients)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-01-12 08:48:58 +0530" MODIFIED_BY="Joey Kwong" STUDY_ID="STD-Oh-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-01-12 08:48:58 +0530" MODIFIED_BY="Joey Kwong">
<P>Comment on another study in letter to the editor. No randomized controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-21 15:57:14 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ohe-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-21 15:57:14 +0530" MODIFIED_BY="[Empty name]">
<P>Not randomized</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-21 15:57:14 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Raff-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-21 15:57:14 +0530" MODIFIED_BY="[Empty name]">
<P>No clinical endpoints reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-21 15:57:14 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ranucci-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-21 15:57:14 +0530" MODIFIED_BY="[Empty name]">
<P>No clinical endpoints reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-21 15:57:14 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Santarpino-2009a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-21 15:57:14 +0530" MODIFIED_BY="[Empty name]">
<P>No untreated control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-21 15:57:14 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Santarpino-2009b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-21 15:57:14 +0530" MODIFIED_BY="[Empty name]">
<P>No untreated control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-21 15:57:14 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schelling-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-21 15:57:14 +0530" MODIFIED_BY="[Empty name]">
<P>Review article</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-21 15:57:14 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schmartz-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-21 15:57:14 +0530" MODIFIED_BY="[Empty name]">
<P>No clinical endpoints reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-21 15:57:14 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tabardel-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-21 15:57:14 +0530" MODIFIED_BY="[Empty name]">
<P>No clinical endpoints reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-22 18:02:33 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Teoh-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-22 18:02:33 +0530" MODIFIED_BY="[Empty name]">
<P>No data regarding major clinical outcomes available, unclear randomization procedure</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-21 15:57:14 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Thompson-1980">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-21 15:57:14 +0530" MODIFIED_BY="[Empty name]">
<P>No clinical endpoints reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-21 15:57:15 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Thompson-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-21 15:57:15 +0530" MODIFIED_BY="[Empty name]">
<P>No clinical endpoints reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-21 15:57:15 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Toledo_x002d_Pereyra-1980">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-21 15:57:15 +0530" MODIFIED_BY="[Empty name]">
<P>Study in children</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-21 15:57:15 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Turkoz-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-21 15:57:15 +0530" MODIFIED_BY="[Empty name]">
<P>No clinical endpoints reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-21 15:57:15 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Us-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-21 15:57:15 +0530" MODIFIED_BY="[Empty name]">
<P>No clinical endpoints reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-21 15:57:15 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vallejo-1977">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-21 15:57:15 +0530" MODIFIED_BY="[Empty name]">
<P>Study in children</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-21 15:57:15 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Van-Overveld-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-21 15:57:15 +0530" MODIFIED_BY="[Empty name]">
<P>No clinical endpoints reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-21 15:57:15 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vogelzang-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-21 15:57:15 +0530" MODIFIED_BY="[Empty name]">
<P>No control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-21 15:57:15 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wan-1997b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-21 15:57:15 +0530" MODIFIED_BY="[Empty name]">
<P>No clinical endpoints reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-21 15:57:15 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Weis-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-21 15:57:15 +0530" MODIFIED_BY="[Empty name]">
<P>Review article</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-21 15:57:15 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Whitlock-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-21 15:57:15 +0530" MODIFIED_BY="[Empty name]">
<P>Review (debate article)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-21 15:57:15 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wu-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-21 15:57:15 +0530" MODIFIED_BY="[Empty name]">
<P>Not randomized</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-21 15:57:15 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yaeger-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-21 15:57:15 +0530" MODIFIED_BY="[Empty name]">
<P>No clinical endpoints reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-03-31 16:07:31 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yasser-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-03-31 16:07:31 +0530" MODIFIED_BY="[Empty name]">
<P>This study was listed two times in our database under names <LINK REF="STD-Yasser-2009" TYPE="STUDY">Yasser 2009</LINK> and <LINK REF="STD-Amr-2009" TYPE="STUDY">Amr 2009</LINK>. First author's name was Yasser Mohamed Amr. This study was included under name <LINK REF="STD-Amr-2009" TYPE="STUDY">Amr 2009</LINK>. And <LINK REF="STD-Yasser-2009" TYPE="STUDY">Yasser 2009</LINK> was excluded.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-21 15:57:15 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yasuura-1977">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-21 15:57:15 +0530" MODIFIED_BY="[Empty name]">
<P>No clinical endpoints reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>Compared to other recent meta-analyses (<LINK REF="REF-Ho-2009" TYPE="REFERENCE">Ho 2009</LINK>; <LINK REF="REF-Whitlock-2008" TYPE="REFERENCE">Whitlock 2008</LINK>), some discrepancies were present regarding study-inclusion; only these discrepancies were mentioned in this table. Many other eligible trials were aimed at intermediate endpoints only and in spite of several attempts to reach the authors, no information regarding major clinical endpoints could be gathered and all these studies were excluded.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2011-03-10 01:32:23 +0530" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2011-03-10 01:32:23 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00490828">
<CHAR_METHODS MODIFIED="2011-03-10 01:32:23 +0530" MODIFIED_BY="[Empty name]">
<P>Randomized, placebo-controlled, blinded trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-03-10 01:32:23 +0530" MODIFIED_BY="[Empty name]">
<P>92 high risk cardiac surgery patients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-03-10 01:32:23 +0530" MODIFIED_BY="[Empty name]">
<P>hydrocortisone</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-03-10 01:32:23 +0530" MODIFIED_BY="[Empty name]">
<P>Immunologic markers, health care related quality of life, PTSD one and a half year No</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-10 01:32:23 +0530" MODIFIED_BY="[Empty name]">
<P>status: completed, but not yet published</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2011-03-10 01:32:23 +0530" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2011-01-12 08:48:58 +0530" MODIFIED_BY="Joey Kwong" STUDY_ID="STD-DECS-trial">
<CHAR_STUDY_NAME MODIFIED="2010-09-21 15:57:16 +0530" MODIFIED_BY="[Empty name]">
<P>Dexamethasone for Cardiac Surgery trials</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2010-09-21 15:57:16 +0530" MODIFIED_BY="[Empty name]">
<P>Multicentre, randomized, placebo-controlled, double blind trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-09-01 23:48:14 +0530" MODIFIED_BY="[Empty name]"/>
<CHAR_INTERVENTIONS MODIFIED="2010-09-21 15:57:16 +0530" MODIFIED_BY="[Empty name]">
<P>Dexamethasone</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-09-21 15:57:16 +0530" MODIFIED_BY="[Empty name]">
<P>Occurrence of major complications at 30 days</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2010-09-21 15:57:16 +0530" MODIFIED_BY="[Empty name]">
<P>May 2006</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2011-01-12 08:48:58 +0530" MODIFIED_BY="Joey Kwong">
<P>s.dieleman@umcutrecht.nl</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2010-09-21 15:57:16 +0530" MODIFIED_BY="[Empty name]">
<P>sub-project DECS-PNAF (post-operative new-onset atrial fibrillation)</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2011-02-22 16:47:37 +0530" MODIFIED_BY="Nicole Ackermann" STUDY_ID="STD-NCT00879931">
<CHAR_STUDY_NAME MODIFIED="2010-09-21 15:57:16 +0530" MODIFIED_BY="[Empty name]">
<P>Influence of Corticoids on Renal Function in Cardiac Surgery</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2010-09-21 15:57:16 +0530" MODIFIED_BY="[Empty name]">
<P>Randomized, Placebo-controlled double blind trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-02-22 16:47:37 +0530" MODIFIED_BY="Nicole Ackermann">
<P>Estimated enrolment: 80 patients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-21 15:57:17 +0530" MODIFIED_BY="[Empty name]">
<P>Methylprednisolone</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-09-21 15:57:17 +0530" MODIFIED_BY="[Empty name]">
<P>Renal dysfunction and renal failure postoperatively in cardiac surgery within 48 hours after cardiac surgery</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2010-09-21 15:57:17 +0530" MODIFIED_BY="[Empty name]">
<P>September 2010</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2010-09-21 15:57:17 +0530" MODIFIED_BY="[Empty name]">
<P>Stefaan.Bouchez@Ugent.be</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2010-09-02 00:05:09 +0530" MODIFIED_BY="[Empty name]"/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2010-09-21 15:57:17 +0530" MODIFIED_BY="[Empty name]" STUDY_ID="STD-SIRS-trial">
<CHAR_STUDY_NAME MODIFIED="2010-09-21 15:57:17 +0530" MODIFIED_BY="[Empty name]">
<P>Phase 3 study of perioperative steroids' effects on death or myocardial infarction in patients undergoing cardiac surgery requiring cardiopulmonary bypass</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2010-09-21 15:57:17 +0530" MODIFIED_BY="[Empty name]">
<P>Randomized, placebo-controlled, double blind trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-09-21 15:57:17 +0530" MODIFIED_BY="[Empty name]">
<P>Target sample size 10.000</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-21 15:57:17 +0530" MODIFIED_BY="[Empty name]">
<P>Methylprednisolon</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-09-21 15:57:17 +0530" MODIFIED_BY="[Empty name]">
<P>Composite death or Myocardial infarction at 30 days</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2010-09-21 15:57:17 +0530" MODIFIED_BY="[Empty name]">
<P>June 2007</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2010-09-21 15:57:17 +0530" MODIFIED_BY="[Empty name]">
<P>Rwhitlock1@cogeco.ca</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2011-01-12 08:48:58 +0530" MODIFIED_BY="Joey Kwong" STUDY_ID="STD-STRESS-trial">
<CHAR_STUDY_NAME MODIFIED="2010-09-21 15:57:17 +0530" MODIFIED_BY="[Empty name]">
<P>Reduction of the cardiac proapoptotic stress response by dexamethasone in patients undergoing coronary artery bypass grafting</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2010-09-21 15:57:17 +0530" MODIFIED_BY="[Empty name]">
<P>Randomized, placebo-controlled, single blinded trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-09-21 15:57:17 +0530" MODIFIED_BY="[Empty name]">
<P>Target sample size: 96</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-21 15:57:17 +0530" MODIFIED_BY="[Empty name]">
<P>Dexamethasone</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-09-21 15:57:17 +0530" MODIFIED_BY="[Empty name]">
<P>Expression of p38 in cultured cells and cardiac tissue</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2010-09-21 15:57:18 +0530" MODIFIED_BY="[Empty name]">
<P>December 2008, recruiting</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2011-01-12 08:48:58 +0530" MODIFIED_BY="Joey Kwong">
<P>Dr. Christa Boer, VU Medical Center, Amsterdam, The Netherlands. C.Boer@vumc.nl</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES/>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2011-03-31 16:03:54 +0530" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2011-03-02 22:02:30 +0530" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-24 23:38:16 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Abd.-El_x002d_Hakeem-2003a">
<DESCRIPTION>
<P>Quote: "Randomization was by using the sealed envelope method so that there would be equal number of patients in the two groups"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-24 23:52:55 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Abd.-El_x002d_Hakeem-2003b">
<DESCRIPTION>
<P>Quote: "Randomisation was done by using the sealed envelope method so that there would be equal number of patients in the two groups"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:34:36 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="UNKNOWN" STUDY_ID="STD-Amr-2009">
<DESCRIPTION>
<P>No information on randomisation or allocation concealment was available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:35:15 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="UNKNOWN" STUDY_ID="STD-Andersen-1989">
<DESCRIPTION>
<P>No information on randomisation or allocation concealment was available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-25 00:48:04 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bingol-2005">
<DESCRIPTION>
<P>Quote: "These patients were divided into two groups randomly by using random numbers on the computer"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:35:43 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="YES" STUDY_ID="STD-Boscoe-1983">
<DESCRIPTION>
<P>Quote: "consecutive patients were selected by random number allocation for one or two groups"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:35:51 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="UNKNOWN" STUDY_ID="STD-Bourbon-2004">
<DESCRIPTION>
<P>Quote: "Patients were randomised equally to one of the three following groups"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-26 01:13:03 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cavarocchi-1986">
<DESCRIPTION>
<P>No information regarding Randomization procedure or allocation concealment was available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:36:32 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="UNKNOWN" STUDY_ID="STD-Celik-2004">
<DESCRIPTION>
<P>No information regarding the exact randomisation method or concealment of allocation was available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:37:00 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="UNKNOWN" STUDY_ID="STD-Chaney-1998">
<DESCRIPTION>
<P>No information regarding the exact randomisation procedure or concealment of allocation was available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:37:37 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="UNKNOWN" STUDY_ID="STD-Chaney-2001">
<DESCRIPTION>
<P>No information regarding the exact randomisation method or concealment of allocation was available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-26 01:50:56 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Codd-1977">
<DESCRIPTION>
<P>Quote: "Randomization by hospital number". Concealment not guaranteed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-26 01:49:34 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Coetzer-1996">
<DESCRIPTION>
<P>Quote": "Patients were allocated by random card draw to on of the groups". Concealment of allocation was not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-26 01:17:14 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Demir-2009">
<DESCRIPTION>
<P>no information with regard to randomization method or concealment of allocation was available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-26 01:18:33 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-El-Azab-2002">
<DESCRIPTION>
<P>No information regarding the exact randomization procedure or concealment of allocation was available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-26 01:20:03 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Enc-2006">
<DESCRIPTION>
<P>No information regarding randomization procedure or allocation concealment was available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-26 01:21:30 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Engelman-1995">
<DESCRIPTION>
<P>No specified randomization method or concealment of allocation was specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-25 02:29:18 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ferries-1984">
<DESCRIPTION>
<P>Quote: "the randomization was planned so as to create four groups of 20 patients by random number allocation using a standard table of random numbers"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:38:50 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="YES" STUDY_ID="STD-Fillinger-2002">
<DESCRIPTION>
<P>Quote: "Randomization was performed by the hospital pharmacy with prepared syringes of solution administered by the anaesthesiologist intraoperatively and by the cardiothoracic intensive care unit nurses"<BR/>Comment: the exact manner of randomization was not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-25 16:31:26 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Giomarelli-2003">
<DESCRIPTION>
<P>Quote: "Patients were randomized according to a computer-generated sequence and assigned either to the standard care..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:32:20 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Halonen-2007">
<DESCRIPTION>
<P>Quote: "Randomization lists were produced by a biostatistician. The groups were block-randomized with block sizes of 6, separately in each hospital"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-25 22:59:34 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Halvorsen-2003">
<DESCRIPTION>
<P>Quote: "a block randomization schema was used with 20 patients allocated to each block". "The sealed envelope..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-25 23:36:29 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Harig-1999">
<DESCRIPTION>
<P>Quote: "Cohorts of 10 patients were randomized independently" Comment: Concealment of allocation was unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-26 01:26:36 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jansen-1991a">
<DESCRIPTION>
<P>No randomization method, nor concealment of allocation was described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-25 23:53:13 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kilger-2003a">
<DESCRIPTION>
<P>Quote: "patients were allocated randomly to two groups"<BR/>Comment: allocation procedure was not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-26 01:28:07 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kilger-2003b">
<DESCRIPTION>
<P>no information on Randomization procedure or concealment of allocation was available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-26 00:11:48 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Liakopoulos-2007">
<DESCRIPTION>
<P>Quote: "Following a computer-generated sequence, patients were randomly assigned to receive either a ..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-26 01:29:39 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Loef-2004">
<DESCRIPTION>
<P>No information on randomization procedure or concealment of allocation was provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:41:26 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="UNKNOWN" STUDY_ID="STD-Mayumi-1997">
<DESCRIPTION>
<P>Quote: "a chief anaesthesiologist, who was not directly involved in the present study, was responsible for opening an envelope indicating the drug" Comment: this quote indicates a sealed envelope method used for randomization and allocation concealment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-26 01:32:40 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McBride-2004">
<DESCRIPTION>
<P>No information available regarding randomization procedure or allocation concealment was provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-26 01:38:08 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Morton-1976">
<DESCRIPTION>
<P>Quote: "The drug and placebo were supplied, packaged and randomly coded by the upjohn company"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-26 01:42:03 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Oliver-2004">
<DESCRIPTION>
<P>No information on randomization procedure or allocation concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:42:46 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="YES" STUDY_ID="STD-Prasongsukarn-2005">
<DESCRIPTION>
<P>Quote: "All vials of the steroid and placebo medication were prepared and randomized by the hospital pharmacy. The steroid and placebo solution were visually indistinguishable"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-26 19:35:43 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rao-1977">
<DESCRIPTION>
<P>No randomization procedure, concealment of allocation or blinding was described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:43:54 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="YES" STUDY_ID="STD-Rubens-2005">
<DESCRIPTION>
<P>Quote: "The perfusionist performed the treatment assignment immediately pre-operatively by opening a sealed numbered envelope. Randomization was in blocks of four generated using SAS version 8.2"<BR/>Quote: "all syringes containing the MPSS or the Placebo were prepared in the hospital pharmacy and labelled with a code"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-27 17:04:37 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rumalla-2001">
<DESCRIPTION>
<P>Randomization procedure was not specified, probably no concealment of allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-27 17:05:38 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sano-2003">
<DESCRIPTION>
<P>Randomization procedure was not specified. Probably no concealment of allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-27 17:13:02 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sano-2006">
<DESCRIPTION>
<P>Quote: "Were prospectively randomized into two groups by our operation-registry staff who were not involved in this study"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-27 17:54:28 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Schurr-2001">
<DESCRIPTION>
<P>Comment: Study was unblinded, allocation concealment was not done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:44:37 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="YES" STUDY_ID="STD-Sobieski-2008">
<DESCRIPTION>
<P>Quote: "On the day of surgery, patient enrolled in the study were randomized by the pharmacy."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-02 22:02:30 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Starobin-2007">
<DESCRIPTION>
<P>No information on randomization procedure or concealment of allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:45:01 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="YES" STUDY_ID="STD-Tassani-1999">
<DESCRIPTION>
<P>Quote: "The study drug or placebo was prepared in the morning at the hospital pharmacy."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-28 17:44:15 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Toft-1997">
<DESCRIPTION>
<P>No randomization procedure or concealment of allocation was described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-28 17:53:06 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Turkoz-2001">
<DESCRIPTION>
<P>Randomization procedure and concealment of allocation was not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-28 17:57:22 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Volk-2001">
<DESCRIPTION>
<P>Randomization procedure and concealment of allocation were not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:45:36 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="UNKNOWN" STUDY_ID="STD-Volk-2003">
<DESCRIPTION>
<P>Qote: "Patients were randomized to receive..." No randomization procedure or concealment of allocation was described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-28 23:51:34 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wan-1999">
<DESCRIPTION>
<P>Randomization procedure and concealment of allocation were not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-29 00:03:37 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Weis-2006">
<DESCRIPTION>
<P>Quote: "... in identical vials in a double-blind fashion. The vials were prepared by a study nurse who was not involved in the care of patients participating in the trial"<BR/>Comment: randomization procedure is not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-29 00:31:00 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Weis-2009">
<DESCRIPTION>
<P>Quote: "patients were randomly allocated to two groups by block randomization"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:46:36 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="NO" STUDY_ID="STD-Whitlock-2006">
<DESCRIPTION>
<P>Quote: "Block randomization via a computer-generated sequence was performed on the day of surgery by the local hospital pharmacy"<BR/>Comment: Adequate randomization, bu no information about concealment after randomization</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-29 00:37:38 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yared-1998">
<DESCRIPTION>
<P>Randomization procedure and concealment of allocation were not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-29 00:45:17 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Yared-2007">
<DESCRIPTION>
<P>Quote: "A computer-generated random table was used"<BR/>Comment: adequate randomization, but no description of concealment after randomization</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-29 00:50:48 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yilmaz-1999">
<DESCRIPTION>
<P>Quote: "Twenty patients were randomly divided in two groups"<BR/>Comment: no information on randomization procedure or concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:45:43 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="UNKNOWN" STUDY_ID="STD-von-Spiegel-2001">
<DESCRIPTION>
<P>Quote: "individuals were randomized into two groups under controlled, double-blind conditions"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2010-02-01 17:22:09 +0530" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-12" LEVEL="GROUP" NO="12">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-13" LEVEL="GROUP" NO="13">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2010-08-25 16:41:03 +0530" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2011-02-22 16:41:28 +0530" MODIFIED_BY="Nicole Ackermann" NO="7">
<NAME>Intention to treat analyses</NAME>
<DESCRIPTION>
<P>Were analyses performed according to the 'intention to treat' principle?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2010-08-25 16:47:34 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Abd.-El_x002d_Hakeem-2003a">
<DESCRIPTION>
<P>Comment: Study-medication was single-dose and no cross-overs were mentioned. This absence of cross-overs seems realistic, given the very short duration of the treatment protocols.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2010-08-25 16:47:44 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Abd.-El_x002d_Hakeem-2003b">
<DESCRIPTION>
<P>Comment: Study-medication was single-dose and no cross-overs were mentioned. This absence of cross-overs seems realistic, given the very short duration of the treatment protocols.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2010-08-25 00:45:34 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Amr-2009">
<DESCRIPTION>
<P>Comment: Study-medication was single-dose and no cross-overs were mentioned. This absence of cross-overs seems realistic, given the very short duration of the treatment protocols.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2010-08-25 01:04:14 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Andersen-1989">
<DESCRIPTION>
<P>Comment: Study-medication was single-dose and no cross-overs were mentioned. This absence of cross-overs seems realistic, given the very short duration of the treatment protocols.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2010-08-25 00:51:42 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bingol-2005">
<DESCRIPTION>
<P>Comment: No cross-overs were mentioned. This absence of cross-overs seems realistic, given the very short duration of the treatment protocols.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2010-08-25 01:04:54 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Boscoe-1983">
<DESCRIPTION>
<P>Comment: No cross-overs were mentioned. This absence of cross-overs seems realistic, given the very short duration of the treatment protocols.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2010-08-25 01:20:27 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bourbon-2004">
<DESCRIPTION>
<P>Comment: Study-medication was single-dose and no cross-overs were mentioned. This absence of cross-overs seems realistic, given the very short duration of the treatment protocols</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2010-08-25 01:23:49 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cavarocchi-1986">
<DESCRIPTION>
<P>Comment: Study-medication was single-dose and no cross-overs were mentioned. This absence of cross-overs seems realistic, given the very short duration of the treatment protocols</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2010-08-25 01:29:43 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Celik-2004">
<DESCRIPTION>
<P>Comment: No cross-overs were mentioned. This absence of cross-overs seems realistic, given the very short duration of the treatment protocols</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2010-08-25 01:39:10 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chaney-1998">
<DESCRIPTION>
<P>Comment: No cross-overs were mentioned. This absence of cross-overs seems realistic, given the very short duration of the treatment protocols</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2010-08-25 01:46:55 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chaney-2001">
<DESCRIPTION>
<P>Comment: No cross-overs were mentioned. This absence of cross-overs seems realistic, given the very short duration of the treatment protocols</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2010-08-25 01:54:29 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Codd-1977">
<DESCRIPTION>
<P>Comment: Study-medication was single-dose and no cross-overs were mentioned. This absence of cross-overs seems realistic, given the very short duration of the treatment protocols</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2010-08-25 02:02:28 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Coetzer-1996">
<DESCRIPTION>
<P>Comment: Study-medication was single-dose and no cross-overs were mentioned. This absence of cross-overs seems realistic, given the very short duration of the treatment protocols</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2010-08-25 02:06:16 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Demir-2009">
<DESCRIPTION>
<P>Comment: Study-medication was single-dose and no cross-overs were mentioned. This absence of cross-overs seems realistic, given the very short duration of the treatment protocols</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2010-08-25 02:09:58 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-El-Azab-2002">
<DESCRIPTION>
<P>Comment: Study-medication was single-dose and no cross-overs were mentioned. This absence of cross-overs seems realistic, given the very short duration of the treatment protocols</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2010-08-25 02:16:09 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Enc-2006">
<DESCRIPTION>
<P>Comment: Study-medication was single-dose and no cross-overs were mentioned. This absence of cross-overs seems realistic, given the very short duration of the treatment protocols</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2010-08-25 02:18:31 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Engelman-1995">
<DESCRIPTION>
<P>Comment: Study-medication was single-dose and no cross-overs were mentioned. This absence of cross-overs seems realistic, given the very short duration of the treatment protocols</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2010-08-25 02:27:47 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ferries-1984">
<DESCRIPTION>
<P>Comment: Study-medication was single-dose and no cross-overs were mentioned. This absence of cross-overs seems realistic, given the very short duration of the treatment protocols</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2010-08-25 02:42:55 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fillinger-2002">
<DESCRIPTION>
<P>Comment: No cross-overs were mentioned. This absence of cross-overs seems realistic, given the very short duration of the treatment protocols</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2010-08-25 16:32:25 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Giomarelli-2003">
<DESCRIPTION>
<P>Comment: No cross-overs were mentioned. This absence of cross-overs seems realistic, given the very short duration of the treatment protocols</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2010-08-25 17:19:53 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Halonen-2007">
<DESCRIPTION>
<P>Comment: No cross-overs were mentioned. This absence of cross-overs seems realistic, given the very short duration of the treatment protocols</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-02-22 16:39:44 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="NO" STUDY_ID="STD-Halvorsen-2003">
<DESCRIPTION>
<P>Quote: "Six patients were excluded from the efficacy analysis because of anaphylactoid reaction, development of acute abdominal complications, a perforated ventricular ulcus and protocol violation"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2010-08-25 23:37:20 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Harig-1999">
<DESCRIPTION>
<P>Comment: No cross-overs were mentioned. This absence of cross-overs seems realistic, given the very short duration of the treatment protocols</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2010-08-25 23:44:33 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Jansen-1991a">
<DESCRIPTION>
<P>Quote: "After evaluation of the data, three patients in the placebo group were excluded from the postoperative study because they required dexamethasone treatment in the intensive care unit."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2010-08-25 23:53:39 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kilger-2003a">
<DESCRIPTION>
<P>Comment: No cross-overs were mentioned. This absence of cross-overs seems realistic, given the very short duration of the treatment protocols</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2010-08-26 01:28:28 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kilger-2003b">
<DESCRIPTION>
<P>Comment: No cross-overs were mentioned. This absence of cross-overs seems realistic, given the very short duration of the treatment protocols</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2010-08-26 00:13:01 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Liakopoulos-2007">
<DESCRIPTION>
<P>Two patients were excluded from the study because of post-operative bleeding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2010-08-26 00:27:35 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Loef-2004">
<DESCRIPTION>
<P>Comment: No cross-overs were mentioned. This absence of cross-overs seems realistic, given the very short duration of the treatment protocols</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-02-22 16:41:28 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="NO" STUDY_ID="STD-Mayumi-1997">
<DESCRIPTION>
<P>Quote: "but patients who underwent intra-aortic balloon pumping or allogeneic blood transfusion were excluded from this study"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2010-08-26 00:46:30 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McBride-2004">
<DESCRIPTION>
<P>Comment: No cross-overs were mentioned. This absence of cross-overs seems realistic, given the very short duration of the treatment protocols</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2010-08-26 01:38:38 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Morton-1976">
<DESCRIPTION>
<P>Comment: Single-dose study medication. No cross-overs were mentioned. This absence of cross-overs seems realistic, given the very short duration of the treatment protocols</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2010-08-26 01:43:21 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Oliver-2004">
<DESCRIPTION>
<P>Three patients were excluded (lateral thoracotomy, retrosternal mass, surgery cancelled)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2010-08-26 19:21:33 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Prasongsukarn-2005">
<DESCRIPTION>
<P>Comment: No cross-overs were mentioned. This absence of cross-overs seems realistic, given the very short duration of the treatment protocols</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2010-08-26 19:52:19 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rao-1977">
<DESCRIPTION>
<P>Comment: No cross-overs were mentioned. This absence of cross-overs seems realistic, given the very short duration of the treatment protocols</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2010-08-26 19:52:34 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rubens-2005">
<DESCRIPTION>
<P>Comment: No cross-overs were mentioned. This absence of cross-overs seems realistic, given the very short duration of the treatment protocols</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2010-08-27 16:58:12 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rumalla-2001">
<DESCRIPTION>
<P>Comment: No cross-overs were mentioned. This absence of cross-overs seems realistic, given the very short duration of the treatment protocols</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2010-08-27 17:06:07 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sano-2003">
<DESCRIPTION>
<P>Comment: No cross-overs were mentioned. This absence of cross-overs seems realistic, given the very short duration of the treatment protocols</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2010-08-27 17:14:23 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sano-2006">
<DESCRIPTION>
<P>Comment: No cross-overs were mentioned. This absence of cross-overs seems realistic, given the very short duration of the treatment protocols</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2010-08-27 17:53:47 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schurr-2001">
<DESCRIPTION>
<P>Comment: No cross-overs were mentioned. This absence of cross-overs seems realistic, given the very short duration of the treatment protocols</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2010-08-27 18:06:28 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sobieski-2008">
<DESCRIPTION>
<P>Comment: No cross-overs were mentioned. This absence of cross-overs seems realistic, given the very short duration of the treatment protocols</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2010-08-28 17:23:36 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Starobin-2007">
<DESCRIPTION>
<P>Comment: No cross-overs were mentioned. This absence of cross-overs seems realistic, given the very short duration of the treatment protocols</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2010-08-28 17:34:57 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tassani-1999">
<DESCRIPTION>
<P>Comment: No cross-overs were mentioned. This absence of cross-overs seems realistic, given the very short duration of the treatment protocols</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2010-08-28 17:44:42 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Toft-1997">
<DESCRIPTION>
<P>Comment: No cross-overs were mentioned. This absence of cross-overs seems realistic, given the very short duration of the treatment protocols</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2010-08-28 17:53:10 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Turkoz-2001">
<DESCRIPTION>
<P>Comment: No cross-overs were mentioned. This absence of cross-overs seems realistic, given the very short duration of the treatment protocols</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2010-08-28 17:58:16 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Volk-2001">
<DESCRIPTION>
<P>Comment: No cross-overs were mentioned. This absence of cross-overs seems realistic, given the very short duration of the treatment protocols</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2010-08-28 18:05:14 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Volk-2003">
<DESCRIPTION>
<P>Comment: No cross-overs were mentioned. This absence of cross-overs seems realistic, given the very short duration of the treatment protocols</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2010-08-28 23:51:51 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wan-1999">
<DESCRIPTION>
<P>Comment: No cross-overs were mentioned. This absence of cross-overs seems realistic, given the very short duration of the treatment protocols</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2010-08-29 00:05:07 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Weis-2006">
<DESCRIPTION>
<P>Comment: no cross overs were mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2010-08-29 00:26:58 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Weis-2009">
<DESCRIPTION>
<P>Comment: No cross-overs were mentioned. This absence of cross-overs seems realistic, given the very short duration of the treatment protocols<BR/>Quote: "No other steroids were given during the study period"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2010-08-29 00:51:42 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Whitlock-2006">
<DESCRIPTION>
<P>Comment: No cross-overs were mentioned. This absence of cross-overs seems realistic, given the very short duration of the treatment protocols</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2010-08-29 00:38:03 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yared-1998">
<DESCRIPTION>
<P>Comment: No cross-overs were mentioned. This absence of cross-overs seems realistic, given the very short duration of the treatment protocols</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2010-08-29 00:43:49 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Yared-2007">
<DESCRIPTION>
<P>Patients receiving additional steroids were excluded from the trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2010-08-29 00:51:28 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yilmaz-1999">
<DESCRIPTION>
<P>Comment: No cross-overs were mentioned. This absence of cross-overs seems realistic, given the very short duration of the treatment protocols</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2010-08-28 23:44:36 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-von-Spiegel-2001">
<DESCRIPTION>
<P>Comment: No cross-overs were mentioned. This absence of cross-overs seems realistic, given the very short duration of the treatment protocols</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="STUDY" MODIFIED="2011-03-31 16:03:40 +0530" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding during pre-, peri- and postoperative care?</NAME>
<DESCRIPTION>
<P>Were patient caregivers blinded to treatment allocation?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-24 23:43:45 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Abd.-El_x002d_Hakeem-2003a">
<DESCRIPTION>
<P>Quote: "Randomized double-blind placebo controlled study. This was performed by an anaesthesiologist not involved with the patients perioperative care."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-25 00:02:13 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Abd.-El_x002d_Hakeem-2003b">
<DESCRIPTION>
<P>Quote: "Randomized double-blind placebo controlled study. This was performed by an anaesthesiologist not involved with the patients perioperative care."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-29 19:57:33 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Amr-2009">
<DESCRIPTION>
<P>Quote: "Randomized placebo controlled trial", implicates an unblinded study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-29 19:57:45 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Andersen-1989">
<DESCRIPTION>
<P>Quote: "Randomized placebo controlled trial", implicates an unblinded study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-25 00:49:42 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bingol-2005">
<DESCRIPTION>
<P>Quote: "Our study-team, the patients and the spirometry technician were blind to the study whereas the pharmacist and the statistical data analysts were not blind to the coding of the groups"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-29 20:02:39 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Boscoe-1983">
<DESCRIPTION>
<P>Quote: "group 2 received in addition 30 mg/kg methylprednisolon",<BR/>Comment: Placebo medication was not mentioned. Probably unblinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-26 01:10:46 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bourbon-2004">
<DESCRIPTION>
<P>No information regarding blinding was available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-25 01:26:04 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Cavarocchi-1986">
<DESCRIPTION>
<P>Comment: Study was designed to evaluate the effect of different types of oxygenators, which makes blinding impossible</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:36:37 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="YES" STUDY_ID="STD-Celik-2004">
<DESCRIPTION>
<P>Quote: "An anaesthesia research nurse performed the randomisation and prepared the two syringes of solution that were administered"<BR/>Quote: "Therefore, all physicians and nursing staff caring for the patients were blinded to the treatment group."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:37:08 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="YES" STUDY_ID="STD-Chaney-1998">
<DESCRIPTION>
<P>Quote: "An anaesthesia research nurse performed the randomisation and prepared the two syringes of blinded solution that were administered. All physicians and nursing staff caring for the patients perioperatively were unaware of treatment group"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:37:43 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="YES" STUDY_ID="STD-Chaney-2001">
<DESCRIPTION>
<P>Quote: "An anaesthesia research nurse performed the randomisation and prepared the two syringes of blinded solution that were administered. All physicians and nursing staff caring for the patients perioperatively were unaware of treatment group"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-26 01:16:16 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Codd-1977">
<DESCRIPTION>
<P>Quote: "randomized placebo-controlled trial" implicates an unblinded study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-25 02:00:49 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Coetzer-1996">
<DESCRIPTION>
<P>Quote: "The first author of the study was blinded"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-25 16:54:34 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Demir-2009">
<DESCRIPTION>
<P>No information regarding blinding was present</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-25 02:11:38 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-El-Azab-2002">
<DESCRIPTION>
<P>Quote: "This dosage was masked"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-25 02:16:33 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Enc-2006">
<DESCRIPTION>
<P>Quote: "double blind, randomized prospective study"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-25 02:22:43 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Engelman-1995">
<DESCRIPTION>
<P>Quote: "the blood study was carried out in a blinded fashion as to the steroid/no steroid group"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-25 02:30:56 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ferries-1984">
<DESCRIPTION>
<P>Quote: "Neither surgeon, perfusionist nor laboratory technician knew which patient was in which group"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:38:55 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="YES" STUDY_ID="STD-Fillinger-2002">
<DESCRIPTION>
<P>Quote: "study patients, investigators, and other physicians and nurses caring for the patient perioperatively were blinded to the treatment group"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:39:12 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="YES" STUDY_ID="STD-Giomarelli-2003">
<DESCRIPTION>
<P>Quote: "an anaesthesia nurse performed the randomisation and prepared the syringes of blinded solution that were administered by the anaesthesiologist managing the case. All physicians and nursing staff caring for the patient perioperatively were unaware of the treatment groups."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-25 17:24:24 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Halonen-2007">
<DESCRIPTION>
<P>Quote: "The study group remained unknown to all caring nurses and physicians. The randomization codes were opened after the end of the study. It was unnecessary to break the code for any of the patients, so blinding was ensured"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:39:47 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="YES" STUDY_ID="STD-Halvorsen-2003">
<DESCRIPTION>
<P>Quote: "to maintain the double blinded study design, the sealed envelope was opened immediately before surgery, and the study drug was prepared in identical appearing syringes by a nurse who did nog participate in the treatment of the study patients".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:40:17 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="NO" STUDY_ID="STD-Harig-1999">
<DESCRIPTION>
<P>Comment: The absence of information regarding blinding implicates an unblinded study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-25 23:46:13 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jansen-1991a">
<DESCRIPTION>
<P>Comment: The study is qualified as a "Randomized, double-blind trial", but no blinding-method was not specified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-25 23:58:56 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kilger-2003a">
<DESCRIPTION>
<P>Quote: "one limitation of this study is that is was performed only in a randomized controlled, but not in a double-blind manner."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-27 17:52:54 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kilger-2003b">
<DESCRIPTION>
<P>Quote: "die patienten erhielten randomisiert vor narkoseeinleitung"<BR/>Comment: absence of blinding manners implies no blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-31 16:03:40 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Liakopoulos-2007">
<DESCRIPTION>
<P>qualifying the study as "prospective placebo-controlled randomized trial" implies an unblinded study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-02 22:01:48 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Loef-2004">
<DESCRIPTION>
<P>Quote: "patients were randomized in a double-blind fashion"<BR/>Comment: No further information regarding blinding procedures was available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:41:32 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="YES" STUDY_ID="STD-Mayumi-1997">
<DESCRIPTION>
<P>Quote: "a chief anaesthesiologist, who was not directly involved in the present study, was responsible for opening an envelope indicating the drug"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-26 00:46:01 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-McBride-2004">
<DESCRIPTION>
<P>Quote: "Ethical consideration required that the peri-operative physician was aware of the randomisation group"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-26 01:39:28 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Morton-1976">
<DESCRIPTION>
<P>Quote: "The code was not revealed until the study was completed and all the data had been collected and interpreted"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:42:26 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="NO" STUDY_ID="STD-Oliver-2004">
<DESCRIPTION>
<P>Quote: "Perfusionists were aware of subjects assigned to hemofil, but no other study assignment. All remaining operating room and intensive care unit personnel were blinded to group identity"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:43:07 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="YES" STUDY_ID="STD-Prasongsukarn-2005">
<DESCRIPTION>
<P>Quote: "A planned interim analyses was performed after 50 % enrolment...Therefore, study enrolment was terminated on February 29, 2001 and the code was broken."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-26 19:37:13 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rao-1977">
<DESCRIPTION>
<P>The study was classified as a "prospective randomized study". This implicates an unblinded study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:43:56 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="YES" STUDY_ID="STD-Rubens-2005">
<DESCRIPTION>
<P>Quote: "all the members of the surgical and anaesthetic teams were blinded to the use of MPSS.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:16:31 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rumalla-2001">
<DESCRIPTION>
<P>Study was classified as a "randomized control study". This implicates an unblinded study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-27 17:18:24 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sano-2003">
<DESCRIPTION>
<P>Quote: "these patients were randomly divided into two groups"<BR/>Comment: no remark concerning blinding implicates an unblinded study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-27 17:25:22 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sano-2006">
<DESCRIPTION>
<P>Quote: "Were prospectively randomized into two groups by our operation-registry staff who were not involved in this study"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:44:23 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="NO" STUDY_ID="STD-Schurr-2001">
<DESCRIPTION>
<P>Study was qualified as: "prospective randomized"<BR/>Comment: absence of blinding manner implies an unblinded study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-27 18:07:02 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sobieski-2008">
<DESCRIPTION>
<P>Quote: "At the completion of the study, the pharmacy unblinded all the patient treatment groups"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-28 17:28:38 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Starobin-2007">
<DESCRIPTION>
<P>Study was classified as a "prospective open randomized trial"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-28 17:35:18 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tassani-1999">
<DESCRIPTION>
<P>Quote: "the study was performed double-blinded"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:21:30 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Toft-1997">
<DESCRIPTION>
<P>Probably an unblinded study, since blinding is not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:21:49 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Turkoz-2001">
<DESCRIPTION>
<P>The study was classified as a prospective randomized study, which implicates an unblinded study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:45:24 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="YES" STUDY_ID="STD-Volk-2001">
<DESCRIPTION>
<P>The study was classified as a "randomized, controlled, double-blind, prospective trial"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-28 18:06:50 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Volk-2003">
<DESCRIPTION>
<P>The study was classified as a "randomized controlled blinded prospective trial"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:47:54 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wan-1999">
<DESCRIPTION>
<P>Quote: "The ICU staff was blinded as to the pretreatment of steroids"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:26:58 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Weis-2006">
<DESCRIPTION>
<P>Quote: "... in identical vials in a double-blind fashion. The vials were prepared by a study nurse who was not involved in the care of patients participating in the trial"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:27:56 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Weis-2009">
<DESCRIPTION>
<P>Study was classified as prospective, randomized, double-blinded, placebo controlled"<BR/>Comment: when concealment of allocation was disclosed is unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:46:41 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="YES" STUDY_ID="STD-Whitlock-2006">
<DESCRIPTION>
<P>Quote: "all patients, clinicians, and statisticians were blinded until the completion of data analyses by group"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:30:03 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yared-1998">
<DESCRIPTION>
<P>Study was classified as " a prospective, randomized, double-blind, placebo-controlled study"<BR/>Comment: there is no information available with regard to the timing of disclosure of allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:30:21 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yared-2007">
<DESCRIPTION>
<P>Study was classified as " a prospective, randomized, double-blind, placebo-controlled study"<BR/>Comment: there is no information available with regard to the timing of disclosure of allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:31:35 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yilmaz-1999">
<DESCRIPTION>
<P>Study was classified as " a prospective, randomized, double-blind, placebo-controlled study"<BR/>Comment: there is no information available with regard to the timing of disclosure of allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:45:47 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="YES" STUDY_ID="STD-von-Spiegel-2001">
<DESCRIPTION>
<P>Quote: "Throughout the entire study, the care of the patients was managed by anaesthesiologists and intensivists who were not involved in the study"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="STUDY" MODIFIED="2011-03-31 16:03:30 +0530" MODIFIED_BY="[Empty name]" NO="9">
<NAME>Blinded data collection?</NAME>
<DESCRIPTION>
<P>Was data collection blinded to treatment allocation?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-24 23:45:10 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Abd.-El_x002d_Hakeem-2003a">
<DESCRIPTION>
<P>Quote: "Randomized double-blind placebo controlled study. This was performed by an anaesthesiologist not involved with the patients perioperative care." Comment: probably blinded data-collection.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-29 19:53:37 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Abd.-El_x002d_Hakeem-2003b">
<DESCRIPTION>
<P>Quote: "Randomized double-blind placebo controlled study. This was performed by an anaesthesiologist not involved with the patients perioperative care." <BR/>Comment: probably blinded data-collection</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-29 19:57:36 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Amr-2009">
<DESCRIPTION>
<P>Quote: "Randomized placebo controlled trial", implicates an unblinded study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-29 19:57:47 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Andersen-1989">
<DESCRIPTION>
<P>Quote: "Randomized placebo controlled trial", implicates an unblinded study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-25 00:50:04 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bingol-2005">
<DESCRIPTION>
<P>Quote: "Our study-team, the patients and the spirometry technician were blind to the study whereas the pharmacist and the statistical data analysts were not blind to the coding of the groups"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-29 20:02:39 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Boscoe-1983">
<DESCRIPTION>
<P>Quote: "group 2 received in addition 30 mg/kg methylprednisolon",<BR/>Comment: Placebo medication was not mentioned. Probably unblinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-26 01:10:57 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bourbon-2004">
<DESCRIPTION>
<P>No information regarding blinding was available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-25 01:25:14 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Cavarocchi-1986">
<DESCRIPTION>
<P>Comment: Study was designed to evaluate the effect of different types of oxygenators, which makes blinding impossible</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-31 16:03:30 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Celik-2004">
<DESCRIPTION>
<P>Comment: It was not specified whether data-collection, adjunction of endpoints or analyses were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:37:13 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="YES" STUDY_ID="STD-Chaney-1998">
<DESCRIPTION>
<P>Quote: "An anaesthesia research nurse performed the randomisation and prepared the two syringes of blinded solution that were administered. All physicians and nursing staff caring for the patients perioperatively were unaware of treatment group"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:37:55 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="YES" STUDY_ID="STD-Chaney-2001">
<DESCRIPTION>
<P>Quote: "An anaesthesia research nurse performed the randomisation and prepared the two syringes of blinded solution that were administered. All physicians and nursing staff caring for the patients perioperatively were unaware of treatment group"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-26 01:16:26 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Codd-1977">
<DESCRIPTION>
<P>Quote: "randomized placebo-controlled trial" implicates an unblinded study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:38:26 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="YES" STUDY_ID="STD-Coetzer-1996">
<DESCRIPTION>
<P>Quote: "the first author of the study was blinded"<BR/>Comment: it was assumed that this first author did the data collection, but adjudication of endpoints and further analyses are probably done together with the unblinded co-authors</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-26 01:17:25 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Demir-2009">
<DESCRIPTION>
<P>No information regarding blinding was present</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-26 01:18:43 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-El-Azab-2002">
<DESCRIPTION>
<P>Quote: "This dosage was masked"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-26 01:20:38 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Enc-2006">
<DESCRIPTION>
<P>Quote: "double blind, randomized prospective study"<BR/>Comment: whether data-collection was blinded was not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-26 01:21:55 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Engelman-1995">
<DESCRIPTION>
<P>Quote: "the blood study was carried out in a blinded fashion as to the steroid/no steroid group"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-26 01:23:54 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ferries-1984">
<DESCRIPTION>
<P>No information available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-26 01:25:09 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fillinger-2002">
<DESCRIPTION>
<P>Investigators were blinded; probably blinded data collection</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-26 01:25:26 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Giomarelli-2003">
<DESCRIPTION>
<P>No information available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-25 22:51:39 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Halonen-2007">
<DESCRIPTION>
<P>Quote: "The randomization codes were opened after the end of the study"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:07:52 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Halvorsen-2003">
<DESCRIPTION>
<P>Comment: "by a nurse who dit not participate in the treatment" implicates blinding during hospital care period, during which data was collected.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:40:22 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="NO" STUDY_ID="STD-Harig-1999">
<DESCRIPTION>
<P>Comment: The absence of information regarding blinding implicates an unblinded study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-29 20:20:59 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Jansen-1991a">
<DESCRIPTION>
<P>Comment: The study is qualified as a "Randomized, double-blind trial", but no blinding-method or duration was not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-26 01:27:37 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kilger-2003a">
<DESCRIPTION>
<P>Quote: "one limitation of this study is that is was performed only in a randomized controlled, but not in a double-blind manner."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-27 17:52:57 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kilger-2003b">
<DESCRIPTION>
<P>Quote: "die patienten erhielten randomisiert vor narkoseeinleitung"<BR/>Comment: absence of blinding manners implies no blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-02 22:01:40 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Liakopoulos-2007">
<DESCRIPTION>
<P>qualifying the study as "prospective placebo-controlled randomized trial" implies an unblinded study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-02 22:01:49 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Loef-2004">
<DESCRIPTION>
<P>Quote: "patients were randomized in a double-blind fashion"<BR/>Comment: No further information regarding blinding procedures was available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:41:35 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="YES" STUDY_ID="STD-Mayumi-1997">
<DESCRIPTION>
<P>Quote: "The patient names, but not drug names, included in the two groups were told by the anaesthesiologist to the senior author at the end of study"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-26 01:32:32 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-McBride-2004">
<DESCRIPTION>
<P>Quote: "Ethical consideration required that the peri-operative physician was aware of the randomisation group"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-26 01:39:41 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Morton-1976">
<DESCRIPTION>
<P>Quote: "The code was not revealed until the study was completed and all the data had been collected and interpreted"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:42:23 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="YES" STUDY_ID="STD-Oliver-2004">
<DESCRIPTION>
<P>Quote: "Perfusionists were aware of subjects assigned to hemofil, but no other study assignment. All remaining operating room and intensive care unit personnel were blinded to group identity"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:43:22 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="YES" STUDY_ID="STD-Prasongsukarn-2005">
<DESCRIPTION>
<P>Quote: "A planned interim analyses was performed after 50 % enrolment...Therefore, study enrolment was terminated on February 29, 2001 and the code was broken".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-26 19:37:26 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rao-1977">
<DESCRIPTION>
<P>The study was classified as a "prospective randomized study". This implicates an unblinded study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:16:22 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rubens-2005">
<DESCRIPTION>
<P>It is unclear when allocation was disclosed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:16:32 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rumalla-2001">
<DESCRIPTION>
<P>Study was classified as a "randomized control study". This implicates an unblinded study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-27 17:18:27 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sano-2003">
<DESCRIPTION>
<P>Quote: "these patients were randomly divided into two groups"<BR/>Comment: no remark concerning blinding implicates an unblinded study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-29 23:55:28 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sano-2006">
<DESCRIPTION>
<P>Quote: "Were prospectively randomized into two groups by our operation-registry staff who were not involved in this study"<BR/>Comment: whether data collection, adjudification of endpoints or analyses were blinded was not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:18:34 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Schurr-2001">
<DESCRIPTION>
<P>Study was qualified as: "prospective randomized"<BR/>Comment: no remark regarding blinding implicates an unblinded study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-27 18:07:16 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sobieski-2008">
<DESCRIPTION>
<P>Quote: "At the completion of the study, the pharmacy unblinded all the patient treatment groups"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-28 17:28:49 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Starobin-2007">
<DESCRIPTION>
<P>Study was classified as a "prospective open randomized trial"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-28 17:35:31 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tassani-1999">
<DESCRIPTION>
<P>Quote: "the study was performed double-blinded"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-28 17:45:59 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Toft-1997">
<DESCRIPTION>
<P>Probably an unblinded study, since blinding is not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:21:53 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Turkoz-2001">
<DESCRIPTION>
<P>The study was classified as a prospective randomized study, which implicates an unblinded study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:23:46 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Volk-2001">
<DESCRIPTION>
<P>The study was classified as a "randomized, controlled, double-blind prospective trial"., but it is unclear when allocation was disclosed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-02 22:02:42 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Volk-2003">
<DESCRIPTION>
<P>The study was classified as a "randomized controlled blinded prospective trial", but it is unclear when allocation was disclosed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-28 23:56:55 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wan-1999">
<DESCRIPTION>
<P>Quote: "The ICU staff was blinded as to the pretreatment of steroids"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:26:54 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Weis-2006">
<DESCRIPTION>
<P>Quote: "... in identical vials in a double-blind fashion. The vials were prepared by a study nurse who was not involved in the care of patients participating in the trial"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:27:49 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Weis-2009">
<DESCRIPTION>
<P>Study was classified as prospective, randomized, double-blinded, placebo controlled"<BR/>Comment: when concealment of allocation was disclosed is unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:46:42 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="YES" STUDY_ID="STD-Whitlock-2006">
<DESCRIPTION>
<P>Quote: "all patients, clinicians, and statisticians were blinded until the completion of data analyses by group"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:29:26 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yared-1998">
<DESCRIPTION>
<P>Study was classified as " a prospective, randomized, double-blind, placebo-controlled study"<BR/>Comment: there is no information available with regard to the timing of disclosure of allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:30:53 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yared-2007">
<DESCRIPTION>
<P>Study was classified as " a prospective, randomized, double-blind, placebo-controlled study"<BR/>Comment: there is no information available with regard to the timing of disclosure of allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:31:40 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yilmaz-1999">
<DESCRIPTION>
<P>Study was classified as " a prospective, randomized, double-blind, placebo-controlled study"<BR/>Comment: there is no information available with regard to the timing of disclosure of allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:46:01 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="YES" STUDY_ID="STD-von-Spiegel-2001">
<DESCRIPTION>
<P>Quote: "Throughout the entire study, the care of the patients was managed by anaesthesiologists and intensivists who were not involved in the study"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-10" LEVEL="STUDY" MODIFIED="2011-03-31 16:03:45 +0530" MODIFIED_BY="[Empty name]" NO="10">
<NAME>Blinded adjudification of endpoints?</NAME>
<DESCRIPTION>
<P>Were endpoints adjudicated in a blinded manner?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:53:37 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Abd.-El_x002d_Hakeem-2003a">
<DESCRIPTION>
<P>Quote: "Randomized double-blind placebo controlled study. This was performed by an anaesthesiologist not involved with the patients perioperative care." Comment: unclear whether adjudification of endpoints were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-29 19:53:33 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Abd.-El_x002d_Hakeem-2003b">
<DESCRIPTION>
<P>Quote: "Randomized double-blind placebo controlled study. This was performed by an anaesthesiologist not involved with the patients perioperative care." <BR/>Comment: unclear whether adjudication of endpoints or data-analyses were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-29 19:57:39 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Amr-2009">
<DESCRIPTION>
<P>Quote: "Randomized placebo controlled trial", implicates an unblinded study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-29 19:57:49 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Andersen-1989">
<DESCRIPTION>
<P>Quote: "Randomized placebo controlled trial", implicates an unblinded study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:56:08 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bingol-2005">
<DESCRIPTION>
<P>Quote: "Our study-team, the patients and the spirometry technician were blind to the study whereas the pharmacist and the statistical data analysts were not blind to the coding of the groups"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:57:36 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Boscoe-1983">
<DESCRIPTION>
<P>Quote: "group 2 received in addition 30 mg/kg methylprednisolon",<BR/>Comment: Placebo medication was not mentioned. Probably unblinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-29 20:03:29 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bourbon-2004">
<DESCRIPTION>
<P>No information regarding blinding was available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-25 01:25:59 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Cavarocchi-1986">
<DESCRIPTION>
<P>Comment: Study was designed to evaluate the effect of different types of oxygenators, which making blinding impossible</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:36:50 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="UNKNOWN" STUDY_ID="STD-Celik-2004">
<DESCRIPTION>
<P>Comment: It was not specified whether data-collection, adjudication of endpoints or analyses were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:37:18 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="NO" STUDY_ID="STD-Chaney-1998">
<DESCRIPTION>
<P>Quote: "An anaesthesia research nurse performed the randomisation and prepared the two syringes of blinded solution that were administered. All physicians and nursing staff caring for the patients perioperatively were unaware of treatment group"<BR/>Comment: Adjudication of endpoints or analyses were not specified; probably unblinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:38:04 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="NO" STUDY_ID="STD-Chaney-2001">
<DESCRIPTION>
<P>Quote: "An anaesthesia research nurse performed the randomisation and prepared the two syringes of blinded solution that were administered. All physicians and nursing staff caring for the patients perioperatively were unaware of treatment group"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-26 01:16:28 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Codd-1977">
<DESCRIPTION>
<P>Quote: "randomized placebo-controlled trial" implicates an unblinded study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:38:28 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="NO" STUDY_ID="STD-Coetzer-1996">
<DESCRIPTION>
<P>Quote: "the first author of the study was blinded"<BR/>Comment: it was assumed that this first author did the data collection, but adjudication or endpoints and further analyses are probably done together with the unblinded co-authors</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-26 01:17:27 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Demir-2009">
<DESCRIPTION>
<P>No information regarding blinding was present</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-29 20:09:22 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-El-Azab-2002">
<DESCRIPTION>
<P>Quote: "This dosage was masked"<BR/>Comment: Since no information on adjudification or analyses was provided, this was assumed to be unblinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-26 01:21:00 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Enc-2006">
<DESCRIPTION>
<P>Quote: "double blind, randomized prospective study"<BR/>Comment: whether analyses were blinded was not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-29 20:11:28 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Engelman-1995">
<DESCRIPTION>
<P>Quote: "the blood study was carried out in a blinded fashion as to the steroid/no steroid group".<BR/>Comment:"The blood study" refers to data-collection and not to data-analysis; we assumed unblinded analyses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-26 01:24:02 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ferries-1984">
<DESCRIPTION>
<P>No information available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:05:59 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fillinger-2002">
<DESCRIPTION>
<P>Although investigators were blinded, it was not stated that adjudification of endpoints was blinded as well</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-26 01:25:33 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Giomarelli-2003">
<DESCRIPTION>
<P>No information available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:07:02 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Halonen-2007">
<DESCRIPTION>
<P>Quote: "The randomization codes were opened after the end of the study."<BR/>Comment: this implicates unblinded adjudification of endpoints</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:07:55 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Halvorsen-2003">
<DESCRIPTION>
<P>Comment: "by a nurse who dit not participate in the treatment" implicates blinding during hospital care period, during which data was collected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:40:23 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="NO" STUDY_ID="STD-Harig-1999">
<DESCRIPTION>
<P>Comment: The absence of information regarding blinding implicates an unblinded study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-29 20:21:03 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Jansen-1991a">
<DESCRIPTION>
<P>Comment: The study is qualified as a "Randomized, double-blind trial", but no blinding-method or duration was not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-26 01:27:40 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kilger-2003a">
<DESCRIPTION>
<P>Quote: "one limitation of this study is that is was performed only in a randomized controlled, but not in a double-blind manner."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-27 17:52:58 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kilger-2003b">
<DESCRIPTION>
<P>Quote: "die patienten erhielten randomisiert vor narkoseeinleitung"<BR/>Comment: absence of blinding manners implies no blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-31 16:03:43 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Liakopoulos-2007">
<DESCRIPTION>
<P>qualifying the study as "prospective placebo-controlled randomized trial" implies an unblinded study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-31 16:03:45 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Loef-2004">
<DESCRIPTION>
<P>Quote: "patients were randomized in a double-blind fashion"<BR/>Comment: No further information regarding blinding procedures was available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-29 23:50:24 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mayumi-1997">
<DESCRIPTION>
<P>Quote: "After the statistical analysis was completed, the used drug for each group and the used dose of the steroid in each patient were disclosed to the senior author"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:13:14 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-McBride-2004">
<DESCRIPTION>
<P>Quote: "Ethical consideration required that the peri-operative physician was aware of the randomisation group"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-26 01:39:43 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Morton-1976">
<DESCRIPTION>
<P>Quote: "The code was not revealed until the study was completed and all the data had been collected and interpreted"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:42:28 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="UNKNOWN" STUDY_ID="STD-Oliver-2004">
<DESCRIPTION>
<P>Quote: "Perfusionists were aware of subjects assigned to hemofil, but no other study assignment. All remaining operating room and intensive care unit personnel were blinded to group identity"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:43:24 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="YES" STUDY_ID="STD-Prasongsukarn-2005">
<DESCRIPTION>
<P>Quote: "A planned interim analyses was performed after 50 % enrolment...Therefore, study enrolment was terminated on February 29, 2001 and the code was broken"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:15:19 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rao-1977">
<DESCRIPTION>
<P>The study was classified as a "prospective randomized study". This implicates an unblinded study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:16:12 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rubens-2005">
<DESCRIPTION>
<P>It is unclear when allocation was disclosed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:16:34 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rumalla-2001">
<DESCRIPTION>
<P>Study was classified as a "randomized control study". This implicates an unblinded study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-27 17:18:32 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sano-2003">
<DESCRIPTION>
<P>Quote: "these patients were randomly divided into two groups"<BR/>Comment: no remark concerning blinding implicates an unblinded study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-29 23:55:40 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sano-2006">
<DESCRIPTION>
<P>Quote: "Were prospectively randomized into two groups by our operation-registry staff who were not involved in this study"<BR/>Comment: whether data collection, adjudification of endpoints or analyses were blinded was not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:18:47 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Schurr-2001">
<DESCRIPTION>
<P>Study was qualified as: "prospective randomized"<BR/>Comment: no remark regarding blinding implicates an unblinded study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-27 18:07:21 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sobieski-2008">
<DESCRIPTION>
<P>Quote: "At the completion of the study, the pharmacy unblinded all the patient treatment groups"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-28 17:28:52 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Starobin-2007">
<DESCRIPTION>
<P>Study was classified as a "prospective open randomized trial"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:20:42 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tassani-1999">
<DESCRIPTION>
<P>Quote: "the study was performed double-blinded"<BR/>Comment: it is unclear when allocation was disclosed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:21:02 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Toft-1997">
<DESCRIPTION>
<P>Probably an unblinded study, since blinding is not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:21:55 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Turkoz-2001">
<DESCRIPTION>
<P>The study was classified as a prospective randomized study, which implicates an unblinded study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:23:35 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Volk-2001">
<DESCRIPTION>
<P>The study was classified as a "randomized, controlled, double-blind prospective trial"., but it is unclear when allocation was disclosed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-02 22:02:53 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Volk-2003">
<DESCRIPTION>
<P>The study was classified as a "randomized controlled blinded prospective trial", but it is unclear when allocation was disclosed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-28 23:56:58 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wan-1999">
<DESCRIPTION>
<P>Quote: "The ICU staff was blinded as to the pretreatment of steroids"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:26:43 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Weis-2006">
<DESCRIPTION>
<P>Quote: "... In identical vials in a double-blind fashion. The vials were prepared by a study nurse who was not involved in the care of patients participating in the trial"<BR/>Comment: It is unclear when allocation was disclosed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:27:40 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Weis-2009">
<DESCRIPTION>
<P>Study was classified as prospective, randomized, double-blinded, placebo controlled"<BR/>Comment: when concealment of allocation was disclosed is unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:46:44 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="YES" STUDY_ID="STD-Whitlock-2006">
<DESCRIPTION>
<P>Quote: "all patients, clinicians, and statisticians were blinded until the completion of data analyses by group"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:29:48 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yared-1998">
<DESCRIPTION>
<P>Study was classified as " a prospective, randomized, double-blind, placebo-controlled study"<BR/>Comment: there is no information available with regard to the timing of disclosure of allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:31:06 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yared-2007">
<DESCRIPTION>
<P>Study was classified as " a prospective, randomized, double-blind, placebo-controlled study"<BR/>Comment: there is no information available with regard to the timing of disclosure of allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:32:00 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yilmaz-1999">
<DESCRIPTION>
<P>Study was classified as " a prospective, randomized, double-blind, placebo-controlled study"<BR/>Comment: there is no information available with regard to the timing of disclosure of allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:46:10 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="NO" STUDY_ID="STD-von-Spiegel-2001">
<DESCRIPTION>
<P>Quote: "Throughout the entire study, the care of the patients was managed by anaesthesiologists and intensivists who were not involved in the study"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-11" LEVEL="STUDY" MODIFIED="2011-03-02 22:03:01 +0530" MODIFIED_BY="[Empty name]" NO="11">
<NAME>Blinded data-analyses?</NAME>
<DESCRIPTION>
<P>Were analyses performed blinded to treatment allocation?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:53:05 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Abd.-El_x002d_Hakeem-2003a">
<DESCRIPTION>
<P>Quote: "Randomized double-blind placebo controlled study. This was performed by an anaesthesiologist not involved with the patients perioperative care." Comment: unclear whether data-analyses were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:54:36 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Abd.-El_x002d_Hakeem-2003b">
<DESCRIPTION>
<P>Quote: "Randomized double-blind placebo controlled study. This was performed by an anaesthesiologist not involved with the patients perioperative care."<BR/>Comment: unclear whether adjudication of endpoints or data-analyses were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:55:03 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Amr-2009">
<DESCRIPTION>
<P>Quote: "Randomized placebo controlled trial", implicates an unblinded study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:55:16 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Andersen-1989">
<DESCRIPTION>
<P>Quote: "Randomized placebo controlled trial", implicates an unblinded study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:57:19 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bingol-2005">
<DESCRIPTION>
<P>Quote: "Our study-team, the patients and the spirometry technician were blind to the study whereas the pharmacist and the statistical data analysts were not blind to the coding of the groups"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:57:38 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Boscoe-1983">
<DESCRIPTION>
<P>Quote: "group 2 received in addition 30 mg/kg methylprednisolon",<BR/>Comment: Placebo medication was not mentioned. Probably unblinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:58:08 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bourbon-2004">
<DESCRIPTION>
<P>No information regarding blinding was available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:58:35 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Cavarocchi-1986">
<DESCRIPTION>
<P>Comment: Study was designed to evaluate the effect of different types of oxygenators, which makes blinding impossible.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:36:56 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="UNKNOWN" STUDY_ID="STD-Celik-2004">
<DESCRIPTION>
<P>Comment: It was not specified whether data-collection, adjudication of endpoints or analyses were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:37:26 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="NO" STUDY_ID="STD-Chaney-1998">
<DESCRIPTION>
<P>Quote: "An anaesthesia research nurse performed the randomisation and prepared the two syringes of blinded solution that were administered. All physicians and nursing staff caring for the patients perioperatively were unaware of treatment group"<BR/>Comment: Adjudication of endpoints or analyses were not specified; probably unblinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:38:11 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="NO" STUDY_ID="STD-Chaney-2001">
<DESCRIPTION>
<P>Quote: "An anaesthesia research nurse performed the randomisation and prepared the two syringes of blinded solution that were administered. All physicians and nursing staff caring for the patients perioperatively were unaware of treatment group"<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:00:41 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Codd-1977">
<DESCRIPTION>
<P>Quote: "randomized placebo-controlled trial" implicates an unblinded study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:38:29 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="NO" STUDY_ID="STD-Coetzer-1996">
<DESCRIPTION>
<P>Quote: "the first author of the study was blinded"<BR/>Comment: it was assumed that this first author did the data collection, but adjudication or endpoints and further analyses are probably done together with the unblinded co-authors</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:01:35 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Demir-2009">
<DESCRIPTION>
<P>No information regarding blinding was present</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:01:59 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-El-Azab-2002">
<DESCRIPTION>
<P>Quote: "This dosage was masked"<BR/>Comment: Since no information on adjudification or analyses was provided, this was assumed to be unblinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:02:34 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Enc-2006">
<DESCRIPTION>
<P>Quote: "double blind, randomized prospective study"<BR/>Comment: whether adjudification of endpoints was blinded was not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:02:53 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Engelman-1995">
<DESCRIPTION>
<P>Quote: "the blood study was carried out in a blinded fashion as to the steroid/no steroid group".<BR/>Comment:"The blood study" refers to data-collection and not to data-analysis; we assumed unblinded adjudification of endpoints</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:04:57 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ferries-1984">
<DESCRIPTION>
<P>No information available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:05:48 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fillinger-2002">
<DESCRIPTION>
<P>Although investigators were blinded, it was not stated that analyses were blinded as well</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:06:27 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Giomarelli-2003">
<DESCRIPTION>
<P>No information available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:07:21 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Halonen-2007">
<DESCRIPTION>
<P>Quote: "The randomization codes were opened after the end of the study."<BR/>Comment: this implicates unblinded data-analyses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:07:57 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Halvorsen-2003">
<DESCRIPTION>
<P>Comment: "by a nurse who dit not participate in the treatment" implicates blinding during hospital care period, during which data was collected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:40:30 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="NO" STUDY_ID="STD-Harig-1999">
<DESCRIPTION>
<P>Comment: The absence of information regarding blinding implicates an unblinded study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:40:35 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="NO" STUDY_ID="STD-Jansen-1991a">
<DESCRIPTION>
<P>Comment: The study is qualified as a "Randomized, double-blind trial", but no blinding-method or duration was specified in detail</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:10:40 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kilger-2003a">
<DESCRIPTION>
<P>Quote: "one limitation of this study is that is was performed only in a randomized controlled, but not in a double-blind manner."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:10:56 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kilger-2003b">
<DESCRIPTION>
<P>Quote: "die patienten erhielten randomisiert vor narkoseeinleitung"<BR/>Comment: absence of blinding manners implies no blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:41:08 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="NO" STUDY_ID="STD-Liakopoulos-2007">
<DESCRIPTION>
<P>qualifying the study as "prospective placebo-controlled randomized trial" implies an unblinded study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-02 22:01:54 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Loef-2004">
<DESCRIPTION>
<P>Quote: "patients were randomized in a double-blind fashion"<BR/>Comment: No further information regarding blinding procedures was available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:12:45 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mayumi-1997">
<DESCRIPTION>
<P>Quote: "After the statistical analysis was completed, the used drug for each group and the used dose of the steroid in each patient were disclosed to the senior author"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:13:22 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-McBride-2004">
<DESCRIPTION>
<P>Quote: "Ethical consideration required that the peri-operative physician was aware of the randomisation group"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:13:46 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Morton-1976">
<DESCRIPTION>
<P>Quote: "The code was not revealed until the study was completed and all the data had been collected and interpreted"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:42:30 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="UNKNOWN" STUDY_ID="STD-Oliver-2004">
<DESCRIPTION>
<P>Quote: "Perfusionists were aware of subjects assigned to hemofil, but no other study assignment. All remaining operating room and intensive care unit personnel were blinded to group identity"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:43:26 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="YES" STUDY_ID="STD-Prasongsukarn-2005">
<DESCRIPTION>
<P>Quote: "A planned interim analyses was performed after 50 % enrolment...Therefore, study enrolment was terminated on February 29, 2001 and the code was broken"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:15:30 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rao-1977">
<DESCRIPTION>
<P>The study was classified as a "prospective randomized study". This implicates an unblinded study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:16:19 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rubens-2005">
<DESCRIPTION>
<P>It is unclear when allocation was disclosed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:16:58 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rumalla-2001">
<DESCRIPTION>
<P>Study was classified as a "randomized control study". This implicates an unblinded study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:17:16 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sano-2003">
<DESCRIPTION>
<P>Quote: "these patients were randomly divided into two groups"<BR/>Comment: no remark concerning blinding implicates an unblinded study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:17:38 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sano-2006">
<DESCRIPTION>
<P>Quote: "Were prospectively randomized into two groups by our operation-registry staff who were not involved in this study"<BR/>Comment: whether data collection, adjudification of endpoints or analyses were blinded was not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:19:00 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Schurr-2001">
<DESCRIPTION>
<P>Study was qualified as: "prospective randomized"<BR/>Comment: no remark regarding blinding implicates an unblinded study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:19:22 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sobieski-2008">
<DESCRIPTION>
<P>Quote: "At the completion of the study, the pharmacy unblinded all the patient treatment groups"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:19:36 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Starobin-2007">
<DESCRIPTION>
<P>Study was classified as a "prospective open randomized trial"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:20:44 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tassani-1999">
<DESCRIPTION>
<P>Quote: "the study was performed double-blinded"<BR/>Comment: it is unclear when allocation was disclosed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:21:17 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Toft-1997">
<DESCRIPTION>
<P>Probably an unblinded study, since blinding is not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:22:08 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Turkoz-2001">
<DESCRIPTION>
<P>The study was classified as a prospective randomized study, which implicates an unblinded study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:45:29 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="NO" STUDY_ID="STD-Volk-2001">
<DESCRIPTION>
<P>Quote: "one patient received both TM and MP and had to be excluded from data-analyses"<BR/>Comment: This implies breaking of the code before data-analyses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-02 22:03:01 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Volk-2003">
<DESCRIPTION>
<P>The study was classified as a "randomized controlled blinded prospective trial", but it is unclear when allocation was disclosed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:25:52 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wan-1999">
<DESCRIPTION>
<P>Quote: "The ICU staff was blinded as to the pretreatment of steroids"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:26:26 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Weis-2006">
<DESCRIPTION>
<P>Quote: "... In identical vials in a double-blind fashion. The vials were prepared by a study nurse who was not involved in the care of patients participating in the trial"<BR/>Comment: It is unclear when allocation was disclosed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:27:31 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Weis-2009">
<DESCRIPTION>
<P>Study was classified as prospective, randomized, double-blinded, placebo controlled"<BR/>Comment: when concealment of allocation was disclosed is unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:46:45 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="YES" STUDY_ID="STD-Whitlock-2006">
<DESCRIPTION>
<P>Quote: "all patients, clinicians, and statisticians were blinded until the completion of data analyses by group"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:29:53 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Yared-1998">
<DESCRIPTION>
<P>Study was classified as " a prospective, randomized, double-blind, placebo-controlled study"<BR/>Comment: there is no information available with regard to the timing of disclosure of allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:31:04 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Yared-2007">
<DESCRIPTION>
<P>Study was classified as " a prospective, randomized, double-blind, placebo-controlled study"<BR/>Comment: there is no information available with regard to the timing of disclosure of allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:31:58 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Yilmaz-1999">
<DESCRIPTION>
<P>Study was classified as " a prospective, randomized, double-blind, placebo-controlled study"<BR/>Comment: there is no information available with regard to the timing of disclosure of allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:46:13 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="NO" STUDY_ID="STD-von-Spiegel-2001">
<DESCRIPTION>
<P>Quote: "Throughout the entire study, the care of the patients was managed by anaesthesiologists and intensivists who were not involved in the study"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-15" LEVEL="STUDY" MODIFIED="2011-03-02 21:59:14 +0530" MODIFIED_BY="[Empty name]" NO="15">
<NAME>Standardized pre-, peri-, and postoperative care?</NAME>
<DESCRIPTION>
<P>Was care standardized in a study protocol in the pre-, peri- and postoperative? period?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:33:50 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="YES" STUDY_ID="STD-Abd.-El_x002d_Hakeem-2003a">
<DESCRIPTION>
<P>Quote: "All patients were pre-medicated with..."<BR/>Quote: "A standard Anaesthetic technique for a patients was performed"<BR/>Quote: "While the patients were in the ICU, standard care and processes were followed until discharge"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:34:06 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="YES" STUDY_ID="STD-Abd.-El_x002d_Hakeem-2003b">
<DESCRIPTION>
<P>Quote: "All patients were pre-medicated with..."<BR/>Quote: "A standard Anaesthetic technique for a patients was performed"<BR/>Quote: "While the patients were in the ICU, standard care and processes were followed until discharge"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-02 21:59:14 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Amr-2009">
<DESCRIPTION>
<P>Quote: "In addition to patients' regular cardiovascular medications, all patients were premedicated with..."<BR/>Quote: "The surgical techniques were standardized in all cases"<BR/>Comment: Specified anaesthesiological care and Cardiopulmonary bypass management was described as well<BR/>Quote: "After completion of the operation, patients were transferred to the ICU, where postoperative care was standardized as follows:... "</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:16:25 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Andersen-1989">
<DESCRIPTION>
<P>Surgical and anaesthesiological procedures and cardiopulmonary bypass management were described in detail, but there was no information regarding the ICU-care</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:16:40 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bingol-2005">
<DESCRIPTION>
<P>No information regarding anaesthesiological techniques was specified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:17:05 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Boscoe-1983">
<DESCRIPTION>
<P>Anaestesiologic management was conducted "as appropriate". No surgical management, ICU-care management was specified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:17:31 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bourbon-2004">
<DESCRIPTION>
<P>No information regarding standardization of study endpoints available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:18:13 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Cavarocchi-1986">
<DESCRIPTION>
<P>Anaestesiologic management and ICU care not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:19:08 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Celik-2004">
<DESCRIPTION>
<P>Anaesthesia technique and surgical procedure was specified. Extubation algorithm was specified, further ICU-care was unspecified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:25:41 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chaney-1998">
<DESCRIPTION>
<P>Anesthesia technique, cardiopulmonary bypass managing, specimen sampling and laboratory handling, post-operative monitoring and care were specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:38:16 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="YES" STUDY_ID="STD-Chaney-2001">
<DESCRIPTION>
<P>Quote: "the anaesthetic technique was standardized"<BR/>Comment: cardiopulmonary bypass managing was specified in detail.<BR/>Quote: "postoperative care was standardized"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:26:34 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Codd-1977">
<DESCRIPTION>
<P>Comment: Only surgical technique was specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:27:04 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Coetzer-1996">
<DESCRIPTION>
<P>Anaestetia technique, cardiopulmonary bypass managing, post operative care was not standardized.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:28:11 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Demir-2009">
<DESCRIPTION>
<P>Postoperative management was not standardized</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:28:32 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-El-Azab-2002">
<DESCRIPTION>
<P>Comment: Only post-operative care was standardized</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:38:37 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="NO" STUDY_ID="STD-Enc-2006">
<DESCRIPTION>
<P>Only anaesthesia technique was standardized</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:30:03 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Engelman-1995">
<DESCRIPTION>
<P>Quote: "all patients were treated similarly in a manner described as fast track"<BR/>Intensive care management was not specified<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:30:35 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ferries-1984">
<DESCRIPTION>
<P>Sugical management of post-operative care was not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:38:58 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="YES" STUDY_ID="STD-Fillinger-2002">
<DESCRIPTION>
<P>Quote: "After surgery, all patients were transferred to the ICU, where postoperative care was at the discretion of a perioperative care team who followed standard clinical protocol for treatment of cardiopulmonary function, including decisions about tracheal extubations."<BR/>Comment: together with standardized anaesthesiologic and cardiopulmonary bypass managing, the whole care was judged as "standardized"<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:34:06 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Giomarelli-2003">
<DESCRIPTION>
<P>Anesthesia technique, cardiopulmonary bypass, myocardial protection and post-operative care at the ICU were specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:32:30 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Halonen-2007">
<DESCRIPTION>
<P>Anesthesia technique was not standardized.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:39:52 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="UNKNOWN" STUDY_ID="STD-Halvorsen-2003">
<DESCRIPTION>
<P>Quote: "all patients were tracheally extubated in the ICU when they were judged to be haemodynamically stable with adequate spontaneous ventilatory function"<BR/>Comment: no further specification was described, which makes it unclear whether ICU care was standardized.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:33:09 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Harig-1999">
<DESCRIPTION>
<P>No information regarding standardization of ICU-care was provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:40:37 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="YES" STUDY_ID="STD-Jansen-1991a">
<DESCRIPTION>
<P>In section "Technique of CPB, technique of anaesthesia and postoperative care" treatment were specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:35:17 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kilger-2003a">
<DESCRIPTION>
<P>Anesthesia technique, Cardio pulmonary bypass management and postoperative care were specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:35:45 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kilger-2003b">
<DESCRIPTION>
<P>pre-peri- and postoperative care was not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:36:35 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Liakopoulos-2007">
<DESCRIPTION>
<P>In section "peri-operative management" all relevant care was specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:37:03 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Loef-2004">
<DESCRIPTION>
<P>In section "anaesthetic management" pre-peri- and postoperative care were specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:41:43 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="YES" STUDY_ID="STD-Mayumi-1997">
<DESCRIPTION>
<P>In sections "technique of cardiopulmonary bypass", "technique of anaesthesia and operation" and "postoperative care" pre-peri- and postoperative care was specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:41:49 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="YES" STUDY_ID="STD-McBride-2004">
<DESCRIPTION>
<P>Management procedures with regard to cardiopulmonary bypass, haemodynamic support or extubation timing were not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:38:54 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Morton-1976">
<DESCRIPTION>
<P>Only information regarding surgical procedure was available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:42:37 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="YES" STUDY_ID="STD-Oliver-2004">
<DESCRIPTION>
<P>Anesthesia technique, Cardiopulmonary bypass managing, blood transfusions and ICU care were specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:43:32 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="YES" STUDY_ID="STD-Prasongsukarn-2005">
<DESCRIPTION>
<P>Quote: "Standatdized anaesthesia and surgical protocols were applied in all cases"<BR/>postoperative care was specified in section "haemodynamic measurement and monitoring"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:40:46 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rao-1977">
<DESCRIPTION>
<P>Only Cardiopulmonary bypass technique was standardized, other care was not specified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:41:14 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rubens-2005">
<DESCRIPTION>
<P>Comment: Post-operative care was not specified and probably unstandardized</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:41:58 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rumalla-2001">
<DESCRIPTION>
<P>Pre-peri- and postoperative care was not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:44:09 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="NO" STUDY_ID="STD-Sano-2003">
<DESCRIPTION>
<P>In section "intraoperative patient management" anaesthetic techniques and CPB management is described. There is no information regarding postoperative management.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:43:37 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sano-2006">
<DESCRIPTION>
<P>Anethesia Technique, Cardiopulmonary bypass managing, Surgery techniques and ICU care were specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:44:32 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="NO" STUDY_ID="STD-Schurr-2001">
<DESCRIPTION>
<P>Quote: "the peri-operative anaesthesia management and medication treatment were identical in both groups"<BR/>Comment: further care was not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:44:28 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sobieski-2008">
<DESCRIPTION>
<P>Post-operative care was not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:45:00 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Starobin-2007">
<DESCRIPTION>
<P>Anesthetic technique, Cardiopulmonary bypass managing, surgery and post-operative care at ICU were not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:45:42 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tassani-1999">
<DESCRIPTION>
<P>Anesthetic Technique, Cardiopulmonary bypass managing, surgery and Post-operative care at the ICU were specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:45:12 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="NO" STUDY_ID="STD-Toft-1997">
<DESCRIPTION>
<P>Only anaesthetic technique and Cardiopulmonary bypass were described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:46:21 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Turkoz-2001">
<DESCRIPTION>
<P>Post-operative care was not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:46:44 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Volk-2001">
<DESCRIPTION>
<P>Post-operative care at the ICu was not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:47:13 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Volk-2003">
<DESCRIPTION>
<P>Post-operative care at the ICU was not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:47:56 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wan-1999">
<DESCRIPTION>
<P>Post-operatieve care is not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:48:20 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Weis-2006">
<DESCRIPTION>
<P>Anesthetic technique, cardiopulmonary bypass managing, Surgery, post operative care at the ICU were not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:49:07 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Weis-2009">
<DESCRIPTION>
<P>In section "Patient management" all details were specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:49:23 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Whitlock-2006">
<DESCRIPTION>
<P>Quote: "Neither operative technique nor anaesthesia was standardized to maintain generalizablility of the study" "Likewise the postoperative ICU-care was not standardized"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:46:56 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="NO" STUDY_ID="STD-Yared-1998">
<DESCRIPTION>
<P>Quote: "patients were weaned to CPAP and extubated according to ICU routine"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:47:05 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="NO" STUDY_ID="STD-Yared-2007">
<DESCRIPTION>
<P>There is no description of peri- or post operative care</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:50:58 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Yilmaz-1999">
<DESCRIPTION>
<P>Post-operative care was not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:47:40 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-von-Spiegel-2001">
<DESCRIPTION>
<P>Quote: "Peri-operative care was standardized according to our clinical routine, with the following guidelines"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-16" LEVEL="STUDY" MODIFIED="2011-03-31 16:03:54 +0530" MODIFIED_BY="[Empty name]" NO="16">
<NAME>Standardization of study endpoints?</NAME>
<DESCRIPTION>
<P>Were study endpoints standardized?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:22:11 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Abd.-El_x002d_Hakeem-2003a">
<DESCRIPTION>
<P>Shivering score after Holtzclaw and secondary endpoints were stated in the Methods section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:34:17 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="YES" STUDY_ID="STD-Abd.-El_x002d_Hakeem-2003b">
<DESCRIPTION>
<P>In sections "Study-design and measurements", "calculation of shunt fraction", "laboratory methods" all endpoints were specified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:35:09 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="YES" STUDY_ID="STD-Amr-2009">
<DESCRIPTION>
<P>In sections "pulmonary measurements", "renal measurements", and "specimen collection" all endpoints were specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:35:22 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="YES" STUDY_ID="STD-Andersen-1989">
<DESCRIPTION>
<P>Timing of blood specimens, types of markers, correction for haemodilution and laboratory methods were specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:23:14 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bingol-2005">
<DESCRIPTION>
<P>Spirometry measurement techniques were not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:23:34 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Boscoe-1983">
<DESCRIPTION>
<P>Timing of blood specimen sampling, laboratory management and interpretation were specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:24:10 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bourbon-2004">
<DESCRIPTION>
<P>Only cardiopulmonary bypass management was specified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:36:08 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="YES" STUDY_ID="STD-Cavarocchi-1986">
<DESCRIPTION>
<P>Blood specimen sampling and handling in the laboratories were specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:25:04 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Celik-2004">
<DESCRIPTION>
<P>Blood specimen sampling and laboratory handling was specified. Definitions of major clinical complications were specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:37:28 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="YES" STUDY_ID="STD-Chaney-1998">
<DESCRIPTION>
<P>Blood specimen sampling and laboratory handling, post-operative haemodynamic monitoring, complication definition and monitoring were specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:38:19 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="YES" STUDY_ID="STD-Chaney-2001">
<DESCRIPTION>
<P>Blood specimen sampling and laboratory handling, post-operative haemodynamic and pulmonary monitoring, and complication definition and monitoring were specified in detail</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:26:36 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Codd-1977">
<DESCRIPTION>
<P>Definition of myocardial infarction, timing of electrocardiogram, serum samples and laboratory investigations were specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:27:05 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Coetzer-1996">
<DESCRIPTION>
<P>Clinical outcome measurements and relevant calculations were specified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:28:14 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Demir-2009">
<DESCRIPTION>
<P>Blood specimen sampling and handling in the laboratory was specified in detail.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:28:51 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-El-Azab-2002">
<DESCRIPTION>
<P>Blood specimen sampling and handling in the laboratory were specified </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:31:04 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Enc-2006">
<DESCRIPTION>
<P>Blood specimen sampling and handling in the laboratory were specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:31:14 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Engelman-1995">
<DESCRIPTION>
<P>Blood specimen sampling, storage and handling in the laboratory were specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:30:42 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ferries-1984">
<DESCRIPTION>
<P>Blood specimen sampling and handling in the laboratory handling were specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:31:47 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fillinger-2002">
<DESCRIPTION>
<P>Blood specimen sampling and handling in the laboratory was specified in detail</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:33:59 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Giomarelli-2003">
<DESCRIPTION>
<P>Blood specimen sampling and handling in the laboratory were specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:32:32 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Halonen-2007">
<DESCRIPTION>
<P>Endopoints 'acute myocardial infarction' and 'stroke' were pre-defined. Infection was not specified, but there was a thorough follow up to check for any major complication.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-04 21:39:07 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Halvorsen-2003">
<DESCRIPTION>
<P>a verbal five points verbal rating scale was applied to assess pain and nausea/vomiting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:33:22 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Harig-1999">
<DESCRIPTION>
<P>In section "blood sampling and biochemical measurements" study-endpoints are specified </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:34:36 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jansen-1991a">
<DESCRIPTION>
<P>In section "hematology" blood specimen sampling and laboratory handling were specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:35:21 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kilger-2003a">
<DESCRIPTION>
<P>Both primary and secondary endpoints were specified </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:35:38 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kilger-2003b">
<DESCRIPTION>
<P>There were no details regarding study-endpoints</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:36:09 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Liakopoulos-2007">
<DESCRIPTION>
<P>In section "data-collection" blood specimen sampling and laboratory handling and relevant information on clinical outcome measures were specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-02 22:02:01 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Loef-2004">
<DESCRIPTION>
<P>Quote:"the injury to glomerular and tubular structure was assessed by measurement of sensitive markers of glomerular and tubular dysfunction and damage" Comment: in section "renal markers" and "laboratory methods" detailed description on plasma and urinary specimen sampling and laboratory handling was provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:37:35 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mayumi-1997">
<DESCRIPTION>
<P>In section "hematology" and "Hemodynamics metabolism and blood gas" detailed information regarding data-collection for pre-defined endpoints was provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:38:19 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McBride-2004">
<DESCRIPTION>
<P>Blood specimen sampling and handling in the laboratory were specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-31 16:03:54 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Morton-1976">
<DESCRIPTION>
<P>Main outcome: myocardia preservation was assessed by laboratory investigation (LDH and CK), ECG-judgement by a cardiologist,</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:42:39 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="YES" STUDY_ID="STD-Oliver-2004">
<DESCRIPTION>
<P>Blood specimen sampling and laboratory handling, post-operative haemodynamic monitoring, complication definition and monitoring were specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:40:28 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Prasongsukarn-2005">
<DESCRIPTION>
<P>Atrial fibrillation monitoring, occurrence (including study definitions of atrial fibrillation) and treatment were specified<BR/>Blood specimen sampling and laboratory handling were specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:43:48 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="UNKNOWN" STUDY_ID="STD-Rao-1977">
<DESCRIPTION>
<P>Quote: "observations were made regarding: acidoses during CPB, Need for supportive therapy; incidence and management of cardiac arrhythmias immediately post-operatively and during the rest of the hospital course; incidence and management of pulmonary complications; consumption of oxygen by the body tissues during cardiopulmonary bypass using the A-V flux formula"<BR/>Comment: Endpoints were no further specified or standardized</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:41:32 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rubens-2005">
<DESCRIPTION>
<P>In sections "primary outcome variables" and "secondary outcome variables" endpoints were specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:42:08 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rumalla-2001">
<DESCRIPTION>
<P>Blood specimen sampling and laboratory handling were specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:43:05 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sano-2003">
<DESCRIPTION>
<P>In section "blood sampling", "analysis of T cell response to PPD antigen" and "cross-stimulation system" endpoints are specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:43:46 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sano-2006">
<DESCRIPTION>
<P>Quote: "Aim: to investigate whether this retardation of recovery of adaptive immunity induced by steroid administration would increase the risk of infection after open heart surgery"<BR/>Comment: retardation of adaptive immunity and infection was not pre-defined.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:44:03 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schurr-2001">
<DESCRIPTION>
<P>Detailed endpoint specifications were present In sections "blood sampling and analyses" and "clinical variables"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:44:42 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sobieski-2008">
<DESCRIPTION>
<P>In sections "Sample collection and clinical variables" and "Cytokine, complement, and plama norepinephrine assays" all endpoints were specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:45:02 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Starobin-2007">
<DESCRIPTION>
<P>In section "study-endpoints" are both primary and secondary endpoints specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:45:04 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="YES" STUDY_ID="STD-Tassani-1999">
<DESCRIPTION>
<P>Blood specimen sampling, laboratory handling, monitoring of relevant clinical, haemodynamic and respiratory parameters and formula's tor calculations were specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:46:01 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Toft-1997">
<DESCRIPTION>
<P>Blood specimen sampling and laboratory handling were specified in detail.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:46:29 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Turkoz-2001">
<DESCRIPTION>
<P>Blood specimen sampling and laboratory handling were specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:46:53 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Volk-2001">
<DESCRIPTION>
<P>Blood specimen sampling and laboratory handling were specified </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:47:27 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Volk-2003">
<DESCRIPTION>
<P>Blood specimen sampling and laboratory handling were specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:48:06 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wan-1999">
<DESCRIPTION>
<P>Blood specimen sampling and laboratory handling were specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:48:22 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Weis-2006">
<DESCRIPTION>
<P>Post-traumatic stress and Health related quality of life were assessed by validated scoring systems</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:48:51 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Weis-2009">
<DESCRIPTION>
<P>Blood specimen sampling and laboratory handling were specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:49:36 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Whitlock-2006">
<DESCRIPTION>
<P>In section "measurements" all relevant details were described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:50:06 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Yared-1998">
<DESCRIPTION>
<P>Primary endpoint was shivering, but no definition of shivering was provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:47:07 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="YES" STUDY_ID="STD-Yared-2007">
<DESCRIPTION>
<P>In section "materials and methods" all relevant information was available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:51:01 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yilmaz-1999">
<DESCRIPTION>
<P>In section "blood sampling", "assay technique" and "follow up" details are described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 00:47:42 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-von-Spiegel-2001">
<DESCRIPTION>
<P>Endpoints and various relevant calculations were described in section "fluid balances" and "double indicator dilution"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-17" LEVEL="STUDY" MODIFIED="2011-03-04 21:39:14 +0530" MODIFIED_BY="[Empty name]" NO="17">
<NAME>Completeness of (follow up) data?</NAME>
<DESCRIPTION>
<P>Was follow up data complete?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:36:35 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Abd.-El_x002d_Hakeem-2003a">
<DESCRIPTION>
<P>Follow-up: ICU-stay. 0% loss to follow up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:36:44 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Abd.-El_x002d_Hakeem-2003b">
<DESCRIPTION>
<P>Follow-up: ICU-stay. 0% loss to follow up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:37:37 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Amr-2009">
<DESCRIPTION>
<P>Follow-up: hospital stay. 0% loss to follow up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-04 21:38:35 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Andersen-1989">
<DESCRIPTION>
<P>Follow-up: seven days. 0% loss to follow up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:38:12 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bingol-2005">
<DESCRIPTION>
<P>Follow-up: 3 months. 0% loss to follow up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:38:30 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Boscoe-1983">
<DESCRIPTION>
<P>Follow-up: 24 hours. 0% loss to follow up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:38:43 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bourbon-2004">
<DESCRIPTION>
<P>Follow-up: 24 hours. 0% loss to follow up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:39:05 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cavarocchi-1986">
<DESCRIPTION>
<P>Follow-up: 24 hours. 0% loss to follow up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:39:12 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Celik-2004">
<DESCRIPTION>
<P>Follow-up: hospital stay. 0% loss to follow up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:39:21 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chaney-1998">
<DESCRIPTION>
<P>Follow-up: hospital stay. 0% loss to follow up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-04 21:38:48 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chaney-2001">
<DESCRIPTION>
<P>Follow-up: hospital stay. 0% loss to follow up.<BR/>Two patients excluded: study violation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-04 21:38:53 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Codd-1977">
<DESCRIPTION>
<P>Follow-up: five days. 0% loss to follow up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:40:35 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Coetzer-1996">
<DESCRIPTION>
<P>Follow-up: unclear, at least &gt; 30 days with completeness of data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:42:19 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Demir-2009">
<DESCRIPTION>
<P>Follow-up: hospital stay. 0% loss to follow up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:42:29 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-El-Azab-2002">
<DESCRIPTION>
<P>Follow-up: hospital stay. 0% loss to follow up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:42:39 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Enc-2006">
<DESCRIPTION>
<P>Follow-up: hospital stay. 0% loss to follow up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:42:48 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Engelman-1995">
<DESCRIPTION>
<P>Follow-up: hospital stay. 0% loss to follow up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:42:57 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ferries-1984">
<DESCRIPTION>
<P>Follow-up: hospital stay. 0% loss to follow up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:43:05 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fillinger-2002">
<DESCRIPTION>
<P>Follow-up: hospital stay. 0% loss to follow up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:43:14 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Giomarelli-2003">
<DESCRIPTION>
<P>Follow-up: hospital stay. 0% loss to follow up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:43:28 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Halonen-2007">
<DESCRIPTION>
<P>Follow-up: ICU stay. 0% loss to follow up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:43:42 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Halvorsen-2003">
<DESCRIPTION>
<P>Follow-up: ICU stay. 0% loss to follow up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:44:46 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Harig-1999">
<DESCRIPTION>
<P>Follow-up: 30 days. 0% loss to follow up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:45:16 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Jansen-1991a">
<DESCRIPTION>
<P>Follow-up: hospital stay. 0% loss to follow up.<BR/>3 patients excluded in placebo-group, due to corticosteroids use</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-04 21:39:14 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kilger-2003a">
<DESCRIPTION>
<P>Follow-up: six months. 0% loss to follow up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:45:49 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kilger-2003b">
<DESCRIPTION>
<P>Follow-up: hospital stay. 0% loss to follow up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:46:01 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Liakopoulos-2007">
<DESCRIPTION>
<P>Follow-up: hospital stay. 0% loss to follow up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:46:12 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Loef-2004">
<DESCRIPTION>
<P>Follow-up: hospital stay. 0% loss to follow up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:46:56 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mayumi-1997">
<DESCRIPTION>
<P>Follow-up: 7 days, 12,5% loss to follow up.<BR/>3 patients excluded: IABP (1), and Bloodtransfusion (2)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:47:10 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McBride-2004">
<DESCRIPTION>
<P>Follow-up: 72 hours. 0% loss to follow up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:47:42 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Morton-1976">
<DESCRIPTION>
<P>Follow-up: unclear, at least 30 days 0% loss to follow up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:48:12 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Oliver-2004">
<DESCRIPTION>
<P>Follow-up: ICU stay. 0% loss to follow up.<BR/>3 patients excluded, because they didn't met inclusion criteria</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:48:39 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Prasongsukarn-2005">
<DESCRIPTION>
<P>Follow-up: hospital stay. 0% loss to follow up.<BR/>2 patients excluded, because they didn't met inclusion criteria</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:48:50 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rao-1977">
<DESCRIPTION>
<P>Follow-up: hospital stay. 0% loss to follow up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:49:06 +0530" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rubens-2005">
<DESCRIPTION>
<P>Follow-up: hospital stay. 0% loss to follow up.<BR/>3 excluded before surgery started</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:49:22 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rumalla-2001">
<DESCRIPTION>
<P>Follow-up: 6 months. 0% loss to follow up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-03 16:23:55 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sano-2003">
<DESCRIPTION>
<P>Follow-up: hospital stay. 0% loss to follow up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:55:38 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sano-2006">
<DESCRIPTION>
<P>Follow-up: hospital stay. 0% loss to follow up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:55:49 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schurr-2001">
<DESCRIPTION>
<P>Follow-up: hospital stay. 0% loss to follow up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:56:05 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sobieski-2008">
<DESCRIPTION>
<P>Follow-up: 72 hours. 0% loss to follow up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:56:19 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Starobin-2007">
<DESCRIPTION>
<P>Follow-up: 72 hours. 0% loss to follow up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:56:30 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tassani-1999">
<DESCRIPTION>
<P>Follow-up: hospital stay. 0% loss to follow up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:56:38 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Toft-1997">
<DESCRIPTION>
<P>Follow-up: hospital stay. 0% loss to follow up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:56:50 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Turkoz-2001">
<DESCRIPTION>
<P>Follow-up: 24 hours. 0% loss to follow up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:56:57 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Volk-2001">
<DESCRIPTION>
<P>Follow-up: hospital stay. 0% loss to follow up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:57:05 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Volk-2003">
<DESCRIPTION>
<P>Follow-up: hospital stay. 0% loss to follow up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:46:22 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="UNKNOWN" STUDY_ID="STD-Wan-1999">
<DESCRIPTION>
<P>Follow-up: hospital stay. 0% loss to follow up.<BR/>77 patients excluded because of a very long CPB time, which was defined as an exclusion criterion</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:58:06 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Weis-2006">
<DESCRIPTION>
<P>Follow-up: hospital stay. 22% loss to follow up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:58:25 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Weis-2009">
<DESCRIPTION>
<P>Follow-up: 28 days. 0% loss to follow up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:58:33 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Whitlock-2006">
<DESCRIPTION>
<P>Follow-up: hospital stay. 0% loss to follow up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:59:18 +0530" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Yared-1998">
<DESCRIPTION>
<P>Follow-up: hospital stay. 8,5% loss to follow up.<BR/>20 exclusions (no study-medication (10), bleeding (3), Aprotinine (1), Additive steroids(6))</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:59:45 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yared-2007">
<DESCRIPTION>
<P>Follow-up: hospital stay. 0 % loss to follow up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 16:47:12 +0530" MODIFIED_BY="Nicole Ackermann" RESULT="NO" STUDY_ID="STD-Yilmaz-1999">
<DESCRIPTION>
<P>Follow-up: hospital stay. 25 % loss to follow up.<BR/>5 patients excluded (2x glucose dysregulation, 3x transfusion need)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-02 01:57:19 +0530" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-von-Spiegel-2001">
<DESCRIPTION>
<P>Follow-up: 20 hours. 0% loss to follow up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2010-03-22 17:32:37 +0530" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2010-03-22 17:32:37 +0530" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2010-02-10 17:41:09 +0530" MODIFIED_BY="[Empty name]">Summary of findings for primary and secondary endpoints. OR with fixed and random effects model and with opposite reciprocal correction</TITLE>
<TABLE COLS="7" ROWS="19">
<TR>
<TD VALIGN="TOP">
<P>
<B>Comparison outcome</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Number of studies</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Participants</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Peto OR (Fixed)</B>
<BR/>
<B>[95 % CI]</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Heterogeneity (I<SUP>2</SUP>%)</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Mantel-Haenszel OR</B>
<BR/>
<B>(random) [95% CI]</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Heterogeneity (I<SUP>2</SUP>%)</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Primary endpoints</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Mortality</P>
</TD>
<TD>
<P>49</P>
</TD>
<TD>
<P>3213</P>
</TD>
<TD>
<P>1.06 [0.58, 1.95]</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1.00 [0.55, 1.82]</P>
</TD>
<TD>
<P>0 </P>
</TD>
</TR>
<TR>
<TD>
<P>Myocardial complications</P>
</TD>
<TD>
<P>26</P>
</TD>
<TD>
<P>2103</P>
</TD>
<TD>
<P>0.95 [0.57, 1.60]</P>
</TD>
<TD>
<P>4</P>
</TD>
<TD>
<P>0.95 [ 0.55, 1.64]</P>
</TD>
<TD>
<P>0 </P>
</TD>
</TR>
<TR>
<TD>
<P>Pulmonary complications</P>
</TD>
<TD>
<P>21</P>
</TD>
<TD>
<P>1340</P>
</TD>
<TD>
<P>0.83 [0.49, 1.40]</P>
</TD>
<TD>
<P>5</P>
</TD>
<TD>
<P>0.90 [0.51, 1.58]</P>
</TD>
<TD>
<P>0</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Secondary endpoints</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Atrial fibrillation</P>
</TD>
<TD>
<P>17</P>
</TD>
<TD>
<P>1399</P>
</TD>
<TD>
<P>0.60 [0.46, 0.78]</P>
</TD>
<TD>
<P>11</P>
</TD>
<TD>
<P>0.61 [0.45, 0.82]</P>
</TD>
<TD>
<P>10 </P>
</TD>
</TR>
<TR>
<TD>
<P>Infections</P>
</TD>
<TD>
<P>16</P>
</TD>
<TD>
<P>1517</P>
</TD>
<TD>
<P>0.86 [0.56, 1.31]</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0.88[0.57, 1.36]</P>
</TD>
<TD>
<P>0 </P>
</TD>
</TR>
<TR>
<TD>
<P>Gastro-intestinal complications</P>
</TD>
<TD>
<P>4</P>
</TD>
<TD>
<P>304</P>
</TD>
<TD>
<P>2.84 [0.40, 20.36]</P>
</TD>
<TD>
<P>36</P>
</TD>
<TD>
<P>1.86 [0.30, 11.68]</P>
</TD>
<TD>
<P>0 </P>
</TD>
</TR>
<TR>
<TD>
<P>Re-thoracotomy</P>
</TD>
<TD>
<P>9</P>
</TD>
<TD>
<P>866</P>
</TD>
<TD>
<P>1.12 [0.47, 2.65]</P>
</TD>
<TD>
<P>34</P>
</TD>
<TD>
<P>1.28 [0.51, 3.22]</P>
</TD>
<TD>
<P>0 </P>
</TD>
</TR>
<TR>
<TD>
<P>Neurological complications</P>
</TD>
<TD>
<P>14</P>
</TD>
<TD>
<P>1171</P>
</TD>
<TD>
<P>0.70 [0.33, 1.48]</P>
</TD>
<TD>
<P>16</P>
</TD>
<TD>
<P>0.87 [0.38, 1.96]</P>
</TD>
<TD>
<P>0 </P>
</TD>
</TR>
<TR>
<TD>
<P>Renal failure</P>
</TD>
<TD>
<P>13</P>
</TD>
<TD>
<P>825</P>
</TD>
<TD>
<P>1.00 [0.45, 2.19]</P>
</TD>
<TD>
<P>26</P>
</TD>
<TD>
<P>1.02 [0.44, 2.36]</P>
</TD>
<TD>
<P>0 </P>
</TD>
</TR>
<TR>
<TD>
<P>Inotrope y/n</P>
</TD>
<TD>
<P>17</P>
</TD>
<TD>
<P>1237</P>
</TD>
<TD>
<P>0.91 [0.67, 1.23]</P>
</TD>
<TD>
<P>49</P>
</TD>
<TD>
<P>0.92 [0.58, 1.45]</P>
</TD>
<TD>
<P>39 </P>
</TD>
</TR>
<TR>
<TD>
<P>Bloodtransfusion y/n</P>
</TD>
<TD>
<P>6</P>
</TD>
<TD>
<P>535</P>
</TD>
<TD>
<P>0.87 [0.54, 1.39]</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0.87 [0.54, 1.40]</P>
</TD>
<TD>
<P>0 </P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD COLSPAN="2">
<P>
<B>WMD (fixed) [95% CI]</B> </P>
</TD>
<TD COLSPAN="2">
<P>
<B>WMD (random) [ 95% CI]</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Number of bloodtransfusions</P>
</TD>
<TD>
<P>4</P>
</TD>
<TD>
<P>122</P>
</TD>
<TD>
<P>-0.19 [-0.44, 0.06]</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>-0.19 [-0.44, 0.06]</P>
</TD>
<TD>
<P>0 </P>
</TD>
</TR>
<TR>
<TD>
<P>Time to extubation (min)</P>
</TD>
<TD>
<P>23</P>
</TD>
<TD>
<P>1351</P>
</TD>
<TD>
<P>-1.81 [-11.46, 7.83]</P>
</TD>
<TD>
<P>93</P>
</TD>
<TD>
<P>-46.87 [-100.25, 6.25]</P>
</TD>
<TD>
<P>93 </P>
</TD>
</TR>
<TR>
<TD>
<P>ICU stay (hours)</P>
</TD>
<TD>
<P>25</P>
</TD>
<TD>
<P>1215</P>
</TD>
<TD>
<P>-2.32 [-2.84, -1.81]</P>
</TD>
<TD>
<P>87</P>
</TD>
<TD>
<P>-5.47 [-8.13, -2.82]</P>
</TD>
<TD>
<P>87 </P>
</TD>
</TR>
<TR>
<TD>
<P>Hospital stay (days)</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>635</P>
</TD>
<TD>
<P>-0.59 [-0.84, -0.34]</P>
</TD>
<TD>
<P>96</P>
</TD>
<TD>
<P>-0.97 [-2.42, 0.47]</P>
</TD>
<TD>
<P>96</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<I>OR: Odds Ratio, CI: Confidence interval, WMD: weighted medan difference.</I>
</P>
<P>
<I>An OR &lt; 1 or a WMD &lt; 0 indicates a benefit of corticosteroids treatment</I>
</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2010-02-16 15:58:51 +0530" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2010-02-10 16:17:02 +0530" MODIFIED_BY="[Empty name]">Dose dependant analyses</TITLE>
<TABLE COLS="5" ROWS="7">
<TR>
<TD VALIGN="TOP">
<P>
<B>Comparison outcome</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>corticosteroid dose</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>studies</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>participants</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>PetoOR (fixed) [95% CI]</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Mortality</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>low</P>
<P>high</P>
</TD>
<TD VALIGN="TOP">
<P>8</P>
<P>41</P>
</TD>
<TD VALIGN="TOP">
<P>726</P>
<P>2423</P>
</TD>
<TD VALIGN="TOP">
<P>1.96 [0.20, 18.85]</P>
<P>1.01 [0.51, 1.79]</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Cardiac complications</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>low</P>
<P>high</P>
</TD>
<TD VALIGN="TOP">
<P>2</P>
<P>24</P>
</TD>
<TD VALIGN="TOP">
<P>535</P>
<P>1568</P>
</TD>
<TD VALIGN="TOP">
<P>1.96 [0.39, 9.80]</P>
<P>0.88 [0.51, 1.52]</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Pulmonary complications</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>low</P>
<P>high</P>
</TD>
<TD VALIGN="TOP">
<P>3</P>
<P>18</P>
</TD>
<TD VALIGN="TOP">
<P>390</P>
<P>950</P>
</TD>
<TD VALIGN="TOP">
<P>1.26 [0.46, 3.42]</P>
<P>0.71 [0.38, 1.31]</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Gastro-intestinal bleeding</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>low</P>
<P>high</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
<P>4</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
<P>304</P>
</TD>
<TD VALIGN="TOP">
<P>not estimable</P>
<P>2.84 [0.40, 20.36]</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Infections</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>low</P>
<P>high</P>
</TD>
<TD VALIGN="TOP">
<P>5</P>
<P>11</P>
</TD>
<TD VALIGN="TOP">
<P>651</P>
<P>866</P>
</TD>
<TD VALIGN="TOP">
<P>0.89 [0.52, 1.52]</P>
<P>0.81 [0.40, 1.62]</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Atrial fibrillation</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>low</P>
<P>high</P>
</TD>
<TD VALIGN="TOP">
<P>4</P>
<P>13</P>
</TD>
<TD VALIGN="TOP">
<P>631</P>
<P>748</P>
</TD>
<TD VALIGN="TOP">
<P>0.61 [0.40, 0.94]</P>
<P>0.60 [0.43, 0.83]</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<I>Low dose: &lt;/=1000 mg Hydrocortisone equivalent, High dose: &gt; 1000 mg hydrocortisone equivalent.</I>
</P>
<P>
<I>OR: Odds ratio, CI: Confidence interval</I>
</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2011-01-12 09:15:48 +0530" MODIFIED_BY="Joey Kwong">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2011-01-12 09:15:48 +0530" MODIFIED_BY="Joey Kwong" NO="1">
<TITLE MODIFIED="2011-01-12 08:48:58 +0530" MODIFIED_BY="Joey Kwong">Glossary of abbreviations used in the tables</TITLE>
<TABLE COLS="2" ROWS="7">
<TR>
<TD>
<P>ASD</P>
</TD>
<TD>
<P>Atrial septum defect</P>
</TD>
</TR>
<TR>
<TD>
<P>CABG</P>
</TD>
<TD>
<P>Coronary artery bypass grafting</P>
</TD>
</TR>
<TR>
<TD>
<P>COPD</P>
</TD>
<TD>
<P>Chronic obstructive pulmonary disease</P>
</TD>
</TR>
<TR>
<TD>
<P>CPB</P>
</TD>
<TD>
<P>Cardiopulmonary bypass</P>
</TD>
</TR>
<TR>
<TD>
<P>IABP</P>
</TD>
<TD>
<P>Intra aortic balloon pump</P>
</TD>
</TR>
<TR>
<TD>
<P>ICU</P>
</TD>
<TD>
<P>Intensive care unit</P>
</TD>
</TR>
<TR>
<TD>
<P>MPSS</P>
</TD>
<TD>
<P>Methylprednisolon sodium succinate</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2011-01-12 08:48:58 +0530" MODIFIED_BY="Joey Kwong">
<COMPARISON ID="CMP-001" MODIFIED="2010-08-31 01:10:22 +0530" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Primary outcome</NAME>
<DICH_OUTCOME CHI2="15.344212139692921" CI_END="1.919502038273462" CI_START="0.6527565862993172" CI_STUDY="95" CI_TOTAL="95" DF="16" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.119360352119891" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="26" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.28318857762062727" LOG_CI_START="-0.18524873746132753" LOG_EFFECT_SIZE="0.04896992007964984" METHOD="PETO" MODIFIED="2010-08-31 01:09:16 +0530" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.4995871860369404" P_Q="1.0" P_Z="0.6819637120534465" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="WEIGHT" STUDIES="17" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1036" TOTAL_2="976" WEIGHT="100.00000000000001" Z="0.40978494492961837">
<NAME>Mortality, including "no major complications"</NAME>
<GROUP_LABEL_1>Corticosteroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.1118778382741574" CI_START="7.434627696717769E-4" EFFECT_SIZE="0.04809953551255486" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.49302253972999627" LOG_CI_START="-3.128740774729041" LOG_EFFECT_SIZE="-1.3178591174995224" MODIFIED="2010-02-16 14:48:22 +0530" MODIFIED_BY="[Empty name]" ORDER="13" O_E="-0.6704545454545454" SE="2.1274416989307845" STUDY_ID="STD-Chaney-2001" TOTAL_1="59" TOTAL_2="29" VAR="0.22094524793388431" WEIGHT="1.6728724749761406"/>
<DICH_DATA CI_END="344.58845534710696" CI_START="0.13472589337416754" EFFECT_SIZE="6.813588444649666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.5373007233063403" LOG_CI_START="-0.8705489278938605" LOG_EFFECT_SIZE="0.8333758977062401" MODIFIED="2009-12-09 21:01:57 +0530" MODIFIED_BY="[Empty name]" ORDER="48" O_E="0.47887323943661975" SE="2.0017877542428333" STUDY_ID="STD-Yared-2007" TOTAL_1="37" TOTAL_2="34" VAR="0.2495536599880976" WEIGHT="1.8894791932731103"/>
<DICH_DATA CI_END="354.68043716013733" CI_START="0.1392872116124779" EFFECT_SIZE="7.0286875805892945" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.5498372350811813" LOG_CI_START="-0.856088755658499" LOG_EFFECT_SIZE="0.8468742397113411" MODIFIED="2009-12-09 20:56:30 +0530" MODIFIED_BY="[Empty name]" ORDER="26" O_E="0.4871794871794872" SE="2.0006577865660504" STUDY_ID="STD-Liakopoulos-2007" TOTAL_1="40" TOTAL_2="38" VAR="0.24983563445101906" WEIGHT="1.8916141444525476"/>
<DICH_DATA CI_END="375.5137349148289" CI_START="0.14783945144821836" EFFECT_SIZE="7.45088884503587" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.574625826529613" LOG_CI_START="-0.8302096575515509" LOG_EFFECT_SIZE="0.872208084489031" MODIFIED="2009-12-09 20:55:32 +0530" MODIFIED_BY="[Empty name]" ORDER="21" O_E="0.5020746887966805" SE="2.000017217556743" STUDY_ID="STD-Halonen-2007" TOTAL_1="120" TOTAL_2="121" VAR="0.2499956956663969" WEIGHT="1.8928260374623351"/>
<DICH_DATA CI_END="372.3848896839504" CI_START="0.1466175227450357" EFFECT_SIZE="7.38905609893065" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.570992050236215" LOG_CI_START="-0.8338141226232083" LOG_EFFECT_SIZE="0.8685889638065036" MODIFIED="2009-12-09 20:50:50 +0530" MODIFIED_BY="[Empty name]" ORDER="8" O_E="0.5" SE="2.0" STUDY_ID="STD-Andersen-1989" TOTAL_1="8" TOTAL_2="8" VAR="0.25" WEIGHT="1.8928586274423191"/>
<DICH_DATA CI_END="6.820467167072353" CI_START="0.0026853936013588454" EFFECT_SIZE="0.1353352832366127" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8338141226232082" LOG_CI_START="-2.570992050236215" LOG_EFFECT_SIZE="-0.8685889638065036" MODIFIED="2009-12-09 20:57:43 +0530" MODIFIED_BY="[Empty name]" ORDER="33" O_E="-0.5" SE="2.0" STUDY_ID="STD-Rubens-2005" TOTAL_1="34" TOTAL_2="34" VAR="0.25" WEIGHT="1.8928586274423191"/>
<DICH_DATA CI_END="372.3848896839504" CI_START="0.1466175227450357" EFFECT_SIZE="7.38905609893065" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.570992050236215" LOG_CI_START="-0.8338141226232083" LOG_EFFECT_SIZE="0.8685889638065036" MODIFIED="2009-12-09 21:01:25 +0530" MODIFIED_BY="[Empty name]" ORDER="46" O_E="0.5" SE="2.0" STUDY_ID="STD-Whitlock-2006" TOTAL_1="30" TOTAL_2="30" VAR="0.25" WEIGHT="1.8928586274423191"/>
<DICH_DATA CI_END="372.3848896839504" CI_START="0.1466175227450357" EFFECT_SIZE="7.38905609893065" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.570992050236215" LOG_CI_START="-0.8338141226232083" LOG_EFFECT_SIZE="0.8685889638065036" MODIFIED="2009-12-09 20:54:39 +0530" MODIFIED_BY="[Empty name]" ORDER="14" O_E="0.5" SE="2.0" STUDY_ID="STD-Codd-1977" TOTAL_1="75" TOTAL_2="75" VAR="0.25" WEIGHT="1.8928586274423191"/>
<DICH_DATA CI_END="2.1284848474346996" CI_START="0.007745265347095721" EFFECT_SIZE="0.12839657289294878" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.32807056280588703" LOG_CI_START="-2.1109636990402896" LOG_EFFECT_SIZE="-0.8914465681172012" MODIFIED="2010-02-15 15:57:16 +0530" MODIFIED_BY="[Empty name]" ORDER="389" O_E="-1.0" SE="1.4327007988227578" STUDY_ID="STD-Bingol-2005" TOTAL_1="20" TOTAL_2="20" VAR="0.48717948717948717" WEIGHT="3.688647581682468"/>
<DICH_DATA CI_END="16.063503542368387" CI_START="0.06225291994130946" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2058402733943532" LOG_CI_START="-1.2058402733943532" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-09 20:55:40 +0530" MODIFIED_BY="[Empty name]" ORDER="22" O_E="0.0" SE="1.4166330911949265" STUDY_ID="STD-Halvorsen-2003" TOTAL_1="147" TOTAL_2="147" VAR="0.4982935153583618" WEIGHT="3.772796718178548"/>
<DICH_DATA CI_END="86.84008009968478" CI_START="0.8138300233867384" EFFECT_SIZE="8.406727331038681" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.93872021536777" LOG_CI_START="-0.0894662924248916" LOG_EFFECT_SIZE="0.9246269614714394" MODIFIED="2009-12-09 20:51:09 +0530" MODIFIED_BY="[Empty name]" ORDER="9" O_E="1.5" SE="1.191366794362541" STUDY_ID="STD-Boscoe-1983" TOTAL_1="17" TOTAL_2="17" VAR="0.7045454545454546" WEIGHT="5.334419768246536"/>
<DICH_DATA CI_END="5.0152107443983525" CI_START="0.05015724028530737" EFFECT_SIZE="0.5015467379898342" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7002891872480179" LOG_CI_START="-1.2996663669507513" LOG_EFFECT_SIZE="-0.29968858985136676" MODIFIED="2009-12-09 20:51:48 +0530" MODIFIED_BY="[Empty name]" ORDER="11" O_E="-0.5" SE="1.1747837924760145" STUDY_ID="STD-Celik-2004" TOTAL_1="30" TOTAL_2="30" VAR="0.7245762711864407" WEIGHT="5.48608178462096"/>
<DICH_DATA CI_END="5.0152107443983525" CI_START="0.05015724028530737" EFFECT_SIZE="0.5015467379898342" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7002891872480179" LOG_CI_START="-1.2996663669507513" LOG_EFFECT_SIZE="-0.29968858985136676" MODIFIED="2009-12-09 20:54:08 +0530" MODIFIED_BY="[Empty name]" ORDER="12" O_E="-0.5" SE="1.1747837924760145" STUDY_ID="STD-Chaney-1998" TOTAL_1="30" TOTAL_2="30" VAR="0.7245762711864407" WEIGHT="5.48608178462096"/>
<DICH_DATA CI_END="3.919742777251082" CI_START="0.11213015332564497" EFFECT_SIZE="0.6629640703765576" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5932575685291956" LOG_CI_START="-0.9502775839972483" LOG_EFFECT_SIZE="-0.1785100077340263" MODIFIED="2010-01-27 15:47:35 +0530" MODIFIED_BY="[Empty name]" ORDER="32" O_E="-0.5" SE="0.9066801892162646" STUDY_ID="STD-Rao-1977" TOTAL_1="75" TOTAL_2="75" VAR="1.2164429530201342" WEIGHT="9.210218153662291"/>
<DICH_DATA CI_END="4.054861208202655" CI_START="0.11767157865154038" EFFECT_SIZE="0.6907546015641871" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6079759935549934" LOG_CI_START="-0.9293284201244663" LOG_EFFECT_SIZE="-0.16067621328473639" MODIFIED="2009-12-09 21:01:43 +0530" MODIFIED_BY="[Empty name]" ORDER="47" O_E="-0.4537037037037037" SE="0.9030202223748913" STUDY_ID="STD-Yared-1998" TOTAL_1="106" TOTAL_2="110" VAR="1.2263234918812007" WEIGHT="9.285028006570087"/>
<DICH_DATA CI_END="4.370298696109262" CI_START="0.4213184819904856" EFFECT_SIZE="1.356940533881184" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.640511120640644" LOG_CI_START="-0.37538948924621707" LOG_EFFECT_SIZE="0.1325608156972134" MODIFIED="2010-05-23 08:24:04 +0530" MODIFIED_BY="[Empty name]" ORDER="25" O_E="0.8571428571428568" SE="0.5967450470366643" STUDY_ID="STD-Kilger-2003a" TOTAL_1="43" TOTAL_2="48" VAR="2.8081632653061224" WEIGHT="21.261824256005152"/>
<DICH_DATA CI_END="3.5352194459463324" CI_START="0.34632784672636474" EFFECT_SIZE="1.106501214829774" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.5484163774555608" LOG_CI_START="-0.46051258730301975" LOG_EFFECT_SIZE="0.04395189507627056" MODIFIED="2009-12-09 20:54:45 +0530" MODIFIED_BY="[Empty name]" ORDER="15" O_E="0.2881355932203391" SE="0.5926498681781125" STUDY_ID="STD-Coetzer-1996" TOTAL_1="165" TOTAL_2="130" VAR="2.8471058633163118" WEIGHT="21.55667558647957"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="15.614465194437894" CI_END="1.6041163182751013" CI_START="0.5675007540105577" CI_STUDY="95" CI_TOTAL="95" DF="15" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.9541159364258411" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="31" I2="3.9352304852347806" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.20523585681188866" LOG_CI_START="-0.24603355710857192" LOG_EFFECT_SIZE="-0.020398850148341613" METHOD="PETO" MODIFIED="2010-08-31 01:09:59 +0530" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.4081267087071869" P_Q="1.0" P_Z="0.8593563727695386" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="WEIGHT" STUDIES="16" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="903" TOTAL_2="875" WEIGHT="100.00000000000001" Z="0.17719353620463185">
<NAME>Cardiac complications, including "no major complications"</NAME>
<GROUP_LABEL_1>Corticosteroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.1118778382741574" CI_START="7.434627696717769E-4" EFFECT_SIZE="0.04809953551255486" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.49302253972999627" LOG_CI_START="-3.128740774729041" LOG_EFFECT_SIZE="-1.3178591174995224" MODIFIED="2009-12-09 21:17:05 +0530" MODIFIED_BY="[Empty name]" ORDER="55" O_E="-0.6704545454545454" SE="2.1274416989307845" STUDY_ID="STD-Chaney-2001" TOTAL_1="59" TOTAL_2="29" VAR="0.22094524793388431" WEIGHT="1.552500208582092"/>
<DICH_DATA CI_END="344.58845534710696" CI_START="0.13472589337416754" EFFECT_SIZE="6.813588444649666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.5373007233063403" LOG_CI_START="-0.8705489278938605" LOG_EFFECT_SIZE="0.8333758977062401" MODIFIED="2009-12-09 21:20:27 +0530" MODIFIED_BY="[Empty name]" ORDER="74" O_E="0.47887323943661975" SE="2.0017877542428333" STUDY_ID="STD-Yared-2007" TOTAL_1="37" TOTAL_2="34" VAR="0.2495536599880976" WEIGHT="1.7535208962714655"/>
<DICH_DATA CI_END="352.82541670943306" CI_START="0.13847236894280432" EFFECT_SIZE="6.9897475830667375" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.547559863135115" LOG_CI_START="-0.8586368779558022" LOG_EFFECT_SIZE="0.8444614925896565" MODIFIED="2009-12-09 21:17:51 +0530" MODIFIED_BY="[Empty name]" ORDER="62" O_E="0.48571428571428577" SE="2.000816826662603" STUDY_ID="STD-McBride-2004" TOTAL_1="18" TOTAL_2="17" VAR="0.2497959183673469" WEIGHT="1.7552231559391087"/>
<DICH_DATA CI_END="7.077805624721046" CI_START="0.0027829698032571454" EFFECT_SIZE="0.14034713864885967" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8498986315891194" LOG_CI_START="-2.555491505972799" LOG_EFFECT_SIZE="-0.85279643719184" MODIFIED="2009-12-09 21:20:07 +0530" MODIFIED_BY="[Empty name]" ORDER="73" O_E="-0.49074074074074076" SE="2.0003430237569173" STUDY_ID="STD-Yared-1998" TOTAL_1="106" TOTAL_2="110" VAR="0.24991426611796982" WEIGHT="1.7560547416339607"/>
<DICH_DATA CI_END="372.3848896839504" CI_START="0.1466175227450357" EFFECT_SIZE="7.38905609893065" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.570992050236215" LOG_CI_START="-0.8338141226232083" LOG_EFFECT_SIZE="0.8685889638065036" MODIFIED="2009-12-09 21:16:07 +0530" MODIFIED_BY="[Empty name]" ORDER="51" O_E="0.5" SE="2.0" STUDY_ID="STD-Andersen-1989" TOTAL_1="8" TOTAL_2="8" VAR="0.25" WEIGHT="1.7566571617854645"/>
<DICH_DATA CI_END="16.372456241572294" CI_START="0.06107819042208459" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2141138383697911" LOG_CI_START="-1.2141138383697911" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-09 21:16:55 +0530" MODIFIED_BY="[Empty name]" ORDER="54" O_E="0.0" SE="1.4263529572376852" STUDY_ID="STD-Chaney-1998" TOTAL_1="30" TOTAL_2="30" VAR="0.4915254237288136" WEIGHT="3.453766623171422"/>
<DICH_DATA CI_END="16.21534295021216" CI_START="0.06270647000909482" EFFECT_SIZE="1.0083684427800512" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2099261383194857" LOG_CI_START="-1.2026876466608056" LOG_EFFECT_SIZE="0.003619245829339949" MODIFIED="2009-12-09 21:17:38 +0530" MODIFIED_BY="[Empty name]" ORDER="60" O_E="0.004149377593360981" SE="1.417181279928267" STUDY_ID="STD-Halonen-2007" TOTAL_1="120" TOTAL_2="121" VAR="0.49790809386890716" WEIGHT="3.4986152760230604"/>
<DICH_DATA CI_END="5.0152107443983525" CI_START="0.05015724028530737" EFFECT_SIZE="0.5015467379898342" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7002891872480179" LOG_CI_START="-1.2996663669507513" LOG_EFFECT_SIZE="-0.29968858985136676" MODIFIED="2009-12-09 21:16:47 +0530" MODIFIED_BY="[Empty name]" ORDER="53" O_E="-0.5" SE="1.1747837924760145" STUDY_ID="STD-Celik-2004" TOTAL_1="30" TOTAL_2="30" VAR="0.7245762711864407" WEIGHT="5.0913283841578725"/>
<DICH_DATA CI_END="1.266411412313257" CI_START="0.01278779390443912" EFFECT_SIZE="0.12725803761999321" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.10257481553271174" LOG_CI_START="-1.8932043716876579" LOG_EFFECT_SIZE="-0.8953147780774731" MODIFIED="2009-12-09 21:19:06 +0530" MODIFIED_BY="[Empty name]" ORDER="66" O_E="-1.5" SE="1.1723305738395526" STUDY_ID="STD-Rubens-2005" TOTAL_1="34" TOTAL_2="34" VAR="0.7276119402985074" WEIGHT="5.112658903703964"/>
<DICH_DATA CI_END="2.6070171273961056" CI_START="0.04663753631150655" EFFECT_SIZE="0.3486902005271375" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.41614388437476696" LOG_CI_START="-1.3312643998137619" LOG_EFFECT_SIZE="-0.45756025771949743" MODIFIED="2009-12-09 21:19:46 +0530" MODIFIED_BY="[Empty name]" ORDER="72" O_E="-1.0" SE="1.026436275942851" STUDY_ID="STD-Whitlock-2006" TOTAL_1="30" TOTAL_2="30" VAR="0.9491525423728814" WEIGHT="6.669342444744815"/>
<DICH_DATA CI_END="7.318115396009987" CI_START="0.1366472029868816" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8643992533953607" LOG_CI_START="-0.8643992533953607" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-01-21 18:47:02 +0530" MODIFIED_BY="[Empty name]" ORDER="230" O_E="0.0" SE="1.015504800579495" STUDY_ID="STD-Amr-2009" TOTAL_1="50" TOTAL_2="50" VAR="0.9696969696969697" WEIGHT="6.813700506319377"/>
<DICH_DATA CI_END="19.696096586817536" CI_START="0.3829959676685315" EFFECT_SIZE="2.746547937240682" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.2943801653099782" LOG_CI_START="-0.41680579842961407" LOG_EFFECT_SIZE="0.4387871834401821" MODIFIED="2009-12-09 21:17:44 +0530" MODIFIED_BY="[Empty name]" ORDER="61" O_E="1.0" SE="1.0051591056077676" STUDY_ID="STD-Halvorsen-2003" TOTAL_1="147" TOTAL_2="147" VAR="0.9897610921501706" WEIGHT="6.954683643928801"/>
<DICH_DATA CI_END="20.899977489268046" CI_START="0.7965128024414793" EFFECT_SIZE="4.080085739410475" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.3201458183458896" LOG_CI_START="-0.09880723934181317" LOG_EFFECT_SIZE="0.6106692895020381" MODIFIED="2009-12-09 21:18:48 +0530" MODIFIED_BY="[Empty name]" ORDER="64" O_E="2.024" SE="0.8335000500166726" STUDY_ID="STD-Oliver-2004" TOTAL_1="62" TOTAL_2="63" VAR="1.4394239999999998" WEIGHT="10.11429791378352"/>
<DICH_DATA CI_END="1.8575336701137521" CI_START="0.0902236753460005" EFFECT_SIZE="0.40938186915960006" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.26893669463292463" LOG_CI_START="-1.0446794854850865" LOG_EFFECT_SIZE="-0.387871395426081" MODIFIED="2009-12-09 21:18:54 +0530" MODIFIED_BY="[Empty name]" ORDER="65" O_E="-1.5" SE="0.7716246467062825" STUDY_ID="STD-Rao-1977" TOTAL_1="75" TOTAL_2="75" VAR="1.679530201342282" WEIGHT="11.80143502649161"/>
<DICH_DATA CI_END="4.031072067237561" CI_START="0.24807296503763238" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.6054205625102385" LOG_CI_START="-0.6054205625102385" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-09 21:17:57 +0530" MODIFIED_BY="[Empty name]" ORDER="63" O_E="0.0" SE="0.7112540705972631" STUDY_ID="STD-Morton-1976" TOTAL_1="22" TOTAL_2="22" VAR="1.9767441860465116" WEIGHT="13.889847325745533"/>
<DICH_DATA CI_END="4.1312397574044315" CI_START="0.35744267040492583" EFFECT_SIZE="1.215187792470628" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.6160804000833917" LOG_CI_START="-0.4467936039981477" LOG_EFFECT_SIZE="0.08464339804262201" MODIFIED="2009-12-09 21:17:12 +0530" MODIFIED_BY="[Empty name]" ORDER="56" O_E="0.5" SE="0.6243374513086698" STUDY_ID="STD-Codd-1977" TOTAL_1="75" TOTAL_2="75" VAR="2.5654362416107386" WEIGHT="18.026367787717955"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="11.546748040166241" CI_END="1.4015657878309087" CI_START="0.4912032500590462" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.8297310830348046" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="33" I2="4.735082451477562" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.14661348784113426" LOG_CI_START="-0.3087387683366769" LOG_EFFECT_SIZE="-0.08106264024777136" METHOD="PETO" MODIFIED="2010-08-31 01:10:22 +0530" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.3986577771076165" P_Q="1.0" P_Z="0.48528180890213835" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="WEIGHT" STUDIES="12" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="540" TOTAL_2="536" WEIGHT="99.99999999999999" Z="0.6978327359613109">
<NAME>Pulmonary complications, including "no major complications"</NAME>
<GROUP_LABEL_1>Corticosteroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.820467167072353" CI_START="0.0026853936013588454" EFFECT_SIZE="0.1353352832366127" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8338141226232082" LOG_CI_START="-2.570992050236215" LOG_EFFECT_SIZE="-0.8685889638065036" MODIFIED="2009-12-15 13:03:02 +0530" MODIFIED_BY="[Empty name]" ORDER="88" O_E="-0.5" SE="2.0" STUDY_ID="STD-Toft-1997" TOTAL_1="8" TOTAL_2="8" VAR="0.25" WEIGHT="1.788587528703641"/>
<DICH_DATA CI_END="119.50989282818936" CI_START="0.46315175084966714" EFFECT_SIZE="7.439839790427749" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.07740385693992" LOG_CI_START="-0.3342766898487863" LOG_EFFECT_SIZE="0.871563583545567" MODIFIED="2009-12-15 13:02:05 +0530" MODIFIED_BY="[Empty name]" ORDER="80" O_E="1.0" SE="1.4166330911949265" STUDY_ID="STD-Halvorsen-2003" TOTAL_1="147" TOTAL_2="147" VAR="0.4982935153583618" WEIGHT="3.5649662688154486"/>
<DICH_DATA CI_END="5.4742862620723205" CI_START="0.05364941725776223" EFFECT_SIZE="0.5419338224011797" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7383275038501002" LOG_CI_START="-1.2704349909974284" LOG_EFFECT_SIZE="-0.2660537435736642" MODIFIED="2009-12-15 13:02:54 +0530" MODIFIED_BY="[Empty name]" ORDER="86" O_E="-0.43999999999999995" SE="1.179957033008155" STUDY_ID="STD-Schurr-2001" TOTAL_1="24" TOTAL_2="26" VAR="0.7182367346938776" WEIGHT="5.138517065321181"/>
<DICH_DATA CI_END="19.9373010618555" CI_START="0.1993934155442883" EFFECT_SIZE="1.99383212820391" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2996663669507516" LOG_CI_START="-0.7002891872480179" LOG_EFFECT_SIZE="0.2996885898513667" MODIFIED="2009-12-15 13:03:15 +0530" MODIFIED_BY="[Empty name]" ORDER="90" O_E="0.5" SE="1.1747837924760145" STUDY_ID="STD-Whitlock-2006" TOTAL_1="30" TOTAL_2="30" VAR="0.7245762711864407" WEIGHT="5.183872328954621"/>
<DICH_DATA CI_END="4.588782160550079" CI_START="0.04628604211281595" EFFECT_SIZE="0.46086501747231745" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6616974412822398" LOG_CI_START="-1.3345499538478311" LOG_EFFECT_SIZE="-0.33642625628279577" MODIFIED="2009-12-15 13:03:22 +0530" MODIFIED_BY="[Empty name]" ORDER="91" O_E="-0.5633802816901408" SE="1.1726056014833777" STUDY_ID="STD-Yared-2007" TOTAL_1="37" TOTAL_2="34" VAR="0.7272706662510273" WEIGHT="5.203148974594302"/>
<DICH_DATA CI_END="18.654982765042313" CI_START="0.18981749327591743" EFFECT_SIZE="1.8817656776458047" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2707948521412287" LOG_CI_START="-0.7216637661810329" LOG_EFFECT_SIZE="0.2745655429800979" MODIFIED="2009-12-15 13:02:18 +0530" MODIFIED_BY="[Empty name]" ORDER="81" O_E="0.46153846153846145" SE="1.1703800552317227" STUDY_ID="STD-Liakopoulos-2007" TOTAL_1="40" TOTAL_2="38" VAR="0.7300391915776532" WEIGHT="5.222955974082715"/>
<DICH_DATA CI_END="6.8967201318596905" CI_START="0.11362474111321061" EFFECT_SIZE="0.8852333248996137" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8386426027244629" LOG_CI_START="-0.9445270932813703" LOG_EFFECT_SIZE="-0.05294224527845368" MODIFIED="2010-01-21 18:50:22 +0530" MODIFIED_BY="[Empty name]" ORDER="232" O_E="-0.11111111111111116" SE="1.0474427062661789" STUDY_ID="STD-Weis-2009" TOTAL_1="19" TOTAL_2="17" VAR="0.9114638447971782" WEIGHT="6.5209314626740165"/>
<DICH_DATA CI_END="1.6709074173963647" CI_START="0.04126863309261544" EFFECT_SIZE="0.26259486883840705" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.2229523869204436" LOG_CI_START="-1.3843799156674257" LOG_EFFECT_SIZE="-0.5807137643734911" MODIFIED="2010-02-15 16:12:39 +0530" MODIFIED_BY="[Empty name]" ORDER="396" O_E="-1.5" SE="0.9441549509633318" STUDY_ID="STD-Bingol-2005" TOTAL_1="20" TOTAL_2="20" VAR="1.1217948717948718" WEIGHT="8.02571326982403"/>
<DICH_DATA CI_END="5.176638739165199" CI_START="0.19317554312497054" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.714047858035458" LOG_CI_START="-0.714047858035458" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-15 13:02:24 +0530" MODIFIED_BY="[Empty name]" ORDER="82" O_E="0.0" SE="0.8388704928078611" STUDY_ID="STD-Morton-1976" TOTAL_1="48" TOTAL_2="48" VAR="1.4210526315789473" WEIGHT="10.16670805789438"/>
<DICH_DATA CI_END="0.8570224625246995" CI_START="0.050106919138860534" EFFECT_SIZE="0.20722633816653774" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="-0.067007795086508" LOG_CI_START="-1.3001022993554185" LOG_EFFECT_SIZE="-0.6835550472209633" MODIFIED="2009-12-15 13:02:36 +0530" MODIFIED_BY="[Empty name]" ORDER="84" O_E="-3.0" SE="0.7243258157237968" STUDY_ID="STD-Rao-1977" TOTAL_1="75" TOTAL_2="75" VAR="1.9060402684563758" WEIGHT="13.636479413472054"/>
<DICH_DATA CI_END="3.5063095899143963" CI_START="0.285200144013642" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.5448502595203324" LOG_CI_START="-0.5448502595203324" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-01-21 18:51:27 +0530" MODIFIED_BY="[Empty name]" ORDER="231" O_E="0.0" SE="0.6400954789890507" STUDY_ID="STD-Starobin-2007" TOTAL_1="30" TOTAL_2="30" VAR="2.440677966101695" WEIGHT="17.461464687005037"/>
<DICH_DATA CI_END="6.318201278591119" CI_START="0.5368983492039066" EFFECT_SIZE="1.8418012478043293" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.8005934570849673" LOG_CI_START="-0.2701079313556974" LOG_EFFECT_SIZE="0.265242762864635" MODIFIED="2009-12-15 13:02:30 +0530" MODIFIED_BY="[Empty name]" ORDER="83" O_E="1.5439999999999996" SE="0.6289352956273975" STUDY_ID="STD-Oliver-2004" TOTAL_1="62" TOTAL_2="63" VAR="2.528064" WEIGHT="18.086654968658568"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2010-08-31 01:13:07 +0530" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Secondary outcome</NAME>
<DICH_OUTCOME CHI2="18.01678194315891" CI_END="0.7842257882272915" CI_START="0.46451074851268237" CI_STUDY="95" CI_TOTAL="95" DF="16" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.6035572117806294" ESTIMABLE="YES" EVENTS_1="144" EVENTS_2="201" I2="11.193907710720206" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="-0.10555888060165582" LOG_CI_START="-0.33300423222849107" LOG_EFFECT_SIZE="-0.21928155641507346" METHOD="PETO" MODIFIED="2010-02-15 17:34:15 +0530" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3229152580739726" P_Q="1.0" P_Z="1.5731515149121694E-4" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="17" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="694" TOTAL_2="695" WEIGHT="100.00000000000001" Z="3.77922828471403">
<NAME>Atrial fibrillation</NAME>
<GROUP_LABEL_1>Favours experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.5813725030178984" CI_START="0.0360329588627444" EFFECT_SIZE="0.3049827687110593" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.41185067960474514" LOG_CI_START="-1.4433000741249682" LOG_EFFECT_SIZE="-0.5157246972601116" MODIFIED="2009-12-15 13:08:20 +0530" MODIFIED_BY="[Empty name]" ORDER="92" O_E="-1.0" SE="1.0897247358851685" STUDY_ID="STD-Abd.-El_x002d_Hakeem-2003b" TOTAL_1="10" TOTAL_2="10" VAR="0.8421052631578947" WEIGHT="1.5031271408955387"/>
<DICH_DATA CI_END="2.5523193809713804" CI_START="0.2871958929483026" EFFECT_SIZE="0.8561633277052543" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.40693501829159306" LOG_CI_START="-0.5418217750238972" LOG_EFFECT_SIZE="-0.06744337836615202" MODIFIED="2010-01-21 18:52:51 +0530" MODIFIED_BY="[Empty name]" ORDER="233" O_E="-0.5" SE="0.5573044368153888" STUDY_ID="STD-Amr-2009" TOTAL_1="50" TOTAL_2="50" VAR="3.2196969696969697" WEIGHT="5.747041506975131"/>
<DICH_DATA CI_END="2.602992800246887" CI_START="0.044010434443699606" EFFECT_SIZE="0.33846542510674216" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.415472966873211" LOG_CI_START="-1.3564443443302567" LOG_EFFECT_SIZE="-0.47048568872852287" MODIFIED="2010-02-15 16:00:05 +0530" MODIFIED_BY="[Empty name]" ORDER="390" O_E="-1.0" SE="1.0408329997330665" STUDY_ID="STD-Bingol-2005" TOTAL_1="20" TOTAL_2="20" VAR="0.923076923076923" WEIGHT="1.647658596750879"/>
<DICH_DATA CI_END="2.787027187090598" CI_START="0.24384376912228348" EFFECT_SIZE="0.8243780770656428" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.44514120522060113" LOG_CI_START="-0.6128883373468981" LOG_EFFECT_SIZE="-0.08387356606314846" MODIFIED="2009-12-15 13:08:24 +0530" MODIFIED_BY="[Empty name]" ORDER="93" O_E="-0.5" SE="0.6214917906348514" STUDY_ID="STD-Celik-2004" TOTAL_1="30" TOTAL_2="30" VAR="2.5889830508474576" WEIGHT="4.621240195618726"/>
<DICH_DATA CI_END="1.9799577861600235" CI_START="0.4093736774222478" EFFECT_SIZE="0.9003013940126613" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="18" LOG_CI_END="0.2966559309518352" LOG_CI_START="-0.3878800857521357" LOG_EFFECT_SIZE="-0.045612077400150275" MODIFIED="2009-12-15 13:08:30 +0530" MODIFIED_BY="[Empty name]" ORDER="103" O_E="-0.6495726495726508" SE="0.40209984471984433" STUDY_ID="STD-Chaney-1998" TOTAL_1="59" TOTAL_2="58" VAR="6.184892979764775" WEIGHT="11.039808095434724"/>
<DICH_DATA CI_END="4.0746930308353155" CI_START="0.10063813823784733" EFFECT_SIZE="0.6403667078432462" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.610094896502771" LOG_CI_START="-0.9972374060850981" LOG_EFFECT_SIZE="-0.19357125479116366" MODIFIED="2009-12-15 13:08:33 +0530" MODIFIED_BY="[Empty name]" ORDER="94" O_E="-0.5" SE="0.9441549509633318" STUDY_ID="STD-Enc-2006" TOTAL_1="20" TOTAL_2="20" VAR="1.1217948717948718" WEIGHT="2.00236287799586"/>
<DICH_DATA CI_END="2.088926998059922" CI_START="0.007020837554470822" EFFECT_SIZE="0.12110333239232973" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.3199232629129438" LOG_CI_START="-2.1536110753933406" LOG_EFFECT_SIZE="-0.9168439062401983" MODIFIED="2009-12-15 13:08:36 +0530" MODIFIED_BY="[Empty name]" ORDER="95" O_E="-1.0" SE="1.4529663145135578" STUDY_ID="STD-Giomarelli-2003" TOTAL_1="10" TOTAL_2="10" VAR="0.47368421052631576" WEIGHT="0.8455090167537406"/>
<DICH_DATA CI_END="0.9218464605938081" CI_START="0.3339766596161344" EFFECT_SIZE="0.5548650300641377" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="62" LOG_CI_END="-0.035341407438404075" LOG_CI_START="-0.4762838833504555" LOG_EFFECT_SIZE="-0.2558126453944299" MODIFIED="2009-12-15 13:08:40 +0530" MODIFIED_BY="[Empty name]" ORDER="96" O_E="-8.780082987551864" SE="0.2590117930511969" STUDY_ID="STD-Halonen-2007" TOTAL_1="120" TOTAL_2="121" VAR="14.905993354108917" WEIGHT="26.606653767426447"/>
<DICH_DATA CI_END="16.063503542368387" CI_START="0.06225291994130946" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2058402733943532" LOG_CI_START="-1.2058402733943532" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-15 13:08:46 +0530" MODIFIED_BY="[Empty name]" ORDER="97" O_E="0.0" SE="1.4166330911949265" STUDY_ID="STD-Halvorsen-2003" TOTAL_1="147" TOTAL_2="147" VAR="0.4982935153583618" WEIGHT="0.8894357271425395"/>
<DICH_DATA CI_END="0.6564220618182393" CI_START="0.1140151372435568" EFFECT_SIZE="0.2735727535188859" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="22" LOG_CI_END="-0.18281683108495608" LOG_CI_START="-0.9430374856378435" LOG_EFFECT_SIZE="-0.5629271583613997" MODIFIED="2009-12-15 13:08:51 +0530" MODIFIED_BY="[Empty name]" ORDER="98" O_E="-6.5" SE="0.4465573756372974" STUDY_ID="STD-Prasongsukarn-2005" TOTAL_1="43" TOTAL_2="43" VAR="5.014705882352941" WEIGHT="8.951066862005694"/>
<DICH_DATA CI_END="0.7398513447484525" CI_START="0.08368454869140005" EFFECT_SIZE="0.2488254928338326" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="13" LOG_CI_END="-0.13085553248648374" LOG_CI_START="-1.0773547216665076" LOG_EFFECT_SIZE="-0.6041051270764956" MODIFIED="2009-12-15 13:08:55 +0530" MODIFIED_BY="[Empty name]" ORDER="99" O_E="-4.5" SE="0.5559783089708951" STUDY_ID="STD-Rubens-2005" TOTAL_1="34" TOTAL_2="34" VAR="3.235074626865672" WEIGHT="5.774490063426356"/>
<DICH_DATA CI_END="1.6386516920254504" CI_START="0.17698038321597984" EFFECT_SIZE="0.5385250267278003" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="17" LOG_CI_END="0.21448665075974754" LOG_CI_START="-0.7520748688539586" LOG_EFFECT_SIZE="-0.26879410904710543" MODIFIED="2009-12-15 13:09:00 +0530" MODIFIED_BY="[Empty name]" ORDER="100" O_E="-1.92" SE="0.5677630211777773" STUDY_ID="STD-Schurr-2001" TOTAL_1="24" TOTAL_2="26" VAR="3.1021714285714284" WEIGHT="5.537262708120726"/>
<DICH_DATA CI_END="3.0994982685728045" CI_START="0.08860668773774988" EFFECT_SIZE="0.5240575113736343" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.49129139808411215" LOG_CI_START="-1.0525334977744683" LOG_EFFECT_SIZE="-0.2806210498451781" MODIFIED="2010-01-21 18:53:21 +0530" MODIFIED_BY="[Empty name]" ORDER="234" O_E="-0.7857142857142856" SE="0.9068503858838142" STUDY_ID="STD-Sobieski-2008" TOTAL_1="13" TOTAL_2="15" VAR="1.2159863945578229" WEIGHT="2.1704913062357454"/>
<DICH_DATA CI_END="4.633047730401521" CI_START="0.5356054985753397" EFFECT_SIZE="1.575273258696742" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="8" LOG_CI_END="0.6658667743976776" LOG_CI_START="-0.2711549731300238" LOG_EFFECT_SIZE="0.1973559006338269" MODIFIED="2010-01-21 18:54:11 +0530" MODIFIED_BY="[Empty name]" ORDER="235" O_E="1.5" SE="0.5504112128302281" STUDY_ID="STD-Starobin-2007" TOTAL_1="30" TOTAL_2="30" VAR="3.3008474576271185" WEIGHT="5.891892164299489"/>
<DICH_DATA CI_END="1.0083891557682534" CI_START="0.0736100762224785" EFFECT_SIZE="0.2724474309257144" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="10" LOG_CI_END="0.0036281666203033434" LOG_CI_START="-1.1330627325606488" LOG_EFFECT_SIZE="-0.5647172829701727" MODIFIED="2010-01-21 18:54:46 +0530" MODIFIED_BY="[Empty name]" ORDER="236" O_E="-2.916666666666667" SE="0.6676978608895886" STUDY_ID="STD-Weis-2009" TOTAL_1="19" TOTAL_2="17" VAR="2.243055555555556" WEIGHT="4.003772249859342"/>
<DICH_DATA CI_END="2.0675924976487225" CI_START="0.21938749430503185" EFFECT_SIZE="0.673501252636575" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.31546494764168137" LOG_CI_START="-0.6587881320443957" LOG_EFFECT_SIZE="-0.17166159220135718" MODIFIED="2009-12-15 13:09:06 +0530" MODIFIED_BY="[Empty name]" ORDER="101" O_E="-1.2068965517241388" SE="0.5722810816381245" STUDY_ID="STD-Whitlock-2006" TOTAL_1="28" TOTAL_2="30" VAR="3.053382564616059" WEIGHT="5.450176367738804"/>
<DICH_DATA CI_END="4.258582216399987" CI_START="0.6144529176527282" EFFECT_SIZE="1.617621175656091" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="10" LOG_CI_END="0.6292650361733342" LOG_CI_START="-0.2115113892413061" LOG_EFFECT_SIZE="0.208876823466014" MODIFIED="2009-12-15 13:09:13 +0530" MODIFIED_BY="[Empty name]" ORDER="102" O_E="1.971830985915492" SE="0.4938762341989879" STUDY_ID="STD-Yared-2007" TOTAL_1="37" TOTAL_2="34" VAR="4.099810128375889" WEIGHT="7.318011353320264"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.874347860698386" CI_END="1.3113381912922324" CI_START="0.5576747678354926" CI_STUDY="95" CI_TOTAL="95" DF="14" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.855160933031152" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="51" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.11771470974583792" LOG_CI_START="-0.253619004849862" LOG_EFFECT_SIZE="-0.06795214755201204" METHOD="PETO" MODIFIED="2010-08-31 01:10:43 +0530" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.895768924998199" P_Q="1.0" P_Z="0.47317264839007933" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="15" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="744" TOTAL_2="743" WEIGHT="100.0" Z="0.7173265267286748">
<NAME>Infections</NAME>
<GROUP_LABEL_1>Corticosteroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.251286985182303" CI_START="0.29390684097051584" EFFECT_SIZE="1.3554689261709507" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.795969437027921" LOG_CI_START="-0.5317903051789383" LOG_EFFECT_SIZE="0.1320895659244913" MODIFIED="2010-01-21 19:00:19 +0530" MODIFIED_BY="[Empty name]" ORDER="237" O_E="0.5" SE="0.7799326450890333" STUDY_ID="STD-Amr-2009" TOTAL_1="50" TOTAL_2="50" VAR="1.6439393939393943" WEIGHT="7.821494976809801"/>
<DICH_DATA CI_END="2.1284848474346996" CI_START="0.007745265347095721" EFFECT_SIZE="0.12839657289294878" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.32807056280588703" LOG_CI_START="-2.1109636990402896" LOG_EFFECT_SIZE="-0.8914465681172012" MODIFIED="2010-02-15 16:02:24 +0530" MODIFIED_BY="[Empty name]" ORDER="391" O_E="-1.0" SE="1.4327007988227578" STUDY_ID="STD-Bingol-2005" TOTAL_1="20" TOTAL_2="20" VAR="0.48717948717948717" WEIGHT="2.317890748179012"/>
<DICH_DATA CI_END="2.0823470337554104" CI_START="0.48955825369412476" EFFECT_SIZE="1.0096683502172579" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="17" LOG_CI_END="0.31855310859700164" LOG_CI_START="-0.31019562305871895" LOG_EFFECT_SIZE="0.004178742769141328" MODIFIED="2009-12-15 13:11:16 +0530" MODIFIED_BY="[Empty name]" ORDER="104" O_E="0.07053941908713668" SE="0.3693301173309874" STUDY_ID="STD-Halonen-2007" TOTAL_1="120" TOTAL_2="121" VAR="7.3311237754170895" WEIGHT="34.87984289152547"/>
<DICH_DATA CI_END="8.764167402264968" CI_START="0.25676375494269754" EFFECT_SIZE="1.5001068399123914" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9427106643228985" LOG_CI_START="-0.5904662817688424" LOG_EFFECT_SIZE="0.1761221912770281" MODIFIED="2009-12-15 13:11:20 +0530" MODIFIED_BY="[Empty name]" ORDER="105" O_E="0.5" SE="0.9005957274825712" STUDY_ID="STD-Halvorsen-2003" TOTAL_1="147" TOTAL_2="147" VAR="1.2329351535836177" WEIGHT="5.866028970434175"/>
<DICH_DATA CI_END="6.766044970944047" CI_START="0.09635707132820523" EFFECT_SIZE="0.8074380953826118" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8303348800271819" LOG_CI_START="-1.016116408396906" LOG_EFFECT_SIZE="-0.09289076418486214" MODIFIED="2009-12-15 13:11:24 +0530" MODIFIED_BY="[Empty name]" ORDER="106" O_E="-0.18181818181818166" SE="1.0846146269015964" STUDY_ID="STD-Jansen-1991a" TOTAL_1="12" TOTAL_2="10" VAR="0.8500590318772135" WEIGHT="4.044390244756518"/>
<DICH_DATA CI_END="18.654982765042313" CI_START="0.18981749327591743" EFFECT_SIZE="1.8817656776458047" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2707948521412287" LOG_CI_START="-0.7216637661810329" LOG_EFFECT_SIZE="0.2745655429800979" MODIFIED="2009-12-15 13:11:28 +0530" MODIFIED_BY="[Empty name]" ORDER="107" O_E="0.46153846153846145" SE="1.1703800552317227" STUDY_ID="STD-Liakopoulos-2007" TOTAL_1="40" TOTAL_2="38" VAR="0.7300391915776532" WEIGHT="3.4733627595090093"/>
<DICH_DATA CI_END="9.166556051199882" CI_START="0.25257287047794413" EFFECT_SIZE="1.5215858090323144" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9622061983858703" LOG_CI_START="-0.5976132999979551" LOG_EFFECT_SIZE="0.1822964491939576" MODIFIED="2009-12-15 13:11:33 +0530" MODIFIED_BY="[Empty name]" ORDER="108" O_E="0.5" SE="0.9162456945817024" STUDY_ID="STD-Prasongsukarn-2005" TOTAL_1="43" TOTAL_2="43" VAR="1.1911764705882353" WEIGHT="5.667350521282894"/>
<DICH_DATA CI_END="6.820467167072353" CI_START="0.0026853936013588454" EFFECT_SIZE="0.1353352832366127" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8338141226232082" LOG_CI_START="-2.570992050236215" LOG_EFFECT_SIZE="-0.8685889638065036" MODIFIED="2009-12-15 13:11:37 +0530" MODIFIED_BY="[Empty name]" ORDER="109" O_E="-0.5" SE="2.0" STUDY_ID="STD-Rao-1977" TOTAL_1="75" TOTAL_2="75" VAR="0.25" WEIGHT="1.1894439365655456"/>
<DICH_DATA CI_END="2.6077807680567924" CI_START="0.04725250648238307" EFFECT_SIZE="0.3510330150388101" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.41627107815451175" LOG_CI_START="-1.3255751496394452" LOG_EFFECT_SIZE="-0.45465203574246676" MODIFIED="2009-12-15 13:11:43 +0530" MODIFIED_BY="[Empty name]" ORDER="110" O_E="-1.0" SE="1.0231690964840563" STUDY_ID="STD-Rubens-2005" TOTAL_1="34" TOTAL_2="34" VAR="0.9552238805970149" WEIGHT="4.544741011354921"/>
<DICH_DATA CI_END="1.876434376050927" CI_START="0.20231900001389" EFFECT_SIZE="0.6161479745599358" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.27333338057040674" LOG_CI_START="-0.6939633302113128" LOG_EFFECT_SIZE="-0.21031497482045303" MODIFIED="2010-01-21 19:00:11 +0530" MODIFIED_BY="[Empty name]" ORDER="239" O_E="-1.5" SE="0.5681948761091234" STUDY_ID="STD-Starobin-2007" TOTAL_1="30" TOTAL_2="30" VAR="3.097457627118644" WEIGHT="14.737008773379895"/>
<DICH_DATA CI_END="6.820467167072353" CI_START="0.0026853936013588454" EFFECT_SIZE="0.1353352832366127" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8338141226232082" LOG_CI_START="-2.570992050236215" LOG_EFFECT_SIZE="-0.8685889638065036" MODIFIED="2009-12-15 13:11:49 +0530" MODIFIED_BY="[Empty name]" ORDER="111" O_E="-0.5" SE="2.0" STUDY_ID="STD-Toft-1997" TOTAL_1="8" TOTAL_2="8" VAR="0.25" WEIGHT="1.1894439365655456"/>
<DICH_DATA CI_END="4.958823274243347" CI_START="0.15548121026092604" EFFECT_SIZE="0.8780682457243307" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6953786308987809" LOG_CI_START="-0.8083220874928153" LOG_EFFECT_SIZE="-0.0564717282970172" MODIFIED="2010-01-21 18:57:55 +0530" MODIFIED_BY="[Empty name]" ORDER="240" O_E="-0.16666666666666652" SE="0.8832812454218258" STUDY_ID="STD-Weis-2009" TOTAL_1="19" TOTAL_2="17" VAR="1.2817460317460319" WEIGHT="6.098260182709067"/>
<DICH_DATA CI_END="19.9373010618555" CI_START="0.1993934155442883" EFFECT_SIZE="1.99383212820391" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2996663669507516" LOG_CI_START="-0.7002891872480179" LOG_EFFECT_SIZE="0.2996885898513667" MODIFIED="2009-12-15 13:11:54 +0530" MODIFIED_BY="[Empty name]" ORDER="112" O_E="0.5" SE="1.1747837924760145" STUDY_ID="STD-Whitlock-2006" TOTAL_1="30" TOTAL_2="30" VAR="0.7245762711864407" WEIGHT="3.4473714093679377"/>
<DICH_DATA CI_END="5.146939006374115" CI_START="0.054480005875527086" EFFECT_SIZE="0.5295330653587567" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7115490216886566" LOG_CI_START="-1.2637628542577373" LOG_EFFECT_SIZE="-0.27610691628454037" MODIFIED="2009-12-15 13:11:59 +0530" MODIFIED_BY="[Empty name]" ORDER="113" O_E="-0.4722222222222223" SE="1.1603079738823945" STUDY_ID="STD-Yared-1998" TOTAL_1="106" TOTAL_2="110" VAR="0.7427684467413149" WEIGHT="3.533925700994662"/>
<DICH_DATA CI_END="6.820467167072353" CI_START="0.0026853936013588454" EFFECT_SIZE="0.1353352832366127" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8338141226232082" LOG_CI_START="-2.570992050236215" LOG_EFFECT_SIZE="-0.8685889638065036" MODIFIED="2009-12-15 13:12:02 +0530" MODIFIED_BY="[Empty name]" ORDER="114" O_E="-0.5" SE="2.0" STUDY_ID="STD-Yilmaz-1999" TOTAL_1="10" TOTAL_2="10" VAR="0.25" WEIGHT="1.1894439365655456"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.100860911975896" CI_END="20.35752021530274" CI_START="0.39655332837165125" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="2.8412747841015795" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="35.50178299594927" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="1.3087248747255928" LOG_CI_START="-0.4016984006284009" LOG_EFFECT_SIZE="0.4535132370485961" METHOD="PETO" MODIFIED="2010-08-31 01:11:02 +0530" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.21215672698324617" P_Q="1.0" P_Z="0.298639070636342" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="101" TOTAL_2="103" WEIGHT="100.00000000000001" Z="1.0393563089738258">
<NAME>Gastro-intestinal bleeding</NAME>
<GROUP_LABEL_1>Corticosteroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.820467167072353" CI_START="0.0026853936013588454" EFFECT_SIZE="0.1353352832366127" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8338141226232082" LOG_CI_START="-2.570992050236215" LOG_EFFECT_SIZE="-0.8685889638065036" MODIFIED="2009-12-15 13:22:58 +0530" MODIFIED_BY="[Empty name]" ORDER="115" O_E="-0.5" SE="2.0" STUDY_ID="STD-Chaney-1998" TOTAL_1="30" TOTAL_2="30" VAR="0.25" WEIGHT="25.236109795003003"/>
<DICH_DATA CI_END="372.3848896839504" CI_START="0.1466175227450357" EFFECT_SIZE="7.38905609893065" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.570992050236215" LOG_CI_START="-0.8338141226232083" LOG_EFFECT_SIZE="0.8685889638065036" MODIFIED="2009-12-15 13:13:35 +0530" MODIFIED_BY="[Empty name]" ORDER="116" O_E="0.5" SE="2.0" STUDY_ID="STD-Prasongsukarn-2005" TOTAL_1="43" TOTAL_2="43" VAR="0.25" WEIGHT="25.236109795003003"/>
<DICH_DATA CI_END="135.1694054755312" CI_START="0.5017305218709879" EFFECT_SIZE="8.235205908186478" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.130878403611925" LOG_CI_START="-0.2995294786474476" LOG_EFFECT_SIZE="0.9156744624822388" MODIFIED="2009-12-15 13:13:37 +0530" MODIFIED_BY="[Empty name]" ORDER="117" O_E="1.0344827586206895" SE="1.4276336207522016" STUDY_ID="STD-Whitlock-2006" TOTAL_1="28" TOTAL_2="30" VAR="0.49064397021090184" WEIGHT="49.52778040999401"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="337.2475316013346" CI_END="7.829081952791375" CI_START="-11.45816404674144" CI_STUDY="95" CI_TOTAL="95" DF="22" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.814541046975032" ESTIMABLE="YES" I2="93.47660162387592" I2_Q="0.0" ID="CMP-002.04" MODIFIED="2010-02-15 18:12:02 +0530" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="7.771561172376096E-16" P_Q="1.0" P_Z="0.7122870907930658" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="23" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="674" TOTAL_2="677" UNITS="" WEIGHT="100.00000000000001" Z="0.36878620209715907">
<NAME>Mechanical ventilation time (minutes)</NAME>
<GROUP_LABEL_1>Corticosteroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-15.871983292013574" CI_START="-57.66801670798639" EFFECT_SIZE="-36.76999999999998" ESTIMABLE="YES" MEAN_1="407.13" MEAN_2="443.9" MODIFIED="2009-12-15 14:13:45 +0530" MODIFIED_BY="[Empty name]" ORDER="118" SD_1="24.1" SD_2="45.1" SE="10.66244934745092" STUDY_ID="STD-Abd.-El_x002d_Hakeem-2003a" TOTAL_1="23" TOTAL_2="23" WEIGHT="21.29464007753079"/>
<CONT_DATA CI_END="55.49904564431685" CI_START="-127.49904564431685" EFFECT_SIZE="-36.0" ESTIMABLE="YES" MEAN_1="480.0" MEAN_2="516.0" MODIFIED="2009-12-15 14:14:06 +0530" MODIFIED_BY="[Empty name]" ORDER="119" SD_1="95.0" SD_2="113.0" SE="46.6840443834936" STUDY_ID="STD-Abd.-El_x002d_Hakeem-2003b" TOTAL_1="10" TOTAL_2="10" WEIGHT="1.1108292822422021"/>
<CONT_DATA CI_END="-382.92782945844635" CI_START="-597.0721705415536" EFFECT_SIZE="-490.0" ESTIMABLE="YES" MEAN_1="404.0" MEAN_2="894.0" MODIFIED="2010-02-15 18:12:02 +0530" MODIFIED_BY="[Empty name]" ORDER="392" SD_1="102.0" SD_2="222.0" SE="54.62966227243218" STUDY_ID="STD-Bingol-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.811198679037212"/>
<CONT_DATA CI_END="151.22371241695555" CI_START="104.77628758304445" EFFECT_SIZE="128.0" ESTIMABLE="YES" MEAN_1="642.0" MEAN_2="514.0" MODIFIED="2010-02-15 16:03:44 +0530" MODIFIED_BY="[Empty name]" ORDER="120" SD_1="54.0" SD_2="36.0" SE="11.8490505948789" STUDY_ID="STD-Celik-2004" TOTAL_1="30" TOTAL_2="30" WEIGHT="17.243171921073042"/>
<CONT_DATA CI_END="346.1870169749377" CI_START="37.812983025062266" EFFECT_SIZE="192.0" ESTIMABLE="YES" MEAN_1="796.0" MEAN_2="604.0" MODIFIED="2009-12-15 14:14:40 +0530" MODIFIED_BY="[Empty name]" ORDER="121" SD_1="294.0" SD_2="315.0" SE="78.66829094368327" STUDY_ID="STD-Chaney-1998" TOTAL_1="30" TOTAL_2="30" WEIGHT="0.39118737985661856"/>
<CONT_DATA CI_END="277.13789205111885" CI_START="-125.13789205111885" EFFECT_SIZE="76.0" ESTIMABLE="YES" MEAN_1="572.0" MEAN_2="496.0" MODIFIED="2010-01-21 19:05:34 +0530" MODIFIED_BY="[Empty name]" ORDER="242" SD_1="298.0" SD_2="263.0" SE="102.62325922193922" STUDY_ID="STD-Demir-2009" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.2298754854676421"/>
<CONT_DATA CI_END="21.33501288643751" CI_START="-261.33501288643754" EFFECT_SIZE="-120.0" ESTIMABLE="YES" MEAN_1="660.0" MEAN_2="780.0" MODIFIED="2009-12-15 14:14:52 +0530" MODIFIED_BY="[Empty name]" ORDER="122" SD_1="120.0" SD_2="180.0" SE="72.11102550927978" STUDY_ID="STD-El-Azab-2002" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.46556564186897215"/>
<CONT_DATA CI_END="247.56409709140877" CI_START="64.43590290859125" EFFECT_SIZE="156.0" ESTIMABLE="YES" MEAN_1="786.0" MEAN_2="630.0" MODIFIED="2009-12-15 14:15:11 +0530" MODIFIED_BY="[Empty name]" ORDER="123" SD_1="135.0" SD_2="60.0" SE="46.71723450719231" STUDY_ID="STD-Engelman-1995" TOTAL_1="10" TOTAL_2="10" WEIGHT="1.1092514720360391"/>
<CONT_DATA CI_END="-80.33243195480338" CI_START="-603.6675680451966" EFFECT_SIZE="-342.0" ESTIMABLE="YES" MEAN_1="594.0" MEAN_2="936.0" MODIFIED="2009-12-15 14:27:09 +0530" MODIFIED_BY="[Empty name]" ORDER="124" SD_1="85.2" SD_2="510.0" SE="133.50631445740686" STUDY_ID="STD-Fillinger-2002" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.13582529345474842"/>
<CONT_DATA CI_END="192.0928083156506" CI_START="-108.09280831565059" EFFECT_SIZE="42.0" ESTIMABLE="YES" MEAN_1="750.0" MEAN_2="708.0" MODIFIED="2009-12-15 14:16:27 +0530" MODIFIED_BY="[Empty name]" ORDER="125" SD_1="162.0" SD_2="180.0" SE="76.57937059025753" STUDY_ID="STD-Giomarelli-2003" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.41281995391150933"/>
<CONT_DATA CI_END="14.547490138331046" CI_START="-16.547490138331046" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="148.0" MEAN_2="149.0" MODIFIED="2009-12-15 14:25:20 +0530" MODIFIED_BY="[Empty name]" ORDER="126" SD_1="69.0" SD_2="67.0" SE="7.9325386899798485" STUDY_ID="STD-Halvorsen-2003" TOTAL_1="147" TOTAL_2="147" WEIGHT="38.473338015637005"/>
<CONT_DATA CI_END="131.00934826732544" CI_START="-395.00934826732544" EFFECT_SIZE="-132.0" ESTIMABLE="YES" MEAN_1="648.0" MEAN_2="780.0" MODIFIED="2009-12-15 14:17:27 +0530" MODIFIED_BY="[Empty name]" ORDER="127" SD_1="234.0" SD_2="354.0" SE="134.19090878297234" STUDY_ID="STD-Harig-1999" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.13444296379885018"/>
<CONT_DATA CI_END="366.0000669866223" CI_START="-54.0000669866223" EFFECT_SIZE="156.0" ESTIMABLE="YES" MEAN_1="840.0" MEAN_2="684.0" MODIFIED="2009-12-15 14:17:43 +0530" MODIFIED_BY="[Empty name]" ORDER="128" SD_1="528.0" SD_2="414.0" SE="107.14486013165345" STUDY_ID="STD-Liakopoulos-2007" TOTAL_1="40" TOTAL_2="38" WEIGHT="0.21088300505892363"/>
<CONT_DATA CI_END="407.5491344388641" CI_START="54.450865561135686" EFFECT_SIZE="230.9999999999999" ESTIMABLE="YES" MEAN_1="1131.6" MEAN_2="900.6" MODIFIED="2009-12-15 14:18:03 +0530" MODIFIED_BY="[Empty name]" ORDER="129" SD_1="214.0" SD_2="188.0" SE="90.07774419910837" STUDY_ID="STD-Loef-2004" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.2983659523932284"/>
<CONT_DATA CI_END="813.7410660942026" CI_START="-469.74106609420255" EFFECT_SIZE="172.0" ESTIMABLE="YES" MEAN_1="2044.0" MEAN_2="1872.0" MODIFIED="2009-12-15 14:18:20 +0530" MODIFIED_BY="[Empty name]" ORDER="130" SD_1="921.0" SD_2="662.0" SE="327.4249277824359" STUDY_ID="STD-Mayumi-1997" TOTAL_1="12" TOTAL_2="12" WEIGHT="0.022581915881354126"/>
<CONT_DATA CI_END="-274.9727425736064" CI_START="-522.4272574263937" EFFECT_SIZE="-398.70000000000005" ESTIMABLE="YES" MEAN_1="519.3" MEAN_2="918.0" MODIFIED="2009-12-15 14:18:41 +0530" MODIFIED_BY="[Empty name]" ORDER="131" SD_1="292.8" SD_2="404.9" SE="63.127311727326855" STUDY_ID="STD-Oliver-2004" TOTAL_1="62" TOTAL_2="63" WEIGHT="0.6075047464868122"/>
<CONT_DATA CI_END="589.6741642546322" CI_START="-397.67416425463216" EFFECT_SIZE="96.0" ESTIMABLE="YES" MEAN_1="1320.0" MEAN_2="1224.0" MODIFIED="2009-12-15 14:18:54 +0530" MODIFIED_BY="[Empty name]" ORDER="132" SD_1="720.0" SD_2="1164.0" SE="251.87920193874527" STUDY_ID="STD-Sano-2006" TOTAL_1="31" TOTAL_2="29" WEIGHT="0.038159234062191"/>
<CONT_DATA CI_END="135.51929038505585" CI_START="-75.51929038505587" EFFECT_SIZE="30.0" ESTIMABLE="YES" MEAN_1="510.0" MEAN_2="480.0" MODIFIED="2009-12-15 14:19:11 +0530" MODIFIED_BY="[Empty name]" ORDER="133" SD_1="204.0" SD_2="174.0" SE="53.83736191959575" STUDY_ID="STD-Schurr-2001" TOTAL_1="24" TOTAL_2="26" WEIGHT="0.8352504615271368"/>
<CONT_DATA CI_END="-201.12917861407504" CI_START="-510.87082138592496" EFFECT_SIZE="-356.0" ESTIMABLE="YES" MEAN_1="185.0" MEAN_2="541.0" MODIFIED="2010-01-21 19:06:31 +0530" MODIFIED_BY="[Empty name]" ORDER="243" SD_1="164.0" SD_2="246.0" SE="79.01717715607339" STUDY_ID="STD-Sobieski-2008" TOTAL_1="14" TOTAL_2="14" WEIGHT="0.387740570265652"/>
<CONT_DATA CI_END="-41.48387149196574" CI_START="-90.51612850803426" EFFECT_SIZE="-66.0" ESTIMABLE="YES" MEAN_1="486.0" MEAN_2="552.0" MODIFIED="2009-12-15 14:19:28 +0530" MODIFIED_BY="[Empty name]" ORDER="134" SD_1="42.0" SD_2="48.0" SE="12.508458676493218" STUDY_ID="STD-Tassani-1999" TOTAL_1="26" TOTAL_2="26" WEIGHT="15.473076396431917"/>
<CONT_DATA CI_END="213.93375193086592" CI_START="-693.9337519308659" EFFECT_SIZE="-240.0" ESTIMABLE="YES" MEAN_1="840.0" MEAN_2="1080.0" MODIFIED="2009-12-15 14:19:39 +0530" MODIFIED_BY="[Empty name]" ORDER="135" SD_1="420.0" SD_2="600.0" SE="231.60310878742538" STUDY_ID="STD-Wan-1999" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.04513313455851333"/>
<CONT_DATA CI_END="115.95461625641627" CI_START="-295.9546162564163" EFFECT_SIZE="-90.0" ESTIMABLE="YES" MEAN_1="696.0" MEAN_2="786.0" MODIFIED="2009-12-15 14:19:55 +0530" MODIFIED_BY="[Empty name]" ORDER="136" SD_1="714.0" SD_2="828.0" SE="105.08081672977667" STUDY_ID="STD-Yared-1998" TOTAL_1="106" TOTAL_2="110" WEIGHT="0.21924888167145706"/>
<CONT_DATA CI_END="533.6666123014782" CI_START="-329.66661230147815" EFFECT_SIZE="102.0" ESTIMABLE="YES" MEAN_1="804.0" MEAN_2="702.0" MODIFIED="2009-12-15 14:20:20 +0530" MODIFIED_BY="[Empty name]" ORDER="137" SD_1="663.0" SD_2="213.3" SE="220.2421145012915" STUDY_ID="STD-Yilmaz-1999" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.049909535748198154"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="184.69805036767548" CI_END="-1.8074771623863604" CI_START="-2.835146591725492" CI_STUDY="95" CI_TOTAL="95" DF="24" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.3213118770559262" ESTIMABLE="YES" I2="87.00581844138388" I2_Q="0.0" ID="CMP-002.05" MODIFIED="2010-02-15 18:11:26 +0530" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="3.3306690738754696E-16" P_Q="1.0" P_Z="8.415045514652786E-19" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="25" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="605" TOTAL_2="610" UNITS="" WEIGHT="99.99999999999999" Z="8.854379717883551">
<NAME>ICU-stay (hours)</NAME>
<GROUP_LABEL_1>Corticosteroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-4.13461345853773" CI_START="-23.06538654146229" EFFECT_SIZE="-13.600000000000009" ESTIMABLE="YES" MEAN_1="52.66" MEAN_2="66.26" MODIFIED="2009-12-15 14:29:34 +0530" MODIFIED_BY="[Empty name]" ORDER="138" SD_1="1.81" SD_2="23.09" SE="4.829367588447563" STUDY_ID="STD-Abd.-El_x002d_Hakeem-2003a" TOTAL_1="23" TOTAL_2="23" WEIGHT="0.29469324126263124"/>
<CONT_DATA CI_END="-14.90382151871349" CI_START="-24.89617848128652" EFFECT_SIZE="-19.900000000000006" ESTIMABLE="YES" MEAN_1="47.3" MEAN_2="67.2" MODIFIED="2009-12-15 14:30:20 +0530" MODIFIED_BY="[Empty name]" ORDER="139" SD_1="5.7" SD_2="5.7" SE="2.54911749434976" STUDY_ID="STD-Abd.-El_x002d_Hakeem-2003b" TOTAL_1="10" TOTAL_2="10" WEIGHT="1.0577206778655235"/>
<CONT_DATA CI_END="4.6715326729265545" CI_START="-9.471532672926566" EFFECT_SIZE="-2.4000000000000057" ESTIMABLE="YES" MEAN_1="64.8" MEAN_2="67.2" MODIFIED="2010-01-25 13:22:46 +0530" MODIFIED_BY="[Empty name]" ORDER="246" SD_1="19.2" SD_2="16.8" SE="3.607991130809498" STUDY_ID="STD-Amr-2009" TOTAL_1="50" TOTAL_2="50" WEIGHT="0.5279828051845327"/>
<CONT_DATA CI_END="-36.47717604547616" CI_START="-106.32282395452384" EFFECT_SIZE="-71.4" ESTIMABLE="YES" MEAN_1="33.6" MEAN_2="105.0" MODIFIED="2010-02-15 18:11:26 +0530" MODIFIED_BY="[Empty name]" ORDER="393" SD_1="16.3" SD_2="78.0" SE="17.81809473540872" STUDY_ID="STD-Bingol-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.021648518163154967"/>
<CONT_DATA CI_END="-3.9237704752806755" CI_START="-7.876229524719322" EFFECT_SIZE="-5.899999999999999" ESTIMABLE="YES" MEAN_1="36.2" MEAN_2="42.1" MODIFIED="2009-12-15 14:30:45 +0530" MODIFIED_BY="[Empty name]" ORDER="140" SD_1="4.1" SD_2="3.7" SE="1.0082988974836116" STUDY_ID="STD-Celik-2004" TOTAL_1="30" TOTAL_2="30" WEIGHT="6.760395703052629"/>
<CONT_DATA CI_END="11.868926439663191" CI_START="-66.06892643966319" EFFECT_SIZE="-27.1" ESTIMABLE="YES" MEAN_1="55.9" MEAN_2="83.0" MODIFIED="2010-01-25 13:24:08 +0530" MODIFIED_BY="[Empty name]" ORDER="247" SD_1="14.64" SD_2="75.6" SE="19.882470671423103" STUDY_ID="STD-Demir-2009" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.017386413358222427"/>
<CONT_DATA CI_END="-6.450297251559725" CI_START="-49.549702748440275" EFFECT_SIZE="-28.0" ESTIMABLE="YES" MEAN_1="24.0" MEAN_2="52.0" MODIFIED="2009-12-15 14:31:01 +0530" MODIFIED_BY="[Empty name]" ORDER="141" SD_1="8.0" SD_2="32.0" SE="10.994948334980428" STUDY_ID="STD-El-Azab-2002" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.056854430774753266"/>
<CONT_DATA CI_END="-16.896086437103868" CI_START="-26.303913562896128" EFFECT_SIZE="-21.599999999999998" ESTIMABLE="YES" MEAN_1="28.8" MEAN_2="50.4" MODIFIED="2009-12-15 14:31:17 +0530" MODIFIED_BY="[Empty name]" ORDER="142" SD_1="2.4" SD_2="7.2" SE="2.4" STUDY_ID="STD-Engelman-1995" TOTAL_1="10" TOTAL_2="10" WEIGHT="1.1932411397170437"/>
<CONT_DATA CI_END="6.665413953313726" CI_START="-24.665413953313724" EFFECT_SIZE="-9.0" ESTIMABLE="YES" MEAN_1="27.0" MEAN_2="36.0" MODIFIED="2009-12-15 14:31:33 +0530" MODIFIED_BY="[Empty name]" ORDER="143" SD_1="11.6" SD_2="28.7" SE="7.992705007275905" STUDY_ID="STD-Fillinger-2002" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.10758782621607366"/>
<CONT_DATA CI_END="0.4631476818108564" CI_START="-6.663147681810859" EFFECT_SIZE="-3.1000000000000014" ESTIMABLE="YES" MEAN_1="32.1" MEAN_2="35.2" MODIFIED="2009-12-15 14:31:49 +0530" MODIFIED_BY="[Empty name]" ORDER="144" SD_1="3.7" SD_2="4.4" SE="1.8179658962697844" STUDY_ID="STD-Giomarelli-2003" TOTAL_1="10" TOTAL_2="10" WEIGHT="2.079597266193698"/>
<CONT_DATA CI_END="-1.1618819584171116" CI_START="-2.4381180415828827" EFFECT_SIZE="-1.7999999999999972" ESTIMABLE="YES" MEAN_1="18.1" MEAN_2="19.9" MODIFIED="2009-12-15 14:32:03 +0530" MODIFIED_BY="[Empty name]" ORDER="145" SD_1="0.5" SD_2="0.9" SE="0.32557641192199416" STUDY_ID="STD-Harig-1999" TOTAL_1="10" TOTAL_2="10" WEIGHT="64.84027325254878"/>
<CONT_DATA CI_END="40.384565469898135" CI_START="-1.9845654698981328" EFFECT_SIZE="19.200000000000003" ESTIMABLE="YES" MEAN_1="91.2" MEAN_2="72.0" MODIFIED="2009-12-15 14:32:16 +0530" MODIFIED_BY="[Empty name]" ORDER="146" SD_1="27.0" SD_2="27.0" SE="10.808650381843382" STUDY_ID="STD-Jansen-1991a" TOTAL_1="12" TOTAL_2="13" WEIGHT="0.05883120759967884"/>
<CONT_DATA CI_END="24.119255375901524" CI_START="-23.319255375901527" EFFECT_SIZE="0.3999999999999986" ESTIMABLE="YES" MEAN_1="50.4" MEAN_2="50.0" MODIFIED="2009-12-15 14:32:40 +0530" MODIFIED_BY="[Empty name]" ORDER="147" SD_1="62.4" SD_2="43.2" SE="12.101883281017399" STUDY_ID="STD-Liakopoulos-2007" TOTAL_1="40" TOTAL_2="38" WEIGHT="0.046929376225675494"/>
<CONT_DATA CI_END="10.565562532181099" CI_START="-4.565562532181099" EFFECT_SIZE="3.0" ESTIMABLE="YES" MEAN_1="29.0" MEAN_2="26.0" MODIFIED="2009-12-15 14:32:55 +0530" MODIFIED_BY="[Empty name]" ORDER="148" SD_1="10.0" SD_2="7.0" SE="3.8600518131237567" STUDY_ID="STD-Loef-2004" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.4612797962933001"/>
<CONT_DATA CI_END="5.393800798475743" CI_START="-2.7938007984757416" EFFECT_SIZE="1.3000000000000007" ESTIMABLE="YES" MEAN_1="25.2" MEAN_2="23.9" MODIFIED="2009-12-15 14:33:35 +0530" MODIFIED_BY="[Empty name]" ORDER="149" SD_1="14.0" SD_2="8.7" SE="2.088712257351217" STUDY_ID="STD-Oliver-2004" TOTAL_1="62" TOTAL_2="63" WEIGHT="1.5754095397271894"/>
<CONT_DATA CI_END="12.653001444581271" CI_START="-12.653001444581271" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="36.0" MEAN_2="36.0" MODIFIED="2009-12-15 14:33:52 +0530" MODIFIED_BY="[Empty name]" ORDER="150" SD_1="29.0" SD_2="24.0" SE="6.45573160751245" STUDY_ID="STD-Rubens-2005" TOTAL_1="34" TOTAL_2="34" WEIGHT="0.1649148516599759"/>
<CONT_DATA CI_END="20.740330691498038" CI_START="-2.3403306914980337" EFFECT_SIZE="9.200000000000003" ESTIMABLE="YES" MEAN_1="43.2" MEAN_2="34.0" MODIFIED="2009-12-15 14:34:08 +0530" MODIFIED_BY="[Empty name]" ORDER="151" SD_1="24.0" SD_2="21.6" SE="5.888032016162895" STUDY_ID="STD-Sano-2006" TOTAL_1="31" TOTAL_2="29" WEIGHT="0.19824871273436007"/>
<CONT_DATA CI_END="11.370671771095605" CI_START="-11.370671771095605" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="24.0" MEAN_2="24.0" MODIFIED="2009-12-15 14:34:26 +0530" MODIFIED_BY="[Empty name]" ORDER="152" SD_1="19.0" SD_2="22.0" SE="5.801469751886265" STUDY_ID="STD-Schurr-2001" TOTAL_1="24" TOTAL_2="26" WEIGHT="0.20420888648779104"/>
<CONT_DATA CI_END="5.685387322434347" CI_START="-7.4853873224343515" EFFECT_SIZE="-0.9000000000000021" ESTIMABLE="YES" MEAN_1="23.7" MEAN_2="24.6" MODIFIED="2010-01-21 19:17:12 +0530" MODIFIED_BY="[Empty name]" ORDER="248" SD_1="2.6" SD_2="12.3" SE="3.3599532309670197" STUDY_ID="STD-Sobieski-2008" TOTAL_1="14" TOTAL_2="14" WEIGHT="0.6088134483187752"/>
<CONT_DATA CI_END="0.3690478389142269" CI_START="-1.9690478389142283" EFFECT_SIZE="-0.8000000000000007" ESTIMABLE="YES" MEAN_1="27.2" MEAN_2="28.0" MODIFIED="2009-12-15 14:34:39 +0530" MODIFIED_BY="[Empty name]" ORDER="153" SD_1="2.1" SD_2="2.2" SE="0.596463939202724" STUDY_ID="STD-Tassani-1999" TOTAL_1="26" TOTAL_2="26" WEIGHT="19.318896549624267"/>
<CONT_DATA CI_END="48.441438472152015" CI_START="-126.44143847215202" EFFECT_SIZE="-39.0" ESTIMABLE="YES" MEAN_1="36.0" MEAN_2="75.0" MODIFIED="2009-12-15 14:35:29 +0530" MODIFIED_BY="[Empty name]" ORDER="154" SD_1="29.0" SD_2="158.0" SE="44.61379860134111" STUDY_ID="STD-Volk-2001" TOTAL_1="12" TOTAL_2="13" WEIGHT="0.0034531249770665697"/>
<CONT_DATA CI_END="-13.220597708989246" CI_START="-62.779402291010754" EFFECT_SIZE="-38.0" ESTIMABLE="YES" MEAN_1="36.0" MEAN_2="74.0" MODIFIED="2009-12-15 14:41:37 +0530" MODIFIED_BY="[Empty name]" ORDER="155" SD_1="7.2" SD_2="43.2" SE="12.642784503423286" STUDY_ID="STD-Volk-2003" TOTAL_1="12" TOTAL_2="12" WEIGHT="0.042999680710524096"/>
<CONT_DATA CI_END="12.307808075042672" CI_START="-18.307808075042672" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="29.0" MEAN_2="32.0" MODIFIED="2009-12-15 14:36:01 +0530" MODIFIED_BY="[Empty name]" ORDER="156" SD_1="9.0" SD_2="23.0" SE="7.810249675906654" STUDY_ID="STD-Wan-1999" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.11267326171754381"/>
<CONT_DATA CI_END="10.787984527618118" CI_START="-32.987984527618124" EFFECT_SIZE="-11.100000000000001" ESTIMABLE="YES" MEAN_1="36.8" MEAN_2="47.9" MODIFIED="2009-12-15 14:36:49 +0530" MODIFIED_BY="[Empty name]" ORDER="157" SD_1="28.0" SD_2="113.6" SE="11.167544250949378" STUDY_ID="STD-Yared-1998" TOTAL_1="106" TOTAL_2="110" WEIGHT="0.055110625166432343"/>
<CONT_DATA CI_END="11.27190700990522" CI_START="-12.251907009905224" EFFECT_SIZE="-0.490000000000002" ESTIMABLE="YES" MEAN_1="33.71" MEAN_2="34.2" MODIFIED="2009-12-15 14:37:06 +0530" MODIFIED_BY="[Empty name]" ORDER="158" SD_1="17.3" SD_2="7.8" SE="6.0010832355500625" STUDY_ID="STD-Yilmaz-1999" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.19084966442035295"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="147.88808002819678" CI_END="-0.14978332365297464" CI_START="-0.6508910213230606" CI_STUDY="95" CI_TOTAL="95" DF="14" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.40033717248801765" ESTIMABLE="YES" I2="90.5333817320972" I2_Q="0.0" ID="CMP-002.06" MODIFIED="2010-05-23 08:58:37 +0530" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Q="1.0" P_Z="0.001738281950866808" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="15" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="312" TOTAL_2="313" UNITS="" WEIGHT="100.0" Z="3.1316479207856887">
<NAME>Hospital stay (days)</NAME>
<GROUP_LABEL_1>Corticosteroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.6197950323045616" CI_START="0.3802049676954383" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="15.0" MEAN_2="14.0" MODIFIED="2010-01-25 13:27:16 +0530" MODIFIED_BY="[Empty name]" ORDER="248" SD_1="1.0" SD_2="2.0" SE="0.31622776601683794" STUDY_ID="STD-Amr-2009" TOTAL_1="50" TOTAL_2="50" WEIGHT="16.342028926060472"/>
<CONT_DATA CI_END="-5.259157299211394" CI_START="-8.040842700788605" EFFECT_SIZE="-6.6499999999999995" ESTIMABLE="YES" MEAN_1="6.3" MEAN_2="12.95" MODIFIED="2010-05-23 08:58:37 +0530" MODIFIED_BY="[Empty name]" ORDER="394" SD_1="1.17" SD_2="2.95" SE="0.7096266624077763" STUDY_ID="STD-Bingol-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="3.2452348086781324"/>
<CONT_DATA CI_END="1.307719678588732" CI_START="-4.107719678588733" EFFECT_SIZE="-1.4000000000000004" ESTIMABLE="YES" MEAN_1="6.9" MEAN_2="8.3" MODIFIED="2009-12-15 14:44:23 +0530" MODIFIED_BY="[Empty name]" ORDER="159" SD_1="4.1" SD_2="6.1" SE="1.3815150175956699" STUDY_ID="STD-Chaney-1998" TOTAL_1="29" TOTAL_2="28" WEIGHT="0.85623850558219"/>
<CONT_DATA CI_END="-0.4739886053713813" CI_START="-7.666011394628619" EFFECT_SIZE="-4.07" ESTIMABLE="YES" MEAN_1="8.53" MEAN_2="12.6" MODIFIED="2010-01-25 13:27:51 +0530" MODIFIED_BY="[Empty name]" ORDER="249" SD_1="2.19" SD_2="6.76" SE="1.8347334047939134" STUDY_ID="STD-Demir-2009" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.48546736303916554"/>
<CONT_DATA CI_END="-0.6959430734667444" CI_START="-1.5040569265332548" EFFECT_SIZE="-1.0999999999999996" ESTIMABLE="YES" MEAN_1="5.2" MEAN_2="6.3" MODIFIED="2009-12-15 14:44:41 +0530" MODIFIED_BY="[Empty name]" ORDER="160" SD_1="0.6" SD_2="0.7" SE="0.206155281280883" STUDY_ID="STD-Enc-2006" TOTAL_1="20" TOTAL_2="20" WEIGHT="38.45183276720111"/>
<CONT_DATA CI_END="2.0254514859279666" CI_START="0.5745485140720328" EFFECT_SIZE="1.2999999999999998" ESTIMABLE="YES" MEAN_1="6.5" MEAN_2="5.2" MODIFIED="2009-12-15 14:44:52 +0530" MODIFIED_BY="[Empty name]" ORDER="161" SD_1="1.1" SD_2="0.4" SE="0.370135110466435" STUDY_ID="STD-Engelman-1995" TOTAL_1="10" TOTAL_2="10" WEIGHT="11.928488267197421"/>
<CONT_DATA CI_END="-0.35268143516087025" CI_START="-2.6473185648391295" EFFECT_SIZE="-1.5" ESTIMABLE="YES" MEAN_1="4.6" MEAN_2="6.1" MODIFIED="2009-12-15 14:45:10 +0530" MODIFIED_BY="[Empty name]" ORDER="162" SD_1="1.5" SD_2="1.7" SE="0.5853773711604051" STUDY_ID="STD-Fillinger-2002" TOTAL_1="15" TOTAL_2="15" WEIGHT="4.769074589317258"/>
<CONT_DATA CI_END="0.8765225405765816" CI_START="-0.8765225405765816" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="6.0" MEAN_2="6.0" MODIFIED="2009-12-15 14:45:25 +0530" MODIFIED_BY="[Empty name]" ORDER="163" SD_1="1.0" SD_2="1.0" SE="0.4472135954999579" STUDY_ID="STD-Giomarelli-2003" TOTAL_1="10" TOTAL_2="10" WEIGHT="8.171014463030236"/>
<CONT_DATA CI_END="2.855824270441497" CI_START="-1.255824270441499" EFFECT_SIZE="0.7999999999999989" ESTIMABLE="YES" MEAN_1="13.1" MEAN_2="12.3" MODIFIED="2009-12-15 14:45:45 +0530" MODIFIED_BY="[Empty name]" ORDER="164" SD_1="6.2" SD_2="2.3" SE="1.0489092078515612" STUDY_ID="STD-Liakopoulos-2007" TOTAL_1="40" TOTAL_2="38" WEIGHT="1.4853547148638966"/>
<CONT_DATA CI_END="2.436100409470227" CI_START="-1.8361004094702258" EFFECT_SIZE="0.3000000000000007" ESTIMABLE="YES" MEAN_1="8.06" MEAN_2="7.76" MODIFIED="2009-12-15 14:46:03 +0530" MODIFIED_BY="[Empty name]" ORDER="165" SD_1="2.9" SD_2="3.5" SE="1.089867174253973" STUDY_ID="STD-McBride-2004" TOTAL_1="18" TOTAL_2="17" WEIGHT="1.3758111677372287"/>
<CONT_DATA CI_END="1.0091972464313135" CI_START="-1.0091972464313135" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="11.0" MEAN_2="11.0" MODIFIED="2009-12-15 14:46:23 +0530" MODIFIED_BY="[Empty name]" ORDER="166" SD_1="2.0" SD_2="1.6" SE="0.5149060158205623" STUDY_ID="STD-Schurr-2001" TOTAL_1="24" TOTAL_2="26" WEIGHT="6.163821355090507"/>
<CONT_DATA CI_END="0.8476985412213363" CI_START="-1.2476985412213366" EFFECT_SIZE="-0.20000000000000018" ESTIMABLE="YES" MEAN_1="4.8" MEAN_2="5.0" MODIFIED="2010-02-15 16:06:05 +0530" MODIFIED_BY="[Empty name]" ORDER="250" SD_1="1.5" SD_2="1.3" SE="0.5345498945314551" STUDY_ID="STD-Sobieski-2008" TOTAL_1="13" TOTAL_2="15" WEIGHT="5.7191235473470785"/>
<CONT_DATA CI_END="5.7366775533684855" CI_START="-0.13667755336848453" EFFECT_SIZE="2.8000000000000007" ESTIMABLE="YES" MEAN_1="13.3" MEAN_2="10.5" MODIFIED="2009-12-15 14:46:44 +0530" MODIFIED_BY="[Empty name]" ORDER="167" SD_1="4.6" SD_2="6.1" SE="1.4983324063771697" STUDY_ID="STD-Tassani-1999" TOTAL_1="26" TOTAL_2="26" WEIGHT="0.7279300189781949"/>
<CONT_DATA CI_END="15.73069098644921" CI_START="-3.930690986449209" EFFECT_SIZE="5.9" ESTIMABLE="YES" MEAN_1="14.6" MEAN_2="8.7" MODIFIED="2009-12-15 14:47:07 +0530" MODIFIED_BY="[Empty name]" ORDER="168" SD_1="16.1" SD_2="6.8" SE="5.0157508321542865" STUDY_ID="STD-Volk-2001" TOTAL_1="12" TOTAL_2="13" WEIGHT="0.06495821272598891"/>
<CONT_DATA CI_END="2.8209925270479816" CI_START="-8.02099252704798" EFFECT_SIZE="-2.5999999999999996" ESTIMABLE="YES" MEAN_1="6.6" MEAN_2="9.2" MODIFIED="2009-12-15 14:47:19 +0530" MODIFIED_BY="[Empty name]" ORDER="169" SD_1="0.9" SD_2="8.7" SE="2.765863337187866" STUDY_ID="STD-Yilmaz-1999" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.21362129315111733"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="10.751601727165967" CI_END="2.1914947344182236" CI_START="0.45232605958576777" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.9956255208773798" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="13" I2="25.592481910983754" I2_Q="0.0" ID="CMP-002.07" LOG_CI_END="0.34074043149654576" LOG_CI_START="-0.34454839078983585" LOG_EFFECT_SIZE="-0.0019039796466450232" METHOD="PETO" MODIFIED="2010-08-31 01:11:55 +0530" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.21617493257517761" P_Q="1.0" P_Z="0.9913104313992606" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="338" TOTAL_2="339" WEIGHT="99.99999999999999" Z="0.010890974471963688">
<NAME>Renal failure</NAME>
<GROUP_LABEL_1>Corticosteroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.820467167072353" CI_START="0.0026853936013588454" EFFECT_SIZE="0.1353352832366127" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8338141226232082" LOG_CI_START="-2.570992050236215" LOG_EFFECT_SIZE="-0.8685889638065036" MODIFIED="2010-01-25 13:31:02 +0530" MODIFIED_BY="[Empty name]" ORDER="251" O_E="-0.5" SE="2.0" STUDY_ID="STD-Demir-2009" TOTAL_1="15" TOTAL_2="15" VAR="0.25" WEIGHT="4.051002478911267"/>
<DICH_DATA CI_END="129.11113502069682" CI_START="0.46981776788555657" EFFECT_SIZE="7.7883698720974" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.1109636990402896" LOG_CI_START="-0.3280705628058871" LOG_EFFECT_SIZE="0.8914465681172012" MODIFIED="2009-12-15 15:03:32 +0530" MODIFIED_BY="[Empty name]" ORDER="170" O_E="1.0" SE="1.4327007988227578" STUDY_ID="STD-Enc-2006" TOTAL_1="20" TOTAL_2="20" VAR="0.48717948717948717" WEIGHT="7.894261240955289"/>
<DICH_DATA CI_END="7.0142285050739455" CI_START="0.38285008774117607" EFFECT_SIZE="1.638718401252704" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.8459799099452869" LOG_CI_START="-0.4169712490388838" LOG_EFFECT_SIZE="0.2145043304532016" MODIFIED="2009-12-15 15:03:47 +0530" MODIFIED_BY="[Empty name]" ORDER="172" O_E="0.8974358974358978" SE="0.7418637624963651" STUDY_ID="STD-Liakopoulos-2007" TOTAL_1="40" TOTAL_2="38" VAR="1.8169864323710476" WEIGHT="29.44246616673301"/>
<DICH_DATA CI_END="16.25267791785107" CI_START="0.06152832198204417" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.210924928953513" LOG_CI_START="-1.210924928953513" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-15 15:04:27 +0530" MODIFIED_BY="[Empty name]" ORDER="173" O_E="0.0" SE="1.422606594884729" STUDY_ID="STD-Prasongsukarn-2005" TOTAL_1="43" TOTAL_2="43" VAR="0.49411764705882355" WEIGHT="8.006687252436386"/>
<DICH_DATA CI_END="372.3848896839504" CI_START="0.1466175227450357" EFFECT_SIZE="7.38905609893065" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.570992050236215" LOG_CI_START="-0.8338141226232083" LOG_EFFECT_SIZE="0.8685889638065036" MODIFIED="2010-01-25 13:31:50 +0530" MODIFIED_BY="[Empty name]" ORDER="253" O_E="0.5" SE="2.0" STUDY_ID="STD-Starobin-2007" TOTAL_1="30" TOTAL_2="30" VAR="0.25" WEIGHT="4.051002478911267"/>
<DICH_DATA CI_END="2.9379668132938463" CI_START="0.0484035472191478" EFFECT_SIZE="0.3771047803668867" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4680468857752871" LOG_CI_START="-1.315122810230546" LOG_EFFECT_SIZE="-0.42353796222762946" MODIFIED="2010-01-25 13:32:58 +0530" MODIFIED_BY="[Empty name]" ORDER="254" O_E="-0.8888888888888888" SE="1.0474427062661789" STUDY_ID="STD-Weis-2009" TOTAL_1="17" TOTAL_2="19" VAR="0.9114638447971781" WEIGHT="14.76936917884545"/>
<DICH_DATA CI_END="125.22137664263677" CI_START="0.4671440237582856" EFFECT_SIZE="7.648295087494541" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.097678473966062" LOG_CI_START="-0.33054920277352023" LOG_EFFECT_SIZE="0.883564635596271" MODIFIED="2009-12-15 15:04:46 +0530" MODIFIED_BY="[Empty name]" ORDER="176" O_E="1.0" SE="1.4263529572376852" STUDY_ID="STD-Whitlock-2006" TOTAL_1="30" TOTAL_2="30" VAR="0.4915254237288136" WEIGHT="7.964682839893338"/>
<DICH_DATA CI_END="1.339220296086902" CI_START="0.014175557454456506" EFFECT_SIZE="0.1377831421159865" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.12685202249786534" LOG_CI_START="-1.8484598534485284" LOG_EFFECT_SIZE="-0.8608039154753315" MODIFIED="2009-12-15 15:04:57 +0530" MODIFIED_BY="[Empty name]" ORDER="177" O_E="-1.4722222222222223" SE="1.1603079738823945" STUDY_ID="STD-Yared-1998" TOTAL_1="106" TOTAL_2="110" VAR="0.7427684467413149" WEIGHT="12.035827276024552"/>
<DICH_DATA CI_END="4.588782160550079" CI_START="0.04628604211281595" EFFECT_SIZE="0.46086501747231745" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6616974412822398" LOG_CI_START="-1.3345499538478311" LOG_EFFECT_SIZE="-0.33642625628279577" MODIFIED="2009-12-15 15:05:03 +0530" MODIFIED_BY="[Empty name]" ORDER="178" O_E="-0.5633802816901408" SE="1.1726056014833777" STUDY_ID="STD-Yared-2007" TOTAL_1="37" TOTAL_2="34" VAR="0.7272706662510273" WEIGHT="11.78470108728944"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.045777155249395" CI_END="2.6530359254875355" CI_START="0.4694831145445815" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.1160446090083291" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" I2="33.67070736959164" I2_Q="0.0" ID="CMP-002.08" LOG_CI_END="0.42374313092290916" LOG_CI_START="-0.32838002297611374" LOG_EFFECT_SIZE="0.04768155397339768" METHOD="PETO" MODIFIED="2010-08-31 01:12:09 +0530" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.1710199898546193" P_Q="1.0" P_Z="0.8037417554081525" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="407" TOTAL_2="411" WEIGHT="100.0" Z="0.2485075164360889">
<NAME>Re-thoracotomy</NAME>
<GROUP_LABEL_1>Corticosteroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.890603857637106" CI_START="0.41353975433227397" EFFECT_SIZE="1.6880576490417227" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.8382572829450851" LOG_CI_START="-0.38348273458241505" LOG_EFFECT_SIZE="0.22738727418133498" MODIFIED="2009-12-15 15:06:24 +0530" MODIFIED_BY="[Empty name]" ORDER="179" O_E="1.016597510373444" SE="0.7176561340062765" STUDY_ID="STD-Halonen-2007" TOTAL_1="120" TOTAL_2="121" VAR="1.9416332363423494" WEIGHT="37.89835142309623"/>
<DICH_DATA CI_END="16.063503542368387" CI_START="0.06225291994130946" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2058402733943532" LOG_CI_START="-1.2058402733943532" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-15 15:06:30 +0530" MODIFIED_BY="[Empty name]" ORDER="180" O_E="0.0" SE="1.4166330911949265" STUDY_ID="STD-Halvorsen-2003" TOTAL_1="147" TOTAL_2="147" VAR="0.4982935153583618" WEIGHT="9.726091624016407"/>
<DICH_DATA CI_END="123.7183209639478" CI_START="0.4442919579351524" EFFECT_SIZE="7.413977006541223" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0924340173686415" LOG_CI_START="-0.352331547789955" LOG_EFFECT_SIZE="0.8700512347893431" MODIFIED="2009-12-15 15:06:42 +0530" MODIFIED_BY="[Empty name]" ORDER="182" O_E="0.9714285714285715" SE="1.436067394758882" STUDY_ID="STD-McBride-2004" TOTAL_1="18" TOTAL_2="17" VAR="0.4848979591836734" WEIGHT="9.464626437948354"/>
<DICH_DATA CI_END="0.9520436209239814" CI_START="0.01799797539739471" EFFECT_SIZE="0.13090018207258686" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="-0.02134315256870153" LOG_CI_START="-1.7447763461851757" LOG_EFFECT_SIZE="-0.8830597493769388" MODIFIED="2009-12-15 15:06:50 +0530" MODIFIED_BY="[Empty name]" ORDER="183" O_E="-1.984" SE="1.0123531890622137" STUDY_ID="STD-Oliver-2004" TOTAL_1="62" TOTAL_2="63" VAR="0.975744" WEIGHT="19.045352293535544"/>
<DICH_DATA CI_END="445.07543235954245" CI_START="0.17120211773768754" EFFECT_SIZE="8.729138363720132" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.6484336223994553" LOG_CI_START="-0.7664908674853644" LOG_EFFECT_SIZE="0.9409713774570456" MODIFIED="2009-12-15 15:06:56 +0530" MODIFIED_BY="[Empty name]" ORDER="184" O_E="0.5384615384615384" SE="2.0059435495071947" STUDY_ID="STD-Rumalla-2001" TOTAL_1="6" TOTAL_2="7" VAR="0.24852071005917162" WEIGHT="4.850826113526218"/>
<DICH_DATA CI_END="406.0194289218663" CI_START="0.15885962215189478" EFFECT_SIZE="8.031194996067258" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.6085468160197243" LOG_CI_START="-0.7989864747561749" LOG_EFFECT_SIZE="0.9047801706317746" MODIFIED="2009-12-15 15:07:08 +0530" MODIFIED_BY="[Empty name]" ORDER="185" O_E="0.52" SE="2.001601922563589" STUDY_ID="STD-Schurr-2001" TOTAL_1="24" TOTAL_2="26" VAR="0.24960000000000002" WEIGHT="4.871892558362104"/>
<DICH_DATA CI_END="5.0152107443983525" CI_START="0.05015724028530737" EFFECT_SIZE="0.5015467379898342" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7002891872480179" LOG_CI_START="-1.2996663669507513" LOG_EFFECT_SIZE="-0.29968858985136676" MODIFIED="2010-01-25 13:34:47 +0530" MODIFIED_BY="[Empty name]" ORDER="256" O_E="-0.5" SE="1.1747837924760145" STUDY_ID="STD-Starobin-2007" TOTAL_1="30" TOTAL_2="30" VAR="0.7245762711864407" WEIGHT="14.142859549515153"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.686448635307658" CI_END="1.4932323625982957" CI_START="0.11623520082498964" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.41661272609581507" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" I2="45.74724354370159" I2_Q="0.0" ID="CMP-002.09" LOG_CI_END="0.17412739375463793" LOG_CI_START="-0.9346623296998143" LOG_EFFECT_SIZE="-0.38026746797258826" METHOD="PETO" MODIFIED="2010-02-16 17:58:25 +0530" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.15830625581168123" P_Q="1.0" P_Z="0.17882951528951394" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="90" TOTAL_2="88" WEIGHT="100.0" Z="1.344367693806693">
<NAME>Re-intubation</NAME>
<GROUP_LABEL_1>Corticosteroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8810230646853519" CI_START="0.014896010403119187" EFFECT_SIZE="0.11455884399268769" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="-0.055012721855311836" LOG_CI_START="-1.8269300330587799" LOG_EFFECT_SIZE="-0.9409713774570457" MODIFIED="2010-02-15 16:06:58 +0530" MODIFIED_BY="[Empty name]" ORDER="395" O_E="-2.0" SE="1.0408329997330665" STUDY_ID="STD-Bingol-2005" TOTAL_1="20" TOTAL_2="20" VAR="0.923076923076923" WEIGHT="39.157186722675526"/>
<DICH_DATA CI_END="6.820467167072353" CI_START="0.0026853936013588454" EFFECT_SIZE="0.1353352832366127" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8338141226232082" LOG_CI_START="-2.570992050236215" LOG_EFFECT_SIZE="-0.8685889638065036" MODIFIED="2009-12-15 15:08:38 +0530" MODIFIED_BY="[Empty name]" ORDER="186" O_E="-0.5" SE="2.0" STUDY_ID="STD-Celik-2004" TOTAL_1="30" TOTAL_2="30" VAR="0.25" WEIGHT="10.605071404057956"/>
<DICH_DATA CI_END="8.750345107287556" CI_START="0.23860218874367287" EFFECT_SIZE="1.4449399623725894" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9420251816206067" LOG_CI_START="-0.6223255767807667" LOG_EFFECT_SIZE="0.15984980241992" MODIFIED="2009-12-15 15:08:44 +0530" MODIFIED_BY="[Empty name]" ORDER="187" O_E="0.4358974358974357" SE="0.918907379146109" STUDY_ID="STD-Liakopoulos-2007" TOTAL_1="40" TOTAL_2="38" VAR="1.184285799670415" WEIGHT="50.23774187326651"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="10.761530348736725" CI_END="1.4806540766097862" CI_START="0.3269406771789072" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.695762924044184" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="16" I2="16.368771834978915" I2_Q="0.0" ID="CMP-002.10" LOG_CI_END="0.17045360668630258" LOG_CI_START="-0.48553104217484594" LOG_EFFECT_SIZE="-0.15753871774427167" METHOD="PETO" MODIFIED="2010-08-31 01:12:46 +0530" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.29240982135456006" P_Q="1.0" P_Z="0.3465026757664714" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="538" TOTAL_2="514" WEIGHT="99.99999999999999" Z="0.9413946301501048">
<NAME>Neurological complication (stroke)</NAME>
<GROUP_LABEL_1>Corticosteroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="20.740492161659734" CI_START="0.37012810097649546" EFFECT_SIZE="2.7706748234163117" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.3168190577693673" LOG_CI_START="-0.4316479410174667" LOG_EFFECT_SIZE="0.44258555837595037" MODIFIED="2009-12-15 15:10:16 +0530" MODIFIED_BY="[Empty name]" ORDER="188" O_E="0.9661016949152543" SE="1.0270581701386172" STUDY_ID="STD-Chaney-1998" TOTAL_1="30" TOTAL_2="29" VAR="0.9480034472852629" WEIGHT="14.075780092281521"/>
<DICH_DATA CI_END="2.396058992196971" CI_START="0.018365984165870753" EFFECT_SIZE="0.20977602701734488" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.3794975064010086" LOG_CI_START="-1.7359857944433885" LOG_EFFECT_SIZE="-0.6782441440211899" MODIFIED="2009-12-15 15:10:24 +0530" MODIFIED_BY="[Empty name]" ORDER="189" O_E="-1.0113636363636362" SE="1.2426453627272254" STUDY_ID="STD-Chaney-2001" TOTAL_1="59" TOTAL_2="29" VAR="0.6475981404958678" WEIGHT="9.615417580910279"/>
<DICH_DATA CI_END="16.577427258976247" CI_START="0.060322991280720356" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2195171309230883" LOG_CI_START="-1.2195171309230883" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-15 15:10:31 +0530" MODIFIED_BY="[Empty name]" ORDER="190" O_E="0.0" SE="1.4327007988227578" STUDY_ID="STD-Enc-2006" TOTAL_1="20" TOTAL_2="20" VAR="0.48717948717948717" WEIGHT="7.233551045247921"/>
<DICH_DATA CI_END="16.21534295021216" CI_START="0.06270647000909482" EFFECT_SIZE="1.0083684427800512" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2099261383194857" LOG_CI_START="-1.2026876466608056" LOG_EFFECT_SIZE="0.003619245829339949" MODIFIED="2009-12-15 15:10:43 +0530" MODIFIED_BY="[Empty name]" ORDER="192" O_E="0.004149377593360981" SE="1.417181279928267" STUDY_ID="STD-Halonen-2007" TOTAL_1="120" TOTAL_2="121" VAR="0.49790809386890716" WEIGHT="7.39284741583529"/>
<DICH_DATA CI_END="378.487272083006" CI_START="0.14898280527446486" EFFECT_SIZE="7.509200726815462" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.578051279458129" LOG_CI_START="-0.8268638524288877" LOG_EFFECT_SIZE="0.8755937135146207" MODIFIED="2009-12-15 15:10:51 +0530" MODIFIED_BY="[Empty name]" ORDER="193" O_E="0.504" SE="2.000064003072164" STUDY_ID="STD-Oliver-2004" TOTAL_1="62" TOTAL_2="63" VAR="0.249984" WEIGHT="3.7117162608060528"/>
<DICH_DATA CI_END="0.6430102765520415" CI_START="0.02479051109381581" EFFECT_SIZE="0.12625590439381817" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" LOG_CI_END="-0.1917820861517028" LOG_CI_START="-1.605714519503423" LOG_EFFECT_SIZE="-0.8987483028275629" MODIFIED="2009-12-15 15:10:58 +0530" MODIFIED_BY="[Empty name]" ORDER="194" O_E="-3.0" SE="0.8305509104292252" STUDY_ID="STD-Rao-1977" TOTAL_1="75" TOTAL_2="75" VAR="1.4496644295302012" WEIGHT="21.524349701578412"/>
<DICH_DATA CI_END="7.960041830350832" CI_START="0.0030618989940917663" EFFECT_SIZE="0.15611804531597112" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.900915349979228" LOG_CI_START="-2.514009139905592" LOG_EFFECT_SIZE="-0.8065468949631819" MODIFIED="2009-12-15 15:11:04 +0530" MODIFIED_BY="[Empty name]" ORDER="195" O_E="-0.46153846153846156" SE="2.0059435495071947" STUDY_ID="STD-Rumalla-2001" TOTAL_1="6" TOTAL_2="7" VAR="0.24852071005917162" WEIGHT="3.6899896020293044"/>
<DICH_DATA CI_END="372.3848896839504" CI_START="0.1466175227450357" EFFECT_SIZE="7.38905609893065" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.570992050236215" LOG_CI_START="-0.8338141226232083" LOG_EFFECT_SIZE="0.8685889638065036" MODIFIED="2010-01-25 13:37:00 +0530" MODIFIED_BY="[Empty name]" ORDER="259" O_E="0.5" SE="2.0" STUDY_ID="STD-Starobin-2007" TOTAL_1="30" TOTAL_2="30" VAR="0.25" WEIGHT="3.711953825850907"/>
<DICH_DATA CI_END="16.372456241572294" CI_START="0.06107819042208459" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2141138383697911" LOG_CI_START="-1.2141138383697911" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-15 15:11:15 +0530" MODIFIED_BY="[Empty name]" ORDER="196" O_E="0.0" SE="1.4263529572376852" STUDY_ID="STD-Whitlock-2006" TOTAL_1="30" TOTAL_2="30" VAR="0.4915254237288136" WEIGHT="7.298078708452631"/>
<DICH_DATA CI_END="5.245930629284399" CI_START="0.20564808445645463" EFFECT_SIZE="1.0386604763366036" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.7198225433038605" LOG_CI_START="-0.686875331444697" LOG_EFFECT_SIZE="0.016473605929581754" MODIFIED="2009-12-15 15:11:24 +0530" MODIFIED_BY="[Empty name]" ORDER="197" O_E="0.05555555555555536" SE="0.8263012948940848" STUDY_ID="STD-Yared-1998" TOTAL_1="106" TOTAL_2="110" VAR="1.4646138386448464" WEIGHT="21.746315767007683"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="31.074392754349876" CI_END="1.2303162506661889" CI_START="0.6677421087031563" CI_STUDY="95" CI_TOTAL="95" DF="16" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.9063851099789769" ESTIMABLE="YES" EVENTS_1="154" EVENTS_2="141" I2="48.5106591575783" I2_Q="0.0" ID="CMP-002.11" LOG_CI_END="0.0900167604356953" LOG_CI_START="-0.17539123571681045" LOG_EFFECT_SIZE="-0.04268723764055755" METHOD="PETO" MODIFIED="2010-02-16 17:58:41 +0530" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.013164928900930684" P_Q="1.0" P_Z="0.5283893034618803" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="17" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="632" TOTAL_2="605" WEIGHT="99.99999999999999" Z="0.630466674613077">
<NAME>Vaso-active medication Y/N</NAME>
<GROUP_LABEL_1>Corticosteroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1293532759214837" CI_START="0.11450924783326763" EFFECT_SIZE="0.3596128392644037" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="14" LOG_CI_END="0.05282981595865157" LOG_CI_START="-0.9411594380334849" LOG_EFFECT_SIZE="-0.4441648110374167" MODIFIED="2009-12-15 15:14:10 +0530" MODIFIED_BY="[Empty name]" ORDER="199" O_E="-3.0" SE="0.5838742081211422" STUDY_ID="STD-Abd.-El_x002d_Hakeem-2003a" TOTAL_1="23" TOTAL_2="23" VAR="2.9333333333333336" WEIGHT="7.129591180134736"/>
<DICH_DATA CI_END="1.7607673970140758" CI_START="0.056768139320961884" EFFECT_SIZE="0.3161573799636859" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.24570198807097937" LOG_CI_START="-1.245895340333014" LOG_EFFECT_SIZE="-0.5000966761310173" MODIFIED="2009-12-15 15:14:18 +0530" MODIFIED_BY="[Empty name]" ORDER="200" O_E="-1.5" SE="0.8761716542303613" STUDY_ID="STD-Abd.-El_x002d_Hakeem-2003b" TOTAL_1="10" TOTAL_2="10" VAR="1.3026315789473684" WEIGHT="3.166101346441412"/>
<DICH_DATA CI_END="6.499135796373182" CI_START="0.6089347545620545" EFFECT_SIZE="1.9893591081124509" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="5" LOG_CI_END="0.8128556114399744" LOG_CI_START="-0.21542923815802303" LOG_EFFECT_SIZE="0.2987131866409757" MODIFIED="2009-12-15 15:14:26 +0530" MODIFIED_BY="[Empty name]" ORDER="201" O_E="1.885245901639344" SE="0.6040196107459612" STUDY_ID="STD-Cavarocchi-1986" TOTAL_1="31" TOTAL_2="30" VAR="2.740929857565171" WEIGHT="6.661946365181113"/>
<DICH_DATA CI_END="5.0152107443983525" CI_START="0.05015724028530737" EFFECT_SIZE="0.5015467379898342" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7002891872480179" LOG_CI_START="-1.2996663669507513" LOG_EFFECT_SIZE="-0.29968858985136676" MODIFIED="2009-12-15 15:14:36 +0530" MODIFIED_BY="[Empty name]" ORDER="202" O_E="-0.5" SE="1.1747837924760145" STUDY_ID="STD-Celik-2004" TOTAL_1="30" TOTAL_2="30" VAR="0.7245762711864407" WEIGHT="1.7611133837678734"/>
<DICH_DATA CI_END="10.473159043353315" CI_START="1.2770987333408892" EFFECT_SIZE="3.6572200027266883" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="15" LOG_CI_END="1.02007769869533" LOG_CI_START="0.10622447415266367" LOG_EFFECT_SIZE="0.5631510864239968" MODIFIED="2009-12-15 15:14:46 +0530" MODIFIED_BY="[Empty name]" ORDER="203" O_E="4.5" SE="0.53680190774278" STUDY_ID="STD-Chaney-1998" TOTAL_1="30" TOTAL_2="30" VAR="3.4703389830508478" WEIGHT="8.434806206467183"/>
<DICH_DATA CI_END="3.223103983080823" CI_START="0.45400332508817487" EFFECT_SIZE="1.209669345492244" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="20" LOG_CI_END="0.5082743168526217" LOG_CI_START="-0.342940966389244" LOG_EFFECT_SIZE="0.08266667523168882" MODIFIED="2009-12-15 15:14:57 +0530" MODIFIED_BY="[Empty name]" ORDER="204" O_E="0.7613636363636331" SE="0.5000080709598798" STUDY_ID="STD-Chaney-2001" TOTAL_1="59" TOTAL_2="29" VAR="3.999870867768595" WEIGHT="9.721855929723015"/>
<DICH_DATA CI_END="2.463751295056511" CI_START="0.40588512404092436" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="11" LOG_CI_END="0.39159686557192325" LOG_CI_START="-0.39159686557192325" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-15 15:15:04 +0530" MODIFIED_BY="[Empty name]" ORDER="205" O_E="0.0" SE="0.46005187454539" STUDY_ID="STD-Codd-1977" TOTAL_1="75" TOTAL_2="75" VAR="4.724832214765101" WEIGHT="11.483905256592863"/>
<DICH_DATA CI_END="3.800606921969656" CI_START="0.06585196863630163" EFFECT_SIZE="0.5002773708898461" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5798529549892754" LOG_CI_START="-1.1814312373293354" LOG_EFFECT_SIZE="-0.30078914117002997" MODIFIED="2009-12-15 15:15:10 +0530" MODIFIED_BY="[Empty name]" ORDER="206" O_E="-0.6470588235294117" SE="1.0345870530653138" STUDY_ID="STD-El-Azab-2002" TOTAL_1="9" TOTAL_2="8" VAR="0.9342560553633218" WEIGHT="2.2707489996497072"/>
<DICH_DATA CI_END="17.2491289611468" CI_START="0.05797394188729606" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.236767169153142" LOG_CI_START="-1.236767169153142" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-15 15:15:20 +0530" MODIFIED_BY="[Empty name]" ORDER="207" O_E="0.0" SE="1.4529663145135578" STUDY_ID="STD-Giomarelli-2003" TOTAL_1="10" TOTAL_2="10" VAR="0.47368421052631576" WEIGHT="1.1513095805241498"/>
<DICH_DATA CI_END="7.171218939875928" CI_START="0.1394463072992304" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8555929818697962" LOG_CI_START="-0.8555929818697962" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-15 15:15:29 +0530" MODIFIED_BY="[Empty name]" ORDER="208" O_E="0.0" SE="1.0051591056077676" STUDY_ID="STD-Halvorsen-2003" TOTAL_1="147" TOTAL_2="147" VAR="0.9897610921501706" WEIGHT="2.4056563476253565"/>
<DICH_DATA CI_END="37.95710877346029" CI_START="1.2237587103934053" EFFECT_SIZE="6.815448810083748" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="1.5792931244203587" LOG_CI_START="0.08769579601636551" LOG_EFFECT_SIZE="0.8334944602183622" MODIFIED="2009-12-15 15:15:38 +0530" MODIFIED_BY="[Empty name]" ORDER="209" O_E="2.5" SE="0.8761716542303613" STUDY_ID="STD-Loef-2004" TOTAL_1="10" TOTAL_2="10" VAR="1.3026315789473684" WEIGHT="3.166101346441412"/>
<DICH_DATA CI_END="6.709448049862102" CI_START="0.4786191828729581" EFFECT_SIZE="1.7920018256557557" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.8266867945715727" LOG_CI_START="-0.32000989901777877" LOG_EFFECT_SIZE="0.25333844777689696" MODIFIED="2009-12-15 15:15:46 +0530" MODIFIED_BY="[Empty name]" ORDER="210" O_E="1.2857142857142856" SE="0.6735753140545635" STUDY_ID="STD-McBride-2004" TOTAL_1="18" TOTAL_2="17" VAR="2.2040816326530606" WEIGHT="5.357113966520532"/>
<DICH_DATA CI_END="2.0695379936971303" CI_START="0.11861776059826751" EFFECT_SIZE="0.4954633813768532" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.315873403822813" LOG_CI_START="-0.9258502793331652" LOG_EFFECT_SIZE="-0.30498843775517614" MODIFIED="2009-12-15 15:15:53 +0530" MODIFIED_BY="[Empty name]" ORDER="211" O_E="-1.3200000000000003" SE="0.7293946381171849" STUDY_ID="STD-Schurr-2001" TOTAL_1="24" TOTAL_2="26" VAR="1.8796408163265306" WEIGHT="4.568546790648711"/>
<DICH_DATA CI_END="1.5730039643424978" CI_START="0.030409897608994877" EFFECT_SIZE="0.2187118869522148" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" LOG_CI_END="0.19672981714960702" LOG_CI_START="-1.5169850421354925" LOG_EFFECT_SIZE="-0.6601276124929427" MODIFIED="2009-12-15 15:16:01 +0530" MODIFIED_BY="[Empty name]" ORDER="212" O_E="-1.5" SE="1.0066445913694333" STUDY_ID="STD-von-Spiegel-2001" TOTAL_1="10" TOTAL_2="10" VAR="0.986842105263158" WEIGHT="2.398561626091979"/>
<DICH_DATA CI_END="0.4524901831112301" CI_START="0.02362446792374399" EFFECT_SIZE="0.10339168156442907" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="8" LOG_CI_END="-0.3443908384850096" LOG_CI_START="-1.6266379639989794" LOG_EFFECT_SIZE="-0.9855144012419945" MODIFIED="2009-12-15 15:16:12 +0530" MODIFIED_BY="[Empty name]" ORDER="213" O_E="-4.0" SE="0.7531983087525438" STUDY_ID="STD-Whitlock-2006" TOTAL_1="30" TOTAL_2="30" VAR="1.7627118644067796" WEIGHT="4.284346009634124"/>
<DICH_DATA CI_END="1.5195481579846906" CI_START="0.4410539887014957" EFFECT_SIZE="0.818659133035941" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="29" LOG_CI_END="0.18171446842753713" LOG_CI_START="-0.3555082459969418" LOG_EFFECT_SIZE="-0.08689688878470228" MODIFIED="2009-12-15 15:16:21 +0530" MODIFIED_BY="[Empty name]" ORDER="214" O_E="-2.0092592592592595" SE="0.31556728174826393" STUDY_ID="STD-Yared-1998" TOTAL_1="106" TOTAL_2="110" VAR="10.041903930200657" WEIGHT="24.407273758813275"/>
<DICH_DATA CI_END="5.193980256192153" CI_START="0.043382619501907915" EFFECT_SIZE="0.4746877596429113" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7155002944186021" LOG_CI_START="-1.3626842282352127" LOG_EFFECT_SIZE="-0.3235919669083053" MODIFIED="2009-12-15 15:16:27 +0530" MODIFIED_BY="[Empty name]" ORDER="215" O_E="-0.5" SE="1.2207358757861475" STUDY_ID="STD-Yilmaz-1999" TOTAL_1="10" TOTAL_2="10" VAR="0.6710526315789473" WEIGHT="1.6310219057425455"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.6088992641573483" CI_END="1.394166372707696" CI_START="0.5443982169584355" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.8711955506345744" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="47" I2="0.0" I2_Q="0.0" ID="CMP-002.12" LOG_CI_END="0.14431460334410218" LOG_CI_START="-0.26408330589041595" LOG_EFFECT_SIZE="-0.05988435127315691" METHOD="PETO" MODIFIED="2010-08-31 01:13:07 +0530" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.8071917899049237" P_Q="1.0" P_Z="0.565434477525666" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="255" TOTAL_2="256" WEIGHT="100.0" Z="0.5747883085539194">
<NAME>Bloodtransfusion Y/N</NAME>
<GROUP_LABEL_1>Corticosteroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="9.10425265963503" CI_START="0.2531996947123757" EFFECT_SIZE="1.518286532247429" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.959244301683102" LOG_CI_START="-0.5965368222913751" LOG_EFFECT_SIZE="0.1813537396958634" MODIFIED="2009-12-15 15:17:33 +0530" MODIFIED_BY="[Empty name]" ORDER="216" O_E="0.5" SE="0.9138735334633755" STUDY_ID="STD-Giomarelli-2003" TOTAL_1="10" TOTAL_2="10" VAR="1.1973684210526314" WEIGHT="6.890806016393712"/>
<DICH_DATA CI_END="2.2591429217522165" CI_START="0.5110771423836521" EFFECT_SIZE="1.0745214323992691" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="15" LOG_CI_END="0.35394370686763926" LOG_CI_START="-0.2915135421686804" LOG_EFFECT_SIZE="0.031215082349479353" MODIFIED="2009-12-15 15:17:39 +0530" MODIFIED_BY="[Empty name]" ORDER="217" O_E="0.5" SE="0.37914478314884625" STUDY_ID="STD-Halvorsen-2003" TOTAL_1="147" TOTAL_2="147" VAR="6.956484641638226" WEIGHT="40.03428299821854"/>
<DICH_DATA CI_END="1.3529839027440564" CI_START="0.24208164480465652" EFFECT_SIZE="0.5723046116977432" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="16" LOG_CI_END="0.131292629568046" LOG_CI_START="-0.6160381385312347" LOG_EFFECT_SIZE="-0.24237275448159437" MODIFIED="2009-12-15 15:17:51 +0530" MODIFIED_BY="[Empty name]" ORDER="219" O_E="-2.896000000000001" SE="0.4389857925284819" STUDY_ID="STD-Oliver-2004" TOTAL_1="62" TOTAL_2="63" VAR="5.189184" WEIGHT="29.86354049319147"/>
<DICH_DATA CI_END="8.463994585423583" CI_START="0.11814752359626596" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.9275753768648568" LOG_CI_START="-0.9275753768648567" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-15 15:17:56 +0530" MODIFIED_BY="[Empty name]" ORDER="220" O_E="0.0" SE="1.0897247358851685" STUDY_ID="STD-Sano-2003" TOTAL_1="10" TOTAL_2="10" VAR="0.8421052631578947" WEIGHT="4.846281154386787"/>
<DICH_DATA CI_END="2.5612228759702846" CI_START="0.2854041920653567" EFFECT_SIZE="0.8549758742886306" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" LOG_CI_END="0.4084473721398291" LOG_CI_START="-0.5445396521832444" LOG_EFFECT_SIZE="-0.06804614002170768" MODIFIED="2009-12-15 15:18:03 +0530" MODIFIED_BY="[Empty name]" ORDER="221" O_E="-0.5" SE="0.5597892954492245" STUDY_ID="STD-Tassani-1999" TOTAL_1="26" TOTAL_2="26" VAR="3.191176470588235" WEIGHT="18.365089337809486"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="1.4829919801869305" CI_END="0.05722665409505273" CI_START="-0.4381783371399422" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.19047584152244473" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.13" MODIFIED="2010-02-16 17:58:53 +0530" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.6862013254569466" P_Q="1.0" P_Z="0.13177120638017492" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="61" TOTAL_2="61" UNITS="" WEIGHT="100.00000000000001" Z="1.5071539282569075">
<NAME>Number of bloodtransfusions</NAME>
<GROUP_LABEL_1>Corticosteroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.64898896664265" CI_START="-1.5889889666426504" EFFECT_SIZE="-0.4700000000000002" ESTIMABLE="YES" MEAN_1="2.86" MEAN_2="3.33" MODIFIED="2010-01-25 13:39:53 +0530" MODIFIED_BY="[Empty name]" ORDER="260" SD_1="1.18" SD_2="1.87" SE="0.5709232289312928" STUDY_ID="STD-Demir-2009" TOTAL_1="15" TOTAL_2="15" WEIGHT="4.900147529401871"/>
<CONT_DATA CI_END="1.2417092557709004" CI_START="-3.6417092557709" EFFECT_SIZE="-1.2" ESTIMABLE="YES" MEAN_1="1.3" MEAN_2="2.5" MODIFIED="2009-12-15 15:19:15 +0530" MODIFIED_BY="[Empty name]" ORDER="222" SD_1="1.6" SD_2="3.6" SE="1.245792920191795" STUDY_ID="STD-Loef-2004" TOTAL_1="10" TOTAL_2="10" WEIGHT="1.0291362248928082"/>
<CONT_DATA CI_END="0.07179810170468759" CI_START="-0.4717981017046875" EFFECT_SIZE="-0.19999999999999996" ESTIMABLE="YES" MEAN_1="1.1" MEAN_2="1.3" MODIFIED="2009-12-15 15:19:26 +0530" MODIFIED_BY="[Empty name]" ORDER="223" SD_1="0.5" SD_2="0.5" SE="0.1386750490563073" STUDY_ID="STD-Tassani-1999" TOTAL_1="26" TOTAL_2="26" WEIGHT="83.0554098937492"/>
<CONT_DATA CI_END="0.8463320500961007" CI_START="-0.6463320500961005" EFFECT_SIZE="0.10000000000000009" ESTIMABLE="YES" MEAN_1="2.1" MEAN_2="2.0" MODIFIED="2009-12-15 15:19:35 +0530" MODIFIED_BY="[Empty name]" ORDER="224" SD_1="0.8" SD_2="0.9" SE="0.38078865529319544" STUDY_ID="STD-Turkoz-2001" TOTAL_1="10" TOTAL_2="10" WEIGHT="11.015306351956125"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2010-09-24 15:46:10 +0530" MODIFIED_BY="Joey Kwong" NO="3">
<NAME>Dose-dependant analyses</NAME>
<DICH_OUTCOME CHI2="14.240422691704365" CI_END="1.9047911889738116" CI_START="0.5393307926202974" CI_STUDY="95" CI_TOTAL="95" DF="13" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.0135642760700498" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="19" I2="8.710574949625357" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.2798473734778273" LOG_CI_START="-0.26814478334004177" LOG_EFFECT_SIZE="0.005851295068892721" METHOD="PETO" MODIFIED="2010-08-31 01:14:30 +0530" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3571328936233614" P_Q="1.0" P_Z="0.9666136445958278" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="WEIGHT" STUDIES="14" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="726" TOTAL_2="660" WEIGHT="100.0" Z="0.04185580926757035">
<NAME>Mortality, high dose</NAME>
<GROUP_LABEL_1>Corticosteroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.1118778382741574" CI_START="7.434627696717769E-4" EFFECT_SIZE="0.04809953551255486" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.49302253972999627" LOG_CI_START="-3.128740774729041" LOG_EFFECT_SIZE="-1.3178591174995224" MODIFIED="2010-02-16 14:49:41 +0530" MODIFIED_BY="[Empty name]" ORDER="357" O_E="-0.6704545454545454" SE="2.1274416989307845" STUDY_ID="STD-Chaney-2001" TOTAL_1="59" TOTAL_2="29" VAR="0.22094524793388431" WEIGHT="2.2893308178828207"/>
<DICH_DATA CI_END="344.58845534710696" CI_START="0.13472589337416754" EFFECT_SIZE="6.813588444649666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.5373007233063403" LOG_CI_START="-0.8705489278938605" LOG_EFFECT_SIZE="0.8333758977062401" MODIFIED="2010-02-10 14:28:26 +0530" MODIFIED_BY="[Empty name]" ORDER="311" O_E="0.47887323943661975" SE="2.0017877542428333" STUDY_ID="STD-Yared-2007" TOTAL_1="37" TOTAL_2="34" VAR="0.2495536599880976" WEIGHT="2.585757738030926"/>
<DICH_DATA CI_END="354.68043716013733" CI_START="0.1392872116124779" EFFECT_SIZE="7.0286875805892945" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.5498372350811813" LOG_CI_START="-0.856088755658499" LOG_EFFECT_SIZE="0.8468742397113411" MODIFIED="2010-02-10 14:28:26 +0530" MODIFIED_BY="[Empty name]" ORDER="349" O_E="0.4871794871794872" SE="2.0006577865660504" STUDY_ID="STD-Liakopoulos-2007" TOTAL_1="40" TOTAL_2="38" VAR="0.24983563445101906" WEIGHT="2.5886794248916236"/>
<DICH_DATA CI_END="372.3848896839504" CI_START="0.1466175227450357" EFFECT_SIZE="7.38905609893065" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.570992050236215" LOG_CI_START="-0.8338141226232083" LOG_EFFECT_SIZE="0.8685889638065036" MODIFIED="2010-02-10 14:28:26 +0530" MODIFIED_BY="[Empty name]" ORDER="336" O_E="0.5" SE="2.0" STUDY_ID="STD-Codd-1977" TOTAL_1="75" TOTAL_2="75" VAR="0.25" WEIGHT="2.5903825034606314"/>
<DICH_DATA CI_END="372.3848896839504" CI_START="0.1466175227450357" EFFECT_SIZE="7.38905609893065" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.570992050236215" LOG_CI_START="-0.8338141226232083" LOG_EFFECT_SIZE="0.8685889638065036" MODIFIED="2010-02-10 14:28:26 +0530" MODIFIED_BY="[Empty name]" ORDER="324" O_E="0.5" SE="2.0" STUDY_ID="STD-Whitlock-2006" TOTAL_1="30" TOTAL_2="30" VAR="0.25" WEIGHT="2.5903825034606314"/>
<DICH_DATA CI_END="6.820467167072353" CI_START="0.0026853936013588454" EFFECT_SIZE="0.1353352832366127" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8338141226232082" LOG_CI_START="-2.570992050236215" LOG_EFFECT_SIZE="-0.8685889638065036" MODIFIED="2010-02-10 14:28:26 +0530" MODIFIED_BY="[Empty name]" ORDER="320" O_E="-0.5" SE="2.0" STUDY_ID="STD-Rubens-2005" TOTAL_1="34" TOTAL_2="34" VAR="0.25" WEIGHT="2.5903825034606314"/>
<DICH_DATA CI_END="372.3848896839504" CI_START="0.1466175227450357" EFFECT_SIZE="7.38905609893065" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.570992050236215" LOG_CI_START="-0.8338141226232083" LOG_EFFECT_SIZE="0.8685889638065036" MODIFIED="2010-02-10 14:28:26 +0530" MODIFIED_BY="[Empty name]" ORDER="325" O_E="0.5" SE="2.0" STUDY_ID="STD-Andersen-1989" TOTAL_1="8" TOTAL_2="8" VAR="0.25" WEIGHT="2.5903825034606314"/>
<DICH_DATA CI_END="2.1284848474346996" CI_START="0.007745265347095721" EFFECT_SIZE="0.12839657289294878" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.32807056280588703" LOG_CI_START="-2.1109636990402896" LOG_EFFECT_SIZE="-0.8914465681172012" MODIFIED="2010-02-15 18:03:39 +0530" MODIFIED_BY="[Empty name]" ORDER="397" O_E="-1.0" SE="1.4327007988227578" STUDY_ID="STD-Bingol-2005" TOTAL_1="20" TOTAL_2="20" VAR="0.48717948717948717" WEIGHT="5.047924878538666"/>
<DICH_DATA CI_END="86.84008009968478" CI_START="0.8138300233867384" EFFECT_SIZE="8.406727331038681" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.93872021536777" LOG_CI_START="-0.0894662924248916" LOG_EFFECT_SIZE="0.9246269614714394" MODIFIED="2010-02-10 14:28:26 +0530" MODIFIED_BY="[Empty name]" ORDER="330" O_E="1.5" SE="1.191366794362541" STUDY_ID="STD-Boscoe-1983" TOTAL_1="17" TOTAL_2="17" VAR="0.7045454545454546" WEIGHT="7.300168873389053"/>
<DICH_DATA CI_END="5.0152107443983525" CI_START="0.05015724028530737" EFFECT_SIZE="0.5015467379898342" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7002891872480179" LOG_CI_START="-1.2996663669507513" LOG_EFFECT_SIZE="-0.29968858985136676" MODIFIED="2010-02-10 14:28:26 +0530" MODIFIED_BY="[Empty name]" ORDER="347" O_E="-0.5" SE="1.1747837924760145" STUDY_ID="STD-Chaney-1998" TOTAL_1="30" TOTAL_2="30" VAR="0.7245762711864407" WEIGHT="7.507718781216407"/>
<DICH_DATA CI_END="5.0152107443983525" CI_START="0.05015724028530737" EFFECT_SIZE="0.5015467379898342" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7002891872480179" LOG_CI_START="-1.2996663669507513" LOG_EFFECT_SIZE="-0.29968858985136676" MODIFIED="2010-02-10 14:28:26 +0530" MODIFIED_BY="[Empty name]" ORDER="342" O_E="-0.5" SE="1.1747837924760145" STUDY_ID="STD-Celik-2004" TOTAL_1="30" TOTAL_2="30" VAR="0.7245762711864407" WEIGHT="7.507718781216407"/>
<DICH_DATA CI_END="3.919742777251082" CI_START="0.11213015332564497" EFFECT_SIZE="0.6629640703765576" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5932575685291956" LOG_CI_START="-0.9502775839972483" LOG_EFFECT_SIZE="-0.1785100077340263" MODIFIED="2010-02-10 14:28:26 +0530" MODIFIED_BY="[Empty name]" ORDER="315" O_E="-0.5" SE="0.9066801892162646" STUDY_ID="STD-Rao-1977" TOTAL_1="75" TOTAL_2="75" VAR="1.2164429530201342" WEIGHT="12.604210167845354"/>
<DICH_DATA CI_END="4.054861208202655" CI_START="0.11767157865154038" EFFECT_SIZE="0.6907546015641871" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6079759935549934" LOG_CI_START="-0.9293284201244663" LOG_EFFECT_SIZE="-0.16067621328473639" MODIFIED="2010-02-10 14:28:26 +0530" MODIFIED_BY="[Empty name]" ORDER="354" O_E="-0.4537037037037037" SE="0.9030202223748913" STUDY_ID="STD-Yared-1998" TOTAL_1="106" TOTAL_2="110" VAR="1.2263234918812007" WEIGHT="12.706587667807232"/>
<DICH_DATA CI_END="3.5352194459463324" CI_START="0.34632784672636474" EFFECT_SIZE="1.106501214829774" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.5484163774555608" LOG_CI_START="-0.46051258730301975" LOG_EFFECT_SIZE="0.04395189507627056" MODIFIED="2010-02-10 14:28:26 +0530" MODIFIED_BY="[Empty name]" ORDER="323" O_E="0.2881355932203391" SE="0.5926498681781125" STUDY_ID="STD-Coetzer-1996" TOTAL_1="165" TOTAL_2="130" VAR="2.8471058633163118" WEIGHT="29.500372855339"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.75049068658124" CI_END="4.143249221534687" CI_START="0.5183455029323497" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.4654810136983911" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.6173410574310407" LOG_CI_START="-0.2853806649690433" LOG_EFFECT_SIZE="0.1659801962309987" METHOD="PETO" MODIFIED="2010-08-31 01:14:52 +0530" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6871208274774749" P_Q="1.0" P_Z="0.47106762146238157" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="310" TOTAL_2="316" WEIGHT="100.00000000000001" Z="0.7207430566636334">
<NAME>Mortality, low dose</NAME>
<GROUP_LABEL_1>Corticosteroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="375.5137349148289" CI_START="0.14783945144821836" EFFECT_SIZE="7.45088884503587" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.574625826529613" LOG_CI_START="-0.8302096575515509" LOG_EFFECT_SIZE="0.872208084489031" MODIFIED="2010-02-10 14:22:20 +0530" MODIFIED_BY="[Empty name]" ORDER="283" O_E="0.5020746887966805" SE="2.000017217556743" STUDY_ID="STD-Halonen-2007" TOTAL_1="120" TOTAL_2="121" VAR="0.2499956956663969" WEIGHT="7.029355722596702"/>
<DICH_DATA CI_END="16.063503542368387" CI_START="0.06225291994130946" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2058402733943532" LOG_CI_START="-1.2058402733943532" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-02-10 14:22:20 +0530" MODIFIED_BY="[Empty name]" ORDER="276" O_E="0.0" SE="1.4166330911949265" STUDY_ID="STD-Halvorsen-2003" TOTAL_1="147" TOTAL_2="147" VAR="0.4982935153583618" WEIGHT="14.010970726436954"/>
<DICH_DATA CI_END="4.370298696109262" CI_START="0.4213184819904856" EFFECT_SIZE="1.356940533881184" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.640511120640644" LOG_CI_START="-0.37538948924621707" LOG_EFFECT_SIZE="0.1325608156972134" MODIFIED="2010-05-23 08:37:26 +0530" MODIFIED_BY="[Empty name]" ORDER="295" O_E="0.8571428571428568" SE="0.5967450470366643" STUDY_ID="STD-Kilger-2003a" TOTAL_1="43" TOTAL_2="48" VAR="2.8081632653061224" WEIGHT="78.95967355096636"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="14.415957507604919" CI_END="1.5185915090333744" CI_START="0.5064758908620773" CI_STUDY="95" CI_TOTAL="95" DF="13" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.8770005629378266" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="29" I2="9.822153726923458" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="0.18144096725909742" LOG_CI_START="-0.29544122298833164" LOG_EFFECT_SIZE="-0.0570001278646171" METHOD="PETO" MODIFIED="2010-08-31 01:15:33 +0530" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.3452159166900832" P_Q="1.0" P_Z="0.6394014520052098" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="14" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="636" TOTAL_2="607" WEIGHT="100.00000000000004" Z="0.46853583553146666">
<NAME>Cardiac complications, high dose</NAME>
<GROUP_LABEL_1>Corticosteroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.318115396009987" CI_START="0.1366472029868816" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8643992533953607" LOG_CI_START="-0.8643992533953607" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-02-10 14:30:16 +0530" MODIFIED_BY="[Empty name]" ORDER="375" O_E="0.0" SE="1.015504800579495" STUDY_ID="STD-Amr-2009" TOTAL_1="50" TOTAL_2="50" VAR="0.9696969696969697" WEIGHT="7.609102763292679"/>
<DICH_DATA CI_END="372.3848896839504" CI_START="0.1466175227450357" EFFECT_SIZE="7.38905609893065" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.570992050236215" LOG_CI_START="-0.8338141226232083" LOG_EFFECT_SIZE="0.8685889638065036" MODIFIED="2010-02-10 14:30:16 +0530" MODIFIED_BY="[Empty name]" ORDER="371" O_E="0.5" SE="2.0" STUDY_ID="STD-Andersen-1989" TOTAL_1="8" TOTAL_2="8" VAR="0.25" WEIGHT="1.9617218061613937"/>
<DICH_DATA CI_END="5.0152107443983525" CI_START="0.05015724028530737" EFFECT_SIZE="0.5015467379898342" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7002891872480179" LOG_CI_START="-1.2996663669507513" LOG_EFFECT_SIZE="-0.29968858985136676" MODIFIED="2010-02-10 14:30:16 +0530" MODIFIED_BY="[Empty name]" ORDER="365" O_E="-0.5" SE="1.1747837924760145" STUDY_ID="STD-Celik-2004" TOTAL_1="30" TOTAL_2="30" VAR="0.7245762711864407" WEIGHT="5.685668285654209"/>
<DICH_DATA CI_END="16.372456241572294" CI_START="0.06107819042208459" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2141138383697911" LOG_CI_START="-1.2141138383697911" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-02-10 14:30:16 +0530" MODIFIED_BY="[Empty name]" ORDER="362" O_E="0.0" SE="1.4263529572376852" STUDY_ID="STD-Chaney-1998" TOTAL_1="30" TOTAL_2="30" VAR="0.4915254237288136" WEIGHT="3.85694456804613"/>
<DICH_DATA CI_END="3.1118778382741574" CI_START="7.434627696717769E-4" EFFECT_SIZE="0.04809953551255486" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.49302253972999627" LOG_CI_START="-3.128740774729041" LOG_EFFECT_SIZE="-1.3178591174995224" MODIFIED="2010-02-10 14:30:16 +0530" MODIFIED_BY="[Empty name]" ORDER="360" O_E="-0.6704545454545454" SE="2.1274416989307845" STUDY_ID="STD-Chaney-2001" TOTAL_1="59" TOTAL_2="29" VAR="0.22094524793388431" WEIGHT="1.733732443358546"/>
<DICH_DATA CI_END="4.1312397574044315" CI_START="0.35744267040492583" EFFECT_SIZE="1.215187792470628" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.6160804000833917" LOG_CI_START="-0.4467936039981477" LOG_EFFECT_SIZE="0.08464339804262201" MODIFIED="2010-02-10 14:30:16 +0530" MODIFIED_BY="[Empty name]" ORDER="358" O_E="0.5" SE="0.6243374513086698" STUDY_ID="STD-Codd-1977" TOTAL_1="75" TOTAL_2="75" VAR="2.5654362416107386" WEIGHT="20.130688869938062"/>
<DICH_DATA CI_END="352.82541670943306" CI_START="0.13847236894280432" EFFECT_SIZE="6.9897475830667375" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.547559863135115" LOG_CI_START="-0.8586368779558022" LOG_EFFECT_SIZE="0.8444614925896565" MODIFIED="2010-02-10 14:30:16 +0530" MODIFIED_BY="[Empty name]" ORDER="359" O_E="0.48571428571428577" SE="2.000816826662603" STUDY_ID="STD-McBride-2004" TOTAL_1="18" TOTAL_2="17" VAR="0.2497959183673469" WEIGHT="1.9601204006053434"/>
<DICH_DATA CI_END="4.031072067237561" CI_START="0.24807296503763238" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.6054205625102385" LOG_CI_START="-0.6054205625102385" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-02-10 14:30:16 +0530" MODIFIED_BY="[Empty name]" ORDER="374" O_E="0.0" SE="0.7112540705972631" STUDY_ID="STD-Morton-1976" TOTAL_1="22" TOTAL_2="22" VAR="1.9767441860465116" WEIGHT="15.511288699880787"/>
<DICH_DATA CI_END="20.899977489268046" CI_START="0.7965128024414793" EFFECT_SIZE="4.080085739410475" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.3201458183458896" LOG_CI_START="-0.09880723934181317" LOG_EFFECT_SIZE="0.6106692895020381" MODIFIED="2010-02-10 14:30:16 +0530" MODIFIED_BY="[Empty name]" ORDER="369" O_E="2.024" SE="0.8335000500166726" STUDY_ID="STD-Oliver-2004" TOTAL_1="62" TOTAL_2="63" VAR="1.4394239999999998" WEIGHT="11.29499779644823"/>
<DICH_DATA CI_END="1.8575336701137521" CI_START="0.0902236753460005" EFFECT_SIZE="0.40938186915960006" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.26893669463292463" LOG_CI_START="-1.0446794854850865" LOG_EFFECT_SIZE="-0.387871395426081" MODIFIED="2010-02-10 14:30:16 +0530" MODIFIED_BY="[Empty name]" ORDER="366" O_E="-1.5" SE="0.7716246467062825" STUDY_ID="STD-Rao-1977" TOTAL_1="75" TOTAL_2="75" VAR="1.679530201342282" WEIGHT="13.179084080319162"/>
<DICH_DATA CI_END="1.266411412313257" CI_START="0.01278779390443912" EFFECT_SIZE="0.12725803761999321" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.10257481553271174" LOG_CI_START="-1.8932043716876579" LOG_EFFECT_SIZE="-0.8953147780774731" MODIFIED="2010-02-10 14:30:16 +0530" MODIFIED_BY="[Empty name]" ORDER="376" O_E="-1.5" SE="1.1723305738395526" STUDY_ID="STD-Rubens-2005" TOTAL_1="34" TOTAL_2="34" VAR="0.7276119402985074" WEIGHT="5.709488838827936"/>
<DICH_DATA CI_END="2.6070171273961056" CI_START="0.04663753631150655" EFFECT_SIZE="0.3486902005271375" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.41614388437476696" LOG_CI_START="-1.3312643998137619" LOG_EFFECT_SIZE="-0.45756025771949743" MODIFIED="2010-02-10 14:30:16 +0530" MODIFIED_BY="[Empty name]" ORDER="367" O_E="-1.0" SE="1.026436275942851" STUDY_ID="STD-Whitlock-2006" TOTAL_1="30" TOTAL_2="30" VAR="0.9491525423728814" WEIGHT="7.447892958985631"/>
<DICH_DATA CI_END="7.077805624721046" CI_START="0.0027829698032571454" EFFECT_SIZE="0.14034713864885967" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8498986315891194" LOG_CI_START="-2.555491505972799" LOG_EFFECT_SIZE="-0.85279643719184" MODIFIED="2010-02-10 14:30:16 +0530" MODIFIED_BY="[Empty name]" ORDER="372" O_E="-0.49074074074074076" SE="2.0003430237569173" STUDY_ID="STD-Yared-1998" TOTAL_1="106" TOTAL_2="110" VAR="0.24991426611796982" WEIGHT="1.9610490620577719"/>
<DICH_DATA CI_END="344.58845534710696" CI_START="0.13472589337416754" EFFECT_SIZE="6.813588444649666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.5373007233063403" LOG_CI_START="-0.8705489278938605" LOG_EFFECT_SIZE="0.8333758977062401" MODIFIED="2010-02-10 14:30:16 +0530" MODIFIED_BY="[Empty name]" ORDER="364" O_E="0.47887323943661975" SE="2.0017877542428333" STUDY_ID="STD-Yared-2007" TOTAL_1="37" TOTAL_2="34" VAR="0.2495536599880976" WEIGHT="1.9582194264241486"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.33259701955559123" CI_END="9.79531336225765" CI_START="0.39378871276744865" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.9639969042942071" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="0.9910183340849621" LOG_CI_START="-0.4047367362757714" LOG_EFFECT_SIZE="0.2931407989045953" METHOD="PETO" MODIFIED="2010-02-10 14:31:31 +0530" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.5641340121789303" P_Q="1.0" P_Z="0.41035140633533884" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="267" TOTAL_2="268" WEIGHT="100.0" Z="0.823275401899581">
<NAME>Cardiac complications, low dose</NAME>
<GROUP_LABEL_1>corticosteroids</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="16.21534295021216" CI_START="0.06270647000909482" EFFECT_SIZE="1.0083684427800512" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2099261383194857" LOG_CI_START="-1.2026876466608056" LOG_EFFECT_SIZE="0.003619245829339949" MODIFIED="2010-02-10 14:31:31 +0530" MODIFIED_BY="[Empty name]" ORDER="384" O_E="0.004149377593360981" SE="1.417181279928267" STUDY_ID="STD-Halonen-2007" TOTAL_1="120" TOTAL_2="121" VAR="0.49790809386890716" WEIGHT="33.4690063186213"/>
<DICH_DATA CI_END="19.696096586817536" CI_START="0.3829959676685315" EFFECT_SIZE="2.746547937240682" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.2943801653099782" LOG_CI_START="-0.41680579842961407" LOG_EFFECT_SIZE="0.4387871834401821" MODIFIED="2010-02-10 14:31:31 +0530" MODIFIED_BY="[Empty name]" ORDER="385" O_E="1.0" SE="1.0051591056077676" STUDY_ID="STD-Halvorsen-2003" TOTAL_1="147" TOTAL_2="147" VAR="0.9897610921501706" WEIGHT="66.5309936813787"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.805186982657267" CI_END="1.3106183816564352" CI_START="0.38239956093718824" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.7079406004048849" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="25" I2="9.144462056775925" I2_Q="0.0" ID="CMP-003.05" LOG_CI_END="0.1174762547203609" LOG_CI_START="-0.4174826150430762" LOG_EFFECT_SIZE="-0.15000318016135766" METHOD="PETO" MODIFIED="2010-08-31 01:16:13 +0530" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.3589961182258168" P_Q="1.0" P_Z="0.27170134064886253" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="344" TOTAL_2="342" WEIGHT="100.0" Z="1.0991530276439516">
<NAME>Pulmonary complications, high dose</NAME>
<GROUP_LABEL_1>Corticosteroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6709074173963647" CI_START="0.04126863309261544" EFFECT_SIZE="0.26259486883840705" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.2229523869204436" LOG_CI_START="-1.3843799156674257" LOG_EFFECT_SIZE="-0.5807137643734911" MODIFIED="2010-02-15 18:04:11 +0530" MODIFIED_BY="[Empty name]" ORDER="398" O_E="-1.5" SE="0.9441549509633318" STUDY_ID="STD-Bingol-2005" TOTAL_1="20" TOTAL_2="20" VAR="1.1217948717948718" WEIGHT="11.077185783327096"/>
<DICH_DATA CI_END="18.654982765042313" CI_START="0.18981749327591743" EFFECT_SIZE="1.8817656776458047" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2707948521412287" LOG_CI_START="-0.7216637661810329" LOG_EFFECT_SIZE="0.2745655429800979" MODIFIED="2010-02-10 14:32:22 +0530" MODIFIED_BY="[Empty name]" ORDER="405" O_E="0.46153846153846145" SE="1.1703800552317227" STUDY_ID="STD-Liakopoulos-2007" TOTAL_1="40" TOTAL_2="38" VAR="0.7300391915776532" WEIGHT="7.208786523757894"/>
<DICH_DATA CI_END="5.176638739165199" CI_START="0.19317554312497054" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.714047858035458" LOG_CI_START="-0.714047858035458" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-02-10 14:32:22 +0530" MODIFIED_BY="[Empty name]" ORDER="400" O_E="0.0" SE="0.8388704928078611" STUDY_ID="STD-Morton-1976" TOTAL_1="48" TOTAL_2="48" VAR="1.4210526315789473" WEIGHT="14.032212487029692"/>
<DICH_DATA CI_END="6.318201278591119" CI_START="0.5368983492039066" EFFECT_SIZE="1.8418012478043293" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.8005934570849673" LOG_CI_START="-0.2701079313556974" LOG_EFFECT_SIZE="0.265242762864635" MODIFIED="2010-02-10 14:32:22 +0530" MODIFIED_BY="[Empty name]" ORDER="396" O_E="1.5439999999999996" SE="0.6289352956273975" STUDY_ID="STD-Oliver-2004" TOTAL_1="62" TOTAL_2="63" VAR="2.528064" WEIGHT="24.96341827212572"/>
<DICH_DATA CI_END="0.8570224625246995" CI_START="0.050106919138860534" EFFECT_SIZE="0.20722633816653774" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="-0.067007795086508" LOG_CI_START="-1.3001022993554185" LOG_EFFECT_SIZE="-0.6835550472209633" MODIFIED="2010-02-10 14:32:22 +0530" MODIFIED_BY="[Empty name]" ORDER="391" O_E="-3.0" SE="0.7243258157237968" STUDY_ID="STD-Rao-1977" TOTAL_1="75" TOTAL_2="75" VAR="1.9060402684563758" WEIGHT="18.821232557795728"/>
<DICH_DATA CI_END="5.4742862620723205" CI_START="0.05364941725776223" EFFECT_SIZE="0.5419338224011797" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7383275038501002" LOG_CI_START="-1.2704349909974284" LOG_EFFECT_SIZE="-0.2660537435736642" MODIFIED="2010-02-10 14:32:22 +0530" MODIFIED_BY="[Empty name]" ORDER="402" O_E="-0.43999999999999995" SE="1.179957033008155" STUDY_ID="STD-Schurr-2001" TOTAL_1="24" TOTAL_2="26" VAR="0.7182367346938776" WEIGHT="7.0922429284104584"/>
<DICH_DATA CI_END="6.820467167072353" CI_START="0.0026853936013588454" EFFECT_SIZE="0.1353352832366127" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8338141226232082" LOG_CI_START="-2.570992050236215" LOG_EFFECT_SIZE="-0.8685889638065036" MODIFIED="2010-02-10 14:32:22 +0530" MODIFIED_BY="[Empty name]" ORDER="399" O_E="-0.5" SE="2.0" STUDY_ID="STD-Toft-1997" TOTAL_1="8" TOTAL_2="8" VAR="0.25" WEIGHT="2.4686299745700384"/>
<DICH_DATA CI_END="19.9373010618555" CI_START="0.1993934155442883" EFFECT_SIZE="1.99383212820391" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2996663669507516" LOG_CI_START="-0.7002891872480179" LOG_EFFECT_SIZE="0.2996885898513667" MODIFIED="2010-02-10 14:32:22 +0530" MODIFIED_BY="[Empty name]" ORDER="392" O_E="0.5" SE="1.1747837924760145" STUDY_ID="STD-Whitlock-2006" TOTAL_1="30" TOTAL_2="30" VAR="0.7245762711864407" WEIGHT="7.1548428076521455"/>
<DICH_DATA CI_END="4.588782160550079" CI_START="0.04628604211281595" EFFECT_SIZE="0.46086501747231745" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6616974412822398" LOG_CI_START="-1.3345499538478311" LOG_EFFECT_SIZE="-0.33642625628279577" MODIFIED="2010-02-10 14:32:22 +0530" MODIFIED_BY="[Empty name]" ORDER="404" O_E="-0.5633802816901408" SE="1.1726056014833777" STUDY_ID="STD-Yared-2007" TOTAL_1="37" TOTAL_2="34" VAR="0.7272706662510273" WEIGHT="7.181448665331234"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.815190537554851" CI_END="3.4201615934209824" CI_START="0.46394951159267134" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.2596754744122303" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-003.06" LOG_CI_END="0.5340466257851207" LOG_CI_START="-0.3335292781298873" LOG_EFFECT_SIZE="0.10025867382761672" METHOD="PETO" MODIFIED="2010-02-10 14:33:09 +0530" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.4034933973127296" P_Q="1.0" P_Z="0.6505529798433853" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="196" TOTAL_2="194" WEIGHT="100.0" Z="0.45299411602636624">
<NAME>Pulmonary complications, low dose</NAME>
<GROUP_LABEL_1>corticosteroids</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="119.50989282818936" CI_START="0.46315175084966714" EFFECT_SIZE="7.439839790427749" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.07740385693992" LOG_CI_START="-0.3342766898487863" LOG_EFFECT_SIZE="0.871563583545567" MODIFIED="2010-02-10 14:33:09 +0530" MODIFIED_BY="[Empty name]" ORDER="406" O_E="1.0" SE="1.4166330911949265" STUDY_ID="STD-Halvorsen-2003" TOTAL_1="147" TOTAL_2="147" VAR="0.4982935153583618" WEIGHT="12.94122542353468"/>
<DICH_DATA CI_END="3.5063095899143963" CI_START="0.285200144013642" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.5448502595203324" LOG_CI_START="-0.5448502595203324" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-02-10 14:33:09 +0530" MODIFIED_BY="[Empty name]" ORDER="407" O_E="0.0" SE="0.6400954789890507" STUDY_ID="STD-Starobin-2007" TOTAL_1="30" TOTAL_2="30" VAR="2.440677966101695" WEIGHT="63.387065598998745"/>
<DICH_DATA CI_END="6.8967201318596905" CI_START="0.11362474111321061" EFFECT_SIZE="0.8852333248996137" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8386426027244629" LOG_CI_START="-0.9445270932813703" LOG_EFFECT_SIZE="-0.05294224527845368" MODIFIED="2010-02-10 14:33:09 +0530" MODIFIED_BY="[Empty name]" ORDER="408" O_E="-0.11111111111111116" SE="1.0474427062661789" STUDY_ID="STD-Weis-2009" TOTAL_1="19" TOTAL_2="17" VAR="0.9114638447971782" WEIGHT="23.671708977466572"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.1008609119758956" CI_END="20.35752021530274" CI_START="0.39655332837165125" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="2.8412747841015795" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="35.50178299594926" I2_Q="0.0" ID="CMP-003.07" LOG_CI_END="1.3087248747255928" LOG_CI_START="-0.4016984006284009" LOG_EFFECT_SIZE="0.4535132370485961" METHOD="PETO" MODIFIED="2010-08-31 01:16:29 +0530" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.2121567269832465" P_Q="1.0" P_Z="0.298639070636342" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="101" TOTAL_2="103" WEIGHT="100.00000000000001" Z="1.0393563089738258">
<NAME>Gastro-intestinal complications, high dose</NAME>
<GROUP_LABEL_1>Corticosteroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.820467167072353" CI_START="0.0026853936013588454" EFFECT_SIZE="0.1353352832366127" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8338141226232082" LOG_CI_START="-2.570992050236215" LOG_EFFECT_SIZE="-0.8685889638065036" MODIFIED="2010-02-10 14:33:54 +0530" MODIFIED_BY="[Empty name]" ORDER="410" O_E="-0.5" SE="2.0" STUDY_ID="STD-Chaney-1998" TOTAL_1="30" TOTAL_2="30" VAR="0.25" WEIGHT="25.236109795003003"/>
<DICH_DATA CI_END="372.3848896839504" CI_START="0.1466175227450357" EFFECT_SIZE="7.38905609893065" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.570992050236215" LOG_CI_START="-0.8338141226232083" LOG_EFFECT_SIZE="0.8685889638065036" MODIFIED="2010-02-10 14:33:54 +0530" MODIFIED_BY="[Empty name]" ORDER="409" O_E="0.5" SE="2.0" STUDY_ID="STD-Prasongsukarn-2005" TOTAL_1="43" TOTAL_2="43" VAR="0.25" WEIGHT="25.236109795003003"/>
<DICH_DATA CI_END="135.1694054755312" CI_START="0.5017305218709879" EFFECT_SIZE="8.235205908186478" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.130878403611925" LOG_CI_START="-0.2995294786474476" LOG_EFFECT_SIZE="0.9156744624822388" MODIFIED="2010-02-10 14:33:54 +0530" MODIFIED_BY="[Empty name]" ORDER="411" O_E="1.0344827586206895" SE="1.4276336207522016" STUDY_ID="STD-Whitlock-2006" TOTAL_1="28" TOTAL_2="30" VAR="0.49064397021090184" WEIGHT="49.52778040999401"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.071304215165256" CI_END="1.6231426870414454" CI_START="0.3997345219469597" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.8054974649595216" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-003.08" LOG_CI_END="0.21035669941397836" LOG_CI_START="-0.3982283434995906" LOG_EFFECT_SIZE="-0.09393582204280614" METHOD="PETO" MODIFIED="2010-09-24 15:46:09 +0530" MODIFIED_BY="Joey Kwong" NO="8" P_CHI2="0.7327612513419732" P_Q="1.0" P_Z="0.5451487522531651" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="418" TOTAL_2="418" WEIGHT="100.0" Z="0.6050455238947143">
<NAME>Infections, high dose</NAME>
<GROUP_LABEL_1>Corticosteroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.251286985182303" CI_START="0.29390684097051584" EFFECT_SIZE="1.3554689261709507" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.795969437027921" LOG_CI_START="-0.5317903051789383" LOG_EFFECT_SIZE="0.1320895659244913" MODIFIED="2010-02-10 14:34:34 +0530" MODIFIED_BY="[Empty name]" ORDER="420" O_E="0.5" SE="0.7799326450890333" STUDY_ID="STD-Amr-2009" TOTAL_1="50" TOTAL_2="50" VAR="1.6439393939393943" WEIGHT="21.008911703976295"/>
<DICH_DATA CI_END="2.1284848474346996" CI_START="0.007745265347095721" EFFECT_SIZE="0.12839657289294878" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.32807056280588703" LOG_CI_START="-2.1109636990402896" LOG_EFFECT_SIZE="-0.8914465681172012" MODIFIED="2010-02-15 18:05:02 +0530" MODIFIED_BY="[Empty name]" ORDER="399" O_E="-1.0" SE="1.4327007988227578" STUDY_ID="STD-Bingol-2005" TOTAL_1="20" TOTAL_2="20" VAR="0.48717948717948717" WEIGHT="6.225966034925267"/>
<DICH_DATA CI_END="6.766044970944047" CI_START="0.09635707132820523" EFFECT_SIZE="0.8074380953826118" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8303348800271819" LOG_CI_START="-1.016116408396906" LOG_EFFECT_SIZE="-0.09289076418486214" MODIFIED="2010-02-10 14:34:34 +0530" MODIFIED_BY="[Empty name]" ORDER="415" O_E="-0.18181818181818166" SE="1.0846146269015964" STUDY_ID="STD-Jansen-1991a" TOTAL_1="12" TOTAL_2="10" VAR="0.8500590318772135" WEIGHT="10.863426723463709"/>
<DICH_DATA CI_END="18.654982765042313" CI_START="0.18981749327591743" EFFECT_SIZE="1.8817656776458047" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2707948521412287" LOG_CI_START="-0.7216637661810329" LOG_EFFECT_SIZE="0.2745655429800979" MODIFIED="2010-02-10 14:34:34 +0530" MODIFIED_BY="[Empty name]" ORDER="419" O_E="0.46153846153846145" SE="1.1703800552317227" STUDY_ID="STD-Liakopoulos-2007" TOTAL_1="40" TOTAL_2="38" VAR="0.7300391915776532" WEIGHT="9.329619432954948"/>
<DICH_DATA CI_END="9.166556051199882" CI_START="0.25257287047794413" EFFECT_SIZE="1.5215858090323144" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9622061983858703" LOG_CI_START="-0.5976132999979551" LOG_EFFECT_SIZE="0.1822964491939576" MODIFIED="2010-02-10 14:34:34 +0530" MODIFIED_BY="[Empty name]" ORDER="422" O_E="0.5" SE="0.9162456945817024" STUDY_ID="STD-Prasongsukarn-2005" TOTAL_1="43" TOTAL_2="43" VAR="1.1911764705882353" WEIGHT="15.222776086941888"/>
<DICH_DATA CI_END="6.820467167072353" CI_START="0.0026853936013588454" EFFECT_SIZE="0.1353352832366127" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8338141226232082" LOG_CI_START="-2.570992050236215" LOG_EFFECT_SIZE="-0.8685889638065036" MODIFIED="2010-02-10 14:34:34 +0530" MODIFIED_BY="[Empty name]" ORDER="426" O_E="-0.5" SE="2.0" STUDY_ID="STD-Rao-1977" TOTAL_1="75" TOTAL_2="75" VAR="0.25" WEIGHT="3.1949036231853345"/>
<DICH_DATA CI_END="2.6077807680567924" CI_START="0.04725250648238307" EFFECT_SIZE="0.3510330150388101" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.41627107815451175" LOG_CI_START="-1.3255751496394452" LOG_EFFECT_SIZE="-0.45465203574246676" MODIFIED="2010-02-10 14:34:34 +0530" MODIFIED_BY="[Empty name]" ORDER="413" O_E="-1.0" SE="1.0231690964840563" STUDY_ID="STD-Rubens-2005" TOTAL_1="34" TOTAL_2="34" VAR="0.9552238805970149" WEIGHT="12.207392948290233"/>
<DICH_DATA CI_END="6.820467167072353" CI_START="0.0026853936013588454" EFFECT_SIZE="0.1353352832366127" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8338141226232082" LOG_CI_START="-2.570992050236215" LOG_EFFECT_SIZE="-0.8685889638065036" MODIFIED="2010-02-10 14:34:34 +0530" MODIFIED_BY="[Empty name]" ORDER="427" O_E="-0.5" SE="2.0" STUDY_ID="STD-Toft-1997" TOTAL_1="8" TOTAL_2="8" VAR="0.25" WEIGHT="3.1949036231853345"/>
<DICH_DATA CI_END="19.9373010618555" CI_START="0.1993934155442883" EFFECT_SIZE="1.99383212820391" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2996663669507516" LOG_CI_START="-0.7002891872480179" LOG_EFFECT_SIZE="0.2996885898513667" MODIFIED="2010-02-10 14:34:34 +0530" MODIFIED_BY="[Empty name]" ORDER="421" O_E="0.5" SE="1.1747837924760145" STUDY_ID="STD-Whitlock-2006" TOTAL_1="30" TOTAL_2="30" VAR="0.7245762711864407" WEIGHT="9.259805416350716"/>
<DICH_DATA CI_END="5.146939006374115" CI_START="0.054480005875527086" EFFECT_SIZE="0.5295330653587567" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7115490216886566" LOG_CI_START="-1.2637628542577373" LOG_EFFECT_SIZE="-0.27610691628454037" MODIFIED="2010-02-10 14:34:34 +0530" MODIFIED_BY="[Empty name]" ORDER="416" O_E="-0.4722222222222223" SE="1.1603079738823945" STUDY_ID="STD-Yared-1998" TOTAL_1="106" TOTAL_2="110" VAR="0.7427684467413149" WEIGHT="9.49229440672628"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.7584206641046514" CI_END="1.5198620553327855" CI_START="0.5165513693584421" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.8860512546789191" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="33" I2="0.0" I2_Q="0.0" ID="CMP-003.09" LOG_CI_END="0.18180417259846415" LOG_CI_START="-0.28688648281895235" LOG_EFFECT_SIZE="-0.05254115511024408" METHOD="PETO" MODIFIED="2010-09-24 15:46:09 +0530" MODIFIED_BY="Joey Kwong" NO="9" P_CHI2="0.7800801285782674" P_Q="1.0" P_Z="0.6603487440643032" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="326" TOTAL_2="325" WEIGHT="100.00000000000001" Z="0.4394317255183934">
<NAME>Infections, low dose</NAME>
<GROUP_LABEL_1>corticosteroids</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.0823470337554104" CI_START="0.48955825369412476" EFFECT_SIZE="1.0096683502172579" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="17" LOG_CI_END="0.31855310859700164" LOG_CI_START="-0.31019562305871895" LOG_EFFECT_SIZE="0.004178742769141328" MODIFIED="2010-02-10 14:35:01 +0530" MODIFIED_BY="[Empty name]" ORDER="428" O_E="0.07053941908713668" SE="0.3693301173309874" STUDY_ID="STD-Halonen-2007" TOTAL_1="120" TOTAL_2="121" VAR="7.3311237754170895" WEIGHT="55.56717852458993"/>
<DICH_DATA CI_END="8.764167402264968" CI_START="0.25676375494269754" EFFECT_SIZE="1.5001068399123914" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9427106643228985" LOG_CI_START="-0.5904662817688424" LOG_EFFECT_SIZE="0.1761221912770281" MODIFIED="2010-02-10 14:35:01 +0530" MODIFIED_BY="[Empty name]" ORDER="429" O_E="0.5" SE="0.9005957274825712" STUDY_ID="STD-Halvorsen-2003" TOTAL_1="147" TOTAL_2="147" VAR="1.2329351535836177" WEIGHT="9.345187707532029"/>
<DICH_DATA CI_END="1.876434376050927" CI_START="0.20231900001389" EFFECT_SIZE="0.6161479745599358" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.27333338057040674" LOG_CI_START="-0.6939633302113128" LOG_EFFECT_SIZE="-0.21031497482045303" MODIFIED="2010-02-10 14:35:01 +0530" MODIFIED_BY="[Empty name]" ORDER="430" O_E="-1.5" SE="0.5681948761091234" STUDY_ID="STD-Starobin-2007" TOTAL_1="30" TOTAL_2="30" VAR="3.097457627118644" WEIGHT="23.477571271624335"/>
<DICH_DATA CI_END="4.958823274243347" CI_START="0.15548121026092604" EFFECT_SIZE="0.8780682457243307" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6953786308987809" LOG_CI_START="-0.8083220874928153" LOG_EFFECT_SIZE="-0.0564717282970172" MODIFIED="2010-02-10 14:35:01 +0530" MODIFIED_BY="[Empty name]" ORDER="431" O_E="-0.16666666666666652" SE="0.8832812454218258" STUDY_ID="STD-Weis-2009" TOTAL_1="19" TOTAL_2="17" VAR="1.2817460317460319" WEIGHT="9.715155923030963"/>
<DICH_DATA CI_END="6.820467167072353" CI_START="0.0026853936013588454" EFFECT_SIZE="0.1353352832366127" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8338141226232082" LOG_CI_START="-2.570992050236215" LOG_EFFECT_SIZE="-0.8685889638065036" MODIFIED="2010-02-10 14:35:01 +0530" MODIFIED_BY="[Empty name]" ORDER="432" O_E="-0.5" SE="2.0" STUDY_ID="STD-Yilmaz-1999" TOTAL_1="10" TOTAL_2="10" VAR="0.25" WEIGHT="1.8949065732227575"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="13.323180530094133" CI_END="0.8312552505649703" CI_START="0.42882991525876674" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.5970486736089288" ESTIMABLE="YES" EVENTS_1="83" EVENTS_2="120" I2="9.931416354415969" I2_Q="0.0" ID="CMP-003.10" LOG_CI_END="-0.08026559848981125" LOG_CI_START="-0.36771492579048876" LOG_EFFECT_SIZE="-0.22399026214015" METHOD="PETO" MODIFIED="2010-09-24 15:46:09 +0530" MODIFIED_BY="Joey Kwong" NO="10" P_CHI2="0.34599485011642583" P_Q="1.0" P_Z="0.002254053654265266" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="378" TOTAL_2="380" WEIGHT="100.0" Z="3.054540783274569">
<NAME>Atrial fibrillation, high dose</NAME>
<GROUP_LABEL_1>Corticosteroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.5813725030178984" CI_START="0.0360329588627444" EFFECT_SIZE="0.3049827687110593" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.41185067960474514" LOG_CI_START="-1.4433000741249682" LOG_EFFECT_SIZE="-0.5157246972601116" MODIFIED="2010-02-10 14:35:43 +0530" MODIFIED_BY="[Empty name]" ORDER="436" O_E="-1.0" SE="1.0897247358851685" STUDY_ID="STD-Abd.-El_x002d_Hakeem-2003b" TOTAL_1="10" TOTAL_2="10" VAR="0.8421052631578947" WEIGHT="2.400845311501355"/>
<DICH_DATA CI_END="2.5523193809713804" CI_START="0.2871958929483026" EFFECT_SIZE="0.8561633277052543" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.40693501829159306" LOG_CI_START="-0.5418217750238972" LOG_EFFECT_SIZE="-0.06744337836615202" MODIFIED="2010-02-10 14:35:43 +0530" MODIFIED_BY="[Empty name]" ORDER="448" O_E="-0.5" SE="0.5573044368153888" STUDY_ID="STD-Amr-2009" TOTAL_1="50" TOTAL_2="50" VAR="3.2196969696969697" WEIGHT="9.179368319305608"/>
<DICH_DATA CI_END="2.602992800246887" CI_START="0.044010434443699606" EFFECT_SIZE="0.33846542510674216" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.415472966873211" LOG_CI_START="-1.3564443443302567" LOG_EFFECT_SIZE="-0.47048568872852287" MODIFIED="2010-02-15 18:05:19 +0530" MODIFIED_BY="[Empty name]" ORDER="400" O_E="-1.0" SE="1.0408329997330665" STUDY_ID="STD-Bingol-2005" TOTAL_1="20" TOTAL_2="20" VAR="0.923076923076923" WEIGHT="2.631695822222639"/>
<DICH_DATA CI_END="2.787027187090598" CI_START="0.24384376912228348" EFFECT_SIZE="0.8243780770656428" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.44514120522060113" LOG_CI_START="-0.6128883373468981" LOG_EFFECT_SIZE="-0.08387356606314846" MODIFIED="2010-02-10 14:35:43 +0530" MODIFIED_BY="[Empty name]" ORDER="444" O_E="-0.5" SE="0.6214917906348514" STUDY_ID="STD-Celik-2004" TOTAL_1="30" TOTAL_2="30" VAR="2.5889830508474576" WEIGHT="7.381200535280517"/>
<DICH_DATA CI_END="1.9799577861600235" CI_START="0.4093736774222478" EFFECT_SIZE="0.9003013940126613" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="18" LOG_CI_END="0.2966559309518352" LOG_CI_START="-0.3878800857521357" LOG_EFFECT_SIZE="-0.045612077400150275" MODIFIED="2010-02-10 14:35:43 +0530" MODIFIED_BY="[Empty name]" ORDER="441" O_E="-0.6495726495726508" SE="0.40209984471984433" STUDY_ID="STD-Chaney-1998" TOTAL_1="59" TOTAL_2="58" VAR="6.184892979764775" WEIGHT="17.633153433719514"/>
<DICH_DATA CI_END="4.0746930308353155" CI_START="0.10063813823784733" EFFECT_SIZE="0.6403667078432462" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.610094896502771" LOG_CI_START="-0.9972374060850981" LOG_EFFECT_SIZE="-0.19357125479116366" MODIFIED="2010-02-10 14:35:43 +0530" MODIFIED_BY="[Empty name]" ORDER="446" O_E="-0.5" SE="0.9441549509633318" STUDY_ID="STD-Enc-2006" TOTAL_1="20" TOTAL_2="20" VAR="1.1217948717948718" WEIGHT="3.198241450617791"/>
<DICH_DATA CI_END="2.088926998059922" CI_START="0.007020837554470822" EFFECT_SIZE="0.12110333239232973" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.3199232629129438" LOG_CI_START="-2.1536110753933406" LOG_EFFECT_SIZE="-0.9168439062401983" MODIFIED="2010-02-10 14:35:43 +0530" MODIFIED_BY="[Empty name]" ORDER="434" O_E="-1.0" SE="1.4529663145135578" STUDY_ID="STD-Giomarelli-2003" TOTAL_1="10" TOTAL_2="10" VAR="0.47368421052631576" WEIGHT="1.3504754877195122"/>
<DICH_DATA CI_END="0.6564220618182393" CI_START="0.1140151372435568" EFFECT_SIZE="0.2735727535188859" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="22" LOG_CI_END="-0.18281683108495608" LOG_CI_START="-0.9430374856378435" LOG_EFFECT_SIZE="-0.5629271583613997" MODIFIED="2010-02-10 14:35:43 +0530" MODIFIED_BY="[Empty name]" ORDER="447" O_E="-6.5" SE="0.4465573756372974" STUDY_ID="STD-Prasongsukarn-2005" TOTAL_1="43" TOTAL_2="43" VAR="5.014705882352941" WEIGHT="14.296945563618824"/>
<DICH_DATA CI_END="0.7398513447484525" CI_START="0.08368454869140005" EFFECT_SIZE="0.2488254928338326" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="13" LOG_CI_END="-0.13085553248648374" LOG_CI_START="-1.0773547216665076" LOG_EFFECT_SIZE="-0.6041051270764956" MODIFIED="2010-02-10 14:35:43 +0530" MODIFIED_BY="[Empty name]" ORDER="435" O_E="-4.5" SE="0.5559783089708951" STUDY_ID="STD-Rubens-2005" TOTAL_1="34" TOTAL_2="34" VAR="3.235074626865672" WEIGHT="9.22321007844259"/>
<DICH_DATA CI_END="1.6386516920254504" CI_START="0.17698038321597984" EFFECT_SIZE="0.5385250267278003" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="17" LOG_CI_END="0.21448665075974754" LOG_CI_START="-0.7520748688539586" LOG_EFFECT_SIZE="-0.26879410904710543" MODIFIED="2010-02-10 14:35:43 +0530" MODIFIED_BY="[Empty name]" ORDER="438" O_E="-1.92" SE="0.5677630211777773" STUDY_ID="STD-Schurr-2001" TOTAL_1="24" TOTAL_2="26" VAR="3.1021714285714284" WEIGHT="8.84430255408902"/>
<DICH_DATA CI_END="3.0994982685728045" CI_START="0.08860668773774988" EFFECT_SIZE="0.5240575113736343" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.49129139808411215" LOG_CI_START="-1.0525334977744683" LOG_EFFECT_SIZE="-0.2806210498451781" MODIFIED="2010-02-10 14:35:43 +0530" MODIFIED_BY="[Empty name]" ORDER="442" O_E="-0.7857142857142856" SE="0.9068503858838142" STUDY_ID="STD-Sobieski-2008" TOTAL_1="13" TOTAL_2="15" VAR="1.2159863945578229" WEIGHT="3.4667818406405084"/>
<DICH_DATA CI_END="2.0675924976487225" CI_START="0.21938749430503185" EFFECT_SIZE="0.673501252636575" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.31546494764168137" LOG_CI_START="-0.6587881320443957" LOG_EFFECT_SIZE="-0.17166159220135718" MODIFIED="2010-02-10 14:35:43 +0530" MODIFIED_BY="[Empty name]" ORDER="437" O_E="-1.2068965517241388" SE="0.5722810816381245" STUDY_ID="STD-Whitlock-2006" TOTAL_1="28" TOTAL_2="30" VAR="3.053382564616059" WEIGHT="8.705205317193158"/>
<DICH_DATA CI_END="4.258582216399987" CI_START="0.6144529176527282" EFFECT_SIZE="1.617621175656091" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="10" LOG_CI_END="0.6292650361733342" LOG_CI_START="-0.2115113892413061" LOG_EFFECT_SIZE="0.208876823466014" MODIFIED="2010-02-10 14:35:43 +0530" MODIFIED_BY="[Empty name]" ORDER="433" O_E="1.971830985915492" SE="0.4938762341989879" STUDY_ID="STD-Yared-2007" TOTAL_1="37" TOTAL_2="34" VAR="4.099810128375889" WEIGHT="11.688574285648965"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.682574325008216" CI_END="0.9431474603447506" CI_START="0.40052135214647644" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.6146142660976841" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="81" I2="35.93267737411223" I2_Q="0.0" ID="CMP-003.11" LOG_CI_END="-0.02542040036196354" LOG_CI_START="-0.3973743263407722" LOG_EFFECT_SIZE="-0.21139736335136783" METHOD="PETO" MODIFIED="2010-09-24 15:46:10 +0530" MODIFIED_BY="Joey Kwong" NO="11" P_CHI2="0.19657191845790434" P_Q="1.0" P_Z="0.02588964359480299" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="316" TOTAL_2="315" WEIGHT="100.00000000000003" Z="2.227863128504869">
<NAME>Atrial fibrillation, low dose</NAME>
<GROUP_LABEL_1>corticosteroids</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9218464605938081" CI_START="0.3339766596161344" EFFECT_SIZE="0.5548650300641377" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="62" LOG_CI_END="-0.035341407438404075" LOG_CI_START="-0.4762838833504555" LOG_EFFECT_SIZE="-0.2558126453944299" MODIFIED="2010-02-10 14:36:08 +0530" MODIFIED_BY="[Empty name]" ORDER="449" O_E="-8.780082987551864" SE="0.2590117930511969" STUDY_ID="STD-Halonen-2007" TOTAL_1="120" TOTAL_2="121" VAR="14.905993354108917" WEIGHT="71.1564743188365"/>
<DICH_DATA CI_END="16.063503542368387" CI_START="0.06225291994130946" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2058402733943532" LOG_CI_START="-1.2058402733943532" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-02-10 14:36:08 +0530" MODIFIED_BY="[Empty name]" ORDER="450" O_E="0.0" SE="1.4166330911949265" STUDY_ID="STD-Halvorsen-2003" TOTAL_1="147" TOTAL_2="147" VAR="0.4982935153583618" WEIGHT="2.3786948569292212"/>
<DICH_DATA CI_END="4.633047730401521" CI_START="0.5356054985753397" EFFECT_SIZE="1.575273258696742" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="8" LOG_CI_END="0.6658667743976776" LOG_CI_START="-0.2711549731300238" LOG_EFFECT_SIZE="0.1973559006338269" MODIFIED="2010-02-10 14:36:08 +0530" MODIFIED_BY="[Empty name]" ORDER="451" O_E="1.5" SE="0.5504112128302281" STUDY_ID="STD-Starobin-2007" TOTAL_1="30" TOTAL_2="30" VAR="3.3008474576271185" WEIGHT="15.757196569814369"/>
<DICH_DATA CI_END="1.0083891557682534" CI_START="0.0736100762224785" EFFECT_SIZE="0.2724474309257144" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="10" LOG_CI_END="0.0036281666203033434" LOG_CI_START="-1.1330627325606488" LOG_EFFECT_SIZE="-0.5647172829701727" MODIFIED="2010-02-10 14:36:08 +0530" MODIFIED_BY="[Empty name]" ORDER="452" O_E="-2.916666666666667" SE="0.6676978608895886" STUDY_ID="STD-Weis-2009" TOTAL_1="19" TOTAL_2="17" VAR="2.243055555555556" WEIGHT="10.707634254419927"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2011-01-12 08:48:58 +0530" MODIFIED_BY="Joey Kwong" NO="4">
<NAME>sensitivity analyses</NAME>
<DICH_OUTCOME CHI2="3.7468478865406" CI_END="8.050741689187587" CI_START="0.6482061629341099" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="2.284412480074901" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" I2="19.93269834154254" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.9058358923782346" LOG_CI_START="-0.18828684415300284" LOG_EFFECT_SIZE="0.3587745241126158" METHOD="PETO" MODIFIED="2010-09-01 17:45:02 +0530" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.2901297072572173" P_Q="1.0" P_Z="0.19865735315660235" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="WEIGHT" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="175" TOTAL_2="175" WEIGHT="100.0" Z="1.2853862228666855">
<NAME>Mortality, trials before 1995</NAME>
<GROUP_LABEL_1>Corticosteroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="372.3848896839504" CI_START="0.1466175227450357" EFFECT_SIZE="7.38905609893065" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.570992050236215" LOG_CI_START="-0.8338141226232083" LOG_EFFECT_SIZE="0.8685889638065036" MODIFIED="2010-09-01 17:43:06 +0530" MODIFIED_BY="[Empty name]" ORDER="312" O_E="0.5" SE="2.0" STUDY_ID="STD-Codd-1977" TOTAL_1="75" TOTAL_2="75" VAR="0.25" WEIGHT="10.326360887096774"/>
<DICH_DATA CI_END="372.3848896839504" CI_START="0.1466175227450357" EFFECT_SIZE="7.38905609893065" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.570992050236215" LOG_CI_START="-0.8338141226232083" LOG_EFFECT_SIZE="0.8685889638065036" MODIFIED="2010-09-01 17:43:06 +0530" MODIFIED_BY="[Empty name]" ORDER="300" O_E="0.5" SE="2.0" STUDY_ID="STD-Andersen-1989" TOTAL_1="8" TOTAL_2="8" VAR="0.25" WEIGHT="10.326360887096774"/>
<DICH_DATA CI_END="86.84008009968478" CI_START="0.8138300233867384" EFFECT_SIZE="8.406727331038681" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.93872021536777" LOG_CI_START="-0.0894662924248916" LOG_EFFECT_SIZE="0.9246269614714394" MODIFIED="2010-09-01 17:43:06 +0530" MODIFIED_BY="[Empty name]" ORDER="311" O_E="1.5" SE="1.191366794362541" STUDY_ID="STD-Boscoe-1983" TOTAL_1="17" TOTAL_2="17" VAR="0.7045454545454546" WEIGHT="29.1015625"/>
<DICH_DATA CI_END="3.919742777251082" CI_START="0.11213015332564497" EFFECT_SIZE="0.6629640703765576" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5932575685291956" LOG_CI_START="-0.9502775839972483" LOG_EFFECT_SIZE="-0.1785100077340263" MODIFIED="2010-09-01 17:43:06 +0530" MODIFIED_BY="[Empty name]" ORDER="307" O_E="-0.5" SE="0.9066801892162646" STUDY_ID="STD-Rao-1977" TOTAL_1="75" TOTAL_2="75" VAR="1.2164429530201342" WEIGHT="50.24571572580645"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="10.08888564581134" CI_END="1.7322461930209494" CI_START="0.5251240958678117" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.9537527016635838" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="23" I2="0.0" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="0.23860961555209914" LOG_CI_START="-0.279738053199647" LOG_EFFECT_SIZE="-0.020564218823773885" METHOD="PETO" MODIFIED="2010-09-01 17:45:17 +0530" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6081629943673383" P_Q="1.0" P_Z="0.8764162134061644" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="WEIGHT" STUDIES="13" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="861" TOTAL_2="801" WEIGHT="99.99999999999999" Z="0.15551387879049547">
<NAME>Mortality, trials after 1995</NAME>
<GROUP_LABEL_1>Corticosteroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.1118778382741574" CI_START="7.434627696717769E-4" EFFECT_SIZE="0.04809953551255486" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.49302253972999627" LOG_CI_START="-3.128740774729041" LOG_EFFECT_SIZE="-1.3178591174995224" MODIFIED="2010-09-01 17:42:31 +0530" MODIFIED_BY="[Empty name]" ORDER="294" O_E="-0.6704545454545454" SE="2.1274416989307845" STUDY_ID="STD-Chaney-2001" TOTAL_1="59" TOTAL_2="29" VAR="0.22094524793388431" WEIGHT="2.0483405781884727"/>
<DICH_DATA CI_END="344.58845534710696" CI_START="0.13472589337416754" EFFECT_SIZE="6.813588444649666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.5373007233063403" LOG_CI_START="-0.8705489278938605" LOG_EFFECT_SIZE="0.8333758977062401" MODIFIED="2010-09-01 17:42:31 +0530" MODIFIED_BY="[Empty name]" ORDER="279" O_E="0.47887323943661975" SE="2.0017877542428333" STUDY_ID="STD-Yared-2007" TOTAL_1="37" TOTAL_2="34" VAR="0.2495536599880976" WEIGHT="2.3135636225225906"/>
<DICH_DATA CI_END="354.68043716013733" CI_START="0.1392872116124779" EFFECT_SIZE="7.0286875805892945" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.5498372350811813" LOG_CI_START="-0.856088755658499" LOG_EFFECT_SIZE="0.8468742397113411" MODIFIED="2010-09-01 17:42:31 +0530" MODIFIED_BY="[Empty name]" ORDER="290" O_E="0.4871794871794872" SE="2.0006577865660504" STUDY_ID="STD-Liakopoulos-2007" TOTAL_1="40" TOTAL_2="38" VAR="0.24983563445101906" WEIGHT="2.316177753126512"/>
<DICH_DATA CI_END="375.5137349148289" CI_START="0.14783945144821836" EFFECT_SIZE="7.45088884503587" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.574625826529613" LOG_CI_START="-0.8302096575515509" LOG_EFFECT_SIZE="0.872208084489031" MODIFIED="2010-09-01 17:42:31 +0530" MODIFIED_BY="[Empty name]" ORDER="286" O_E="0.5020746887966805" SE="2.000017217556743" STUDY_ID="STD-Halonen-2007" TOTAL_1="120" TOTAL_2="121" VAR="0.2499956956663969" WEIGHT="2.3176616496371567"/>
<DICH_DATA CI_END="372.3848896839504" CI_START="0.1466175227450357" EFFECT_SIZE="7.38905609893065" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.570992050236215" LOG_CI_START="-0.8338141226232083" LOG_EFFECT_SIZE="0.8685889638065036" MODIFIED="2010-09-01 17:42:31 +0530" MODIFIED_BY="[Empty name]" ORDER="287" O_E="0.5" SE="2.0" STUDY_ID="STD-Whitlock-2006" TOTAL_1="30" TOTAL_2="30" VAR="0.25" WEIGHT="2.3177015542798847"/>
<DICH_DATA CI_END="6.820467167072353" CI_START="0.0026853936013588454" EFFECT_SIZE="0.1353352832366127" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8338141226232082" LOG_CI_START="-2.570992050236215" LOG_EFFECT_SIZE="-0.8685889638065036" MODIFIED="2010-09-01 17:42:31 +0530" MODIFIED_BY="[Empty name]" ORDER="280" O_E="-0.5" SE="2.0" STUDY_ID="STD-Rubens-2005" TOTAL_1="34" TOTAL_2="34" VAR="0.25" WEIGHT="2.3177015542798847"/>
<DICH_DATA CI_END="2.1284848474346996" CI_START="0.007745265347095721" EFFECT_SIZE="0.12839657289294878" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.32807056280588703" LOG_CI_START="-2.1109636990402896" LOG_EFFECT_SIZE="-0.8914465681172012" MODIFIED="2010-09-01 17:42:31 +0530" MODIFIED_BY="[Empty name]" ORDER="295" O_E="-1.0" SE="1.4327007988227578" STUDY_ID="STD-Bingol-2005" TOTAL_1="20" TOTAL_2="20" VAR="0.48717948717948717" WEIGHT="4.516546618596698"/>
<DICH_DATA CI_END="16.063503542368387" CI_START="0.06225291994130946" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2058402733943532" LOG_CI_START="-1.2058402733943532" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-09-01 17:42:31 +0530" MODIFIED_BY="[Empty name]" ORDER="291" O_E="0.0" SE="1.4166330911949265" STUDY_ID="STD-Halvorsen-2003" TOTAL_1="147" TOTAL_2="147" VAR="0.4982935153583618" WEIGHT="4.619582620134651"/>
<DICH_DATA CI_END="5.0152107443983525" CI_START="0.05015724028530737" EFFECT_SIZE="0.5015467379898342" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7002891872480179" LOG_CI_START="-1.2996663669507513" LOG_EFFECT_SIZE="-0.29968858985136676" MODIFIED="2010-09-01 17:42:31 +0530" MODIFIED_BY="[Empty name]" ORDER="289" O_E="-0.5" SE="1.1747837924760145" STUDY_ID="STD-Celik-2004" TOTAL_1="30" TOTAL_2="30" VAR="0.7245762711864407" WEIGHT="6.717406199692547"/>
<DICH_DATA CI_END="5.0152107443983525" CI_START="0.05015724028530737" EFFECT_SIZE="0.5015467379898342" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7002891872480179" LOG_CI_START="-1.2996663669507513" LOG_EFFECT_SIZE="-0.29968858985136676" MODIFIED="2010-09-01 17:42:31 +0530" MODIFIED_BY="[Empty name]" ORDER="284" O_E="-0.5" SE="1.1747837924760145" STUDY_ID="STD-Chaney-1998" TOTAL_1="30" TOTAL_2="30" VAR="0.7245762711864407" WEIGHT="6.717406199692547"/>
<DICH_DATA CI_END="4.054861208202655" CI_START="0.11767157865154038" EFFECT_SIZE="0.6907546015641871" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6079759935549934" LOG_CI_START="-0.9293284201244663" LOG_EFFECT_SIZE="-0.16067621328473639" MODIFIED="2010-09-01 17:42:31 +0530" MODIFIED_BY="[Empty name]" ORDER="282" O_E="-0.4537037037037037" SE="0.9030202223748913" STUDY_ID="STD-Yared-1998" TOTAL_1="106" TOTAL_2="110" VAR="1.2263234918812007" WEIGHT="11.369007452731978"/>
<DICH_DATA CI_END="4.370298696109262" CI_START="0.4213184819904856" EFFECT_SIZE="1.356940533881184" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.640511120640644" LOG_CI_START="-0.37538948924621707" LOG_EFFECT_SIZE="0.1325608156972134" MODIFIED="2010-09-01 17:42:31 +0530" MODIFIED_BY="[Empty name]" ORDER="285" O_E="0.8571428571428568" SE="0.5967450470366643" STUDY_ID="STD-Kilger-2003a" TOTAL_1="43" TOTAL_2="48" VAR="2.8081632653061224" WEIGHT="26.033937458686705"/>
<DICH_DATA CI_END="3.5352194459463324" CI_START="0.34632784672636474" EFFECT_SIZE="1.106501214829774" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.5484163774555608" LOG_CI_START="-0.46051258730301975" LOG_EFFECT_SIZE="0.04395189507627056" MODIFIED="2010-09-01 17:42:31 +0530" MODIFIED_BY="[Empty name]" ORDER="288" O_E="0.2881355932203391" SE="0.5926498681781125" STUDY_ID="STD-Coetzer-1996" TOTAL_1="165" TOTAL_2="130" VAR="2.8471058633163118" WEIGHT="26.394966738430355"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.398479990034611" CI_END="2.0000660065661435" CI_START="0.42839961679662997" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.9256497776053867" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="0.30104432857118874" LOG_CI_START="-0.3681509263163339" LOG_EFFECT_SIZE="-0.03355329887257258" METHOD="PETO" MODIFIED="2010-09-01 17:48:01 +0530" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.4939178251543417" P_Q="1.0" P_Z="0.8441841604254222" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="WEIGHT" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="180" TOTAL_2="180" WEIGHT="100.0" Z="0.19654430264543352">
<NAME>Cardiac complications, trials before 1995</NAME>
<GROUP_LABEL_1>Corticosteroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="372.3848896839504" CI_START="0.1466175227450357" EFFECT_SIZE="7.38905609893065" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.570992050236215" LOG_CI_START="-0.8338141226232083" LOG_EFFECT_SIZE="0.8685889638065036" MODIFIED="2010-09-01 17:46:43 +0530" MODIFIED_BY="[Empty name]" ORDER="328" O_E="0.5" SE="2.0" STUDY_ID="STD-Andersen-1989" TOTAL_1="8" TOTAL_2="8" VAR="0.25" WEIGHT="3.8629662902379756"/>
<DICH_DATA CI_END="1.8575336701137521" CI_START="0.0902236753460005" EFFECT_SIZE="0.40938186915960006" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.26893669463292463" LOG_CI_START="-1.0446794854850865" LOG_EFFECT_SIZE="-0.387871395426081" MODIFIED="2010-09-01 17:46:43 +0530" MODIFIED_BY="[Empty name]" ORDER="325" O_E="-1.5" SE="0.7716246467062825" STUDY_ID="STD-Rao-1977" TOTAL_1="75" TOTAL_2="75" VAR="1.679530201342282" WEIGHT="25.95187420488734"/>
<DICH_DATA CI_END="4.031072067237561" CI_START="0.24807296503763238" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.6054205625102385" LOG_CI_START="-0.6054205625102385" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-09-01 17:46:43 +0530" MODIFIED_BY="[Empty name]" ORDER="313" O_E="0.0" SE="0.7112540705972631" STUDY_ID="STD-Morton-1976" TOTAL_1="22" TOTAL_2="22" VAR="1.9767441860465116" WEIGHT="30.54438462048632"/>
<DICH_DATA CI_END="4.1312397574044315" CI_START="0.35744267040492583" EFFECT_SIZE="1.215187792470628" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.6160804000833917" LOG_CI_START="-0.4467936039981477" LOG_EFFECT_SIZE="0.08464339804262201" MODIFIED="2010-09-01 17:46:43 +0530" MODIFIED_BY="[Empty name]" ORDER="321" O_E="0.5" SE="0.6243374513086698" STUDY_ID="STD-Codd-1977" TOTAL_1="75" TOTAL_2="75" VAR="2.5654362416107386" WEIGHT="39.64077488438836"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="13.205096039343188" CI_END="1.9775985132659122" CI_START="0.4841787614650973" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.9785250118562668" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="16" I2="16.698826216585907" I2_Q="0.0" ID="CMP-004.04" LOG_CI_END="0.29613812691162783" LOG_CI_START="-0.3149942648340006" LOG_EFFECT_SIZE="-0.009428068961186399" METHOD="PETO" MODIFIED="2010-09-01 17:48:17 +0530" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.28013219416085233" P_Q="1.0" P_Z="0.9517784735503271" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="WEIGHT" STUDIES="12" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="723" TOTAL_2="695" WEIGHT="100.00000000000001" Z="0.060473559763059404">
<NAME>Cardiac complications, trials after 1995</NAME>
<GROUP_LABEL_1>Corticosteroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.1118778382741574" CI_START="7.434627696717769E-4" EFFECT_SIZE="0.04809953551255486" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.49302253972999627" LOG_CI_START="-3.128740774729041" LOG_EFFECT_SIZE="-1.3178591174995224" MODIFIED="2010-09-01 17:46:45 +0530" MODIFIED_BY="[Empty name]" ORDER="340" O_E="-0.6704545454545454" SE="2.1274416989307845" STUDY_ID="STD-Chaney-2001" TOTAL_1="59" TOTAL_2="29" VAR="0.22094524793388431" WEIGHT="2.8472819541669945"/>
<DICH_DATA CI_END="344.58845534710696" CI_START="0.13472589337416754" EFFECT_SIZE="6.813588444649666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.5373007233063403" LOG_CI_START="-0.8705489278938605" LOG_EFFECT_SIZE="0.8333758977062401" MODIFIED="2010-09-01 17:46:45 +0530" MODIFIED_BY="[Empty name]" ORDER="335" O_E="0.47887323943661975" SE="2.0017877542428333" STUDY_ID="STD-Yared-2007" TOTAL_1="37" TOTAL_2="34" VAR="0.2495536599880976" WEIGHT="3.215953451477088"/>
<DICH_DATA CI_END="352.82541670943306" CI_START="0.13847236894280432" EFFECT_SIZE="6.9897475830667375" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.547559863135115" LOG_CI_START="-0.8586368779558022" LOG_EFFECT_SIZE="0.8444614925896565" MODIFIED="2010-09-01 17:46:45 +0530" MODIFIED_BY="[Empty name]" ORDER="331" O_E="0.48571428571428577" SE="2.000816826662603" STUDY_ID="STD-McBride-2004" TOTAL_1="18" TOTAL_2="17" VAR="0.2497959183673469" WEIGHT="3.219075391948461"/>
<DICH_DATA CI_END="7.077805624721046" CI_START="0.0027829698032571454" EFFECT_SIZE="0.14034713864885967" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8498986315891194" LOG_CI_START="-2.555491505972799" LOG_EFFECT_SIZE="-0.85279643719184" MODIFIED="2010-09-01 17:46:45 +0530" MODIFIED_BY="[Empty name]" ORDER="342" O_E="-0.49074074074074076" SE="2.0003430237569173" STUDY_ID="STD-Yared-1998" TOTAL_1="106" TOTAL_2="110" VAR="0.24991426611796982" WEIGHT="3.2206005182764357"/>
<DICH_DATA CI_END="16.372456241572294" CI_START="0.06107819042208459" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2141138383697911" LOG_CI_START="-1.2141138383697911" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-09-01 17:46:45 +0530" MODIFIED_BY="[Empty name]" ORDER="338" O_E="0.0" SE="1.4263529572376852" STUDY_ID="STD-Chaney-1998" TOTAL_1="30" TOTAL_2="30" VAR="0.4915254237288136" WEIGHT="6.3342003599739165"/>
<DICH_DATA CI_END="16.21534295021216" CI_START="0.06270647000909482" EFFECT_SIZE="1.0083684427800512" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2099261383194857" LOG_CI_START="-1.2026876466608056" LOG_EFFECT_SIZE="0.003619245829339949" MODIFIED="2010-09-01 17:46:45 +0530" MODIFIED_BY="[Empty name]" ORDER="333" O_E="0.004149377593360981" SE="1.417181279928267" STUDY_ID="STD-Halonen-2007" TOTAL_1="120" TOTAL_2="121" VAR="0.49790809386890716" WEIGHT="6.416452690264936"/>
<DICH_DATA CI_END="5.0152107443983525" CI_START="0.05015724028530737" EFFECT_SIZE="0.5015467379898342" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7002891872480179" LOG_CI_START="-1.2996663669507513" LOG_EFFECT_SIZE="-0.29968858985136676" MODIFIED="2010-09-01 17:46:45 +0530" MODIFIED_BY="[Empty name]" ORDER="332" O_E="-0.5" SE="1.1747837924760145" STUDY_ID="STD-Celik-2004" TOTAL_1="30" TOTAL_2="30" VAR="0.7245762711864407" WEIGHT="9.337485013409825"/>
<DICH_DATA CI_END="1.266411412313257" CI_START="0.01278779390443912" EFFECT_SIZE="0.12725803761999321" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.10257481553271174" LOG_CI_START="-1.8932043716876579" LOG_EFFECT_SIZE="-0.8953147780774731" MODIFIED="2010-09-01 17:46:45 +0530" MODIFIED_BY="[Empty name]" ORDER="336" O_E="-1.5" SE="1.1723305738395526" STUDY_ID="STD-Rubens-2005" TOTAL_1="34" TOTAL_2="34" VAR="0.7276119402985074" WEIGHT="9.376605139153359"/>
<DICH_DATA CI_END="2.6070171273961056" CI_START="0.04663753631150655" EFFECT_SIZE="0.3486902005271375" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.41614388437476696" LOG_CI_START="-1.3312643998137619" LOG_EFFECT_SIZE="-0.45756025771949743" MODIFIED="2010-09-01 17:46:45 +0530" MODIFIED_BY="[Empty name]" ORDER="343" O_E="-1.0" SE="1.026436275942851" STUDY_ID="STD-Whitlock-2006" TOTAL_1="30" TOTAL_2="30" VAR="0.9491525423728814" WEIGHT="12.231559315811701"/>
<DICH_DATA CI_END="7.318115396009987" CI_START="0.1366472029868816" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8643992533953607" LOG_CI_START="-0.8643992533953607" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-09-01 17:46:45 +0530" MODIFIED_BY="[Empty name]" ORDER="330" O_E="0.0" SE="1.015504800579495" STUDY_ID="STD-Amr-2009" TOTAL_1="50" TOTAL_2="50" VAR="0.9696969696969697" WEIGHT="12.496311681954811"/>
<DICH_DATA CI_END="19.696096586817536" CI_START="0.3829959676685315" EFFECT_SIZE="2.746547937240682" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.2943801653099782" LOG_CI_START="-0.41680579842961407" LOG_EFFECT_SIZE="0.4387871834401821" MODIFIED="2010-09-01 17:46:45 +0530" MODIFIED_BY="[Empty name]" ORDER="334" O_E="1.0" SE="1.0051591056077676" STUDY_ID="STD-Halvorsen-2003" TOTAL_1="147" TOTAL_2="147" VAR="0.9897610921501706" WEIGHT="12.75487444499867"/>
<DICH_DATA CI_END="20.899977489268046" CI_START="0.7965128024414793" EFFECT_SIZE="4.080085739410475" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.3201458183458896" LOG_CI_START="-0.09880723934181317" LOG_EFFECT_SIZE="0.6106692895020381" MODIFIED="2010-09-01 17:46:45 +0530" MODIFIED_BY="[Empty name]" ORDER="339" O_E="2.024" SE="0.8335000500166726" STUDY_ID="STD-Oliver-2004" TOTAL_1="62" TOTAL_2="63" VAR="1.4394239999999998" WEIGHT="18.54960003856381"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.0167667540437444" CI_END="1.1886696056806023" CI_START="0.13859339369772536" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.40588391768658644" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" I2="50.41568401527162" I2_Q="0.0" ID="CMP-004.05" LOG_CI_END="0.07506115792446012" LOG_CI_START="-0.858257470654966" LOG_EFFECT_SIZE="-0.39159815636525297" METHOD="PETO" MODIFIED="2010-09-01 17:49:36 +0530" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.15557047540210744" P_Q="1.0" P_Z="0.10003005312825552" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="WEIGHT" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="123" TOTAL_2="123" WEIGHT="100.0" Z="1.64470794728783">
<NAME>Pulmonary complications, trials before 1995</NAME>
<GROUP_LABEL_1>Corticosteroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.176638739165199" CI_START="0.19317554312497054" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.714047858035458" LOG_CI_START="-0.714047858035458" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-09-01 17:46:53 +0530" MODIFIED_BY="[Empty name]" ORDER="353" O_E="0.0" SE="0.8388704928078611" STUDY_ID="STD-Morton-1976" TOTAL_1="48" TOTAL_2="48" VAR="1.4210526315789473" WEIGHT="42.71154050323813"/>
<DICH_DATA CI_END="0.8570224625246995" CI_START="0.050106919138860534" EFFECT_SIZE="0.20722633816653774" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="-0.067007795086508" LOG_CI_START="-1.3001022993554185" LOG_EFFECT_SIZE="-0.6835550472209633" MODIFIED="2010-09-01 17:46:53 +0530" MODIFIED_BY="[Empty name]" ORDER="348" O_E="-3.0" SE="0.7243258157237968" STUDY_ID="STD-Rao-1977" TOTAL_1="75" TOTAL_2="75" VAR="1.9060402684563758" WEIGHT="57.28845949676186"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.297529664087314" CI_END="1.8913449432675042" CI_START="0.5690112960215159" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.0373989769574594" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="23" I2="0.0" I2_Q="0.0" ID="CMP-004.06" LOG_CI_END="0.2767707426451077" LOG_CI_START="-0.24487911189822148" LOG_EFFECT_SIZE="0.01594581537344319" METHOD="PETO" MODIFIED="2010-09-01 17:49:46 +0530" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.6061727748814175" P_Q="1.0" P_Z="0.9046221513077689" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="WEIGHT" STUDIES="10" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="417" TOTAL_2="413" WEIGHT="99.99999999999999" Z="0.11982452813461965">
<NAME>Pulmonary complications, trials after 195</NAME>
<GROUP_LABEL_1>Corticosteroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.820467167072353" CI_START="0.0026853936013588454" EFFECT_SIZE="0.1353352832366127" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8338141226232082" LOG_CI_START="-2.570992050236215" LOG_EFFECT_SIZE="-0.8685889638065036" MODIFIED="2010-09-01 17:46:55 +0530" MODIFIED_BY="[Empty name]" ORDER="368" O_E="-0.5" SE="2.0" STUDY_ID="STD-Toft-1997" TOTAL_1="8" TOTAL_2="8" VAR="0.25" WEIGHT="2.3473259173820664"/>
<DICH_DATA CI_END="119.50989282818936" CI_START="0.46315175084966714" EFFECT_SIZE="7.439839790427749" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.07740385693992" LOG_CI_START="-0.3342766898487863" LOG_EFFECT_SIZE="0.871563583545567" MODIFIED="2010-09-01 17:46:55 +0530" MODIFIED_BY="[Empty name]" ORDER="367" O_E="1.0" SE="1.4166330911949265" STUDY_ID="STD-Halvorsen-2003" TOTAL_1="147" TOTAL_2="147" VAR="0.4982935153583618" WEIGHT="4.678629132256406"/>
<DICH_DATA CI_END="5.4742862620723205" CI_START="0.05364941725776223" EFFECT_SIZE="0.5419338224011797" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7383275038501002" LOG_CI_START="-1.2704349909974284" LOG_EFFECT_SIZE="-0.2660537435736642" MODIFIED="2010-09-01 17:46:55 +0530" MODIFIED_BY="[Empty name]" ORDER="362" O_E="-0.43999999999999995" SE="1.179957033008155" STUDY_ID="STD-Schurr-2001" TOTAL_1="24" TOTAL_2="26" VAR="0.7182367346938776" WEIGHT="6.743742808651224"/>
<DICH_DATA CI_END="19.9373010618555" CI_START="0.1993934155442883" EFFECT_SIZE="1.99383212820391" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2996663669507516" LOG_CI_START="-0.7002891872480179" LOG_EFFECT_SIZE="0.2996885898513667" MODIFIED="2010-09-01 17:46:55 +0530" MODIFIED_BY="[Empty name]" ORDER="366" O_E="0.5" SE="1.1747837924760145" STUDY_ID="STD-Whitlock-2006" TOTAL_1="30" TOTAL_2="30" VAR="0.7245762711864407" WEIGHT="6.803266641903956"/>
<DICH_DATA CI_END="4.588782160550079" CI_START="0.04628604211281595" EFFECT_SIZE="0.46086501747231745" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6616974412822398" LOG_CI_START="-1.3345499538478311" LOG_EFFECT_SIZE="-0.33642625628279577" MODIFIED="2010-09-01 17:46:55 +0530" MODIFIED_BY="[Empty name]" ORDER="361" O_E="-0.5633802816901408" SE="1.1726056014833777" STUDY_ID="STD-Yared-2007" TOTAL_1="37" TOTAL_2="34" VAR="0.7272706662510273" WEIGHT="6.828565135371037"/>
<DICH_DATA CI_END="18.654982765042313" CI_START="0.18981749327591743" EFFECT_SIZE="1.8817656776458047" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2707948521412287" LOG_CI_START="-0.7216637661810329" LOG_EFFECT_SIZE="0.2745655429800979" MODIFIED="2010-09-01 17:46:55 +0530" MODIFIED_BY="[Empty name]" ORDER="358" O_E="0.46153846153846145" SE="1.1703800552317227" STUDY_ID="STD-Liakopoulos-2007" TOTAL_1="40" TOTAL_2="38" VAR="0.7300391915776532" WEIGHT="6.854559660379508"/>
<DICH_DATA CI_END="6.8967201318596905" CI_START="0.11362474111321061" EFFECT_SIZE="0.8852333248996137" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8386426027244629" LOG_CI_START="-0.9445270932813703" LOG_EFFECT_SIZE="-0.05294224527845368" MODIFIED="2010-09-01 17:46:55 +0530" MODIFIED_BY="[Empty name]" ORDER="363" O_E="-0.11111111111111116" SE="1.0474427062661789" STUDY_ID="STD-Weis-2009" TOTAL_1="19" TOTAL_2="17" VAR="0.9114638447971782" WEIGHT="8.558010822596486"/>
<DICH_DATA CI_END="1.6709074173963647" CI_START="0.04126863309261544" EFFECT_SIZE="0.26259486883840705" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.2229523869204436" LOG_CI_START="-1.3843799156674257" LOG_EFFECT_SIZE="-0.5807137643734911" MODIFIED="2010-09-01 17:46:55 +0530" MODIFIED_BY="[Empty name]" ORDER="359" O_E="-1.5" SE="0.9441549509633318" STUDY_ID="STD-Bingol-2005" TOTAL_1="20" TOTAL_2="20" VAR="1.1217948717948718" WEIGHT="10.53287270620158"/>
<DICH_DATA CI_END="3.5063095899143963" CI_START="0.285200144013642" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.5448502595203324" LOG_CI_START="-0.5448502595203324" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-09-01 17:46:55 +0530" MODIFIED_BY="[Empty name]" ORDER="364" O_E="0.0" SE="0.6400954789890507" STUDY_ID="STD-Starobin-2007" TOTAL_1="30" TOTAL_2="30" VAR="2.440677966101695" WEIGHT="22.916266583255428"/>
<DICH_DATA CI_END="6.318201278591119" CI_START="0.5368983492039066" EFFECT_SIZE="1.8418012478043293" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.8005934570849673" LOG_CI_START="-0.2701079313556974" LOG_EFFECT_SIZE="0.265242762864635" MODIFIED="2010-09-01 17:46:55 +0530" MODIFIED_BY="[Empty name]" ORDER="357" O_E="1.5439999999999996" SE="0.6289352956273975" STUDY_ID="STD-Oliver-2004" TOTAL_1="62" TOTAL_2="63" VAR="2.528064" WEIGHT="23.736760592002305"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2011-04-06 12:32:57 +0530" MODIFIED_BY="Joey Kwong">
<FIGURE FILENAME="Flow chart study selection MAR11.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2011-03-10 01:48:29 +0530" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>
Study selection chart
</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAloAAANnCAYAAADpyPYtAACAAElEQVR42uydCbgV1ZloTfrZnaSTvPg63f06Gu1OojFxiiYao8RZEJwHVBBQcUIUUBAEnAdAkVFxAFFQAQGZFVRwAhUnVEABkUGRQQKCIIgyyH69dnqfV/dw7uVeuBfuhbW+r74z1DlVdepU1V71773/vcuaNWuDiEhl5rvvNoaVK78OQ4e+GR5++IX4yGuvXyJS2dnFXSAiVYENG74La9eu/2/p+vsjr0VEFC0RERERRUtEREREFC0RERERRUtERERE0RIRERERRUtERERE0RIRERFRtERERERE0RIRERFRtEREREQULRERERFRtEREREQULRERERFRtEREREQULRERERFFS0REREQULRERERFFS0RERETREhERERFFS0RERETREhEREVG0RERERETREhEREVG0RERERBQtEREREVG0RERERBQtEREREUVLRERERBQtEREREUVLRERERNESEREREUVLREREZAcUrY0bN4b169cXmbJk3//uu+8qdFs++eST8MQTT2zTHf3KK6+E1157rVyXyb566KGHwjfffOORLCJSScgv68papm3u2r5mzZrQt2/fsGzZsu3+W+fNm1ch5ekzzzwTpk+frmiVhS+//DI8/PDD4Xvf+174t3/7t/jHrFu3Ls779ttvQ79+/cJuu+0WGjduHObPn19h2/HBBx+Ev/zlL+FPf/rTNtvJQ4cODT/5yU/CXXfdVa7LXbhwYdhjjz3CrFmzvLKJiFQCCCoMHjw47L777uEf/uEfQpcuXcLHH39cbtf2VatWhRYtWoRddtklzJ49e7v+1mnTpoUjjzwy/PGPfyz3ZZ988smhe/fuitaW8Jvf/Cacc845BefVqFEjfP3117nXAwYMiAdcedOpU6cSRWv58uWhd+/e5bpO5G5rRasitktERMqfevXqhf/8z/+skGUvWrSoUogWIJLlIVoVVd7vlKKF4Fx00UUF59WuXTv3fPHixdHoK2LHd+vWrUTRqlu3bujatWu5rvOvf/3rVotWRWyXiIiUP1deeWXYb7/9KmTZS5curTSide+99261aFVkea9oFSNaK1eujM85kJo2bRr69+8fxowZE2rVqhXtme/vv//+sZ6aasZrrrkmXHvtteHiiy8O7777bm5548ePD5dddlkMszKPgxMIR7Idb7zxRjxADjjggDBjxow4r3PnzuGnP/1pOPHEE8MNN9xQsG798ccfDz169AhXX311OP3003PvP/vss+G6664LDRo0CDfeeGOMQBUnWsV9lvXdc889oWXLlnEezwtt1+rVq+Pv+P3vfx/mzJmTW+4777wTbr/99niSn3DCCWHKlCnx/dGjR4eaNWvGk+Luu+8Ov/rVr8LZZ5+9SVs5ERHZNqJVqBygXCt0bedaTpSMcqR58+ZFRIvreIcOHUKbNm3CueeeGx577LEtuu5PmjQprvumm26K5QdNbUpafiHRKqlM/tvf/habB7EcAgcvv/xywfKe/ULVYSr/gDLv5ptvjuXbUUcdFXr27BnfpxYML/jd734Xpk6dGurUqROl7YEHHlC0NhfR+uyzz+KOT4a7YsWKsPfee4ejjz46/vn8ubTxYoen6kYOwAMPPDA+Z4cjY9SXw8EHHxwP6CRa/BE0ttuwYUM466yz4gGcOPzww4uNHC1ZsqSIXPGnppOAkwVY56GHHhruuOOOgqJV0mc5iBAp4CRiH7z11lubbBcH/uuvvx7np3p8Pn/YYYfFExVoTEnbsK+++ioezJxkp5xySmxg+Omnn4Yf/ehHsf2YiIhsW9EqrhwodG2nqvD//J//kwsWDBkypIhoISAjR46Mz5Ez5n300Udlvu6fdNJJ8TuAWKUb9eKWny9alKfFlcnM+8Mf/hAmT56cW/5ee+1VsLxnG2hm1L59+1wAAmF89dVXcxGwXXfdNQwaNCjurwkTJsTvs0y+e//994d/+qd/qjSBhCojWnDEEUdEK0+8+OKL8Y/jj2Zq3bp1lBG+yzquv/76IqHJBQsWFIloJfgzEbjSiBbL4A++9dZbcxE1aNSoUbT3tC3Yev369QuKVnGf5WT78Y9/HO8qEh9++GHsLFBou9g32ZOR33/BBRfk5n/++edxPhG49H0iYwlODu4ERERk24pWSWVG/rWdCFa1atWKRIayovWv//qvsWxIy+Kz9Eos63Wfhu20lZ47d25sdE+AY3PLz4pWSWUy0TWkL0GghIBIceU925JEi6jYD37wgyI1TJSpCGT2+6k8Zvuzr3c60eIPOv/88wvOywpYcTuehuyJXr16xfBqIWh83rZt24Lz8kUrP/RZkmjBk08+GXtI/vu//3uMigFVeshXcWRFq7jPInH85vfff7/gMvK3i+ha9mQ85phjNtm33E2kkxdRzZ5w3HmUd09IERHZvGiVVGbkX9spN2kGk8i20aJHP8/pAViIslz3iVJRK/K//tf/Cq1atYoRoc0tP1t+llQmU3YRpSpEofKe4EcSLSJUP/zhD3OZCoDoH+8RoEhlZxKrJKII104pWlTTIUyFuPTSS8skWsOGDStyMKbIFd+heu+QQw4psvz33ntvq0WLvCVEmFgP1YakqyCUynNMvtD68kWruM+y3O9///tFTgIOoiRemxMt7nr23HPPIsulXRvhVEVLRGT7ixbXdCI/JZUZ+df2448/voikJNFiPlVy//iP/5iTkvxlleW6TxUly6Oc+ed//udYg7S55WfLz5LKZFI4MS/b7oznRM02J1q0p2b+m2++mZvfp0+fXBmvaOXx3HPPxaq3/Pwg7DR6A+YfSNTnpio/Dpg777wz95kvvvgi/OxnP4t3Bvxh7NTUvomwJhJEOgSSvo0aNSo2sAMOOtpsZSNcBx10UO71scceG5eTGiZmIenofffdl3tNKJRtHDhwYK6OGBmjIT5tpLIRtrTtJX0WMaL9GHXjzOOE4I6i0Hal8HKqK584cWJ8nRr2E2alnVrK4cLJ0LFjxyLyl92fIiJSPtD+qlB6B8ofmoeUVA7kX9sJMPB63LhxuchTKh+BBu7UsIwdOzYui6rBVA6U5bqfrRGh6U0qT0taPs9T+VlSmYxw0TSGZVGm0Swm5ckqVN4TWKHNcpLTX/7yl+G2227LbR+N7ZE8SFWFJCNP6+J1WfOX7TCilQwY8aA3YLt27WJItFA1H40DCUPy51JFR3UdgvT222/nPkNvRN5np/7Lv/xLrrEcknHFFVfE9/lzqQ/nz2LHc3dADz4a93HAUifNZ55//vn4XSyeRuTZxuxZ0fqP//iPaNoYepMmTXLziCghd6yTgyQ1KqRnBQcfB3jqxVHcZ8myy0HL+0gc1ZSJ7HYhjxx0fI4Tgh4ZwHYhV4RaqYpNckn9OI0g+e2EgBFeGldydzNz5kyviiIi5QBlD73yKCe4xnPzTGcranMov7K1DoXKgULX9rVr1+Z65nHDTbSMZKjNmjWL4kMk6s9//nOcz/JSlWRZr/uIIe3GaCx/4YUXRmFJka5Cy0dskCqiXyNGjCixTE4RL8patp2IVTY9Rba8J+JHmUmVaZJNolo0nqf8o4dmEjiCDimBK70lETUEjde0EUtl404nWtmQYklZzRGj0gwvQ70tf0ZqNJ6FEGyKCJWF/EhWggOeUCohSuw9H6JNmHzq7VgSxX2W1xh6odQSxW1XFvZZNjwrIiKVk7KUGUgEZRptpwrlnEJ8CpVLpYWyg6q84sqP0i6/pDKZdVBVuCXlPZ9BzgottzLjoNIiIiIiipaIiIiIoiUiIiIiipaIiIiIoiUiIiKiaImIiIiIoiUiIiKiaImIiIgoWiIiIiKiaImIiIgoWiIiIiKKloiIiIgoWiIiIiI7qmgx+vfHH3/stA2mNWvWeJSLiFRyli5dapm1jaZvvvlmxxetf/zHfwzVqlVzquDpF7/4RTjvvPO8gomIVGK4Id51110tt7bB9POf/zxcccUVO75o7bHHHp5Z24C33347nHrqqe4IEZFKzMqVK8M+++zjjtgGvPLKK9s8AKFoKVoiIqJoKVqKlihaIiKKlihaipaiJSIiipaipWgpWiIiomgpWoqWKFoiIoqWKFqKlqIlIiKKlqJVBUTrgw8+CJdcckno1KlT2LBhQ3xvypQp4eKLLw7t2rULq1atiu8tWbIktGzZMjRp0iTMnTu3yDKeeeaZ8Nxzz+U+W1oWLFgQBg4cGOrWrbvJMhUtERHZHqJV2nLx008/Db169QoDBgyIy7dcVLQKMnHixPDtt9+GWrVqhfHjx8f3+vbtGxYvXhwaNmwYOnbsGN8bOnRoPAAeeuih+NlEq1atct8rK5dddln4/PPPw8KFCzc5SBUtERHZHqJV2nLxnHPOCd99912YOXNmaNGiheWiolUy7du3DytWrIgHTTL4l156KTRv3jw+X7duXXzk4Pvzn/8cn48ePTo0btw4DveTDybevXv3MGLEiPDss8/G5SIlvXv3jtGxN998M+y3337x9bJly8Lq1avDuHHj4p3B2rVr44E+aNCg0Llz5zBr1qywaNGiMGzYsDB27Niwfv36MHjw4Hggd+jQITz99NNxnRs3bozL7dOnT5g/f358L/u9dAfCdnfr1k3REhFRtLaoXGSImb333jv32T/96U+xDCpLuZhf7u0o5aKiVQCiVPvvv3+YM2dOkffbtm27yXtEtvgzoUGDBqFr167xTz/uuOPiwZj48ssvw+677x7/4MmTJ4eePXvGP3PMmDGhXr168TPHHHNMztg5MJYvXx7XyUHG50jlz/c/++yz3Pyjjz46zJgxI7Rp0yY0atQobl86ediWjz76KLz33nvhxhtvjAde9nscmM2aNQtff/116Nevn6IlIqJobXG5+Mc//jGWN1QP/vrXv45SU5ZyMb/c21HKRUWrGLDda665JveanT98+PAin8Hge/TokXt9xBFH5A640047bZNQ6cEHH5x7fvLJJ4c33ngjd4BlDyj+4Bo1asR5TFg/n6E+HF544YVw7bXX5uZzp9ClS5fw+OOPx/mHHnpoPHiOPfbYeKAnCn2Pum/uGIYMGaJoiYgoWltcLiI7VCPee++9oXbt2mUqFwuVeztKuahoFQN1zA888EB8Tv0w4UlIYVP+sIcffjiGL/nTMHPM+eWXX46fu/LKK2PEKsshhxySe16nTp3cZ6dOnZo7oFg+y+NPZplpfvaAYtuOP/74uA0cfLNnz46Wng6oww47LM6jvnzChAnxvWnTphX8HmbPScDBzmcULRERRWtLykWg/KLh/PTp0+Pr0paLhcq9HaVcVLQysKMvuOCC2MiPMCcHIo39DjzwwPhHYMKnn356/MPPPPPMaOq8z59B/TGfbdq0aXj++edjKDILf9Zuu+2W+9OIZnGQ86dTx83Bt+eee4b+/fvHum96buy1116xIeC8efNimBQjpz0X8P6+++4bez7STozqR+rJ03Iwcw4m6szprTFp0qRNvseJUb9+/Rh+JYTKaO6KloiIolXWcjHJDs1iqJZLlKVczC/3dpRyUdHKgz+HBndbQ2m/z4HD+opjc38w9r05aLSfGu4X+h7bsHTp0iKhVEVLRETRKmu5SDunrS0XN1fuVcVyUdGSckXREhHZsURLFC1FS9ESERFFS9FStBQtERFRtBQtRUsULRERRUsULUVL0RIREUVL0ariosVBOXLkyDgoJknbtgZ6O7Ru3brCfuvHH38cbrvttpgZN8GgoEgQkM2ewUHJAaZoiYgoWmWBFAhPPvlkePXVV3PvkWIhpX8oBOXmu+++myv7GO7mk08+2Sa/lbKOsum1116Lr0k1cdNNN8WJMRR5n8GxU5oIRWs7iBYHFfk40gFE7o6S0jLAI488UuL8lGStIiCJG91syQkCjA2VMtzShRURYwynDz/8UNESEVG0ygyiRab2BAm8yQtZHI8++mgUs4os+4ojjdHIMEJklH/xxRfj+Ibk9SLwQZnJtqXkporWdhAt/gQy3SbIrcFEolEy43LAsROJdvFICv8TTjghZq49//zz4wCYJElj8MwmTZrEzLbZ5ZU3bBsHTMrGS1I5BswkIgfkB7nhhhs2ySOiaImIKFqlgZv3O++8M0aHuIF/7LHHcjKRysannnoq1qxQNpIVHplJZd/NN98cE4hmy87875YXV111VQwwEEVD+BIMFQTk5qIWiOSqilYFixYH3qWXXhonjDfx/vvvhyuuuKLIZ/ljGB+JDO+MlcQwA4gLBxPRrnQwpdfMI7KEaDE0QUWKFmDtCA/rJcstnHHGGfE1mX7J8ss4UIqWiIiiVdZyEdGi5oTxC3nODTwykV82Xn311bHqjqrDrGgxlM8777xTpOwkCJH9bnlBZnjGJSYD/JQpU+J7DLXz7LPP5oITrJPfqGhVsGiRDZY6Y6avvvqqyLyTTjopHkjAfOQJoWAYAIYb4GDhYMKcOdAIj/K6cePGcfBp/kRM+tZbb42fb9iwYYX91hSpuv/+++NjGvaAEc85oPid1EuPGDFC0RIRUbTKXC5SkwPNmjWLw+5QNUfVIWVMtmxEnGibRdUitSyp7EO0KC+yZSeRsex3yxPGZqQdVoLhfFJZySNNhB588EFFq6JFqyRoJHfffffF8Y8YoRw4eAid8gdyoDGSOW2zOCBpcE7VIe25GKCSg5oG6MgNBxB/clpOeUM9NNuWhhQgukWIFlFEsDjA8wf2VLRERBSt0oCUUL1HmTd//vwYiaJco+0vy01lI+UmTWko+yiXEK1U9g0fPjxMnDhxk7Iz+93ygnKPMjA7pE5qWkMNT8eOHWM5jVQqWttRtETREhFRtETRUrQULRERUbQULUVL0RIREUVL0dqpRYu66Gy9bnHvJWjUR5stemOsWrUqNoRPjegrmmy6hkLJSNkeYNs3lwdM0RIRUbSKKxezU0mfow3X9iA1cE9QFmfZ3GtFaxuKFg3+jjzyyNzrBQsWhN133z02risEjd1pEHjdddeFSZMmRekiD1dFQgM+1vf666/H1zTEp0EhWXoT5PLiNQ3k77777pjqgQaIipaIiKJVFp555plw+umnxxQM9GpPHa/yoeyjV+K2hs5eNKivXr16bFRPo/s77rgjlyyVcrpFixahefPm8TWpH0g7MWrUKEVre4jWtGnTYpfV8ePHx9f9+vULNWvWjM+JELED58yZE1/zSH4qRIuefYgWPQ/J20EPBxK3kUiUiFL+d7cWemwk0brgggviIwcaYkivQ5LJZcWLAyo/hYWiJSKiaG0OegeSjgHoQUh5Ri9CEo9SrpFvi7yRq1evDk2bNo03/yQDpSaF+anHH0PDkYOLyBNCRELRZcuWbfVvS2Ub5S3blA04ZOensjJJIeW9orWdRIuddPbZZ8c/B0GpVatWnEdWWfJjNWjQIHYdJfs6CdmyosUBRbdWPsufjv3TDTb73fKAHF1JtK655pq4ndg7JwTbRZLUJFoMPcDdyFtvvaVoiYgoWmUWLRKVku6IEU8QpbPOOis2maFsobkMo6IgWnXq1IlCxWvKPDK08xkggTe1L6RYoGxkeYxaUl6wbSwbGBmF9aZmPwhdyhJPRI6k5E888YSiVdGihUiRXO2ee+4pIlpEoshaywCU1Psm0UphSGye6jgGpuSA6tq1a060EA9Ei4gT4Uuy4/K57HfLW7SAuwdsnYga1YqXX355HIqHfCfAiUDuEEVLRETRKku5mI1oIVOUYynje8quzmvmpapDIlvU7jC0TgowEBCoXbt2FLS0vPIqE4mq5Q9ajcyxLtowUzuVT6tWrRStihatQgwcODAMHjw4tmciUkVVHAcnjyQwRWYImRIxwtyJGmHpZGEnXMqEod94441xWbfffnvMqJv9bnnAOtKAmLQLQ7xIFJdIES0aJpIwjmhWRTRSVLRERHYc0SrE6NGj44DSjHNIWUaNDjfytF0+8cQTY/lI+yiqFSnnCC4w3A3lEmMcEllCgq6//vqYjZ1aFspNZIuAxNaCwJ1yyilR8qgupBxmvGGqJolo1a1bN66PIXnYVspGykiGBFK0toNobY5s7z6eUwdd2uyyhXoGlgfFNUxMVFSPQ0VLRGTHF62yQHmYLXOoyku9AXk/O6+iykTWl+2Vn09F9jhUtETREhFRtETRUrQULRERUbQUrR1OtGhgTsN26qIZfby4akF6MJBOobJAXTl/LmFZ6qZvueWW3CDW77//fnxvc1WMipaIiKIlilaFitbs2bNzvSFosFdSXW7qSbi9IVlb+/bt43PqppEfRia/8MILYw+Sli1bxt9hr0MREUVLFK3tKlr0jKCHBMnXSEbKwUm+EHoOIi5kjk/dWs8999zYow+RWbFiRczhQc8GUirQI7Bdu3axQd5LL70Uv0c314qArrNkviXbbSJF3Mjz1aVLl/he/fr1FS0REUVLFK1tI1rk/ECGevfuXUS0yKGFICER0LBhw4KPSbiIbCFayBmilVI/9O/fP1bXkZOExG0MX1ARpD8U4UuZbhFDolh0w035UCpCiBQtERFFSxStgpBfg0SeKaknMERO48aN43NEhYSk+YKVqgyTaN11111RpMgZcuutt8bEpbSLatOmTRwOBxGZN29ezBBfEZB1HmkkcsXvSXm+kC66z5JbBOEjh4miJSKiaImitU1EqxAIE+JCY3giXSQDJUEbjc2pmiPZ2f333x/HaaK6js/RRoqDuFOnTvE9JIvs8ES4kDmGHKAaj+9UBETTqJ4kISnPb7vtttgYnm0AEsIxKKiN4UVEFC1RtLaraImiJSKyo7FmzZqwyy67xDELq9K03377haOOOqpKbfNxxx0X6tWrp2iJoiUisjNBExba7Val6eSTT47jCVe17aY5j6JVDKRHYKLKLz2m54UO2tJAWy/SLWQh7UKhIQL4LO2syko2DUXa3uw2s66KGIpH0RIRkYrioosuiuMmyg4kWj179owDT5JD61e/+lUc+ZvG8jQkz4oL6RPOPvvsUi2TRuo0UE8ji9N4njpcejfmQ5uwyZMnl2mbaRfWokWL0Lx58/iaxvqNGjUKRx99dG6bmc86FS0REVG0FK3tJlpEfk466aT4nFHI6UH44Ycf5iJSM2bMiI3cgV6HL774Yuzhl4XvkL8K3nrrrZiHK2VpX7VqVahWrVpsVE9yVCCCxTIXL14cpk6dGqZMmVKmbSY6lraXATxTpIxG/UBjeBKaKloiIqJoKVrbVbSASBNCdfvtt8co0dChQ+P7DGMzbNiwcM0110S5ImEpsoSYUV0HHBAvv/xy7AVI/irEis9nIZ/WH/7wh5jsFPgckTOWzXdTb8GyQISN9BIJ0lKwLCQOwXriiScULRERUbQUrW0nWkSCSCaaEnomXnvttXDCCSdEeUGikmgRIUq5sBColEeLasXURophbhAcXtPrIF+0eE3kih4gNWvWjLmuUhUi8xCXsooWubL69etX5L0HH3wwVhuOGjUq5vNChi6//HJFS0REFC1Fa9uIVnEQnWratGlOnFKjd/JlIWAdOnSIkkYCU6oIGV4nQTus1q1bx8zsCBs5tOjumXogEGG6+uqrw/jx42PEjHXRngrhI/8WUnfDDTfEqFdp2mrx/bp168aM9LQtQ+KAXF9ZjGiJiIiipWhVCtGC1M4pv2fghg0bijSKL5QEFPkhylSI1BuQqsIs+Z+nrVWhno6lpSKSkypaIiKiaCla5SJaomiJiIiipWgpWoqWiIgoWopW1RIt2lRRTUjVYTZ5abY6L/91fjVjNmloep5NiFqRZBOYJhjrStESERFFS9HabqKFLDEgM43cGYj51ltvjY3IGbuIhu4MBzBmzJj4Wd7PNjqn9yA9FYFehSQ0JZkoGdnJcUUDeXoB0tuQJKgVBb0Waaif0kfMnTs3PicZqqIlIiKKlqK13USrU6dOUY4SJCpFUBAX6N+/f6hevXqYOXNm+OKLL3I9+ehN2KxZsyKpIsjBlRKd0pOQ1BDI2lVXXVVhv5toGQ3heaxfv36MnDVo0GCLhvVRtERERNFStMpVtM4777yYrDRLVrSGDBkSFi5cGCNcJCtNojVw4MDYU/DEE0/MVRciWo888kh4/vnnQ506dbaJaCVef/31mBGexKqkfRg8eHBo1aqVoiUiIoqWorVtRKtQwtJu3bqFkSNH5l4THcoXLWBoHWQL0UKwOnfuHIWKfFajR4/OidbmIlr5aR7KA3JppW1gzMb0+4hsKVoiIqJoKVrbRLQKgfjwx5KElKSiiBECRaSKqkLkKSUFTUlASWBKBAn4zmGHHRbmz58fE5UyrA4N02vXrh2rHamWPOqoo6KwMbg0Q+WUJytWrIjZ7BFIpI+qwx49esTxGp9++mlFS0REFC1Fa/uJViIN1Lw56JlYFSDqVhEoWiIiomgpWlJBKFoiIqJoKVqiaImIiKKlaClaipaIiIiipWiJoiUiIorWzilav/jFL2IPvKo0kS2+qm0zubpq1apVYf9jVdsflWmqKh01ZOeC49Lzs/iJlEKiaFUJ0dp///3Db3/72yo1/exnP4uCWJW2+b/+679CmzZtKuQ/ZAikXXbZpcr9j5Vh+uEPfxiuuOIKrz5S6WA4sh//+Meep8VMXPPmzZvngaJoVX7RqoqQyHTo0KHuiP/hzjvvDPfdd587Ygt44403wumnn+6OkEoHef5I3iyFIf/im2++6Y5QtBQtRUvRUrREFC1FS9FStBQtRUvRElG0FC1FS9ESRUvRUrRE0VK0FC1FS9FStBQtRUtE0VK0FC1FS9FStBQtEUVL0VK0FC1RtBQtRUsULUVL0VK0FC1Fq7z57rvvFC1FSxQt2YxoFXetVLRE0VK0SuTRRx8NZ5xxRnj99de3SLS4+JT1ArRx48bw2Wefxefz58/fJr/zm2++2eS9lStX5rbn22+/VbRE0dqK83r58uVh1apV8VxbunTpNvtNrDORPY/Z/nXr1m21aL3//vvh3HPPDY888oiiJYqWolV2evfuHbMhM/3lL3+J+4ALVGlFi8/XrFkzPPXUU3Ef5gtbIT7++ONw+eWXx+FAxo0bV+Jn169fHz7//POt+o1sGxn027Vrl7sw89tmzpwZh9y4++67o2zOmjVL0ZKdXrQ4/2+88cbQpEmT8MQTT8RztTTZ0q+77rowadKkeL5Onjy5xM8uXLiwXCJEAwYMCJ07d47POY/Hjx8fXnnllbBmzZrQvn37MGTIkDJles+K1quvvhqvben6+PDDDytaomht7QG19957h8MPPzwKxxFHHBGOPPLIUK1atfDXv/41HHXUUeHoo48Oxx57bDjuuOPC8ccfH0444YQ4Va9ePdSoUSNexDgxGX/w5JNPjgM+c+IyUfBSmJ911lnh7LPPDuecc06oXbt2vFM6//zz41SnTp1Qt27dOExGvXr1QoMGDcKFF14Yt+3iiy8ODRs2DJdcckm49NJLw2WXXRYvgAz1cuWVV4bGjRtH0bn66qvjxEWyWbNm4ZprrgnXXnttaN68eWjRokVo2bJlnFq1ahWuv/76cOaZZ+YuJGn6zW9+E7e9S5cum91vyArrSAKz1157xTvb0aNHx/EjeeSiygWQ6BnPESy2fcGCBeHll1+O3+ViyAnNBXLKlClh5MiRUYJuuumm0KNHj/iZGTNm5MTsgw8+iBdRLtZPP/30ZreT5Q4fPjw+b9q0aZg9e3aMZCVGjRoVvvrqK0VLjGj9j8D069cvPn/rrbfi9e3TTz+NN1I8vvbaa/HcZbzVgQMHxnP6gQceiKI1derUeA7z3jvvvBM/k84LzmuiTJwfvM81AzGaM2dOPN9ZLoJDVOyFF14ocRvnzp0bHnvssSha3LzddtttOeF78skn4zBiXGO6du1aJtHq3r17vObnXxe5prdt2zbetLVu3TpeP9P1lHVyfeVay/WQay/XmXQ95trMNbpRo0bxms31j2s413Ou60xc47nec92vX79+LAMoDygXUhlBeUG5QflBOcL1m3KF/cm2c90+5ZRT4rZSDvF/899RRp144omxvKLsogyjLKNMo2zj91LWUe4xUQZSFjLMm6KlaJUbyMqDDz4YPvnkk3gCc+IT4eAERiY++uijOE2fPj1MmzYtfPjhh7Gw56LC3RvhZS5gTO+++2684Lz99tvxIsUdEhcZLixcSNLFZMKECVFAuGC99NJL4cUXX4wXF2Ri7Nix4fnnnw/PPfdcPNDHjBkTpQWpQAq4YDGNGDEiDBs2LEaWEA+iN4MHDw6DBg2KFxsmLpr9+/ePF87HH388Xpz69u0b+vTpE0/4/AvKQQcdFE/ue++9t0yiBZy43NFy0QAeqUZAMLn48phEC7HhYrNs2bIYlmc+F2a2k4nfQMSNfce+4neyLv4DRJL9TMSL/6AkEKqOHTvGCyNixoWH/c1vhEWLFsULFf+VoiWKVlHR4vxhHMC1a9dGUeD85bwlQszNyw033BCvS0m0uJ499NBD8fXq1avjuc01gGsZ5y83OSyHc5drDOcLcoGwcV5yLWUdnOfFwXyuB3wG0eJamSLwyAbRLK63yNt5551XJtEiioes5F8X2UZ+CxM3jVw/uZZyTeU77C/2W7ru8nu4FnNN5trMNZr9xTU7Xb/Zbwgh13au8ewjfgvXfybKA8oF9gv7lfKCayHlB+UI4svvZB9SzlDmcA3lf+D6yH/N/qSM4vpKmUXZRRnGvkvlGtdxyjr+G8o+ykDKQsRO0VK0yg2rDv8uWOwDLqylrTrMj2hxVwTcqaVHoknc1QHRuCRaSA8XbC4evXr1ivNpN0UEiwsWF7AkWlyQUwHBepBN7uzy21Zx8eCukgtdPkTxWCd3nmlbKDyAggAZU7RE0SoqWhTenK+IEdEYrg+ct0SKKLgp2JNYpRtMXnPuE5liWrx4cTzHb7755niOJtFKN2Sc05z7nKPc8OaDfHBeIxfAzRVRJLaLCA3RbqJMgFghMAgOssANVllEK1UdIjHcOFp1qGgpWorWVotWVrASpRUt7tgIU3MycmFO0SVC4cgO4WoiXDxyEeY9qh646yRiyJ0jIkYBcMstt8Q7KpbXqVOncPvtt0eh4uLMHRZh7w4dOsSqSS6eXJCJRvHZkujZs2e8q+NOENhOtoULMY3xKQCIZpVXw3xFS6qyaHEzQhUZ1V9EWojaUOUPnK9EYmgiwXnHucX5s2TJkvgdriNMRLmIzlCtRfSc841Cmxsulsm5TnSHawxNJXjOjRXViESoiHaz7M2RIlrAdYLlEP0hksY2IEep401ZRSsreX/6058ULVG0FK0tg3ZUWcEqq2gVB1ErokVEnAjfs395LInUQ4g73XTBzz6yzPSc5aZoVopKlbTc/Ia3aR1pWeWJoiVVPaJVHJwrnEs8EtEielVSo/bsuck5l73WpOfpMywn24Nwc+d1SdeQtPzseb6lopW9VipaomhtwUlJochEw0KiJel1oXQAOxPlmUeLun+q5cra1bqqomjJjipaWYjwpKq8HQUTlv49FU4qB2lQT6eo9HpnuYYrWuXMAQccsEmjx9///vc7ZXK6ihKtnQ1FS3YG0doRUbT+Hlmk53l+uUj1qShaWwTtB/IPKHqL7OwoWoqWKFqK1s4JHRvyy8XSpNFRtKQghEJ33313o1mKlqIlipaipWiFv+cd/PnPf240S9EqP8gobDRL0VK0RNFStBStv0MvTqNZila5sWLFivCTn/zEaJaipWiJoqVouSP+G1J2/OAHPzCaVVlFiyR25FeqShP5YUi8WdW2m5OhokSLO5qqtj8qw0RuMoZvEqlsMPQKWc09TwtPP/vZzypMtMjOXtX2B7kLyVlY1bab0UZ2eNEi1JjGeKoqE1mMs2MFVoUpjVNVEZApnXG3qtr/WBkmxjTb0bq9y44Bw7iQTd3ztPDEzWV559UDEqhWxXKRxNNVbZsPO+ywGJnc4UVrjz328Iq2DSBZIBnWRUSk8sLwQvvss487YhvA6AJlGd9S0RJFS0RE0RJFS9FStERERNFStBQtRUtERBQtRUvREkVLRETREkVL0VK0RERE0VK0FC1FS0REFC1FaycRrSlTpoSLL744tGvXLqxatSq+98knn4SRI0eGYcOGxedZnnnmmfDcc8/Fz3755ZehZcuW4dprrw1/+9vfyryNCxYsiMPt1K1bN8ydO1fREhGR7S5apS0XP/3009CrV68wYMCAuPziysqdrVxUtPLo27dvWLx4cUyK1rFjx/jeRRddFDZs2BCTxnGwJVq1ahXGjx+fe/3OO++EtWvXxgzmt912W5m38bLLLguff/55WLhw4SYHqaIlIiLbQ7RKWy6ec845cci4mTNnhhYtWhRbVu5s5aKilYEDhAMHXnrppdC8efP4/MorrwydOnUKL774YujXr198b/To0THb9hdffLHJcp566qkoXVkw8e7du4cRI0aEZ599Nq4LKWFoFIasYYiF/fbbL74mVT9Ze8eNGxfvDJC3iRMnhkGDBoXOnTuHWbNmhUWLFsU7ibFjx4b169fHFP8cyB06dMgNtrlx48a43D59+oT58+fH97LfS3cg/JZu3bopWiIiitYWlYvffPNN2HvvvXPfYzxCyqCSysr8cjG/3NtRykVFqxjatm0b5syZE59j7AcddFAclDcN8NygQYPQtWvX+AczVld6f8KECeG3v/1tPGiyUK24++67xz+Y8aV69uwZ/8wxY8aEevXqxc8cc8wxOWPnwFi+fHncDg4yPletWrX4/c8++yw3nyFvZsyYEdq0aRMaNWoUtzmdPGzfRx99FAdsvfHGG+OBl/0eB2azZs3C119/nRNIRUtERNHaknLxj3/8YyxvqB789a9/HaWmuLKyULmYX+7tKOWiolUAdvTw4cNzr++///74p9SuXTuGQOGII47IHXCMYZQNixI2ZWyjfA4++ODc85NPPjm88cYbuQMse0DxB9eoUSPOY8L6+UwKz77wwguxHViaz51Cly5dwuOPPx7nH3roofHgOfbYY+OBnij0Peq+uWMYMmSIoiUiomhtcbmI7FC1eO+998b3N1dWZsvFQuXejlIuKlp5UBdMKBJWrFgR7bt69erxNeHTNDAklsxgqEAIlehUFv64fA455JDc8zp16uS+P3Xq1NwBxTo5CPiTsf00P3tAIXLHH398PGg4+GbPnh0tPR1QSB7zqC8nwgbTpk0r+D3MnpOAg53PKFoiIorWlpSLQPl1ySWXhOnTp5eqrEzlYqFyb0cpFxWtDDT2O/DAA+NOx3oJiUL//v3jQUZ9cDJcPtu0adPw/PPPx7Aj3HDDDeG+++4LPXr0CB988EGRZfNn7bbbbrk/jWgWBzl/OvXeHHx77rlnXBcHLj039tprr9gQcN68eTFMipHTngt4f9999429HAnhUv1I3XlaDmbOwUSdOb01Jk2atMn3OFnq168fw6+EUNesWaNoiYgoWltULiItNIsh0pX9fn5ZWVy5mF/u7SjloqJVSrBdpnxonJfgD6Ket7SkHhvFsbk/GPveHOvWrYtTcd9jG5YuXVoklKpoiYgoWmUtF0sq/7JlZUlsrtyriuWioiXliqIlIrJziJYoWoqWoiUiIoqWoqVoKVoiIqJoKVqKlihaIiKKlihaipaiJSIiipaipWgpWiIiomgpWlVbtHbZZZdw6aWXVqmJRG1nnHFGldpmErGecMIJnlkiIpUY0i1UxXLxr3/9azjrrLOq1DYjWWzzDi9aZHodNWpUlZpq1aoVWrduXeW2u9DgoSIiUrkgUWhVK19InHrLLbdUue1OGe13aNGqilx11VVh6NCh7ggREZH/5qKLLgrPPvusO0LRUrREREQULUVL0RIREVG0FC1FS0RERNFStBQtRUtERETRUrQULREREUVL0VK0REREFC1FS9FStERERBQtRUvREhERUbQULUVL/j9k+Hfa/hPDd8iOxdKlSz22K+E0f/58D05FS9FStLYNgwYNimNzHXXUUU7bcfrNb34Th8GQHYdvvvkm/MM//IPHdyWcuObNmjXLg1TRUrQUrYrnzjvvDPfdd587YjszY8aMOOC57DisWrUqCrRUPk477bTw5ptvuiMULUVL0VK0FC1RtETRUrQULUVL0RJFSxQtRUvRUrRE0VK0FC1RtBQtRUvRUrQULUVL0RJFSxQtRUvRUrQULVG0RNFStBQtRUsULUVL0RJFS9FStBQtRUvRKm9I0rd48WJFS9ESRUvRKka0UoJZRUsULUWrzPTu3Tv86Ec/Cs2bNy8iXKUVra+//jqMHDkyJjh94403isxbt25daN26dam35ZFHHgkbNmyokN85duzY8Mknn+Rev/DCC2H06NFlXs7MmTPDTTfdFN57773cex988EF4++2343OOoU6dOoW1a9eG7777Ltx7772hX79+ipZskWgtXLgwjBo1KgwYMCAee1lWrFgRbr/99lKvt1evXhX2m7LLLut5n2XChAnhlltuCZ999lnuvddffz0nOUgQn0kMGTIkno9LliypENFauXJl3J6f/OQn4eGHH1a0RNFStLZMtMiGzJQVrtKK1oMPPhimTp0axeKpp57aZP7FF19c4veRkb59+1bY70Pesjz++ONh/fr1UQp79uxZ5uW99dZbYdmyZaFmzZrx9bhx4+LFPknnxx9/HLp16xY+/PDDsGDBgvDFF1/EY4v9o2hJWUXrmmuuieKCcL388ssFC8KS+PLLL8OwYcMq5HcUOnfT+ba587645XHDglRdeOGF8b37778/TJkyJfeZ1157Ld68wPLly8MTTzwR5s2bV26/KYnWmjVrwj333BP+5V/+JXd9VLRE0dpKDjnkkPC///f/Dv/+7/++U00//elPcxeSrHAdeeSRoUuXLpvdb++++27Yf//9Y3QIgYExY8bEqM7kyZPDJZdcEt9DbCgoeB/5IAp23XXXxQsr0jJ37txw1llnxc8SASIC9dBDD8X3zzvvvHjBfeCBB3Lr5Q6Wz/EZLsSIIfPr16+fu7tlPSeccEKUlZtvvjleQGvUqBEmTpwYhQnRQhJ5v02bNvE77du3L9XxgpACw+NQkPF7gCqGG264IRaOMHv27NCuXTsjWrJFotW/f/9w+OGHx2Oc8yv/eE3n10svvRSjytzsvP/++/FcQ9IGDhwYmjZtGiNEF1xwQVzGo48+Gm8OiJQ9/fTToWXLlnFCYhJEbDmmOV8XLVoUz8HnnnsuPiaIsHHuTps2LS47e74VOu/53UmSSoIbGc5nIna1atWKN4OTJk2K89gPaRnsC9bDuV2eokWE7Be/+MUm10WiWjtb+fCDH/wg3HXXXZ60ipYRrfKKaDHtuuuuoV69enF/lCaixYX7888/D+eee26sxkC8unbtGi/8WdFq0aJFlJvhw4dHaUKgiABxF5s+07Bhw3gHzrrhjDPOiAMq8/7GjRtznwMu3BQoDALLfO42ESh+D1UNifQdJOydd94JjRo1itucRIuLNM8peL799tsivy1J0jPPPFPkfX4bd9HIFGKXtpXXLJu7/CSp3Bnz28ePH69oSZlFK8kVNz6IUf7xyvHNMXbttddGqaFKnBuYtB7OkR49euSiTEgP5wjnU/Xq1eN8znMesxLEcc25OWLEiHi+ct5wfF955ZVFzpN0fqUIVnpd6LzP59VXX43nF9eMLE8++WQcDxK5IqpEcwIEKF+0ErfeemuUwfISLW4UqfrMvwk1oiWKlqK1VaLFRYULdBq9vrRVh9xFp/ZIl19+eawuq1OnTpSv6dOnRwmCBg0axAKDCBYX3Q4dOsQ2U9y9cpFmGVycKVhOPfXUWBA0adIkLjctIz0CBQ3bzl00bSiSaPXp0ydewBNp2YgW6+Z/RuaIChAN4yLNnTtSyOfY7gSviVBRYCUozJAm9hPr5ndA27Zt4zZTKFDNQwGVInyI2pZWbyhaO7doUdUNVKd17Nhxk+OV45vjjnOGY4xIFBHV559/Pn6G19z4pM9yg9O4cePcNY/5iAvnJlXeCUQD+WI5rA/RYhl8B7HLP7+SaKXXhc57tjPbDpQbLc4vpCrBtYHrBlEyzqW77747vp8iePym7t27x+dUHQI3NiyrvEQrtdEiosZ18F//9V8VLVG0FK0th6oD7hpp9JmltKLFRYmGulyMkawkFlzcufjRSJZqCwoBIl4UGAgIbbtS2yYuYMgJn0VgZs2aFatAuODymsgTUoYYpSo5LtpsO3f53GFzgUa0eJ2NaPGfshzmc2fN9tKuiudU+fG7KcBSxIlqleJgnUTSEDt+CwUBBRfLpMDgNyB0n376afw8ETRENCtvipaURbSokudc4Pwiups9XlNVHO8RFeKcpdqcGwmqezgfkBjOY45PPst3eJ/zgeMyRceIHqXzETinOHY5VzjOOQc5L2mDle1Uwrk7Z86c3LI53+gcUui8Z/7gwYOL/a2IzW233RbPL851QASRq3Szw7azXdyAEb1ju4g8lxeFeh1yHUNCubYoWqJoKVrlhukdKgeK1s4tWrJtMY+WoqVoKVqKlqIlipYoWoqWoqVoKVqiaImipWgpWoqWKFqKlqIlipYoWoqWoqVoKVqKlihaomgpWoqWoqVoiaIlipaipWgpWqJoKVqKlihaomgpWoqWorWNueOOO8L1118f8+M4bb+JfEh77rmnB+QOJlokwfT4rnwTiUkVLUVL0VK0tgkkBkW2GCLDaftODFAtOxYUXh7blW9KmfhF0VK0FC0RERFFS9FStERERBQtRUvRUrREREQULUWr/GBwYwZIZapfv34c6Di9ToMXi4iI7CxQ9qVy8Oyzzw59+/bNvabMFEWrTDAC/G9/+9vY0yQ77b333h5QIiKy00HZt9dee21SLh5wwAGxzBRFq8w8+uijmxxQAwYMcMeIiMhOSY8ePTYpF0eOHOmOUbS2DMKk5ClKB9OBBx4YNm7c6I4REZGdkjVr1oR/+7d/y5WLhx9+uDtF0do6UqI6pqefftodIiIiOzUdOnTIlYsvvviiO0TRKh97/8tf/uLOEBGRnZ6VK1eGn/3sZ+H44493Z1RG0aJ3wiuvvFKlpksvvTR07dq1ym33l19+6VEuIlLJmT17dpUrX1Jv/Kq23V999dWOL1qEGs8777wqNZ1zzjlVbpsPOuigUKtWLa9gIiKVmK+//tpycRtNZBKoU6fOji9ae+yxh2fWNuDtt98Op556qjtCRKQSQzXcPvvs447YBhDRQrgULVG0REQULVG0FC1FS0REFC1FS9FStERERNFStBQtUbRERBQtUbQULUVLREQULUVL0VK0RERE0VK0FK0iTJkyJVx88cWhXbt2YdWqVfG9Dz74IFxyySWhU6dOYcOGDbnPPvnkk2HUqFHh888/L/P2LFiwIAwcODDUrVs3zJ07V9ESEZFKKVqFykWSgDOo87Bhw+JzWL9+fXjsscfCiBEjtmibdtRyUdHKo2/fvmHx4sWhYcOGoWPHjvG9iRMnhm+//TYm4hw/fnx8b+jQoaFbt27hu+++CxdeeGGZt+eyyy6LgrZw4cJ4wCtaIiJSGUWrULl40UUXxcADZSMSBqtXrw533313HNFkS9hRy0VFKwPSlCJWL730UmjevHmR+e3btw8rVqyIz88+++zw4Ycfxudkql22bFnuc5h49+7do9U/++yz8eAbN25cGDBgQFi7dm148803w3777Rd69+4dv5c/H7EbNGhQ6Ny5c5g1a1ZYtGhRvGsYO3ZsvGMYPHhwFD4G2EwDTm/cuDEut0+fPmH+/Pnxvez34NNPPw2jR4+OgqhoiYgoWltaLl555ZWxlofBnfv165f7/OOPP15QtLamXCSL/VNPPRW/d+utt0a5q0rloqJVDG3btg1z5szJvX7ooYfC/vvvn3vv97//fa7K8Iorroh/XIKx/nbffff4B0+ePDn+8cuXL4/L5CCCY445Jmfs+fPHjBkTqlWrFr//2Wef5eYfffTRYcaMGaFNmzahUaNGcVvSicKB/dFHH4X33nsv3HjjjfHAy34PYWvWrFk8YLMnhaIlIqJolbVcRHYYcu3000+PMrY50dqacrFnz57hhhtuCNddd1144YUXwjfffFOlykVFqwDs/OHDh2/yPlZ8zTXXxOdUI06fPj0X0ZowYUKRzx588MHxkT+wRo0a8eBiSvXO6YAqNJ+DMIViOaiuvfba3PwvvvgidOnSJR7McOihh8aD59hjj432nij0Peq+uWMYMmSIoiUiomhtcbl4//33R4GpXbt2aNWq1WZFa2vLRSJOtP+qiuWiopUHUSqq7YBqwqypz5w5MzzwwAPxOdWI6aA7/vjjo61nOeSQQ+IjfzJ/Ypo/derU3AHF8gvNz4oW62T5HDQcfIy2zkGcDqjDDjsszsvK3rRp0wp+D7PH9jnY+YyiJSKiaG1JuVi9evX4mmrF0047rVSitTXlYla0qlq5qGhloLHfgQceGP8ITJiQKH/IBRdcEBsD0mYqhTUxYRoDcvClPzfBn7Xbbrvl/rRevXqFvfbaKzb0mzdvXqwT3nPPPUP//v3jQZo/nzAqRr5kyZL4fd7fd999Q8uWLWO4tl69erGePC0HM+dg2nvvvWNvjUmTJm3yPU6M+vXrx2pJQqhr1qxRtEREFK0yl4tA+UX5R5viFA1CXqiKo4NYfmP2rSkXiabREJ9mOpSBVa1cVLRKAX8iDfMKUdo/ZnOf29x8DuDNsW7dujgV9z0O3qVLlxYJpSpaIiKK1pZAIIJpS9lZykVFSxQtERFFSxQtRUvREhERRUvRUrQULXeEiIiiJYqWKFoiIoqWKFqKlqIlIiKKlqKlaClaipaIiKIlO5lo7bLLLjFFf1WaSLZ26aWXVqltbtKkSfjzn//smSUiUolZtWpVlSwXzzzzzJhPqyptc+PGjXMJXndo0Xr33XfDI488UqUmksPxB1W17WbQThERqdy89dZbVa58OfLII+NQeFVtu1MC8h1atKoiV111VRg6dKg7QkRE5L9hRJZnn33WHaFoKVoiIiKKlqKlaImIiChaipaiJSIiomgpWoqWoiUiIqJoKVqKloiIiKKlaClaIiIiipaipWgpWiIiIoqWoqVoiYiIKFqKlqIl/5/ly5c7OVX6SUQULUVL0apyPPPMM3Fsrn333dfJqdJOHKPDhg3zhBVRtBQtRatqceedd4b77rvPHSGVmgcffDDccsst7ggRRUvRUrQULRFFS0TRUrQULVG0RNESUbQULUVL0VK0RNFStEQULUVL0VK0RBQtEUVL0VK0RNESRUtEFC1FS9GqNKI1Z86c8Pzzz4dXXnklfPfdd7n3V65cuc0KwXXr1oUbb7wxPlY0jzzySNiwYYMHiaIlomiJoqVoVaxovfTSS6F169bx+fz588OVV16Zk5F0om4rGjVqFL799tti5yOBffv23eL5omiJKFqiaCla21S0LrjggjBhwoTc6yOOOCLMmzcvnHDCCWHGjBmhTp06YcCAAaFly5Zx/pgxY0KnTp3CO++8E84///w47/3334/zeO+FF14IPXv2DEuXLg0vv/xyuP7662NkjO+0b98+vPnmm0W+N3DgwNzyGjduHP/DevXq5bbnyy+/jJ+95557wsyZM0PNmjXDG2+8Ebe7a9eu8ftjx46N0bA0f8GCBbntnDx5chg1alR47bXXwoUXXhimT58ezjrrrLhslsM28jkuRkT0Bg8eHL8zevRoDyJFS0TRUrRE0do60UKgXnzxxdzr6tWrh2+++SZccskl8XX28d13341yQxQMGSH6lY1AIUu1a9cOs2fPDr169YonOMKC+CBzPXr0CE888UTue2+99VZ46qmnYjUe60S0eJ/IVqpCRNhOO+20nAym7WnYsGF8/OSTT6IgIV4lbSdDvaRoHd/duHFjaNGiRdyG4cOHh379+sX1rlixwoNH0RJRtBQtUbTKR7Q+/PDDcN1118XnCxcuDNdee218fvHFF4e1a9fGx/QaYSLC9fnnn8fIEGKEICWQmrSMp59+Otx+++3h008/DR999FGUGt57+OGHc98jcoYgLV68OLYTQ4R4n/9yzZo1cZm8v2jRonDppZfGqsH87WJZX3/9dahbt26UM96fO3duke1kvVxs2LYkY4hWgwYNwtSpU8Pbb78do2tsP1E31q1wKVoiipaiJYrWVosWfPbZZ7Ex/MSJE6OAAPuSCBXLoO0Wj1999VUcQ5Fo0erVq0Pv3r2jRCUQFuYjLESpkKr+/fvHed26dYvrQHqy3xsxYkTo3r17lCTe//jjj2P7MAQtbduTTz4ZXn/99fiaZbJ8omNI2auvvhrbZVG9iHAx/29/+1tuO4mQPfTQQ6FVq1ahWbNm8TcSbeM3IXrIINtC5I0I2KxZs+LrtD5RtEQULUVLFK2tEq0dHaoEkbdx48aFJUuWuEMULRFFSxQtRUvRKk9okC+KloiiJYqWolVpRYtqRdpJ8Zh9Xhpo87S17Z5YF1WJZYHqxWz1ZnlCtSTty4CqyJKgXRltxsoTfhudBfKhSrQi4X9Yv369oiWiaClaipaiVZ4sW7YsHHDAAbGnH2kXDj744NimqjTcdNNNsT3V1kC7LRqwl4UuXbrEXoVsc3lD2zFSWdAejWrJfLJSSFs02oyVB0gO0sZEe7V8oT3jjDPKZT38LnqQZqFDAT1FaeeWP0/RElG0FC1FS9HaSmrVqrXJc9o90ZCcnnvTpk2LjehpBE/jeZgyZUpMiopo0SPwueeeiz0JV61aFVMz0LOQ6BDPyWvFPFJOkP+Kwp7l0Ygd6FX42GOPFREnvkdKB1I1sC3k1UIKeU3OLISHiQsODeYRhffeey+KW3r/iy++CCNHjozrItcXEBliHr0Qs9uaYPmIFr0x2W6WTb4ufidyR+P7tA/o3YhosS9YN7JE5wHWR/4vRAzIQ5ZSW2T3a3afIK10BmCZLA/oXcl+hZT6IrsvtgS2g+/nixG/j0jerbfeqmiJKFqKlqKlaJUnNWrUiL0HmQ477LBcZAcROffcc2NvPVI5kDCUHoAPPPBAlCJ6HVJAk8AUuSEacu+998akoUSpeCQ6dvrpp0fpIncWn+H79HBMmep5Hyni/07wO5EnhKdDhw5x3TfccEPcpmuuuSZG30hKyufYVmTtgw8+iNuV3qfX4plnnhnlilQRyAnrRGSQoey25osWMnXZZZfF5KlJjJiQoQTra9OmTRg2bFh83adPnyiPpKHg97FOYBnZiFnar9l9Qu/MlGyVHpXjx4+P24IoUpWYco1l90VZQerY1ttuuy3KXUq3MWnSpJiGg16dJIlVtEQULUVL0VK0SoBCm7xXpW3XUyiiRUGMYFHAU5XFeom2kLaBPFnIAikYSDpKNAdhoE1TyoXFfIQGWUoik02USlskJqJb+YlUASFCWogoJQFjmUm02DakL71P7i3aTOW/n1028kL1WJqX3dZ80aKtGqJFg3vSSCAPhUTr1FNPDe3atYuv2QbkhagR28L/gPSRXiKR3a/Z35xEi4gYotW5c+cY0cv+jvx9UV4RLUBcyTfGf6loiShaipaitUND1IEqnPxG0RUR0WIdv/vd72L1GRGf/fffPzY0R2aQHSJCVBmSbZ68VES2qBJr2rRpuPrqq2OV38033xznUUXG9iFiVLM9+uijcR4RLQSCIYCQK6rDaHOEqNE+6KSTToqRKB5Tg2x+fxrjsEmTJvFYQLyQD6QOAUIKicAwrBDbifggbul9BPHYY4+NUTHWTdSMdSABVNtltzXB8da2bdtYBXnKKafEKBXVi4hPSsaaejuSP6x58+Zx+/it/P6TTz45igZkk7AmsvuVqsG0TxAw9hViSrSK/+PEE0+M6+V/Oe644+J6s/tiS0AgqerNwvoR5vK6eCtaIoqWoqVoVWqIbuyyyy7hhz/8YazSSRGRbZ3eAWmhYC4EhXMaqofPEW1JIBgJxKnQMrKfKQ3FfT61fSrt+/nzNrcdbHs2elTc/shfHuugOhVJK+1+zX+PZRTqAVrWfbc5UhVieaFoiShailYVgXYsDCUzZMiQnWpCrhCtNH3/+9+PDcAvv/xy82hVEYiulVePxKqGoiWiaClaVQQaadesWTNWUe1ME9VEWdFi+ulPfxqOOeaYmNpARNESUbRE0dpqdvaqwyRYdP1fvnx5hSYs3RysP41VWJXJT47K69ImaC2O/GrKik4uWhFkBxKHsiSuVbREFC1FS9GqcqKVFaxERYgWDcQPPPDA2CCcht75DaWBHmk04KbHHe2LqjL0uEMiaIRPGzMavKe2ZlsiasB/khK30nD97LPPLtP3i4NtLI0Eby10bqCTAw37gYs4jfgHDx6saIkoWoqWorXjQV6lrGBVpGgBPeWA3m60EUtCwMmMhJD3ilxZZCgvLkkoPf/IpE7D8bImCSVRJu+lXoMpmWk2oWf+90paH5BCgR6K5KViHqkn6PlITisiUPSEZB2kZOCRZaTfTe9B5JLfxXJ4JGlpfsJSIOpzzz33hHr16uXeIxUD202vQiBtA70y2eZzzjknl8yU9bDslKcru6/oYZi2saJJvwfR5vfQI7RQVnxFS0TRUrQUrR2aihItUh7cddddUbToJZhNBoqYICv9+vUrNkkoEkFKClIXfPjhh2VOEnr33XdHgUI2sslMswk9s98jFUFx60uwPAp7cmexzXyH7eczyESjRo3ib0W0SC3BcokekYCU+cgnvfv4HPJHTq38PFrAvmHYHJKUpnEP6cTBNrNf6TGKiKX8VEgY60FmEC72a0pgmr+v0jZuC1g3KSqA/U80NWW2V7REFC1FS9FStDKUNWEpUkFUg+SbRKryk34m0SouSSgSlERiS5KEEm0imkLEqrhkptnvlbS+LLzmgoREpaFsLr300viYFS2EjmONCBrbkS5miNkVV1wRxas40UIqyKjPNt1+++1FtiNFAfkMkbDsvLQd2QSm+fuqPEWL5VBtmibWmeA/5P/NggxyvClaIoqWoqVoKVpbAWPnkbCUoXKoWqN9EdVZKeknERkKf5J4IiSFkoTyeRJvMjwMslLWJKEk5UwZ0bPJTNMykK7s90paX0omCk888USsnmP7qVZENpBKBJTtoZqUdTGWI+kz+K0MT0M1IsMLAW24eE3vV6JU2YSlCFb6P/idv/zlL+N+ZFxC2mwNGjQorpftYFuRF5ZHlSI9SIkiZROYkjw2u694zO6nigCJJMpHIlRkkgjhHXfcEZPUIsCKloiipWgpWopWBVGWZKAlJTfN/05+ws38pKDFJeTMvr+59aXPpGhOcZJRiGzjeJ6znvReaRunpwSufJ62ael7hb6f/1uy+2pre0RuCfk9EBUtEUVL0VK0FC2RSoKiJaJoKVqKlqIlomiJKFqKlqKlaFWsaKWEpTxmn5cGGnozbe36y5JbKpEa+tOuaUuquqjOo31aRUE1Z+qFWNrfsr0przEUFS0RRUvRUrQUrf+BBtkHHHBATHFAL7uDDz44NuguDaQASIk6txQatmdTPZQG2jBVr149PqcnIHm4ygoN0B9//PGC82jTVVpJgkKiSGqE1KC+pM/S9osG8NsK2oPRqD8feh3Sc1LRElG0FC1FS9EqZ+hJmP+caE9KpEmvPPI60RMtJbck11Pr1q2jaJFNnt6C9JTLJhZFInhOeohs8tFsUlIgdcNjjz0WZS9BZI3vsh4+T5Zy5qfEovTsA5ZJ77j8+Ww/aQwQyQSCwXbyeZZNb0TygdFwPZs0FYEkjQOvSXr61ltvxe1g2Xw2u/2Fkpjy2+k1iWhl92NKWEoPyezySO1Abz/Wl/ZtmpfdLgSQ3pmsG1Ii1LJKKvsln8mTJytaIoqWoqVoKVoVIVoM3k2qAqbDDjssvoeApESa5FxiiJYxY8bEPFokFUVqEAlEi3xRRGryE4vySHSMDOfZ5KPZpKTA+6RH4P9OkA6BakmSfSJTXFwQPhKDImEpHxXzkY/8+Xyf7SUJazZqg+y0bNky5qziM4jfzTffXCRpKnnI2Hb2NdnvESO+y0TKhuz25+fWIp0DyVTZL+yf7H6EtN3Z5SGNrJvP5K8ru119+vSJcsdv5LdmE6GWBvYj20YKC3431acJ5E7RElG0FC1FS9GqgISlhSJa2USaRDtY79SpU0P37t1jLinkgagNGdcp7JElIkXZxKIU3ohKqhrMJhYtlJQ0m3AUmUC02IYuXbqEK6+8MkZjrr766vi99FkKdSI82flEsZK0ZdNGsL18lggUokXVIetnjL9s0tQkWogUYoO4IVMDBgyI38lu/6RJk4qIFmLEcD1EoLp27VpkP6bfmL+8lLyU9bKvs/Oy20VyVeSI30kELZsIdWsjWoqWiKKlaClailYFRLRoTE7CUqImCMr+++8fPvrooyKJNKkyJApENRWRLdofNW3aNEoNVX5EhJhHctBsYlGGdGEeES2iTin5aDYpKQMn00aJCBmPKecV1Y1puB+Ekaz1RKNIqMojQsj7DJmDzGXnE0UjASfHT3aswNq1a0eBIUEnwtWqVatYRUcC0WzS1BTlYmIbiV6R6JTtIft7dvvZhmwSU5aFJLI8tiG7HxFHEpayf7PL4zcgP4hW/rqy28X+ZR4ik58ItbTw2UIDh3OeIeflMYi1oiWiaClaipaiVQpKSgqKMKUknnwuJeiEbO81xKnQMkrTw43oy9Yk7MxfB9uZelam35BNJJqNfuVvcxLA9H522fmfZR77JiVMze7H9Ji/vOz+y84rLplrfiLUyoSiJaJoKVqKlqIlomiJKFqKlqKlaClaomiJiKKlaClaipaIoiWiaClaipaiJaJoiShaipaipWgpWqJoiYiipWgpWtuqAPvRj34UE1w6OVXWiVQbhYYfEhFFS9FStCo1pCYgX5WTU2WfKmPaCRFFS9ESRUtERETRUrQULREREUVL0VK0REREFC1FS/4OQ4wMHjw4DBo0KFSvXj0O+MtzJoYcERERUbRE0doKjjrqqLDLLrsUmapVq+aOERERRUvRUrS2lueee24T0ZowYYI7RkREFC1FS9EqDw455JCcZJ100knuEBERUbQULUWrvBgyZEiUrO9973vh3XffdYeIiIiipWgpWuUFCQ/33XffULt2bXeGiIiIolW5Rev1118PXbt2rVLTBRdcEFq3bl3ltvuzzz7zKBcREUVrZxItquHuuusupwqeiMAdfPDBHuUiIqJo7Uyitccee7jntwFvv/12HFRXRERE0VK0RNESERFFS9FStBQtERFRtBQtRUvRUrRERETRUrRE0RIREUVL0VK0FC0REVG0FC1FS9FStERERNFStIphypQp4eKLLw7t2rULq1atiu+tX78+PPbYY2HEiBFFPjtu3LhwySWXhCZNmsRM7mVhwYIFYeDAgaFu3bph7ty5ipaIiIiiteOLVt++fcPixYtDw4YNQ8eOHeN7q1evDnfffXfMep7YuHFjuOeee8Kbb74Zpk+fXubtueyyy8Lnn38eFi5cGFauXKloiYiIKFo7tmgRldqwYUN8/tJLL4XmzZvn5j3++ONFRGvo0KExAzqDP+dHs4hQde/ePUbAOCAQNaJfAwYMCGvXro1ytt9++4XevXuHZcuWbTJ/4sSJYdCgQaFz585h1qxZYdGiRWHYsGFh7NixMbo2ePDgMH78+NChQ4fw9NNP58SP5fbp0yfMnz8/vpf9Hnz66adh9OjRoVu3boqWiIgoWorWthWtLG3btg1z5swpVrSQq48//jgOOXPzzTcX+e6XX34Zdt999yg+kydPjkK0fPnyuEzkCo455phcJCt//pgxY0K1atXi9xk3MM0/+uijw4wZM0KbNm1Co0aN4vbts88+cRls20cffRTee++9cOONN0Yhy34PYWvWrFn4+uuvQ79+/RQtERFRtBSt7SNaSMnw4cOLvJcvWlkQmXzSeH+ITY0aNaI0MaX2WEm0Cs1HzmgnBi+88EK49tprc/O/+OKL0KVLl7g9cOihh0apOvbYY2NUK1Hoe7QJI5JGFE7REhERRUvR2uaiRbspqu1gxYoVuWrBkkQLocnnkEMOiY/ID3JDlAumTp2aEy2WX2h+VrRmzpwZjj/++ChTSNns2bPjdiTROuyww+K8c845J0yYMCG+N23atILfI+JFFAwJ5DOKloiIKFqK1jYTLRrBH3jggVFQiBCdfvrp8X1EhWq3Cy+8MFfdRzVf69atY3SJCFgWJGa33XbLyUyvXr3CXnvtFRvAz5s3L7aV2nPPPUP//v1jm7D8+VQfEqlasmRJ/D7v77vvvqFly5bh22+/DfXq1Yvtx9JyiFghWXvvvXfsxThp0qRNvocw1q9fP1ZLUrW4Zs0aRUtERBQtRWvbiVZZKUtvwc2JzebmI3ubY926dXEq7ntI3dKlS4tUMSpaIiKiaClalVK0RNESERFFS9FStBQtERFRtBQtRUvREhERUbQULVG0RERE0VK0FC1FS0REFC1FS9FStERERBStqihau+yyS6hZs2aVmn73u9+FP//5z1Vqm8mSf8YZZ3iUi4iIorUziRYDLDMOYFWazj333HDPPfdUue1etWqVR7mIiChaO5NoVUWuuuqqMHToUHeEiIiIoqVoKVoiIiKKlqKlaImIiChaipaipWiJiIgoWoqWoiUiIqJoKVqKloiIiKKlaClaipaIiIiipWgpWiIiIoqWoqVoiYiIKFqKliha+WzcuDG8+OKLTlV8+uyzzzyYKyGzZs3y+KyE0/vvv+/BqWgpWorWtuHhhx8Ou+66a6hTp45TFZ3OOuus8IMf/MCDuZKxZs2aOB6sx2jlm/hfpk2b5kGqaClailbFc+edd4b77rvPHVHFC/T/+q//ckdUMhif9De/+Y07ohJy2mmnhTfffNMdoWgpWoqWoiWKlqIlipaipWgpWoqWKFqiaClaipaiJYqWoqVoiaKlaClaipaipWgpWqJoKVqiaClaipaipWgV5quvvgrr1q3b5P1vv/02LF68uFTL+Oabb8LSpUsr7Pd/9913Yf78+dtt/5NeY/369ZsU0IqWoiWKlqKlaClailax3HXXXeGVV14JV1555SbznnzyydCzZ88Sv79w4cIoQZ9//nmYPHlyhf1+lt2sWbOC8xAg1l9ayprLit/41FNPhV69eoXZs2fH95DKk046SdFStETRUrQULUVL0Sq+gKlWrVpYsGBBTiCWLFkSxo4dG5YtWxbeeuutnGjNmDEjjBs3Lj6fN29ePNlXrlwZTj/99DBx4sQwderUMGXKlChdiBvPN2zYEAYPHhw++eSTMHLkyCLrZnkkJFy7dm3Mk/POO++E/v37x+hagm156aWXYtLC1atXh6ZNm8ZjgigbE+v54IMPwk033RR69OgRl/PGG2+E559/Pq6fdX799ddxO1g+28l6zznnnPibS8uDDz4YXn311bjOW2+9Nb43aNCgcMkllyhaipZsB9HimsA5rWiJoqVoVWrRghdeeCH84Q9/iNEa6NChQxgzZky44YYbcqI1YcKEMGzYsHDNNddEWXnkkUeiyHCha9SoUYwovfzyy+Ghhx6K31+xYkW45557okhxYUCASD6IhAERpfvvvz/KXL169cLrr78eWrRoEddLYtYEETUKwXPPPTeKFstArM4///xw9913hzlz5sQLbu/evaNgsW1I19y5c0O/fv3ihBA98MAD8ftsN5RVkCZNmhQjfs8880y48cYbo3DyGxWtnU+0iG6OGjUqDBgwIMycObPIPI6J22+/vdTrTedcRUC1f5s2bbb5vuSczF63Oee5xlDtzw0Q5ycT+3FLROu1114LtWrViolMs9cKRUsULUVrm4kW0nHttdfGqFNpChiiNAhAzZo1Y8HBfk/zkmjde++94b333ovvc5KnAoLPJNF6++23o2ghQxQ4yFOXLl2ioND+6+qrr47tuAAB69SpU3x+9tlnx2pBfhtRse7du+e2jwKN5SA0iFKqOiSyxYX7ggsuiFGtJFrIH9vKxZ0IF4Xh448/Hr/PupmIbhUnSETeiOalKbsPv/zyy9C+ffu4HygoKMQOOuig+DlFa+cRLW42OJ4RBW4uChWEJcFxxE3LtuDiiy8u+D7nR9++fUu9HM6h/PaJJR3j2X3AecINVTrvFy1aFG/GCrUJLUm0nnvuuXDUUUdFwUoTN2usb2eauDEdPXq0J62ipWhVlYgW7YwQoPHjx8c7cRp8N2nSJO57okPs/7Zt24ZPP/00nHDCCfECyUWTtkm33HJLvGjyOHz48PhZomAUPkgU24qonHrqqbG6DqH6+OOP43qpLkQGkbbHHnssjBgxIrRs2TJeQIhsZQs1olBnnnlmFELEijtavte5c+ec3CFkN998c6wqZPuRspNPPjluB7+Li/QZZ5yRK1xOOeWUMrXTQtCI6uXfSRrR2vlEi+rtww8/PEo98sHNASKQokfpmKDKm2gqbfuIunJecDwPHDgw3ihw/HE8s4xHH300DBkyJB7HTz/9dDwXmDjWEwg+xzfHNOfdeeedF49rHrMRNW5UOAcQuoYNG8Zl8hnWgzC1a9cufPjhh/HGavr06fHcIuLLNnDTQMQW2E7WxQ1MjRo14vWAG6LSFPJpH3DO8Fu54cp2ZOFmqLQgWlyPvve97xWRLKaf//zn8XzamaYf//jHoWPHjp60ipaiVVVEiztbpuXLlxd5HxHKh0hQqvqD7B0pgpaFefnvFYLqjc2RXS/P03d4L9vrL7ttkO7A0/vZ35T/2dIIUnmgaFV90UpydeSRR+YEn8gvosSxiWTwP3MjgaRQbXbdddfl1oN0EW1NEScEjIgs50v16tXjfM5zHrNCUr9+/XjcclNCJIdIMucZEeN0TvCaam1EC4m69NJL4/vdunWLokS0GVFkXUmGkLEUzSU6jPzxexBEzjduMlLUOh8+g7jlVwOmZRMNRzhp/4lwAc/LUvWVIlpIHjdPWdGy6lAULUWr0ouWbFsUraovWkSF4KOPPoqRBTpHEGlCBJB55AmRIZJLRJdIFJFe2ifxGV537do191naEzZu3Dh3zWM+goXMIUiJ1q1bR/liOawP+WEZfCfdCCB2RKbYJpaThIfrBp1M+D6RN6SKdadtALaBjiN169aNMoRwEUWmzRXrIELGeoiaJegMQ1Q8X8LSMom8EUXmRi5FYWh2UNpqw6xoJWhKcPTRRytaomgpWlsOVQfcseZHexQtRUu2v2hRdUYkB9mhihrZQCKofmc5SBLvvfvuu/GcpecskkIaFaJKRIg4jxEUPst3eJ/qd1KUpOgYHTB4THA9oCqSiBWRJqJFs2bNilXriFMSH6r7iHpRtYl4sVw6kBANo5qd7yOCSAoShczRHIBetUgR7RoRLpZBNSTfQ3T4HnKJ6JQE20IvXZYB7BfWzzZDoXZtZRGtBMJZ1mUpWoqWKFoRqhG4W9tjjz2KCFdFiBYX3FR9yLS56j7mb65t05YmLi1N4/2UQLWik6MWBwVraapEFa0dV7Rk22IeLUVL0apAaE9AyJ0u/zvTRM+6bDuEJFxUB5S3aBHSJ7UD7Ui4U8/eQReCxuyXX355iZ/ZksSlVGtwQd0cKYFqadaREqmWF9yRH3/88WXOBq9oKVqiaClailalhF5uxx57bKzv35kmGtnm965h2meffWLvnfKGnDRJTGhrgXRRfUFYnioPqgCoVqBxLbKBaNELkSoEHukZlU0emhKXAtUffBdYHr0PaeOSjQohWSyrdu3amyyX3lF8n3Yn2XQT2XWwXfS+gpSklHYkKZFqSj2xtckNU7sYRUvREkVL0VK0dgh29qrDNJ144omx23VFtdGimzfLb968eRQgokV0B6dtB5B4FGgLkkSLRrRIB68vu+yyIslDU+JSLgY8p9cRy6A9CpJFioiUkwtatWoVH8nWnr9cBIr0EWSXJ6KXRCutg/YfvIcEUZWYTVKaekr16dMn1+OqNL0cC4FA0j6F7vmKlqIlipaipWgpWlVctHbdddfYnTtFbaAiEpZCimgRuUoSgdykpKT0PkqFURItBOaKK66IYoYQZZOHptxWNBBGiGhPRZI9RA3hQXxSfiAiZg0aNIjP6SGVv1zy8PD51I09iVZaB7m0aHQMNATOJilNokVvKgSHZRRKW5GluISlNO6lt9ahhx662bEfFS1FSxQtRUvRUrQqMVSvZZP7lVW0ygJttMhuTvssokIIBRPrJykpFzi6olOlSXSJKj26rSMtJP3kO0TEkKokPylxKdJCl3TaVSFWJEIkCSIJRHkvQa4fEiYed9xxcXuyyyUaRv4d2q7RgyolUE3rIIpGxA/h4rvZJKUpkSpVobzP79pajGgpWqJoKVqKlqK1g7I90zsUigRRDUdj8/RYSECITG0uipQEJFXrZZdLRIsIXUlVftnkqPlJStP7pdmGbYGipWiJoqVoKVqKlqJVaaD6jjZXOwqKVuWEanPaQ15//fVOlWzif8m26VS0FC1FS9FStETRqoLQK5X2gE6VayrLoO2KlihailalEy3yYmXHU6NtVGnvHskaTZut7QkN7GlsT1uwzW0fjdhnzpy5xeui+oKqTEVLRBQtRUvRUrRKDT0CWTbQKJ7ee6WBlA3ksCpOgEoLObG2NsdVGlutpO2jRyJ5vbYUGvRnpVTREhFFS9FStBStzUI2eFI2EM2iZyENg4lq8ZoefNmhbnjdvn37KCz09HvsscfCueeeGyNH/FeMAUeon2SzCNT5558f0y3Q25C2VvynMGrUqJgb64knnggtW7aMEpTgsyyDXooMbkv+Kxq102sQIUvLoYH7WWedFb+TBs+l9yI9Gtmu/O1jHtvNdhGdIl1DWSDVhqIlIoqWoqVo7eSihey0a9cuZnovrWghLaRTIPM8okUOL3ruMbAsw/8kqDpDihAkRIaIEZnb2a6bbropShg9BJP4kPuK16ReIM0C2dpZPslHgef0KiR1Q4K0EOTjSvm7yINFugkyxmeXAw0bNowSltbHsDwMNksahvztS6J188035wbuze/NWFweLUVLRBQtRUvRUrQiVP0RhUqpDjZHymn1t7/9LXZxR35o80SWd6SFyFZabosWLcLTTz8dHn744Sgy06ZNiyc9EsLn+/fvHz9PVR7yhiTRhgo5Q4IYZge5Ia8VIkjGdYbXIV9WSsnAd+gFVrdu3Zi6gSgW30OossthHoLF+wgXkOR00aJFoUmTJjG3V3b7EEaWheSxjSynLGkf+DztvhQtEVG0FC1FaycWrbKA3KxevTqXbwp5SSA7SFIWxiXkPSayxPOZJCs8TzmwEApEj2XzyMR3+Qzz+Q7ixnpZDp9LsAxe89m0XSnylL8cPpe+n7aHbeMxf/vYJp6zTJZR1uF4+C7LU7RERNFStBQtRUsqIYqWiChaipaipWiJoiUiipaipWgpWqJoiYiiJYqWolUO3HHHHTHlAQ3OnarmRG9NhhQREVG0FC1Fq5KxYsWKcMUVV4TmzZs7VeFp0KBBHswiomgpWoqWiIiIoqVoKVoiIiKKlihaipaIiIiipWgpWiIiIoqWorWjQfZthmc57rjjwu677x7233//+Jxx+LY2K7eIiEhVg7KvRo0asSz8v//3/4aDDjooPj/11FPLNIyYoiU5GIiYLvDZieiWiIjIzkiDBg02KRdbtWrljlG0toxZs2aF73//+7mD6Z/+6Z/CggUL3DEiIrJTMmXKlCKS9c///M9hyZIl7hhFa8s588wzjWaJiIj8D1QfGs1StMqNiRMnGs0SERH5H8aNG2c0S9EqX4444gijWSIiIv/DH/7wB6NZlVW0jjzyyPgHVaXpV7/6Vfj9739fpbb5l7/8ZRz8WUREKi/r1q0Lhx9+eJUrF//zP/8z9savSttMT8l77713xxet//iP/wiLFi1yquDptddei+kpRESk8rJy5crw61//2nJrG0xjx44N55577o4vWnvssYdn1jbg7bffjrlNRESkcovWPvvs447YBrzyyivhvPPOU7RE0RIRUbRE0VK0FC0REVG0FC1FS9ESERFFS9FStOT/sXceUFIVaf9m07fZsLq6uwZEEUFQMijCIiBKEkSCZJAgQQQliYCIBBEQBBEFjCQFCYIkkaAECUoWJCNJAQHJGaz//3m/r/rc6ekZZpiexPyec+6Zmds31K3uuffpt6rekmgJIYRES0i0JFoSLSGEEBItiVa6Fa3z58+7ESNGuMmTJ8e7zjNt2jT3+eefu+PHjyeqPGR7Hzt2rKtVq5bbvn27REsIIUSaFK3EPheHDh3qVq5cmegyXanPRYlWGCdOnHB9+vRxr7/+erzrgOy08+fPv6zyNGnSxO3du9f9+OOP9oGXaAkhhEiLopWY5+LatWtdwYIF3dy5c/VclGjFzciRI2N9eMLXTZ8+3bVo0cIdPHgw1v6Y+KBBg8z0Z86caR9I5mj66KOP3NmzZ93SpUtdzpw53bvvvusOHToU63XmORw3bpzr37+/27JliyU8mzRpkiU941vEJ598YoLXu3dvN3XqVDvnr7/+asf94IMP3O7du21dcD/YsWOHlXvgwIESLSGEkGhF9bl45swZN2TIENeuXbtYopWU5+LJkyfd+PHjbb9u3brZedLTc1GidZkfqHr16tnfyFDJkiXdxYsXQ68dPnzY3XTTTfYGr1692t74X375xXXq1Mk+RPDggw+GjD389RkzZriiRYva/rt27Qq9Xrx4cbdhwwb3wgsvuGbNmrlt27aF/lEoy8aNGy1c26VLF/vgBfdD2Fq3bm0f2NGjRyeraOXIkcPVr18/3S+VKlVy69at0x1ZCBEvfOHmfpGe7m81a9a051Q0n4vDhw+3Z0wk0UrKc3HYsGGuc+fOdtw5c+a406dPp6vnokTrMj9QTPjMGwoVK1aM1YSYN29e+8kb+Mgjj9iHi8W3O/sPVKTX+RA++eSTth0fqueeey70Ov/QAwYMsPIAIVo+PCVKlDB790Taj7ZvvjFMmDAhWUWrWLFi1m8tvS9vvvmm/RMKIUR8cK/gfpue7m8TJ050WbJkidpzcdmyZfbc4m+eR7T4IFfRei4ScaJPWHp8Lkq0LlO0MOcvv/zSfm/evLmFH4Pky5cvFLrkTfQfONqv/QfqyJEjEV8PitamTZtcqVKl7EPDh2/r1q1WDv+BKlSokL1WtWpVt2DBAlu3fv36iPth9sghH3a2SS7RulKaDglZ808phBCXEq3u3bunqzJHu+lw//79bt68ebYwrx+tPadOnYraczEoWuntuSjRCoPKJ4pBaNWHMCOt27dvn2vVqpWbNWuWhSKD8GZde+21oTeNcGrmzJmto9/OnTtNym699VY3ZswYd+HChVivE0bFyH/++Wfbn/XZs2d37du3t7bpOnXquDZt2oSOg5nzYbrzzjtttMby5ctj7UfTZt26da1ZkhBq+D+AREuiJYSQaCXlueiJ1HSYlOciTXwNGzZ0TZs2tWdgensuSrSSCB32EsKl3sBLvc6H+lKcO3fOlrj248N74MCBGKFUiZZESwgh0UoNMspzUaIlJFoSLSGEREtItCRaEi2JlhBCoiXRkmhJtCRaEi0hhERLoiUkWkKiJdESQki0hERLoiXRkmgJISRaEi2JlkRLoiXRSlswmoZJz7VoSU+LREuiJdFKZ6J1ww03uO+++05LMi8kcWVKIolW2oEJWjNlyqRFS7paknO4vUTrf0Xrtttu03MrBRbmUmQGmStetGrUqOEeeughLcm8kNl36NChEi2JlhYtEq00DPmjqlSpoudWCizMqzhq1KgrX7SEkGhlskzL3Fy1aEmLy4033ijREkKiJSRa6Ve0/ByagwcP1qIlzSxMOwZMJCzREkKiJSRa6Vq0+vXr5/71r3+5nj17atGSJparr77aJgyWaAkh0RISrXQvWq+++qrNdC9EWuGFF15w7733nkRLCImWkGhJtISQaEm0hERLCImWREtItCRaQqIlhERLoiUkWhItISRaQqKVYUWLY3zyySdu9erV7uLFi2779u1JLhfHmTFjhh03Ejx4N23alOTznDlzxr300kt2vqSyfPlyt3TpUlu2bdtm686fPx9at3bt2qi+dzt37nRdu3ZNdNm///77UJmYrSGhrFy50n388cex1p84ccINHz7crVq1SqIl0RISLSEkWtESrZMnT7ry5ctbEloe+ohRpUqVXMeOHZNcroMHD7omTZq4li1bRnz9/fffT5Jo/fTTT/bz7Nmzrlu3blF5cFPmf//7365OnTp2XA/Sde+997oDBw6E6jwazJ8/3943ZC6+a4wkRiRJLFKkiDt06FCCz4dIjR07Ntb6H374wa5vypQpEi2JlpBoCSHRioZo8aB7+OGHY227Z88e17Zt26iUbeDAgXGKVlJACOKKlCWVEiVKuDfeeCPW+uBnpXbt2lE7329+85uIonWpa6Ren3rqqaiVo0KFChItiZaQaAkh0YqWaK1Zs8b22b9/f6zXdu/ebT/PnTtn+Y969Ohh0kQTF1Iwfvx416dPHzdnzhxXs2ZNN3nyZLdv3z7XrFkze6j6pjCSVSIEw4YNcy1atHCbN28Olfnll1+2pi/269Wrl82jyTEbNWoUitIcPnzYzk9usHfeecfW0VRG1Klhw4Zu9uzZbvHixXZeT6Qys45IzoABA9ysWbNc3bp1bSLYSDCXJ+UOp127dvaTY1BvbMP1jBs3zvXv39+Scvbu3du2oU4nTZpk17Vjxw5bd+rUKduXa5k4cWLouL/73e9sm8aNG9txIl1jJFq1ahXjuiO9v9Q79ca5aWJlmpDgtRHFpMyUvVChQiHR4j2eN29e6H1JTP1JtISQaAkh0fo/Cbr++uvj3YbjMWkqD0Wa0zp16mQP7Ndee83ly5fPffvtt27RokXub3/7m8kX0bD8+fO7zz77LHSOYsWK2cP6xRdfdNdcc409tGmCy5s3r22HVD3wwAOuVq1aJhhEi9gWnn/+eXufOD/7emmpVq1aKNqzZMkS98c//jHeMp8+fdq98sorLk+ePG7MmDG2b/bs2S9LtOwmlylTSJ6Qw7vvvtvNnTvX+j8hKT4iyGSz999/v/1O9Gnr1q3WJHnDDTe4LVu2hEQLKdu7d6+79dZbrf9V+DUmVrSQIc4N9evXN0GimbhLly4mSYCA5s6dOyRhTEDsRQsxYnuaKJk2hybehNafREsIiZYQEq3/Dxm7//nPf8b5OtGk6667LvQ3MnDLLbfYA5IHMk1NnquuuioUhWrevLk9mIIRLU/WrFlNAqBs2bIhIatatapFhoAHMnLgI2tIGQLDPI4rVqyIJSHIgBet+MrM8ZlvD44dO+b+8pe/RLxuJomNJFrB5lQvWjBhwgT3+OOPh/7+/PPPTar4fH3wwQeuQ4cOVi76U3koczCi5ZsOS5cuHaqf4DUSeVqwYIEtGzduvKRoERWkHikDnwUfDaQ8XrQQw+rVq4f2qVixor2vlAXZZF8WBhosW7YswfUn0RJCoiWEROv/hIB94urYzQP9t7/9rTt69Kj9TXPYH/7wB4sOTZ06NYZo/eMf/wiJFmLl+ziFi1blypWt3oFO+F60eOB70Ro5cmRIBhYuXGhCwYOdCFok0SIi40UrvjIjRF4U+PtPf/pTxOtGOGgyC0IUClmIJFo0AwZFi7r3c076yBHRK6ahCfbFogzhohWsk+A18tNPzOzrNi7ROnLkiEXRZs6cGVpHFBFoUvV1i0AhuOGiRVTy2muvjVFW9k9o/Um0hJBoCSHR+j+KFi0aq2M3wuT7Bd11112hB/bXX39tkQ5ABpACDw9mL1pPP/20GzRoUCzR4sF6xx132IPcS4VvqkIq/Gg4RIsmP6Cpin5cyErOnDktssLvNWrUsP5GCBBNXMGmw7jK7GXFi0JwnyB9+/Z15cqVi7GO49E0GoxC0dzG+RGtxx57LPQaIxSJqiGJ/nOGqOTKlcveF+qB6/DNoIihF6FgnQSvMRL0eaNfVxDKQp83mjMZ6MBng3L6lA4ffvhhqG7p20ZzrBc+RMuLHc2/9N3i3DTDkvYiofUn0RJCoiWEROv/oAmLBzrNeHTSpvN0MM8SUa/ChQu70aNHm0DRlMdDlmgK0rRhwwbrEP/73//eHqQ0cdHfCnGiuYz0BQULFrQmKyIxHA+I8Nx+++3umWeecevXr7cmxaZNm7pdu3ZZsxepBhAR+lchKKSbQAp5DbHi+pAwzo2gce1ffPFFnGUm6tWgQQOXI0eOUAf24D5BEDlkBJHhmnjAhj9kaQZkG66DplKaJ+l87iE3FhGsAgUKWPQPpk2bZnWGCPpO87xGOZA4onHZsmWzukWOgtcYDqJGv7Cbb77Z+o7RPIkwM2IS6O+FONG8x0/SRBAVpA583QJ1zjlbt25tx6PJk+1ovqSuOH779u0TVX8SLSEkWkJItMIgokIupUgPP5qQ4srnlBAuXLiQpLxTvj8T0ZVg+eKK9ESjzL7cRKciJRP1oy/j4/jx47G24ZiITEKJ7xoTArJ7KYhE+gEKQahr3wSbVCRaQki0hEQrQ4uWEMmJREsIiZaQaEm0hJBoSbSEREsIiZZES0i0JFpCoiWEREuiJYRES4joi9bcud+5c+cuqCaEREuiJYRES4gogl9lGjVqgTt/XqIlJFoSLSEkWkJEE/xKoiUkWhItISRaQiSXaM2Zs1ZNh0KiJdESQqIlRJSxpkNVg5BoSbSEkGgJkTxItIRES6IlhERLCImWkGhJtISQaEm0hERLCImWREtItCRaQki0hERLoiWEREsIiZaQaEm0hJBoSbSEREsIiZZES0i0JFpCSLSEREuilcIcOHDAfffdd2727Nnu008/dR9//LF7//333fDhw92IESPc2LFj3ZQpU9zChQvd5s2b3bFjx6JeBqRh3759bvXq1W7WrFlu0qRJ9vlCLijHyJEj3bhx49xnn33mFi1a5LZu3epOnTol0ZJoCSHREhItiVba4PTp0yZLgwYNcs2bN3clSpRwt912m8uZM6crVaqUq1evnmvWrJl79tlnXceOHV23bt1c+/btXatWrWz7KlWquAceeMBlzZrVZcuWzT366KP2OgKwbt26BD/4jx8/7ubOnev69+/vGjdu7IoWLeoyZ87s7r33Xle6dGnXoEEDOx+fLQTjpZdesvM888wztr5y5cquSJEiobLzN+VFxjZt2iTRkmgJIdESEi2JVsqwceNGExqkKEuWLK5ixYrulVdecePHj7co1oULlzcDBVGtJUuWuA8++MAkAFlCvurUqeNGjRrlDh48GGN7IlW9e/d2Dz/8sLv99ttN2vr27esmT55sZbxcDh06ZPL47rvvunbt2rnChQu7HDlymMBxjUePHpVoSbSEkGgJiZZEK3rQBIdcEX0qUKCARYSQIiJayQlyNWPGDIs6IV358uWzKFT+/PmtLH369HHffPONO3/+fLKWY+/evdYEyntJ9K1mzZrW5Hi5UinRkmgJiZYQEi2JlluxYoU1u911113u+eeft+a81GD+/PmuevXqVp8I1q233uq6du1qApjS0I9r6tSp7vHHH3e5cuWy9/bw4cMSLYmWkGgJIdGSaCWM5cuXuxo1aljkaMyYManWSfzLL7905cuXt2ZEIkrnzp2z9Xv27HE9e/Y0AezUqZP7+eefU6V8dKBHWCgHzZhHjhyRaEm0hERLCImWRCsyCEvr1q2teXD06NHJ3iQXF4gU9VasWDEbnRiXANC0+PLLL7u7777bRhKmVlMe5aXzPBEuRlSmB2GRaAkh0RISLYlWCkLECFFgZOCZM2dSrRw8/Bn5R31dvHgxQfv88MMP1rTIqMfUHCXIYIAyZcrYAAHkS6Il0RISLSEkWhlctGgWpM5Jb5CakvLLL7+4+vXr2yjCy5UUZJERgh9++GGq1ikjFpFFOsxLtCRaQqIlhEQrg4oWTW+IDXWemsk6d+3aZaJHNC2pzZX0myKHV5cuXVK1bletWmWpIcgxJtGSaAmJlhASrQwmWidOnHCFChVy/fr1S9Vy0C+MxKL0CYsWNH3+85//tISpqSkPdI7nM4BASrQkWkKiJYREK4OIFpEsyjZw4MBULcfOnTutHHQgjzZnz5515cqVsxxcqQmJWInWkXtMoiXREhItISRaV7hoEcl66KGHLC1CasJ8iDStDR48ONnOQToI8l3R9yu1ZYs6f+uttyRaEi0h0RJConUlixb1y9yDqQ15usjsnhJiWbBgQff555+n6vXu37/fRnWSo0yiJdESEi0hJFpXoGiR0Zzkn6nZ8R3eeecdV6lSpQSnb0gqa9eudffcc4/JTmoyb9486xeH/Em0JFpCoiWEROsSD2+SVEZ6eKdF0aLPEnMFMjdgasJ0NdmzZ3fbt29P0fP26tUrTXy2WrZsmSKRvGiJ1smTJ60v38SJEyVaQki0hEQr5Vi6dKk9nP785z/bw3PHjh1pWrSGDBliZUltXnzxRXvIpzT0kyK31caNG1P1+vlsMGVPakfXLiVajJhkmiNGb/IaYiPREkKiJa4A0eJhSOLJtL4QlfAPKJbf//731ul6w4YNaVK0iGaltmTQZIlkMOoxNXjjjTdchw4dUv1zjuSk9uchLtFCAInUXnXVVTE+302aNElT/3+kzEiLaTOEREuINA1RB27ozZo1S/NL5cqVYzyIWK6++mqLAuzevTtNiRaTM/NATW0+/vhj16BBg1Q7/759+0z0Tp8+nar1QLMzHfTTomjxZefWW2+N9dmmb19a+v9r3LixvZ9CSLSEuELxTYe++ZBIyaFDh+y1tBbRomw8VFObunXrupkzZ6ZqGWrWrOm++OKLVK8L5mVkbsS0JlpAfz4y2t94442h19Ja06EQEi0hMoBo/eEPf3AtWrRwP/30U4zX0ppo8VBfvXp1grfngTt//nybziYcsq5fbooCOsEntG8S59myZUvEkYmUj6l6WC5cuJCoMvTt29f17t07wdvTaZ+IYHhHcc6NsF2uLLVp08Z98MEHaVK0PIyOZBDBNddcI9ESQqIlRMpCs0VcI+fSkmghLFmyZEmUZJHkk+jTddddF2NwwrZt21yFChUsB1ZiIQs8CUoTwrhx49zTTz9tIvLggw/GGGgADD7w9VulSpVElQOBrF69eoK2ZbQd25IaIlu2bDHSYlAHa9ascT169Lis6YO4xtatW6dp0fIw4Td9D4UQEi0h0gRpSbQQwty5cyd4+2XLloUidN9//7374x//GKPz+vvvv39ZosUkywnpJ0az1S233BKaXJrRkuXLlw+9TtkYbcZE1CzHjx9PVDmQo9KlSydIUIPNnCQb5dp9HSCiQH+vf//735YGITEQDfPHSOuiJYSQaAkh0YoDIhFM/3K53HTTTTEiOXRovxzRmjNnjqtTp84lt5s+fbrLnz9/6O/NmzdbPZJ/C8hqT58z/3di2bt3rytQoECi96OJmI7iwGTVwaa0m2++2c2dOzfR4hkUSImWEBItIUQ6FK0ffvjB3XfffZe176ZNm2JN13O5orVkyRLLBn8pyF5PqgxGoAIDDKhH3xeqXbt2rlixYjbCE+FKbB8txI0RdImFJkQftcqbN6/Vg4cm0cQONliwYIGrVq2aREsIiZYQIj2L1tGjR61/0eXAxNPhqRAuV7TI4fXf//73ktsxEfQ//vEPqzM6wk+YMMH9/e9/DzUlembNmuWuv/56y42VGGgarVixYqL24ZqDGfW5jpEjR4b+JgI3efLkRB1zypQp7qmnnpJoCSHREkKkZ9GCHDlyJDpJ6NChQy2iFUk6Lke0aH7MmjVrgiJQdH5v27atGzBggMkIHfAjgWTF9Vpc0An9mWeeSfD2K1eudKNGjYoloF26dAn9nTlzZhshmRjoaM+IPomWEBItIUQ6F63atWu7GTNmJHh7xII+REAkiWY/z5gxY9wTTzxxWeWgrxjiklDoGE//p2nTpkV8fcWKFZbgNjHQFDpixIgEbUti0WAKhoULF9rP2bNnu6pVq9rv9PkiopXYCbKR1dTM5yXREkKiJYREK0oMHjzYde7cOUHbEiUiAStz3LH86U9/CokOI/4aNmxo0yR5EUsMlIGyJAQe+kSePvzww9A6pC+Ys4zIErKVGAoVKhQxUhfO+vXrQ3XAQp8wpljyPP/885bWAXFLyPGCMKKRDPWkTZBoCSHREkKkc9EiSSgP9uDowdRg3bp1MUYURoIoFrmuGNUX7HAORJjor0WeL6Zg+fzzzxN1/nnz5rkyZcpE7Xro/3Y5MHoxtSf4lmgJIdESQqIVRWrVqhVLXFKDkiVLuq+++irO1xltGF9/MkTswIEDl3XuRo0apWo2dk+5cuVSfSoiiZYQEi0hJFpRhPQIZDhP7agW/ZtIz5DYPk1JZfHixTaRM6MaU5OJEye6smXLpvpnVKIlhERLCIlWlGnatKnN9ZfaVK5cOdZIvuQEgUAokJzUhFQZ5NxatGiRREsIiZYQ4koTLTpfMx1Paj/omffw7rvvtil+UoKXXnrJOvGnBdGlA39aQKIlhERLCIlWMsBUMWQ2v9x+TtFi7NixlvjzxIkTyXoemirz5cuX6Dxi0YYO8EyQndg5ESVaQki0hBDpSLSADuH333+/jUZMTV555RXrr5RcssWoROZqTKnIWVy0b9/e5cmTx+3ZsyfNfAYkWkJItISQaCUjgwYNsvJt3749VctBU1pw0uhoQSTruuuuc7t3707V6yOSlRzXJ9ESQqIlhEQrDYsWkHCTZsRt27alajl69OhhzYjBZKRJgXkHSaq6fPnyVL2ud99915otEzs9j0RLCImWEOIKEC349NNPrWN6aufY4qGPHCU2CWkQMse3a9fO3XfffW7r1q2pdi30w+J9L126tNu3b1+afN8lWkJItISQaKUQRFzoqP3000+7n3/+OdXKwTyI5Lpiqp7EZl0nelWqVCnXsmXLy87YHg3IPs81MNKRqXbSKhItISRaQki0UhCkgCa87NmzW2f5CxcupEo5yAzfoUMHS65KE+ClOHTokGvbtq11Np80aVKq1R+RK1JIEE378ssv0/xnVKIlhERLCIlWKkB/rSeeeMIVKFDAjRkzJtXKsWbNGpuqhizyU6ZMifU6Uavu3bvbHI7dunVL9jQRccHITUYV5siRw/Xv39+mCEoPSLSEkGgJIdFKRb799lsTLprBKHtqNSkSHfLCNWzYMLdixQqLYBF5Qxb27t2bKuVasmSJa968uQkWaSpIBpuekGgJIdESQqKVBmCORCI22bJls6axcePGuSNHjqRoGUhBgcz4Oq1UqZJJQkrP27hhwwbXr18/V6JECRM/RhWmZn8wiZYQEi0hJFrpXLQ8jKSjDxSylTVrVlelShWbN3HhwoVRby6j39Vnn31mMlCyZEmbNqhjx45uwYIFlo+KEZK1atUy+atRo4YbOHCgW7ZsmY06jCb0u5owYYKNZCxatKhF92imJNqX3pFoCSHREkKilUZhcmSa9IgyVaxY0WXJksU6gTdo0MDk68MPP7Q0DUTDiEZRH8gT/aiY+ockoqxfunSp9b+iSZBRelWrVnW5cuWy5rh69eq5t99+261evTrOcnC8WbNmmfwgDLfddpsJUePGjd2AAQNs4uovvvjCrVu3zv3www+Wp4smPqSRptBdu3ZZn7Svv/7aJPKtt95yXbp0cY899pg1TdIhn2MhJESzriQkWkJItISQaKUTeECTt2ratGkmODQ1IkplypSxqX5Iioo8EYFCpPLnz29Nb0hakyZN3IsvvuiGDx/uvvrqqyTlnWKk5MaNG220Ik189OWqXbu25bNCBBmZiEDdeeedJlF0+KcciFWzZs1M9pAPJt1O7bkRJVpCSLSEEBItIdESQki0hJBoCSHREqSgrCcAAF8VSURBVEKiJYRESwiJlhASLSGEREtItIQQEi0hJFpCSLSEkGgJIdESQqIlhERLCCHREhItIYRES4iMJFo7d+5077zzjiXqJAkoualSCh7SlStXTvbzkOCUTPA9e/YMXfMDDzxgSVQTysqVKy23VkpBbrCyZctaglSJlhASLSFEOhQtHuLIg597j+SdTAqdkiT3g5p6JbEoBDO1FypUKEHzHpLNnmMAiVNTkgoVKrgdO3ZItISQaAkh0qNoPfPMM5aVPQjTy8CmTZvcxIkTbV5CQMYGDx7sVq1aZQ/cb775xrKy8ztT1LAfEyYzjc5rr70Wkrc5c+ZYtIw5B5lXcPz48W7mzJk2Bc769evdG2+8YdsxNc6MGTPc0KFDLeIE06dPd6NHjw5NSM20N5988omtCy83sB0Z3ik352LanK5du1pkiLIGIaK1ePFi1717d7dnz56I+1MOMsIzzc6xY8csSzxl6Ny5s/0dBCGivETO4OLFi1ZH1AlT91yqLs6cOWMiyJyMfl5Ess9T/9Tx999/H6qn2bNnu48++sjmi4xUbxItISRaQog0IFpMc4MYhcMcg02bNrXf+/TpYwvNbEzW/Omnn7rNmzfbtDRMXYNY9O7d2+YivP32220qmpYtW9qUOlwTkysjBPfee6/JBZLCOqRj//79dhyg2RIxYa7DNWvW2JyINNcRdWIaHn4iMsWLF3dr16515cqVizWnYd26da2cTBaNXAGC9dxzz8W6RkSLOQ/Hjh1r0+rEtT9T/ngRu+uuu0yGkDykM0jr1q1N7JBAfz3IFxJUp06dS9YF144sIVy+ORXRor5XrFhhE3IDdY3YdurUySQuvN4kWkJItIQQaUS0qlWrZpGRcCZMmGBz/gGRlHz58oW2Z35CL2kwd+5c16ZNG4vgMB8hMBlz7ty57XeiRp999pnLmTOn/Y2YjRgxInQuokTAJM5s06NHD2vCpJnu+PHj9lr16tXtGIhXw4YNbR0iR2THw8TTXph4+P/nP/9xhw8fjle0fNMh10JELtL+QdHyZZ06darNtRgEYaP81B2UL1/eLVmyxCbB9kIYX11wPQhTEEQLWaMemF8RkUNyOCYLk2yH15tESwiJlhAijYgWklW1atUY64jY0Dz44IMP2t9EqugrFC5aXr6CouVFZO/eva558+YW3erYsWMMSYlLtIiO0RzHhM5DhgwxyfDNfY0aNXLLly+3cnnR6tChQwzRQjJuvvlmixj58lEmjvHss8/GK1pEnOLaH9HyHdJ9WYmsEY0KQvmRNaSNJtGaNWta/y4gAnepunjzzTetGRNotqU8XrQQLMqL1CBVCKA/bni9SbSEkGgJIdKIaPGQ5OHP+caMGWPRmC1btthrtWrVci+//LKN1EO+aK4i4kMfIh7wN954o0VU+vbta9EbHvbXXXed9TlCGmjGYkFYEAoEwYsSzZI0kREtYx/6FvXq1cuawViIXNEXimZCIkXUBbz99tu2DvGpVKlSaL2H/l41atSwflCUE1kh0kM0yEelPHSQp37pJ0XTXaT9faSJZkH6TV1//fUmmhzz8ccfjzFqkWZHmgm7dOliAkc0iyZPRHbevHmXrAuaUQsXLuzKlCljAnzw4EETMspHn67bbrvNRiIyKjRz5syuSZMmEetNoiWEREsIkUZEy0N/Id9hOwh9tRL6IPVNhwhZcB8kwkec4oPXkbWgvJw7dy7UqT6h0Mzmo1KXIrysce2fkCY5tqH5Mng81vnrT2hdEL26FMHRkpHqTaIlhERLCJGGRCsa0MSVJUuWUL8qceUh0RJCoiWERCuVoGmOPko0eQmJlhBCoiWEREsIiZYQEi0hJFpCSLSEkGgJIaImWiTT5HcSemrRkhYWPo+MppRoCSHREiJdixY5kZgOhg7mWrSklYV0EnwuS5UqJdESQqIlRPoVLS1a0ssi0RJCoiWEREuLFomWEBItITIyJM9kTj8tl78wqXXRokVVFym4CCEkWkKIDMJTTz1lkzYLIYRESwghJFpCCImWEEJItIQQQqIlhJBoSbSEEBItIYSQaAkhJFpCCCHREkIIiZYQQqIl0RJCSLSEEEKiJYSQaKkKhBASLSGEkGgJIYRESwgh0RJCCImWEEJItIQQEi0hhJBoCSGEREsIIdESQgiJlhBCSLSEEBItIYSQaAkhhERLCCHREkIIiZYQQki0hBASLSGEkGgJIYRESwgh0RJCCImWEEJItIQQEi0hhJBoCSGEREsIIdESQgiJlhBCSLSEEBItIYSQaAkhhERLCCHREkIIiZYQQki0hBASLSGEkGgJIYRESwgh0RJCCImWEEJItIQQEi0hhJBoCSGEREsIIdESQgiJlhBCSLSEEBItIYSQaAkhhERLCCHREkIIiZYQQki0hBASLSGEkGgJIYRESwgh0RJCCImWEEJItIQQEi0hhJBoCSGEREsIIdESQgiJlhBCSLSEEBItIYSQaAkhhERLCCHREkIIiZYQQki0hBASLSGEkGgJIYRESwgh0RJCCImWEEJItIQQVwinT592NWvWdFWqVHFZsmRx999/v/1eu3Ztd+bMGVWQEEKiJYQQSaFhw4YuU6ZMMZbWrVurYoQQEi0hhEgqmzZtcr/97W9DkvXXv/7V7d+/XxUjhJBoCSFENKhWrVpItDp37qwKEUJItIQQIlqsWrXKJOvaa691hw8fVoUIISRaQggRTcqWLet69+6tihBCSLSEECLarFy50p08eVIVIYSQaAmRkfjuu+/crFmztGjJkMvmzZt1ExBCoiVE8vDTTz9Z36F69epp0ZIhFz7/QgiJlhDJwo4dO1zhwoVVESLDctttt6kShJBoCSHREkKiJYRESwiJlhASLSEkWkIIiZYQEi0hJFpCSLSEkGgJIdESQqIlhERLCImWEEKiJYRESwiJlhBpSbS++uor179//9DfzNvXvn1799xzz7n9+/eH1s+ePds1atTIPfPMM+7ixYuxjjNlyhQ3cOBA17Nnz1ivvffee65jx47u9OnTdtyJEyemej099dRT7ueff461PjXKGFdZLocBAwa4V199NeJrH3/8sXv//ffd4sWL0+znN77yS7SEkGgJka5E69dffzXRqlSpUmjdt99+686ePWvC9PLLL4e269evn1u6dKn7/vvvYx3nxx9/dM2aNbPfN2zYEOv1r7/+2mQCevXq5T766KNY24wZMyZR15nY7eHLL7+0svpriou4yphU4ipzfGVJLFOnTnWdOnWKtX7Pnj0myoBIplXiKr9ESwiJlhDpTrRg165dMUTLM378eJMuILqTN29eN2HChFjRLOb669q1q02wPHPmTIuYbNq0yW3bti0UKVu2bFlItPr06RNLYpiYuUSJEhZp4fjffPONe/fddy3Ks27dOotwMK0K51++fLnJ4a233mpRtHDhY93gwYMtMsXxxo0bZ+WYP3++u/POO91bb71l1/z666+7I0eOhOSQaI+/3mAZT5w4YdE8/kZA+XvGjBlu6NChbufOnaFzb9++3Q0aNMhNnjzZ6iH8OoJlDpZrxYoVMcpCZv9Jkya5L774wq6B8/C3F0WOGX5sOH78uPv888/tvYgkKlu3bnXZs2d3w4YNs7qYN2+eW7JkSYxtIl1bsG4oI9fItQwZMiRiOYLlP3/+vPvkk0/sfLzHSBRcTvklWkJItIS4YkRrwYIF7q677jJh8A9GRKdatWr2IAyHB6+PknTr1s2ECO65554EiRaTMzdu3Nh+RwS4Bh74derUsXVEy2iWRLh89CdfvnyxykGz5oEDBywSxzk4RtGiRS0ShwBUrFjRIjsIzP33329ixrkRizNnzrjKlSvHKiOC8Msvv9jDHzGgfEgC80muWbMmdG6aXG+66SY71+rVqyNehy9zsFwImi8LYuLPV7x4cbdlyxYTsnbt2tl+I0eONNkLP/aFCxdclSpVbJu33347oqggd3fccYc140KFChVC0T1P+LWF1w31Rrl4f3nPw8sRXn4k7YUXXrD3D/HOli1bxPc4IeWXaAkh0RLiiopoEZUqVKhQrPU8QOMTLZocvWh5sUiMaJUvX94iLV5Y4NSpU+7mm2+O0SwZSbSIihBBadGihRs+fLjt/+STT4Ze96IF5cqVM9GgPxpyEcSXkWjdI488YmXxUkSELWfOnK5Hjx4mCEGI+nkiXYcvc3i5fFnmzJlj9ejPd/DgQZOXPHnyWB2MGjUq4rHZr23btvYachwuKmPHjrUIFLJ14403WnRq+vTpseov/Noi1c1jjz0WinZFKkd4+elzhSBCwYIF7XoSW36JlhASLSGuONGCSH15Iq1DtJ599tmQpPi+SImJaDVs2NB+r1mzpjWRwdq1a+0nzVwffvihe/jhh0MRraDUeIjSHD161KIiRE0iiRbX6yUBuXnzzTdd9+7dQ3KJYPgyci7Eg2iVL8/GjRvdsWPHXO3atU1eggTlL9J1+DKHl8uXhfOXKlXKZATJo7kPEJ/69euHIlDhx6YPXMmSJUOi8vzzz8coFxEzopTA+0QTIpGxc+fOWXOhJ/zaItVNULTCyxGp/DSLetFC3HktseWXaAkh0RIi3YrW6NGjXe7cuUMC0rlzZ+vjxEOWJiQgwsCoQaITNGcF4eGLCBQrVsyiRUjXfffdZ6KTNWtWi1zQ/EQfLPrj1K1b15rCgtEg1ufKlcv2ZXuamKpWrWqCRR+mVq1a2XYcA9FDEooUKWJNeUEQBKJZNCGyIAtEUXw/ICI0rVu3tsgU5/vss89sZCX1VaZMGZMr5CNYRiJjmTNndk2aNDHBoKM818aCIHrWr1/vrr32WvsJ4dcBvswsvlw0dfqyAOdBhCir7w9HGWvVqhU6V/ixEUKa3ti3efPm7tFHH7Xonoe+YLzHNKkioXSKR4IRmmCfu/BrC68byossIr1xXWOw/DQ50jTYpk0b+1zSR40oVmLLL9ESQqIlRLoVrXB48NLHJhwiRQmFTtM8PImOJBQiHUF54yEdH+HNdh6/X1yvx7WeCExc0GwX3J/ror/SpQi/jrjOnZCyhJ8vUh1R75Q10nkoc/A6Dh06FLG8ka4tvrqJVI74tr/c8ku0hJBoCXFFiJYQ6R2JlhASLSEkWkJItISQaAkh0RJCoiWEREsIIdESQqIlhERLCImWEBItISRaQqRT0WIoP8PztWjJiMv//M//6EYghERLiOSB4fHkJGLuQS3Ju5Cxnal0VBdpa6lXr55uBEJItIQQ6R2y3ftEo0IIIdESQgiJlhBCoiWEEBItIYSQaAkhJFpCCCHREkIIiZYQQqIlhBASLSGEkGgJISRaEi0hhERLCCEkWkIIiZYQQki0hBBCoiWEkGhJtIQQEi0hhJBoCSEkWkIIIdESQgiJlhBCSLSEEBItIYSQaAkhhERLCCHREkIIiZYQQki0hBASLSGEkGgJIYRESwgh0RJCCImWEEJItIQQGUy0fv31V3f+/PkYS5Dg+osXLybrhXz55Zfu66+/TpFKu3DhQrzXnRC2bt3qJk2aFOfrO3fudKNGjdInVAiJlhAio4rW4cOH3TvvvON+85vfuBtuuMHE4Ny5c/bamTNn3OjRo921117rWrRo4Xbv3p1sF/HJJ5+4v/3tb65v374pUmkrVqxw5cuXd5kyZXK1atVyc+fOTfQx3nvvPffggw9GfG39+vWuaNGiLm/evPqECiHREkJkVNHyZM2a1VWtWjXia4888og7efJk6O9+/foly4UULlw4XtH66KOP3I8//njJ47z//vvum2++ueR2U6ZMMdH69ttvk+V6Bg0aJNESQqIlhJBoOVegQAHXoEGDiK9Vq1Yt9DtNZQ888ECyXAjHjUu09u3b526++eaoita8efNMtL7//vtkuZ4hQ4ZItISQaIlEQovA7373O5crVy4tGWTJnDmzO3DggERr6dKlLnv27CY8nTt3tr9ff/11d/fdd5u05MuXz7Vt29a2nTlzpmvXrp2rV6+e69Kli/vll19sPf28iIi1b9/eXgtGxxCtPn36mGxlyZLFVa9e3bY/evSolQEpatWqlRszZkyKiRZ9t3r37u1eeOEFK8+IESNsPf2zKMtDDz0UY/thw4a5p59+2vYpU6ZMDNGKVCdbtmxxLVu2dOXKlXMLFy509913n9UnNxohJFoiI/Lmm2+6F1980R68WjLGwvMyuVqX0l1Eq3///q5IkSL2O325Fi9ebLLSs2dPN3/+fLt5rlmzxmQC6GxfsGBB16NHD/u7e/fuJmleVth32bJlIdEqW7asycfPP//srrnmmtDNeNeuXbZtpIgW5aCPl1+aN2/uXnnlldDfcd3QEyJaXbt2tSZG2LZtm22/ceNGd+rUKZPFoEh98MEHMcTriSeeCL0eV51wnDZt2pjNU84TJ07YB65GjRq62wqJlsiwosWzQmQcKlSoINGKJFqA+CAf27dvD61r1qyZe/LJJ90bb7xhC53N69ata4JBh/fly5eHtl23bp11uveiFWw6RFL4h7uUaBF1+uKLL0ILUbXBgweH/kYAL1e0/vnPf1rUzl8LHdw//PBDe23gwIExROuWW26xflnBm4V/Pa468XVKJMtDVC/4txASLSHREhKtdC5aCERcUZSggIWL1k8//WSyQioDT+nSpV23bt1iHWfPnj227apVqyKeJ1y0ihUrZtJxKdEKJ1pNh4zI5PW4mvGCIrV3717bFrHzvPXWW6HX46oTQOSCYsVx8+fPr/88IdESEi0h0bpSROvxxx+Ps5N748aNEyVaNWvWdHny5IlxjJUrV1rk6re//a179dVXQ+uJcnnxiiRaftuUFq3Zs2dbrq3/+Z//sWbI8GsJFy36W3Es+nIFRcvXQ1x1ItESEi0hJFoSrQwgWp9//rn7wx/+YP2jgtDviCayoDxky5bNfidC5aNUmzdvDm0zduxYW0eH8EOHDlnT3dChQ+01On3TmZ4+S7yGSBE5AmQjKDWIF32/gM5yHHP16tV2zvgYOXJkjObJuJg6dWrE9A6Ilz9vlSpV3I033miRKso7YMAAt2HDBnuNernnnntC+5Ge4q677nL79++3v+mD5esqvjqhDuiz5aFpMXfu3PrPExItIdESEq0rRbT8A/7++++3Pk69evVyTZo0cZ06dYqxDX2q/vrXv7qKFSu6HTt22Og5BII+SF4wgA7eJEHlNYSJkYNA5AuJYP3tt9/uPv7445Do0fmdBKCcgxF61113nStevHhI/pARRuQFm+cuFzrg05xHOSgPEScWzv/nP//ZLVmyxLYjYodAsR3X45v/6Bj/8MMPW11Mnz49JGh33HGH+/vf/+4effRR99hjj1myV58dPlKdcG3U+dVXX+2mTZvmNm3aZHnLOO6MGTP03yckWkKiFQ+0ihw/fjyUaDsILQ28lhBoNUkOSPR98ODBGOto3SFlkf+Z3ES6tsTUTXh9kw0gOFMMv7NeopUIeOPDI1tBTp8+naBK5Y1ESMK35W86zyd2Sh/249ypwQ8//BDrnyUSNDciS5STkZOMKkxInQgh0RIZDZ4zwYFUiRUtWkPobsKXb9JBhEM6nUu1bngJ4RjRnmaOc9MNhZyKQQgwkArI//QwsIv+vtGSQr8dgYvLqZtIMKiLwApBEOqLY7OOEf4SLSGEkGiJNAQJsOmyQkoeWg8SK1q0PDCIi7Q4pAvycsHDn2gRXV2QCSI3X331lX3JBVofaEXhyzMP+O+++866d8CRI0dsSjZaX9iP9D4IAHkjwyWK3IfAPL10KaHbiv8SzfnJqchUbfQZ5gs4+5AeiBYVBMv/9CCLfqQ9x0PSjh07ZsclAEKZWc8sLsEuNNQD5aS8kydPdnPmzLHrad26tfVr9imKuCbqhgBApLohQMC+cYEI+sghLWBcKy03lDOpSLSEEEKiJZJBtOhKwUKXDXIT0oc1MU2Hw4cPt4FGCAIRrtdee83S+yAaXiaQAmSEXIb0j0VwkA/6/jZq1MiEgZQ7/GRAEz/Zlu4wlStXNkHhdQ+yglwxoIqk2xwfGaIPrh/kBJQFMSLfJHMKI2v0zY1LtN59910r54IFC6xunn32WZNCrqNjx46h6B9l9nANCBjb0lca8UHqkBbqkagTZadekT76R/NapLqhRSYhM6Ugplw/ILkIIoIn0boE2DHJNnlDtKSdhazxPs+YEFcKDIqhTyYDTbRk3IW+qV60/HLVVVeZLCREtHw3DKI99HX9+uuvTWiASI2XCZq2/DpGzq9YsSL0t5cWP7qezyaQExEp868H5YbmSkSDCFCdOnVMYJApBo8tWrQolmghWAghIpEQ0UJ+vLBRRqJSJPP2/aDDRYtjk1wbSfLXwWh+Hx1je66F7eKrm3BmzZrlnnvuuRjXBG+//XasPlp+AJlEKx4Y7UdHb74VaEk7C9Ma8e1ECEW0xJUc0WJBvBiARWQoIaJFkxUjwWn6YhQ4ERlEiUFa9P/iWBMnTrQIV+3atd2nn35qcsZAKITr7Nmzrn79+vaAL1++vEWukBH6TpHDkShQiRIlQoEIP6iLPrtEmNgOCeF8RNAosx/ghXzQJDpu3DhrFiWFEvLWoUMHK5MvW3DAGf8TCBORK85HPSBZjExHohgoRVMiUuL7XyFL5LrkS/n48eNtQBfl5lq4ZspesmRJ6x/MrCMvvfSSlSdS3XDsoPjFhe9zRj9kRtczLR6d/iVaCRCtYFZzkTYgl5hES0i0xJUsWjfccIM9g+gfBQltOqTPEELj9/NEGoGIVAVf932pInWAT0grAvsHj3kp6BfFeS/V4d6/jjTGtW34euoh0gCrSPtfqm4Sck0nT54M/R6tAWoSLSHREkKiJaIMnclpJgsfna08WhkPiZaQaAkh0RIphERLoiXREhItISRaQqIlJFoSLYmWEBItIdESEi2JlpBoCYmWEBItiZZES0i0hJBoCYmWkGglq2gxRJTcGeQvAYaXjhgxIsnZYRNzoyaHR0pCvhbymaTk+SVaQqIlJFpCopXBRIscI0888USMyS9Jw0+Ct9dffz1FLjqakzKT4ZekcJdi6tSpoeRyKTUptERLSLSEREtItDKYaJHZlmy3TMgZhLme4hItpif46KOPQhN/MlUCs32PHj3aIkUestzOmDHDMtyyT6R9mc+K85CkLjHH8TA1wYQJE+wayJ5755132nQE5HRhKgWSvBGt8/sxNQFzSZGxF9EKnh/IskviPWZ/hx07drjp06dbpmKJlhASLZE4mEuQRKZkNNeSMRbeb/+Ml2j9fxAT5kBq2rSpTQJ6KdFigkw/0/ejjz5qAoOIFC9e3K1du9amTFi9erVNa8CUBZA9e3abciDSvmSiZV4rolAJPU6QJk2a2E/kDCpWrGjTFHCO3Llz2zqmUejVq5dl561SpYqtY34nRCt4fppMmSaB6Q0oB9M+MGM6mXP98SVaQki0ROJgjsD169drySCLn1JIouX+Nz3/rbfear8jJv/5z39CKfjjEi3mYKLZDYgctWnTxibMbNiwoa1D1piziok+kSkfRqQ5MtK+gFQhOgk9ThCOUbRoUZOyoGgBs8ADES9Ei/kG27ZtG/qW5ZsO/fl5nUk3mTSUhSgfc17lzJnTjiHREkKiJYRI36R4RIuoj58Lys90Hp9o0YTGhNUwatQom9Gc5jsvSDRFIkiIG81zNPlhuHHtC0wAiugk9DhBNm7c6ObNm+eyZcsWEi1v0/fee6/9pDmSPgI0TRLW9KL1/PPPxzg/ElSqVCmLbBHFIvTJ8Zm4NG/evBHPL9ESEi2JlhBCohUnSArNZcgIfacAyaDJjJnQ/QznHkbn0axG/yciQkSYaIZjHYJTqVIlG82HoOTKlctVq1bNmveITEXa98CBA7YdN+qEHicI4sRoSWYdByJhlJ1yM2P6Cy+8YNLG/pyPpkOOQ3MkkTKaJv35gddoouQ49O+qW7euSR4zuofP4SXREkKiJYSQaF0SIjgJmeE8yKFDh+J9fdq0adYuT38nfg4ePDjB+yb0OEBqivCO/PTFAkTp2LFjJo7Bmc/p+I40+e3CCc5mzjbIYDRGJkq0hERLCCEyoGglB5yfKBJlIVq2efPmVD1OWkCiJa4U6MtJt4MsWbK4q6++2v3rX/+y3/Plyxfq5ymEEBKtZIZoEOkT0spxJFpCRA8GojCMO7i8/PLLqhghhERLSLSESCr0pfz9738fkqxrrrkmlI9OCCEkWkKiJUQSqV27tqJZQgiJVrSgQ3iwU3kQcnLRN4PO6X47v6TUFDcQPF9qnF+iJTIS5L5TNEsIIdGKEuSTuueee6xTevXq1U2uoH///jatDfMMtmrVytI3TJw40eXPn99+kpw0JSA31pNPPmnlI+s8qRlI10BqBomWEMkDuecUzRJCSLQSAdPczJ8/3w0bNszt3r3bDR061O3bt89eI7knlClTxnJQIVcvvvhiaF/yXnkB8wlQ/d/JCVGrxx57zJKcgs95xbQ/Pmu8RCvjQHTlT3/6k7vpppu0JPNy/fXXu3//+9+qi3S8EJXkXi+ERCvKokVSz8aNG9syd+7c0Pply5a5jh07um+++caSfyJeL730kr3GdDck+yRzPPTt29eyvEcimGk+JSAhKdI3efLk0LrwvFsSrYwBk4EXLlxYFSFEAmBGDaYdE0KiFWXRIm0CUSkWEnt61q1bZ9PvMKqIJgESjPoJp4loEbWiWQ4WLlxoU+R4gsk+U1q0gD5ZPXv2DEW5UqrZUqIl0RJCoiWERCtB0Nfp2WefdYsWLbJoFx1ea9asaZLA9DRkSqcfFhM0k9+KyaKHDx9uzXRr1qyxYzB3IPMP+gmekxum92EanjFjxoRC4Ejg2rVrJVoSLSGEREuItCNalwORLKbySU3CM1IHo2sSLYmWEEKiJYTyaF3BSLQkWkJItISQaAmJlkRLCImWEBItiZZES0i0hJBoCZFORItRiO+++651Il++fLl74403rN/Tli1b3GeffWad48mtRY4q/ikZ0UdKBf6eM2eOmzZtmjt48GCMY7If6R/ov0U6iSlTplhy0w8++MCtX7/e0kQwwpEko/xO/i7OO3r0aBv9mFQ++ugjd+bMGYmWREsIIdESIvUjWuPHjzfRQbpKlChh68inRVZ48mkxGtE/yJ566ilLRkpmaJ+UtFatWjFSRSBa5LIi7UKdOnVMtgCh8yMCWU8KCdJGcI7nnnvOpvLJmTNnkqbP4XglS5Z0x48fl2hJtIQQEi0hUl+0iP6QKwvRyZcvn8kQ0+h4cUGKyLROVKpZs2YWgWJiWQ9S9c4774T+Jso1ZMgQ26dRo0ah9QiUlygvWoCING3a1AStYcOGl10HiB/RM8RQoiXREkJItIRIcdHaunWr69Wrl8lQEHJnEXEiW/zzzz/vPv3005BoIUH79++33FqIFs2KTzzxRGhf9hsxYkQs0Vq1apXtG4lw0apfv76t27Bhw2XXwcCBA63JsmzZspYXTKIl0RJCSLSESFHRIupD8tHwiA/zF/rM7wULFnQ//fST/U6fKt90uH37dms6BOYYpC8XESqiVsH8VUSV3nzzTfud+RE5H5CNPtjcSMJRoOmQial/+eUX9+ijj152NGrnzp0WjUPYKLdES6IlhJBoCZEmRh0iTPTLgsWLF4fW00xIBng6v3/99dfu7bffts7wCBPRr1mzZtlkvkGIhn388cfWGR6ZomlxxowZNr0P0J+Lsq5YscL+/uqrr2wSa2SNDvlkek9KIlSaOFNiUmuJlkRLCImWEBItIdGSaAkhJFpCoiXRkmgJiZYQEi0hJFpCoiXREkKiJYRES0i0JFpCCImWkGhJtCRaQqIlhERLCImWkGhJtISQaAkh0RISLYlWvJBcl3QgPncbaUmYoWDv3r2XVQZyuT3wwAOWY87D70wx5WdbIBedzyGXGMgN17lz56jVFzNBMC8oefLCExgHyxxe/nDIm0ey4B49erjKlSvbuvfee8917NjxkvsG37v777/fyhSEGSfCyxYf/rwJJbHHT4n363I/HxItISRaEi2RpkSrQ4cOlifOgwwgDMzRyUwFl0uhQoUs71wQZmNAaiCxc3mSV86TlHlAIx0XsUSGqLtwgmUO/h7kxx9/tNkigFkdfPnIueeTG8e1bzj58+ePJVqJvd7geRNCNOszvuOTEJq6SgtlkmgJidZlwqTQV111lWvdurWWNLRkypTJMuqLtCVa06dPdy1atHAHDx4MratSpYpbt26d/V61atXQFFHABOtMNUX067XXXrOJ0nlwvv766yYqCNu4ceNsWyJaJP3t3r2727Nnj63r06ePycbhw4dtH5/kFzlBdr799lv7m2muSPjr5ap379420TvHW7hwoU0AH7yG0aNH27FI8PvJJ59YOdhn6tSpoTphOwQyCLM0VKtWzbVp08YSBke6Dl/m8N89JBju2rWrTXnFMZjei/sQLFu2LCQ8wX1Jdjx79mz72ycVXrNmjZs8ebLLnj17DNHimigLiZT5H+KLJPVAlMhPVL9v3z6LQPopw/x543pvmBZswoQJ9nfw+MAXImSbeoa4zhkk+P757bkWpgDz7xdRzjvvvNO99dZblqyZWTcmTZrkvvjiCysD27B9t27d7Hr854M5aHkfSRLN+yXREiKVRYtvQfzDa0lbC9+wRdoTrXr16tkDrX///q5kyZIWxbr77rtDTYbM0cnD0LN79253++23u0WLFrmWLVu69u3b2/oHH3zQZI39SpcuHRItZkwYO3asK1CgQAzZ4MFPExkigFQxIwIPVN/kVrNmTfuJXPFAZhvmIQUe4E2aNAlFsHmNyFm2bNnsAf7CCy9YdAkpZB0g+wgRQhYOD3aa/eK6jkuJFiBYNA0CYoosxSdaSCBTbXXq1MnElQWZQLBuvvnmWKJFPSOdCOott9xis1Fw7Ygj2z7zzDO2LdOAUV/B80a6Jl9/1Efw+JTdz8tKeVkinTNI+PvH9jfddJPJy+rVq2O8X0gN0s05fR0UL17cRA2Ja9eunZszZ441YfvPB58fjoEoJiZKJ9ESIplEKyPATT28aUGIyxGtIkWKmJD4Bw4Ps3Llytm8mz6itWDBgtD2iBhNWz4alDt3bvv9oYcesoc5S1C0fNNh3rx5LToRlA3Ow4OUh7yPpniIihBxocl58+bNMUSLbf2DO1euXKF+ZdWrV7eozoABA9zIkSNtHfOV8lDnYZ0zZ047ZnyiFek6IokWZaA8LIhDULQgT548cYoWwvfII4/Yw52Fa+U6kUTgvQv//+7bt28oukdd+kgecsJPXg8SPG+kayKCV7RoUROh4PGpn7Zt29o6PgP58uWLeM4gkd4/v334++VFC5mivnwdUDYEbsSIEaH9/OcDeF+JaDE3rERLCIlWssPDxU9QLURSRIvID/1moHnz5rYvUQvfBFWqVCmLUARFy0sEERL2AZrNeCjSeZnIWLhoMcF5uLSUL1/e9mHidZoXgWYrhIyHLDzxxBO2DtFq2LChraN5yj+4mdQdyfHRHOYIJULnRYt+YojWxo0bTSgRgPCJ1hEtIiZxXUck0aLpD9FkQYoog590/lKiRdQd6fP1ygTwCJAXWt674CAC6NevX0i0vPwwbyrSQzMvMsV7Q91R/uB5I10T9TFv3rxQxM8fH/EiAuajlxUqVIh4ziDh79+FCxdC24e/X0gNc72yHZ8t3hvEk+bWcNHyn49XX33VBI+ol490SrSEkGglK/fcc0+KjMYRV75o0RemVatW1sRHUw4QXWjQoIH12/HCEhSt6667zvrS8IClXxEw0g4pGjZsmPXD8Z3DkR763hDBQEjq1q1rzUOcly8MRCr2799v5S1TpoyJCNvde++99vBmHWXg8872CA2RDWSAvkI0SdP0RMSKBzL7InVEbKiHW2+91R6inBdJ6NKlS4wO+ohJpUqVTJI4Xvh1cAxfZuTH/45MePid/YhKEa0hEkQd0SeJJjWaPyl/cF8mqM+cObMJCNtR/0SYuAbOSzOdhz5cNPGy73fffef+8Y9/mDRyzscff9yuh9eRm5deesn28edF5iK9NwgXdclrweMjgUSNXn75ZdezZ0+TG0Qu0jk94e8fInvttdeGhDb4fhH9ohmX37l2mlhZR90i0jRb0gTJF0n/+aDciDfN29TR5Y6ElWgJIdFKMDTX8KASIqmi5SFCE074iEEvWjQd0rcmfFQYD3VeJ0LhibRdXAT3I9KBkASFhnWRQK4iddAOwnF4eCekLJGuIzkIr18Eg8U3ISaW+Mobfk3UWXAARDj01UrsqL+E1lfwPU3oPtRL+L4SLSEkWskGzRLR/lYnMrZoJebYWbJkCfWLEiK9I9ESEi0RC/qZJDQXjZBoRROaxmhCii8aIoRESwiJVrqGvhg+L5EQKSlaQki0hJBoXfGQk4iRO0JItISQaAkh0Yoy5AaSaAmJlhASLSEkWskAD9FIc7IJIdESQqIlhEQridx3333JMueXkGgJIdESQqKV4QlOmyKEREsIiZYQEq0oixZTVggh0RJCoiWERCvKMA0FE+0KIdESQqIlhEQryjCnGpOyCiHREkKiJYREK8owie7GjRtVEUKiJYRESwiJVrR58MEH3YYNG1QRQqIlhERLCIlWtClZsqRbv369KkJItISQaAkh0Yo2pUqVcuvWrVNFiIj88ssv7o9//KO74447tGjRcoklU6ZMmmlDSLRETB566CG3du1aVYSIkzNnzrgTJ05o0aLlEsvp06d1wxASLRGT0qVLuzVr1qgihBCJYuDAgW7hwoWqCCEkWiI+HnnkEbdq1SpVhBAiUTCjRI4cOdRUJoRES8RHmTJl3MqVK1URQohEM2TIEFe1alVVhBASLREX5cqVcytWrFBFCCESzcWLF13ZsmXdqFGjVBlCSLREJMqXL++WL1+uihBCXBZM4UUT4o8//qjKEEKiJcJ59NFH3TfffKOKEEJcNoMGDXI1atRQRQgh0RLhkGBv2bJlqgghxGVz4cIFSxUzduxYVYYQEi0RpFKlSm7JkiWqCCFEkvj+++9dzpw53b59+1QZQki0hOexxx5zixcvVkUIIZJMv379XL169VQRQki0hOfxxx93ixYtUkUIIZLM+fPnXYkSJdzEiRNVGUJItARUqVJFoiWEiBpM6ZUrVy534MABVYYQEi1RrVo1t2DBAlWEECJq9O7d2zVs2FAVIYRES1SvXt3Nnz9fFSGEiBrnzp1zxYoVc1OmTFFlCCHRytiQ++bLL79URQghogpzqNKEeOjQIVWGEBKtjC1a8+bNU0UIIaJO9+7dXdOmTVURQki0Mi61atVyc+bMUUUIIaLOmTNnXJEiRdzMmTNVGUJItDImtWvXdrNnz1ZFCCGShW+//dblzp3bHT58WJUhhEQr41G3bl33xRdfqCKEEMnGiy++6Fq2bKmKEEKilfEgi/OsWbNUEUKIZOPUqVOucOHCip4LIdHKeDRo0ED9J4QQyQ5TfeXJk8cdO3ZMlSGERCvj8OSTT7oZM2aoIoQQyU7Hjh3dc889p4oQQqKVcSB787Rp01QRQohk5+TJk65AgQLuq6++UmUIIdHKGDRq1MhNnTpVFSGESBEWLlzo8uXL506cOKHKEEKideXTpEkTTZMhhEhR2rZt6zp06KCKEEKideXz1FNPSbSEECnK8ePHXd68ed2iRYtUGUJItK5smjVr5j799FNVhBAiRWHqr4IFC1rqByGEROuKpXnz5m7SpEmqCCFEitOqVSvXuXNnVYQQEq0rl6efftpNmDBBFSGESHGOHj1qubWWLl0aWrdjxw5VjBASrSsHpsUYP368KkIIkSowBdh9993ntm7d6sqVK2fTggkhJFrpmrNnz9q0OyyVKlVynTp1Cv2t/hJCiJSGye3/8pe/uEyZMrlixYqpQoSQaKV/ChUqZDe14ELHVCGESCn27NljUazgfeiWW25RxQgh0Ur/TJ48OZZoEcIXQoiUYvDgwe5vf/tbjPvQb3/7W3fu3DlVjhASrfTNr7/+6nLlyhW6uT344IOqFCFEivPTTz+5+vXru9/85jeh+9G2bdtUMUJItNI/o0ePDt3YFi9erAoRQqQay5cvd0WLFrX70dy5c1UhQki00j8XLlxwt99+u6tQoYIqQwiRJhg3bpwNzBFCZBDRorPmlbz06dPH+malpzL/8ssv+oQLkUzQlPfOO+9o0aIlygutSBKtMJgDkDA2M81rSTsLnWX379+vJ6IQycADDzzgihQpYvOgatGiJXrLn//8ZzdmzBiJVpBXXnnFDRo0SHfeNAZ5djZt2qSKECIZKF++vPvoo4/cxo0btWjREsWFmVjee+89iZZES6IlhERLoqVFi0RLoiXREkJItLRokWhJtIRESwiJlhYtEi2JlkRLoiWEREuipUWLREuiJdGSaAkh0dKiRaIl0RISLSEkWlq0SLQkWkkXrTfffNM1atTIJkqNBjt27HD333+/TbC6fv1617lz5yQfk2kuypYta79f6pgkWJs2bZrbuXOn5dY5ffp06DV+f+6559zEiRMlWkJkYNH69NNPXZUqVVytWrVivcb987vvvou1nhyF3IsS85AaP358kh90a9ascU8++WRUHpobNmyw++fzzz8fleMx7VDhwoXd2rVrQ+u+/vprm4d2yZIlSa6DaNSfFolWqorW7t273dChQ93SpUste3l8HD582M2YMSNBx82fP39oJnsmgo4GTCbtie+YwdcKFSrkTp06FeP1Xr162Q1ZoiVExhUt7pOTJk1y06dPj7GeB0revHljbb9q1So7R2IfUu3atUvygw7pS4gYJfT6eXCSgDIaD+GVK1e6EiVKxJI55n+83DpgOqN169ZFrf60SLRSVbSeeeYZV7lyZffNN9/Eeu3EiRMmVogYglCpUiXXsmVL++by/vvv2zpmq+/fv39oH755TZ482WXPnt1Ea+HChfaNxB9v9uzZdjM4e/ZsjOMTfQo/d3BbyJMnj/0MHhP5+/LLL22KAI7FNBz8k/rrIaLFxNPdu3cPiSTT93jRYntutkznkxKiRVkvXryop6IQqSha3377rcucObPd/8JFpX379nafixQJ+uSTT9z333/vhgwZYuu4F3L/4OeoUaNsrkPuW0TMkSPWEQXz+3Pf4j41duzYiMfx50L+3n333VBUbdGiRRGjXB988IEbPny4yQ5C8tBDD1nEDYny0STO5fehbNwrkSCiTm+//batX7ZsWaicLKtXr7YHK2Xl+DNnzrT1kY7LNdBKMHDgQDd//vxQFKpp06ax6oCF1gZ//fzN8bgO1q1YscKOx73+888/j1V//M57xO8EBygb18s6f26ui/Xs6//mmSRhkmilmmghMXzQ7733Xjdv3rwYrw0bNsyEhX8W/qkHDBgQmvOoW7dubsKECfb7PffcYz+5MUydOtUE6+abb7affMCbNGlir/fu3dvm++vUqZNtG378IOHbBkUreMyGDRu6H3/80cpF8+fRo0ftRumnC0C0uPnxT1ygQIEYonX+/PnQeYoXL+62bNmS7KJF+P+2225zjz76qHvxxRfthoysCiFSNqLFfYf7w5w5c+xv/hfpdsBDJb7mKqQjZ86c9rBHCtq2bWvSULVqVbu3EDF/7LHH7HWEjYc++yF1X331lf3ft2nTJuJx2I59kAymPuF+Gl+kDPF49tln7RjNmjVzI0aMcAsWLLBuFlwPXzJ9tImuISNHjrRtqCsEhde4P7Jdx44dYxy/Ro0aVhbKSWtCXMd94oknQmVhqjF/rV6IfB3we4sWLay+ORcSh/h16NDBRPOmm26yeuRLPPvwu9+X7iL169c3mXrrrbdcz549LeKVO3due47wPOC5x7mpe16jXvib6+MZImGSaKWaaHl++OEH+yAH4cPKjaBHjx7uwoULMUSLD7oXLf65vEgcO3bMfqfNHtFCpPgnOHnypHvkkUfsWwjL9u3bYx3fE2nboGj5Y0LFihXthsE/LGWCvn37xhAt33RIc8CRI0dCosU/PN/E/HkOHjyYIk2HXB/fsri5ch0FCxZ0d955p92ouQa+8SGPQojkEy2Wl156yeSKe0GdOnUsssLDm//BuPbhi2mpUqXsd76g+YgLMsI98bXXXrMIOuvop0R0iHWtWrWydRUqVLB9Ih3njTfesD5jbE+EKL6yI0zcZ/mSyt/33XdfqLmNewpywpdO+mNxfyxdurS9xpdT7pH8jtx9+OGHJiPIXfD4fPlGqDgO9+lIx2UdX2A5LwtzTbKOex3bBeuAc1LfwXM8/PDDth/l417OOr6MUo/BfbkvImmse/nll13z5s0tykfLCS0c1atXD5UfOeN1XxdaJFppRrR+/vln2y8IFYw41a5d26QA0eIbkY8KeZnxES3+kfnW40WLjueE6JEJ+k3xz0pTH/iOk8HjeyJtGxQtf0zgGyI3J6JxvtN7v379IooWN9JgRAvp4UZHZAv52bp1a4qIViSIqnEN1HG9evWsTrlxU2ZuujwIklsEhchookXUiC9q/H/xv/fCCy9Ys9pnn30W5z6vv/66CQNRcu5zRF7oEO77JCEM/C/TDIYoIBx8cUTeOG6WLFniPA7CwAPNNw3GVQbEhJ8NGjQwgUE6ypUrZ+fidyJPXBNRJwSE6yJ6j9zdfffd9kXP91NjPbIV3sGdgQK+nMhNpOMih3Xr1rXtiEQhRJyD94KyBOuALioMQPBNk/4cRLr4yX2O16gLJCm4L1EquoTwOs8ZRIxy+yigrz/qhe2RZZ4NkiSJVpoQLT7Ar776qt1kInUaJyzLQh8AbhTcMGhi40PMNyhey5o1q/1z8a2Imw3HI0LDPxJ9APhnoUmPEDD9IpAk+mSFHz9I+Lb8E1133XUWeQsek28/fENESLhuZAtRIZSNsBFO50ZBUwA3CKJs3Bh4nSgax+dbEd/QkrvvVGI7w9N/jPA618UNOFu2bDbIwI8Q5cZ3/PhxPWGFSIRosQ33MZrwwpsIEYVLRZJat25t/Y+QBr4M0b+za9euds/ldb4k0b2BiBMRG+6D/M9Wq1bNvhTyM67j8Dr3CSTCR3XiajaknETOuEfQNMa9HMHj+vgCyU/uF/Qr4/5esmRJ+wLKF1bfv4r7LF90kZ3wSB+RNQQMSeP1SMfl4cu29C/jCyz7cj+nawRfuoN1gEghoZQbQaO/ao4cOawZke25FgYcIILUSXBfmgupE+57/v1BLIm40ZzIoCeuHWHj2ogeImuUn24ukiWJVqqKlo/mRAIRIeIUTI/A9h6a4ZAZ31wIZ86csSW4LkhQ5iIdP65t4yo7/3hsR0d3PgiR+jsRLYpvlGJc15/aohVXEy83IW5u3LRuv/12i9oRLqcJhGhfXPUphETrf5e4UjT4PqPx7csD3DeLEZkJf92vQ06CKQ+IUPF/Szqd+I7D7+HiE75wXLbzzWNsH4yA+fMGj+tfD5aJeyZfcsOPT9SIL3LhUbVIx6UMwWPypdj/HV4HiFTw2vxxwq8/rvqLq16C1xb+3qoJUaKVZpoO0yMIVJkyZazjJZJBx9G0THKkdyAKx83n448/tuHffFOnsz3fPAmrM/KGB0ewD5wQajpM+YWRfTRpEflP7bIw0hvp8yMIgwsRMqJK8TVdapFoSbQyWGb4Q4cORS1XV3oTrUjQPMo3Rzr20jxBR1vki1A7ozgJ+W/evFlPZiHRSsGFpjT6ENHcldplIYrlo2nhC91CKCfRPUmGFomWRCtdkZoJS2leZWQl32Tpt0b/ujvuuMM9/vjj1jeCTrq7du3SmyQyrGghHsFmw0hNVTSLXapZLzz3FhEsHx3iHOTIiusY9DcKRpnoV0qn8PjOQZmIQsUlTvRdSmw2++CCGDKyL5oPbpr4fG6uxC5cC9ckAZJoSbREmhKtSNDHjm+vdC5l9BKdZBkYULNmTevYSufcAwcO6I0TV7xoIT4MmiHhp3+Y0/maQSjB7WiOp6M1HbsTkrHc59fyAkd/Id8ZPtJCfq1g7iwG7lAWRvTFJRcIlh8hGGlhwFBSomiMavQjIS+1IIbhIxjj6lMVXrf0L03IseijSmReAiTRkmiJNC9akSDNB9/AES0SFt51112Wf4zcO3ym+MbNaE8hrrSIFp/74DQ3jEhkZHRwG0bi+YgTwuQzjhOlQgyQHhJ6+uPxk1F9NOPTnE9Hb3I8+Y73NOMHo2iMmOYafPoFJImIFusQLrZHmvgS5HN6MeKvcePGoeZJf37OxTWQHzHY/4py+txfyBvRbCJWjHLkeJzDSyL7UyYiULzGNqwnGsW+5FX0We2RSMrJ34wYRJIoK9sjj4we9AJFZN3XLXXmB/NwPvbxGeB9Z3jql3MgaIwiJLWEH2EZaUCCFomWREuila4gvQY3PnLpkAuHJkcmDeeBwVBuOvleaoSoEGlZtOizhBCR3oG/ST3AwJLg9DU+pYD/HYEhryCRLYSLFA48/IkII0o00SMYRKXIAUUKGf5fEBBEhTQ4pJjwkSqEi9F+/E22deSHfbysISykcCCVA1E1ZINkzz5NDqKC+JCyhugQ5UJcfKJUFqLXLKSRYFvKhTwS2WY/BMnntuLciBv1ShSJDO5IHOXmGcP9gPJwDsrL8UmzQ7mJwJHQFDEiCogYIrGUnde4nmBzJPv5BzrH46Hu15EXkS94DPChXH5ybaLwlDeuJlMtEq1kFS0+yL/73e8sIqEl7SyZMmW6IvpBMfAAYeQmTY4dkhjS2Z7cZkx7wYOEb5nBVCBCpBXR4vOJfPjkmcEpeRAA/zeRHS9eLHzZYHCJb/oiaScpEHyzHX8jCYgIkuElDEkgfxX5/5AZzuMjV376H18u8kURwaJ8CBSihlAhZEgf56eJk32RGyI+yBn/b3wJYj2RMs5L3kO+DAXzcXFe34yIGBKFIj0MfzOCm3MjMJSFqDapKLxQEVGjPkguzf2MCBfnJlLFDBsID/v6eRApE3XItXhhpYyUmZxewWZEH5GjLnndH4soINEu6sm/RpJZyo3shUcctUi0Uky0gG9kWtLWwjfSKxWkipsgDxf6mXAjJeEsN28SEvobbXoYHSoyVkSLhznTuxDlIfJC8xrRF/om+U7kfLaJVCEwfJElNQJRINYjP0gJ6xlYQpQJoaG5CwFBlHySTRJzImcIENsFE6YiNDSPsS2SgkjR/Mj6/v37Wxob5IYIGaMCfXSrUqVKFh1CYtiXaBnRNPZhsEtwah0vQixEiBAp/ke5ZiJYROYoGy0iCA6SRK5C+kQhi0Sn/LyDiBxftNiW5jyiXYhkly5dLOrE8RBFBAlxYzAO9wXeI94r38nfJxjlHukjeP5YvB/kC0RcESz2pVycg/NLtCRaqSpaQqQ2JE7l2zXZp3mQMQ8aCVZ5MPCg4qa+Y8cOVZRI9abD8JxRickhhXjwJcr/TvNWsN9VXL8Hk3HGt214ws3w9cHX/WuUgbLEl6zTbxs8p9/PHzfSsSMlcGW/4L5xXVOkMrNfeDmDx2J//zf17K8rUv1pkWhJtESGh5kA+PbNt2Q62DMhOR3uaYpglBffxvft26eKEikqWlq0aJFoCXHFwmTZNBHQ6ZU+MmSlJoM2zRP0R6FJgVkAhJBoadEi0ZJoCREFdu/ebf076MdCHw8mKWfiWPpp0GGYDr0pNUelyBiiRT+jYOd3+hvS7yrYREj+LJ9agVF+Pk1Cci7BPlZxLfSxIiIc6TVGQDJiMNK28R2blBTB6w/PcUXfscu9Jvq+0ZczodsnNLkpZQoOMEjosWiGpJ9YYpLRSrQkWkJccWzdutVGUNERtkKFCi5Llizuv//9r90geSAwRP/s2bOqKIlWohc6atO5nc7qPk8WnclJgRDcjo7fvkO5nxw6ORf6JDGPaUJGUpLiIdJrdJynM3n4tpc6NvvEJS3UM3WRFNGi32ZCt6cjfkK2oxO+7y/HEkkUKXskofJpI7RItIQQ/wcTZdMplocho8HI6s1IR4acM3qJGyo3XSbeFhKthCx8jvxDmKbr8E7ajPJjJB+d5b2sMNKQlAdEioi2ImiM+vNJR8PFKbg9iTsRlmCuK47L64xIJMpG1Cz8uDz0uFakjzQVjBRkpCKjFkm7EozM8cWE45DOgaic39Yfm2tm8nkvGqRkIFpH2hYf2eNvpIVmfEY2Utd+RCY5u5Amzsk1+WSlRNH4m5GJXbt2tXNwXtJfUAbkiegS10WqBqJKpHng/5n/X0Z9cl7OzzmJbjPykv05DnXHdrxf/E76DEZ7BnOGcc1E7SgDdUf5SUHjJ9am7umewDZEw8gbxujTYP1pkWgJIQIQ0WLYODcFhoEXLVrUIl8MEScXEcPGt23bporKwKLFZ8BLQXikgwetH/XmE2YG00D4fFg8lBEH0jcgK/yOTPA3ksEDnhG3Pu+UP0b49qSRQGyCURjSRdBsR4SWASPIXvC4jMKjOZ19SDnh0zYQiSMlBOfzGetZGGiCxCAayJGPyPljcyySpCIpXD8iQhSMcxHxQgJJX0FaCuqE8wcTt3Kd9K3kHMghUojAsA9iisghl3QFQF7ZH4nj3LxnHIORyMjrww8/bFFrzoNQIY3UNakyeB0J47o5DsdGkryIsSBtvlzULTm+ED9GObMfx0bgeF+I1pFCgmMjYkgY66jD8OmAJFoSLSFEPJw4ccIeEjyAuLEWLFjQ+nwxhQp5eLjR/vjjj6qoDCJaPERJIhpM4eCTh/ppc8KTlbLwoPHJNO+55x773c/XRySG/ZnXkAc6ouDPE5wkOnx7RCnYjMVnMXhcjoMcBY+L8CExSAgyhkwgZ0R/+DyzP/Lj5ZB+jawjwuS39SJJkyliQZ/Hpk2bWmQJMUGOaBpFuhBDrgVBRV6IbBGR8uVGbhBHfuf/i1HFRJWRNa6TYyNxlAmpQ2jI+cXrHIf6oR6QQ4SIJksfraN85A3j/EgWX6L4X0bUOD/RPV7nHOQVCzZ1ck7qzp/DSyzRK64dqWS2Dp+klXMwHRHXHi7hEi2JlhAikTCKkYcODwlu1Dw4c+XKZTdgOjxzwz506JAq6goUrfCFhzBNUjxMeMAiUkRKvDz4ztJ8Vnjw+3kQ+UmUhkgTgsSDn4cR+yMskc4V3N43RQZf57hcA8k4ifgQCUKwgselLxnlJapDFAc55Dg0p5FYNFgHrONvmhSJJPlt/bGRIgSHiBbnQIJoUkRqKAMyQtMjAoKYEvlBvJC6oIB66SL5KPVE8xtC5LcjikQdcmzK4BONUhdECDm2n2vR9zXzCWO5ZuqN94coNdfEcRmljLxxTqSQL1LBybPp8I+IBuuYSBvXTL1xjQgr2yDV/OSccfXhkmhJtIQQSeSnn36yBy03diIKRL0KFChg38q5kfPgOH78uCrqChOt9LYQ9aEJE0FCNiQCWiRaEi0h0i3bt2+3aAD9aejnRWZ75objmzXflPnGTQZ8IdFKyYXImp/CRosWiZZES4grBkYw0qxAJ2H6vNB5lwm1GfHIPHA0N9FEw4hIIdHSokWiJdESQiSRc+fOWf8ORorR2bZ48eImXzz46dhLv5stW7aooiRaWrRItCRaQohocOrUKevYS0dfRnMVLlzY3XHHHZaDiU7IdC7etWuXKkqipUWLREuiJYSIBkeOHLERY4x4Yjh5njx5XI4cOVytWrVstBNTuxw4cEAVJdHSokWiJdESQkSD/fv3W14fkjOSWPKuu+5yefPmtWSSDJFneP3Ro0dVURItLVokWhItIUQ02Llzp+UqIucQSRhpcixSpIglXiTH0LJly6xpUki0tGiRaEm0hBBJ5Ndff7WbHZnASRhJVmw625coUcKmZiGTNwkfz58/L9GSaGnRItGSaAkhkgpShVwhWcgW0sWE2mXKlHEdO3a0bNncIJE0iZYWLVokWhItIUQSIXEqU5IMHz7ctWjRwpobSbBK8yPNkGQS37Fjh0RLixYtEi0hhIgGx44dsw71dKyng32+fPmswz0d7+mAT0f8ffv2SbS0aNEi0RJCiGhw8OBBSyVBSglSS9x9992WaoJJiplMmYmFDx8+LNHSokWLREsIIaIByVOnTp3qevTo4apUqeKyZs1qSVZJtkrSVZKv/r/2zi1oy+n9484dGieYMcZkNBVSNhFFCo0QKikURQxKqewqu+x3aWM7SmWySUkikZGSbaTtiXGWM2cYv/n9zPrPZ/3nemd1u5930/u2oc9n5pr3ee7Nutfm4fp2rXWv6/fff1doaZpCS6ElItIRkDaI9EGkEULEHHPMMenss89Ot912W3r11Vdz2iHSDym0NE2hpdASEWknJMretm1bWrx4cbrjjjtyIm3edCSxNgm2ETk7duzIibcVWpqm0FJoiYi0kz///DN999136ZVXXkm33HJL6t27d458XXzxxWn69Olp2bJl6eeffz5ghdYXX3yR9yb75JNP2ux8EJUIzLvvvnu347xkgGPiMymXeBlhT5xbe+5tZIwVL0K8/vrrHVIeW4yQt7NRX+yNNuxpHdtTBtPqffv27ZD6tOd3s2nTpjRixIi0YMGCfTreCi0RkQOI3377LW3YsCHNmTMnjRkzJvXs2TMdd9xxaciQIWnmzJlp1apV6ZdfftnvQmvu3LnpiiuuSD/88MMeOyDWsC1ZsmS3Y9OmTctl85noX+xp1lonHOW19d7WGtO/W7Zs6ZCy1q9fnx577LGGfbG32rCndWyP0OJlkY6qU3t+N+eee26ett+X463QEhE5wPn111/T2rVr01NPPZWuvvrq1LVr19StW7f8mWOc45qWYFryhRdeaLfQev/993PkjT3HEDfluQ8++CDNmzcvRxVwfEyXfvvtt01RBCINn376af7cq1ev9M4776SXX365qZz+/ftnR0ibEJtlNALnyvE4xho40i1xfOPGjTkSSGSweu9XX32Vn4+A5TuRQhwx9cIBxnUcY/1cXYSOe+gfpnrj2Lp16/L9PJvIz/z583Of8LlaZ67hxQiiJDyDVFC0O+pU7YuyDY3qSxlEQ+kH6hLHN2/enK9jLKjPhx9+mOtEH7AlCXvCEY2stoG6MrYhVniJo6zjzp07c3/TD3ymniFuECPUM34D3Me1fJ88eXKu59KlS7Po4hhRovK3szd+N9Ux4R8FCK0YgzJytWjRovyPmObGW6Gl0BKRg4hdu3Zlx0CUi2hXp06dcvSLKBiOBudIdKyE/+kfcsghOSJQTTnUFqF11llnZUf17LPPplGjRv0tAkJ+SRwkG78++eST+TO773P+mmuuyemQcJxE6nCYw4YNy3kocYY4wnDcPXr0yJ9x2EwXISCY+uHYxIkT81YavFxw77335mNnnnlmdqblvQgUHH04YwQC00z0Af2EYA3RxosL1CMEQxhr6hAkiLj7778/H3v66aezIEBAEE3hGuo5YcKEJkFS1pljvImK40cgIxCoL06+ri/KNtTV96233krDhw/P5TD2jzzyyG51ZsqL+iKyEOY8f+TIkXk8+I0gSKptYJwGDRrU1L/UK+q4ffv2HJWiHxBEDz30UC67S5cuuWzKmTRpUtq6dWu67LLL8ua/TH9TFmMfmRiifK7lmr35u6mOCf/IuOGGG/K+eNGP/DcUdbnooosajrdCS6ElIpLXcyEScHBEd4g6se4Lh4EzxdEhtDAcWBkFa63QwuEeddRR2cETYUA8lOcRX2PHjs2fcXB8x7GR2ogID6KAe3HUWFyHcCNCMXXq1KaIBw6XzzhOHGU8A4f5wAMP5M+08+OPP86Osl+/fn+7lxcOYnrzyCOPzMIHgTJjxozsTMPxE73BgRNRKZ/FfmkIJj4jWDiPiD3llFNyPejrEBH0RUSzqnUm+sQxBEUIAgQrn+v6omxDXX0RDIgM2kYWg+o4nXDCCTlKxXghhjhG/Yhm8bmuDVzbvXv3fB5RV61j1AfxQZJ2+iz6vE+fPk0RrNNPPz0LC6JSiLQyKsTvkb/UfW//bqpjwr53CErEWvQj/zjhfp5D/9aNt0JLoSUiUgtThTgnBBTOg6hICC2M/b4QA20RWjj2cFKs3an+i59oBs4Jp02UASdHdIXIARu6XnLJJfmZ5JXEUXMPaY5w6kRcYuE1QgKnSeQlohUxLRbPYBoMccRxykaM8Ny4lynAcOxEQHjTk88ID9qBw6YNfEYAEalh3Vl1TQ91YEotIkNEW8aNG9c0fca0F9cS3cNR19WZe8KBYwhf8mxS37q+iDbU1TdeRLj++uvzFB9To2WdeT77uUW/MEaIiIgOYdU2EIniOJvvEkliGq6sI/UiohSRQaYBo8+JGiJoKAfRy9jQV1yLWIpxCaFFOdU6d/TvhnqUYxLCCdEW/YjgOvXUU5vWYEVkrDreCi2FlohIqyCyUAot7LDDDsvOpC1ThzgqImdM5+C44jjlEHnAURMhiDUvTD8xtYXDRADgZJlOI7rC9FWsiQonz2ccIGuacN6sycFZ8x3BQWQCY30aURmmsHCwRDWoT9xLOThhptmYYiS6ggON6UemXHG4tDscNAKkbCvRpNGjR2dBg5j46KOPshMn8kN0BDHC1BMRGKJsiK66OiNOY61TOF8ijfEmXLUvog119aWfGQNEB30aEZswnkv/0Je8Fcr11I06xjXVNpRrnSKKU9YREcoYzp49u6mc8ePHZ/G+fPnyLEoYB8Qsv40QlYhBpuJCzCC0Qpjuzd8NzyzHBEO4cc3QoUPzcdrMmPLbYOqTNWF1463QUmiJiLSKww8/PIsrphRxkER5Il1QW986rHvbkCgH63+YJiuPh5MlWlG+wVUtg8hP3WesfFMMxxziIq6j3BAL1Xur36vHuZe6NXqDMupc1p1psfI4ZXGsUZ3ryiyjJc31RfUYwhGhgQgg4XkZqQqxhKirCrCqlW2otrWujpRXfuf+iFRRt4iMIWjr7kEoLVy4cJ/8bhqNSV3fVsurG2+FlkJLRKRZ/vjjjxyV+Omnn2rPt3fDUpwSkYL2bgWgtWysb2KNFIIrIk3l23vk32xJZO1riyjRwfi7UWiJiEi7hRbRG6aj9mTzUm3PhC0vI8TaqnKT03g54ECqL9NyB+vvRqElIiKm4NE0hZZCS0Tknyq0OiKVi6YptBRaIiIKrcKizD1J5WKETVNoKbRERA4qoVWX3iXO8RYcO6yz+zlvivGKPa/7s4N7mcqFN8F404zF0aw1Iv1JbJvAm5DlveUbbHVpZ7iPTTcpJxZb87lMJ1OXyqUu5UtLaXg0TaGl0BIR2esRrWp6F44hWhBTiCb2d+IYG2KyO3eZboY9mXiVn8XabA6JqGKTUKJdpBNiE8ry3vK5dWln2LySctgziZ3C2Q2dvbMQW7zptmbNmtpULnUpX5pLw6NpCi2FlojIPhFa1fQu7FLOZprVdDKkYom9miKVC3n+2CyS3coRTrFjNxEuxE6k1ol7y+fWpZ1hc0o2s4z9nNgYNKJXtInPdalc6lK+NErDo2kKLYWWiMg+EVp16V1IekyaE4QMQoUpPaYJBw4cmAVQmcqlc+fOTVsPsECe8iJNDnkLmdYr7y2fXZd2hj2YEGlxDc9nywNEGqKqUSqXasoXymuUhkfTFFoKLRGRfSK06tK7EA1iag6xRXSK9VGIK6YBEU5lKheEEtEvRA/roEhoPGvWrFx2t27dcnqV8t5q6p9q2plqQmXSqZBKh7rFGq1qKhciV9WUL82l4dE0hZZCS0RknwitRuldIq1J/C3T5LSUbqZaRnlvuT6rubQzrUmpEqlc6lK+tJSGR9MUWgotEZG9KrT2Z3qX5tLOmCpIU2gptERE/vFCa3+nd2mUdsZUQZpCS6ElIvKPF1qapim0FFoiIgotTVNoKbRERBRamqbQUmiJiCi09mA9FVst8Abhvffem1PflOdZI8VO8u15xurVq1tdh7rz7FQ/ceLEVp9r6XnYihUr0hNPPNHidWxVQd3KY2yLUX5nLVpr1pKVaZA60tgpn6074jvjxR5mbNPBXmmtLWdP6sdWIQothZaIiEKrGSMFTvk3jNyCiK/2lM3u7lVh0lwdGokp0u+05lxLz0NIrly5Mu9UHzvTN/dSAQKGDVjjGOmGRowYsdt1CJvWtJFx2xs72bPvWPn8yZMn501d2YeMN1BbErmkY+Ize5O15blss9FeEa7QUmiJiPzrhBbJndl8FAdN9Idd43GabFJaChL24mKjUpJNx3EiJCSjRhjxViP7XBE9QZSRd5D8hJHaB2MvLaJHJJ/GoYegIgpDYmrqEXXgO3/Z/4u9uNivi93s2S4CEUA9Fi5cmPMcVs+19LwQBv369Uvvvfderjd1uPXWW/M5ykU0kKg6ruetRzZepbzYI4y2IdKqfUpC7Oi/u+++O38nDyTlsXks/UYKoRCwbPbKJqxEhKgntnz58t3aWG7XQX15NgnCq/cMGzYslxnl02Z23Cd1EVt8lH3Nd7bd4NlsOss19DXPRFRSb9IrsS0Hb35W+5Frpk2b9rck4gothZaIyEEltBAHTHlhRDbKqTCmuXCw7LTOzuw4d8TKnDlzmq57+OGHs0Mm6vPggw82HUfYMFU2YMCA/J00ODhdciqGw8eBx/XXXXdddvrs9M6WDySLRkjFdB+CLuqAKKEOOHdE27XXXpufdeGFF2aRRFoersGq55p7Xtkv5HDk7/nnn5/FDwKGaBD9xJ5dZfQq0glNnTo1ixX6gTY2mppkJ/5Ils1fds1/4403siBk89UQSPxlDBE0kyZNym0n1RAiqGxjlIsoQ0Ayboi28h4EZ6QiItLGWIR4rOtrxBjPof30H9cQZUPg8nsYPHhwPo8QQzRX+5HvCFXXaCm0REQOaqFFTkAiIRjTaXEcEYDDJXk0a3hGjRqVoxg4GabKysgQAg3HHOt8cPQ4YKIaN954Y17Tw/eYPps5c2aeiir37+J51AWBgvjgPiJCJJDmWoRB1AERR5lsVEoZOHUEBc6fXIsIGcpkWqw8R+SluefFdB31R3RExAsBQ1SPNnKMOsTu9IgNDMFDH3IvIoncjnXrnjg/ZcqULFARUog2phl53po1a9L48eOzQKOt3E9SbfobAcN5BGDZxlLw0QbqQqSM/irvCeHGmBKFol/ZNJY+IqKG8C37mv6hPUTqGH/K4jhl0X76HgFG/3K+7Ef6iOfwWaGl0BIROaiFViNDJDHVhxBAoBDhwokjOMrIF+eIwkQewljPE9EdnDmRKyImkZYHIVDWjcgSURucPtcSGcGRkT6HyAzlRJSNOhDNQmixSJ1rEHuk8kHAxXVMeyIEqueae14phph6Y7qNelPXEA+sRSsjNdxLpC2mDaONjdYkIZ6oN22ifEQcAm/27NlZ+DFtR72YwqPvEVzchzjiOG3j+rKNUTZRLiKOsVi9vIe/PDOiiEQgGTNEG4K22td8pp1E5+jzeC4CkTEnikUb6R+s7EeOU/9/6yayCi0REXF7h3+B1U1pNjLWhd1+++32m0JLoSUiotDSWmNE0Mpp2uaMiFVbtmjQFFoKLRERhZamKbQUWiIiCi1NU2gptEREFFqapim0FFoiIgotTVNoKbRERBRamqbQUmiJiCi0NE1TaCm0REQUWpqm0FJoiYgotDRNoaXQEhFRaGmaptBSaImIKLQ0TaGl0BIRUWhpmkJLoSUiotDSNE2hpdASEVFoaZpCS6ElIqLQ0jSFlkJLRESh1Qpbvnx5uvzyy9NVV1211x3VZ599lj7//PN96hy/++67dOWVV6bXX389/fjjj+m9997r0PIfffTR7ID5vGLFirRly5aG18b5tWvXptNOO223a7/44ovUt2/f9OWXX7b4zGXLlqVXXnkl3X777W2qK2U/88wz6YYbbtirfd7Wfm5L2/ekfIWWQktEZL8JrYcffjg77lWrVu11R7V48eL0xhtvdFh5rW3n2WefnUXN+vXr02OPPdahbZo2bVqaO3du/jxz5sxmxUKc//7779M555yz27mdO3em3r17t/i8TZs2pauvvjp/3rFjR5vqOmzYsNwPje7rqEhoW/u5tW3f0/IVWgotEZH9IrS+/fbbdPTRR6dbb7219jxOecmSJen999/P3z/55JP00ksvpW3btqUXXnghbd26NR//+uuvc4Tl7bffTuvWrau9lyjOnDlz2lxOGfXgnkWLFqXt27enO+64I5133nnpm2++aRI6PBPRWEZ+6IsBAwbk615++eW0YcOGfI5nL126NIu/avnN9Rn1wtlu3Lgxf+/fv38WTu+++2567bXXmq6jjc8//3z68MMPs7gqz1NfolHPPvtsUztp84033th0P8KXvoi+iT5kfK+//vomgUKUjDbymTrxTKJ4r776aj7GdT/88EMaP358Ov300/M5onshCBG+LfVno3Lr6lj2c6Nx5nm0N6JS0XYEYN1YlmNTHcfq7+yrr77K11JX+qX6O1JoKbRERPZpRAvnd+aZZ2anWB7HuY4cOTI7stGjR6c1a9akTz/9NEdinn766dSnT598z1tvvZWGDx+enWSnTp3SI488Unsvn3v06JHLbm05ZX0uvfTS7LAnTJiQv48bNy4LF4RMly5dsvPHSU+aNCmfRzjgZG+55ZZ0//3353JpJw6YqNCYMWOy0z733HPzvdXy64z68gzEBZEsprC4n3PUJQTQnXfemSMuiJkjjjgiC4TyPJEl6odIOvnkk/MxxG6MG3VevXp1nuJbuXJl0/NpA/2F8ECsXHvttbmN8+bNSw899FBuB1OS8+fPb4p6hSCbOHFimjVrVp66vfDCC9M777yTxykia831Z125zdUx+rlunBH39APib8iQIbu1vdFYlmNTll/3O+O6E088Mb344otp7NixOWKr0FJoiYjsN6GFzZgxI0cJymODBg1KCxYsyJ8pk89EYPiMs8Pxcg5Hi1PDcZ5xxhkN7yWKcvPNN+djrS2nNBz7TTfdlB0p34nO8Bkx069fv3wMZ454efzxx9OUKVPysa5du+a1YTjjs846Kx9DLDzwwANZgCHw6sqvGhGUU045JUdmpk+fnkUWfTZ16tR8/rbbbmtqc/fu3bOYI1qEAKie79mzZ34OFm2lboin5557Lq+Xe/LJJ3M/lXXgPHXgM8Iq+pN2UHcigohZptaq9WcNFOf5TBmUNXny5HTPPfe02J/VcpurY9nPdeN8xRVXpA8++GC3e6Ltdc+ujk1Zft3vjHE6/vjjc12HDh2axaBCS6ElIrJfhRYihwhBeey4447L0S6cGxEmhMXgwYPTm2++mSMHOEwcKNEVIhRMwTFt0+henoHY4nxrywn7+OOPsyMmUoFowpkOHDgwH2NxN0IRUYMzpyyiTEyzMZ2E0CJCEovHuadz5845mhULq6vl1/URooKoD2XxDNpHNCWmv4iybN68uWmtE0KPv7HgPc4jHiIqxDQcggmBwbhRB8QBzjzqVtaBPiNKE1Eevsf0JdOg1DEEZmmloKPviGgRXSLahBBpqT+r5TZXx7Kf68YZERTX0h9l2+ueXR2bsvy63xmR0IiERRkKLYWWiMg+F1pcc/755+cpMNbIVM8TgUEY3XXXXVmwIDB69eqVzz3xxBPpmmuuyeIMoXDBBRdkJxlOt3ovx0499dS8zqct5YTxViTOl3JxqjhbhAZTU6w9Yn0Pb08iqnDqTEESSUK04Ww/+uij7CSJjBBpQtAxbcWzEBzV8hFARImqYo9IFf3F83HgJ510Uo6icM+xxx6bp+NCSPIMztHe8jyOGjHB+qNY0E0kj+gM03pEi4jYIBgQT2UdEBhxjOlCrpk9e3ZTVIkyYu1SaaxhCqHEuBM14i9RKiJ6LfVntdzm6hj9zJjWjTMik/Os12Pas2x73bOrY1OOY93vDMHIlCJl85ujTQothZaIyH6JaFWjWFVjGq/Rui4iCjhp1t8gZO67777d3qSr3hvRnraWE9NRZV0RLyHGcL6UUX1GRJLKv7GIu1q/avkIz5hSrEaGyi0ZyufFZwQjUSsECIIgIlDltdVyEG3Vcsu6hrGurLrNQd11VUOIlNtqxLOiTq3pz6o1qmO1n8txju+8PFDX9rpnV8emuXGs2wbCtw4VWiIi+01otdeIRrB2BlESEZb9WU5H7r21p/cSZUFsIbSIWC1cuLDd9XnwwQfzFFz1hYWWjMXrPJ+IlhuOKrQUWiIi/zChFREGpmfKV/z3ZzkHgiHUWE/UmmhTa4wIUHMboTYyokPtEY2aQktERPaz0NI0hZZCS0REoaVpmkJLoSUiotDSNIWWQktERKGlaQothZaIiEJL0zSFlkJLREShpWkKLYWWiIhCS9MUWgotEZGDDFLOkOtv4sSJmqZ1oB166KE5rZJCS0TkIGbXrl05/52maR1r/6ZolkJLRERERKElIiIiotASEREREYWWiIiIiEJLRERERKElIiIiIgotEREREYWWiIiIiEJLRERERBRaIiIiIgotEREREYWWiIiIiCi0RERERBRaIiIiIgotEREREVFoiYiIiCi0RERERBRaIiIiIqLQEhEREVFoiYiIiCi0REREREShJSIiIqLQEhEREVFoiYiIiIhCS0REREShJSIiIqLQEhHZp/zvf3+l//znv+mvv/7/L99FRA50/g8JxL+x0ZKf7AAAAABJRU5ErkJggg==</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2011-04-06 12:32:53 +0530" MODIFIED_BY="Joey Kwong" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2011-04-06 12:32:57 +0530" MODIFIED_BY="Joey Kwong" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2011-04-06 12:32:57 +0530" MODIFIED_BY="Joey Kwong" NO="4" REF_ID="CMP-001.01" SETTINGS="DISTINGUISH_SUBGROUPS:YES;SHOW_EFFECT_ESTIMATE:YES;SHOW_STUDY_NAMES:NO;SHOW_CI_LINES:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of mortality.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2011-04-06 12:32:56 +0530" MODIFIED_BY="Joey Kwong" NO="5" REF_ID="CMP-001.02" SETTINGS="DISTINGUISH_SUBGROUPS:YES;SHOW_EFFECT_ESTIMATE:YES;SHOW_STUDY_NAMES:NO;SHOW_CI_LINES:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of cardiac complications.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2011-04-06 12:32:55 +0530" MODIFIED_BY="Joey Kwong" NO="6" REF_ID="CMP-001.03" SETTINGS="DISTINGUISH_SUBGROUPS:YES;SHOW_EFFECT_ESTIMATE:YES;SHOW_STUDY_NAMES:NO;SHOW_CI_LINES:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of pulmonary complications.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2009-09-09 17:25:28 +0530" MODIFIED_BY="[Empty name]"/>
<APPENDICES MODIFIED="2011-03-31 16:04:53 +0530" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2011-02-18 02:34:44 +0530" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2009-06-12 15:16:43 +0530" MODIFIED_BY="[Empty name]">Search Strategy</TITLE>
<APPENDIX_BODY MODIFIED="2011-02-18 02:34:44 +0530" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">CENTRAL</HEADING>
<P>#1 MeSH descriptor steroids this term only<BR/>#2 MeSH descriptor Anti-Inflammatory Agents this term only<BR/>#3 steroid* in All Text<BR/>#4 dexamethasone in All Text<BR/>#5 predniso* in All Text<BR/>#6 methylpredniso* in All Text<BR/>#7 glucocortico* in All Text<BR/>#8 hydrocortiso* in All Text<BR/>#9 (#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8)<BR/>#10 MeSH descriptor Extracorporeal Circulation explode all trees<BR/>#11 cardiopulmonary next bypass in All Text<BR/>#12 extracorporeal next circulation in All Text<BR/>#13 MeSH descriptor Heart-Lung Machine this term only<BR/>#14 heart next lung next machine in All Text<BR/>#15 cpb in All Text<BR/>#16 MeSH descriptor Cardiac Surgical Procedures explode all trees<BR/>#17 (coronary in All Text near/6 bypass in All Text)<BR/>#18 heart next bypass in All Text<BR/>#19 (heart in All Text near/6 bypass in All Text)<BR/>#20 cardiac next bypass in All Text<BR/>#21 (cardiac in All Text near/6 bypass in All Text)<BR/>#22 cardiac next surgery in All Text<BR/>#23 heart next surgery in All Text<BR/>#24 open next heart in All Text<BR/>#25 (#10 or #11 or #12 or #13 or #14 or #15)<BR/>#26 (#16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24)<BR/>#27 (#25 or #26)<BR/>#28 (#9 and #27)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">MEDLINE (PubMed)</HEADING>
<SUBSECTION>
<HEADING LEVEL="4"> LUMC</HEADING>
<P>
<I>("Extracorporeal Circulation"[MeSH:NoExp] OR &#8220;extracorporeal circulation"[tw] OR "Cardiopulmonary Bypass"[MeSH] OR &#8220;Cardiopulmonary Bypass&#8221;[tw] OR "Heart Bypass, Left"[MeSH] OR "Heart-Lung Machine"[MeSH] OR &#8220;heart lung machine&#8221; OR &#8220;heart lung machines&#8221; OR "Cardiac Surgical Procedures"[MeSH:NoExp] OR &#8220;Cardiomyoplasty&#8220;[mesh] OR &#8220;Heart Arrest, Induced&#8221;[mesh] OR &#8220;Heart Bypass, Right&#8221;[mesh] OR &#8220;Heart Valve Prosthesis Implantation&#8221;[Mesh] OR &#8220;Myocardial Revascularization&#8221;[Mesh:NoExp] OR &#8220;Coronary Artery Bypass&#8221;[Mesh] OR &#8220;Pericardial Window Techniques&#8221;[Mesh] OR &#8220;Cardiomyoplasty&#8221; OR &#8220;Induced Heart Arrest&#8221; OR &#8220;Deep Hypothermia Induced Circulatory Arrest&#8221; OR &#8220;Right Heart Bypass&#8221; OR &#8220;Fontan Procedure&#8220; OR &#8220;Heart Valve Prosthesis Implantation&#8221; OR &#8220;Myocardial Revascularization&#8221; OR &#8220;coronary atherectomy&#8221; OR &#8220;Coronary Artery Bypass&#8221; OR &#8220;Pericardial Window&#8221; OR "Heart/surgery"[MeSH] OR ((dor OR suma) AND reconstruction) OR &#8220;cardiac bypass&#8221; OR &#8220;heart bypass&#8221; OR &#8220;cardiac surgery&#8221; OR &#8220;heart surgery&#8221; OR &#8220;open heart&#8221;) AND (glucocorticoids OR steroids[ti] OR Dexamethasone OR Methylprednisolone OR Prednisolone OR Prednisone OR Dexamethaso* OR Methylprednisolo* OR Predniso* OR hydrocortisone OR hydrocortiso* OR glucocortico* OR "Anti-Inflammatory Agents"[MeSH:NoExp]) AND (randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized controlled trials [mh] OR random allocation [mh] OR double-blind method [mh] OR single-blind method [mh] OR clinical trial [pt] OR clinical trials [mh] OR "clinical trial" [tw] OR ((singl* [tw] OR doubl* [tw] OR trebl* [tw] OR tripl* [tw]) AND (mask* [tw] OR blind* [tw])) OR "latin square" [tw] OR placebos [mh] OR placebo* [tw] OR random* [tw] OR research design [mh:noexp] OR comparative study [mh] OR evaluation studies [mh] OR follow-up studies [mh] OR prospective studies [mh] OR cross-over studies [mh] OR control* [tw] OR prospective* [tw] OR volunteer* [tw] OR randomised controlled trial OR randomised controlled trials)</I>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4"> UMCU</HEADING>
<P>
<I>(\Steroids"[mh:noexp] OR \Adrenal Cortex Hormones"[mh:noexp] OR \Anti-Inflammatory Agents"[mh]) OR (steroid* [tiab] OR steriod* [tiab] OR predniso* [tiab] OR methylpredniso* [tiab] OR dexamethasone [tiab] OR glucocortico* [tiab] OR hydrocortiso* [tiab]) AND ((\Cardiac surgical procedures"[mh] OR \coronary artery bypass"[tiab] OR \cardiac surgery"[tiab] OR \thoracic surgery"[tiab]) OR (\Extracorporeal Circulation"[mh] OR \Heart-Lung Machine"[mh] OR \cardiopulmonary bypass"[tiab] OR \extracorporeal circulation"[tiab] OR \heart-lung machine"[tiab] OR \heart lung machine"[tiab] OR \cpb"[tiab])) AND (((((meta-analysis [pt] OR meta-analysis [tw] OR metanalysis [tw]) OR ((review [pt] OR guideline [pt] OR consensus [ti] OR guideline* [ti] OR literature [ti] OR overview [ti] OR review [ti]) AND ((Cochrane [tw] OR Medline [tw] OR CINAHL [tw] OR (National [tw] AND Library [tw])) OR (handsearch* [tw] OR search* [tw] OR searching [tw]) AND (hand [tw] OR manual [tw] OR electronic [tw] OR bibliographi* [tw] OR database* OR (Cochrane [tw] OR Medline [tw] OR CINAHL [tw] OR (National [tw] AND Library [tw]))))) OR ((synthesis [ti] OR overview [ti] OR review [ti] OR survey [ti]) AND (systematic [ti] OR critical [ti] OR methodologic [ti] OR quantitative [ti] OR qualitative [ti] OR literature [ti] OR evidence [ti] OR evidence-based [ti]))) BUTNOT (case* [ti] OR report [ti] OR editorial [pt] OR comment [pt] OR letter [pt]) OR (randomized controlled trial[PTYP] OR randomized controlled trials OR controlled clinical trial[PTYP] OR clinical trial[PTYP] OR clinical trials OR (clinical AND trial) OR random allocation OR random* OR double blind method OR single blind method OR (singl* OR doubl* OR trebl* OR tripl*) OR blind* OR mask* OR placebo* OR placebos OR research design OR comparative study OR evaluation studies OR follow up studies OR prospective studies OR control OR controlled OR prospectiv* OR volunteer*)) OR (random* OR randomized controlled trial* OR Randomized Controlled Trial [PT]) NOT (letter [pt] OR editorial [pt] OR comment [pt] OR in vitro [mh]) OR (randomized controlled trial [PTYP] OR drug therapy [SH] OR therapeutic use [SH:NOEXP] OR random* [WORD]))) NOT (\animals"[MeSH Terms] NOT (\humans"[MeSH Terms] OR \hominidae"[MeSH Terms]))</I>
</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">EMBASE</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">LUMC</HEADING>
<P>
<I>(exp extracorporeal circulation/ OR extracorporeal circulation.mp OR cardiopulmonary bypass.mp OR exp coronary artery surgery/ OR exp Heart Lung Machine/ OR heart lung machine$.mp OR heart surgery/ OR exp heart valve surgery/ OR cardiomyoplasty/ OR heart aneurysmectomy/ OR heart ventricle remodeling/ OR minimally invasive cardiac surgery/ OR mustard operation/ OR norwood procedure/ OR open heart surgery/ OR induced heart arrest.mp OR right heart bypass.mp OR Cardiomyoplasty.mp OR Deep Hypothermia Induced Circulatory Arrest.mp OR Right Heart Bypass.mp OR Fontan Procedure.mp OR Heart Valve Prosthesis Implantation.mp OR Myocardial Revascularization.mp OR coronary atherectomy.mp OR Coronary Artery Bypass.mp OR (Dor operation OR dor technique OR suma operation OR suma technique).mp OR cardiac bypass.mp OR heart bypass.mp OR cardiac surgery.mp OR heart surgery.mp OR open heart.mp) AND (exp Glucocorticoid/ OR (steroids OR Dexamethaso$ OR Methylprednisolo$ OR Predniso$ OR hydrocortisone OR hydrocortiso$ OR glucocortico$).ti) </I>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">UMCU</HEADING>
<P>
<I>'human'/exp AND ('corticosteroid'/exp OR 'antiinflammatory agent'/exp OR 'steroid':ti,ab OR 'steroids':ti,ab OR 'dexamethasone':ti,ab OR 'prednisone':ti,ab OR 'prednisolone':ti,ab OR 'methylprednisolone':ti,ab OR 'steriod':ti,ab OR 'steriods':ti,ab) AND (('heart surgery'/exp OR 'heart surgery':ti,ab OR 'heart-surgery':ti,ab OR 'open heart surgery':ti,ab OR 'coronary surgery':ti,ab OR 'coronary artery surgery':ti,ab OR 'coronary artery bypass surgery':ti,ab OR 'cabg':ti,ab OR 'coronary artery bypass graft':ti,ab OR 'coronary bypass graft':ti,ab OR 'coronary bypass graft surgery':ti,ab OR 'heart valve surgery':ti,ab) OR ('extracorporeal circulation'/exp OR 'cardiopulmonary bypass':ti,ab OR 'cpb':ti,ab OR 'extracorporeal circulation':ti,ab OR 'ecc':ti,ab)) AND (random$:ti,ab OR factorial$:ti,ab OR (crossover$ or cross over$ or cross-over$):ti,ab OR placebo$:ti,ab OR (doubl$ adj blind$):ti,ab OR (singl$ adj blind$):ti,ab OR assign$:ti,ab OR allocat$:ti,ab OR volunteer$:ti,ab OR (CROSSOVER PROCEDURE):sh OR (DOUBLE-BLIND PROCEDURE):sh OR (RANDOMIZED CONTROLLED TRIAL):sh OR (SINGLE-BLIND PROCEDURE):sh)</I>
</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">ISI Web of Science</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">UMCU</HEADING>
<P>
<I>TS=(steroid* OR corticosteroid* OR dexamethasone OR prednisone OR prednisolone OR methylprednisolone OR steriod* OR antiinflammatory agent) AND TS=((cardiopulmonary bypass OR cpb OR extracorporeal circulation OR ecc) OR (heart surgery OR heart-surgery OR open heart surgery OR coronary surgery OR coronary artery surgery OR coronary artery bypass surgery OR cabg OR coronary artery bypass graft OR coronary bypass graft OR coronary bypass graft surgery OR heart valve surgery))</I>
</P>
<P>
<I>AND TS=(metaanalysis OR meta-analysis OR review OR consensus OR guideline OR random* OR trial* OR control* OR ((singl* OR doubl* OR trebl* OR tripl*) AND (blind* OR mask*)))</I>
</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">CINAHL</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">UMCU</HEADING>
<P>
<I>((explode \Steroids-" / all TOPICAL SUBHEADINGS / all AGE SUBHEADINGS in DE) OR ((steroid* OR corticosteroid* OR dexamethasone OR prednisone OR prednisolone OR methylprednisolone OR steriod* OR antiinflammatory agent) in de,ti,ab)) AND (((explode \Extracorporeal-Circulation" / allTOPICAL SUBHEADINGS / all AGE SUBHEADINGS in DE)) OR ((cardiopulmonary bypass OR cpb OR extracorporeal circulation OR ecc) in de,ti,ab)) AND ((\Heart-Surgery" / all TOPICAL SUBHEADINGS / all AGE SUBHEADINGS in DE) OR ((heart surgery OR heart-surgery OR open heart surgery OR coronary surgery OR coronary artery surgery OR coronary artery bypass surgery OR cabg OR coronary artery bypass graft OR coronary bypass graft OR coronary bypass graft surgery OR heart valve surgery) in de,ti,ab)) AND ((explode \Clinical-Trials" / all TOPICAL SUBHEADINGS / all AGE SUBHEADINGS in DE) OR ((Randomized controlled trial OR clinical trial* OR clinical-trial* OR control* OR prospectiv* OR volunteer* OR ((singl* OR doubl* OR trebl* OR tripl*) AND (blind* OR mask*)) OR placebo* OR random* OR evaluation studies OR prospective study) in de,ti,ab))</I>
</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">
<I>Metaregister of Controlled Trials (mRCT)</I>
</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">UMCU - LUMC</HEADING>
<P>
<I>(glucocorticoids OR steroids OR steroid OR Dexamethasone OR Methylprednisolone OR Prednisolone OR Prednisone OR Dexamethaso* OR Methylprednisolo* OR Predniso* OR hydrocortisone OR hydrocortiso* OR glucocortico*) AND cardiac surgery</I>
</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">
<I>WHO international Clinical Trials Registry Platform</I>
</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">UMCU-LUMC</HEADING>
<P>
<I>(Steroids AND Cardiac Surgery)</I>
</P>
<P>
<I>Footnote:</I>
</P>
<P>
<I>Two teams (UMCU and LUMC) will run searches. </I>
</P>
</SUBSECTION>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2010-03-22 18:16:16 +0530" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2010-03-22 18:16:12 +0530" MODIFIED_BY="[Empty name]">Study eligibly form</TITLE>
<APPENDIX_BODY MODIFIED="2010-03-22 18:16:16 +0530" MODIFIED_BY="[Empty name]">
<TABLE COLS="6" ROWS="13">
<TR>
<TH>
<P>
<B>Questions</B>
</P>
</TH>
<TH COLSPAN="5">
<P>
<B>Responses</B> </P>
</TH>
</TR>
<TR>
<TD>
<P>Study ID</P>
</TD>
<TD COLSPAN="5">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Publication Date</P>
</TD>
<TD COLSPAN="5">
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>Source</P>
</TD>
<TD>
<P>Medline</P>
</TD>
<TD>
<P>Embase </P>
</TD>
<TD>
<P>Web of Science </P>
</TD>
<TD>
<P> CINAHL</P>
</TD>
<TD>
<P>other</P>
</TD>
</TR>
<TR>
<TD>
<P>NAme of reviewer</P>
</TD>
<TD>
<P>Dieleman</P>
</TD>
<TD>
<P>Van Dijk </P>
</TD>
<TD>
<P> van Paassen</P>
</TD>
<TD COLSPAN="2">
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>
<I>Selection criteria:</I>
</B>
</P>
</TD>
<TD COLSPAN="5">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>1. Randomised clinical trial</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>no</P>
</TD>
<TD COLSPAN="3">
<P>unclear  </P>
</TD>
</TR>
<TR>
<TD>
<P>2. Reporting mortality or AMI or Pulmonary complications</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>no</P>
</TD>
<TD COLSPAN="3">
<P>unclear </P>
</TD>
</TR>
<TR>
<TD>
<P>3. Adult population (age &gt; 18)</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD COLSPAN="3">
<P>Unclear </P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>
<I>Conclusion I</I>
</B>
<BR/>(based on Title only)<BR/>(to be filed in if abstract is unavailable)</P>
</TD>
<TD COLSPAN="2">
<P>Eligible</P>
</TD>
<TD COLSPAN="3">
<P> May be Eligible</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>
<I>Conclusion II</I>
</B>
<BR/>(based on Abstract)</P>
</TD>
<TD COLSPAN="2">
<P>Eligible</P>
</TD>
<TD COLSPAN="3">
<P>May be Eligible </P>
</TD>
</TR>
<TR>
<TD>
<P> <B>
<I>Conclusion III</I>
</B>
<BR/>(based on Whole article)</P>
</TD>
<TD COLSPAN="2">
<P>Eligible</P>
</TD>
<TD COLSPAN="3">
<P>May be Eligible </P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>
<I>Motivation</I>
</B>
</P>
</TD>
<TD COLSPAN="5">
<P/>
</TD>
</TR>
</TABLE>
<SUBSECTION>
<HEADING LEVEL="6">Footnotes</HEADING>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2010-03-22 18:17:03 +0530" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2010-03-22 18:16:35 +0530" MODIFIED_BY="[Empty name]">Data extraction form</TITLE>
<APPENDIX_BODY MODIFIED="2010-03-22 18:17:03 +0530" MODIFIED_BY="[Empty name]">
<TABLE COLS="6" ROWS="80">
<TR>
<TH>
<P>Questions</P>
</TH>
<TH>
<P>Responses</P>
</TH>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
</TR>
<TR>
<TD>
<P>ARTICLE IDENTIFICATION</P>
</TD>
<TD>
<P>Article nr.:</P>
</TD>
<TD>
<P>...........................</P>
</TD>
<TD>
<P>Date:</P>
</TD>
<TD>
<P>....../....../...........</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Name of reviewer:</P>
</TD>
<TD>
<P>Dieleman</P>
</TD>
<TD>
<P>Van Dijk</P>
</TD>
<TD>
<P>Van Paassen</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>First author's name:</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Year of publication:</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>STUDY CHARACTERISTICS</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>1. Total number of patients included</P>
</TD>
<TD>
<P>Steroids</P>
</TD>
<TD>
<P>n =</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Control</P>
</TD>
<TD>
<P>n =</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>2. Adequate sequence generation</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>3. Concealed allocation</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>4. Number of crossovers</P>
</TD>
<TD>
<P>Steroids</P>
</TD>
<TD>
<P>n =</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Control</P>
</TD>
<TD>
<P>n =</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>5. Maximum number of loss-to-follow-up (at any stage)</P>
</TD>
<TD>
<P>Steroids</P>
</TD>
<TD>
<P>n =</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Control</P>
</TD>
<TD>
<P>n =</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>6. Intention to treat analyses</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>7. Blinding during pre-, peri- and postoperative care</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>8. Blinded data-collection and analyses</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>9. Standardized pre- and postoperative care</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>10. Blinding of endpoints</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>11. Selective outcome reporting</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>PREOPERATIVE DATA</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>12. Males (males/total)</P>
</TD>
<TD>
<P>Steroids</P>
</TD>
<TD>
<P>n = ...... / ......</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Control</P>
</TD>
<TD>
<P>n = ...... / ......</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>13. Age</P>
</TD>
<TD>
<P>Steroids</P>
</TD>
<TD>
<P>Mean =</P>
</TD>
<TD>
<P>SD =</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Control</P>
</TD>
<TD>
<P>Mean =</P>
</TD>
<TD>
<P>SD =</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>14. Body Mass Index</P>
</TD>
<TD>
<P>Steroids</P>
</TD>
<TD>
<P>Mean =</P>
</TD>
<TD>
<P>SD =</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Control</P>
</TD>
<TD>
<P>Mean =</P>
</TD>
<TD>
<P>SD =</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>15. Prior cardiac surgery</P>
</TD>
<TD>
<P>Steroids</P>
</TD>
<TD>
<P>n = ...... / ......</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Control</P>
</TD>
<TD>
<P>n = ...... / ......</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>16. Preoperative cardiac status</P>
</TD>
<TD>
<P>NYHA-classification</P>
</TD>
<TD>
<P>Type 1</P>
</TD>
<TD>
<P>Type 2</P>
</TD>
<TD>
<P>Type 3</P>
</TD>
<TD>
<P>Type 4</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Steroids</P>
</TD>
<TD>
<P>n = ...... / ......</P>
</TD>
<TD>
<P>n = ...... / ......</P>
</TD>
<TD>
<P>n = ...... / ......</P>
</TD>
<TD>
<P>n = ...... / ......</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Control</P>
</TD>
<TD>
<P>n = ...... / ......</P>
</TD>
<TD>
<P>n = ...... / ......</P>
</TD>
<TD>
<P>n = ...... / ......</P>
</TD>
<TD>
<P>n = ...... / ......</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Braunwald-classification</P>
</TD>
<TD>
<P>Type 1</P>
</TD>
<TD>
<P>Type 2</P>
</TD>
<TD>
<P>Type 3</P>
</TD>
<TD>
<P>Type 4</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Steroids</P>
</TD>
<TD>
<P>n = ...... / ......</P>
</TD>
<TD>
<P>n = ...... / ......</P>
</TD>
<TD>
<P>n = ...... / ......</P>
</TD>
<TD>
<P>n = ...... / ......</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Control</P>
</TD>
<TD>
<P>n = ...... / ......</P>
</TD>
<TD>
<P>n = ...... / ......</P>
</TD>
<TD>
<P>n = ...... / ......</P>
</TD>
<TD>
<P>n = ...... / ......</P>
</TD>
</TR>
<TR>
<TD>
<P>17. Preoperative atrial fibrillation</P>
</TD>
<TD>
<P>Steroids</P>
</TD>
<TD>
<P>n = ...... / ......</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Control</P>
</TD>
<TD>
<P>n = ...... / ......</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>18. Preoperative myocardial infarction</P>
</TD>
<TD>
<P>Steroids</P>
</TD>
<TD>
<P>n = ...... / ......</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Control</P>
</TD>
<TD>
<P>n = ...... / ......</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>19. Preoperative beta-blocker use</P>
</TD>
<TD>
<P>Steroids</P>
</TD>
<TD>
<P>n = ...... / ......</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Control</P>
</TD>
<TD>
<P>n = ...... / ......</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>20. Hypertension</P>
</TD>
<TD>
<P>Steroids</P>
</TD>
<TD>
<P>n = ...... / ......</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Control</P>
</TD>
<TD>
<P>n = ...... / ......</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>21. Diabetic status</P>
</TD>
<TD>
<P>Steroids</P>
</TD>
<TD>
<P>n = ...... / ......</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Control</P>
</TD>
<TD>
<P>n = ...... / ......</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>22. Renal status (dialysis)</P>
</TD>
<TD>
<P>Steroids</P>
</TD>
<TD>
<P>n = ...... / ......</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Control</P>
</TD>
<TD>
<P>n = ...... / ......</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>23. Type of steroid used</P>
</TD>
<TD>
<P>Dexamethasone</P>
</TD>
<TD>
<P>Methylprednisolone</P>
</TD>
<TD>
<P>Other: .......................................</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>24. Dose of steroid used</P>
</TD>
<TD>
<P>......</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>25. Time of administration</P>
</TD>
<TD>
<P>Before induction</P>
</TD>
<TD>
<P>After induction</P>
</TD>
<TD>
<P>While on CPB</P>
</TD>
<TD>
<P>After CPB</P>
</TD>
<TD>
<P>......</P>
</TD>
</TR>
<TR>
<TD>
<P>26. Preoperative steroid use</P>
</TD>
<TD>
<P>Steroids</P>
</TD>
<TD>
<P>n = ...... / ......</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Control</P>
</TD>
<TD>
<P>n = ...... / ......</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>27. Type(s) of surgery</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Steroids</P>
</TD>
<TD>
<P>Control</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>CABG</P>
</TD>
<TD>
<P>n = ...... / ......</P>
</TD>
<TD>
<P>n = ...... / ......</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>VR</P>
</TD>
<TD>
<P>n = ...... / ......</P>
</TD>
<TD>
<P>n = ...... / ......</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Combined CABG + VR</P>
</TD>
<TD>
<P>n = ...... / ......</P>
</TD>
<TD>
<P>n = ...... / ......</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Other</P>
</TD>
<TD>
<P>n = ...... / ......</P>
</TD>
<TD>
<P>n = ...... / ......</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>28. Duration of procedure</P>
</TD>
<TD>
<P>Steroids</P>
</TD>
<TD>
<P>Mean =</P>
</TD>
<TD>
<P>SD =</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Control</P>
</TD>
<TD>
<P>Mean =</P>
</TD>
<TD>
<P>SD =</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>29. Duration of CPB</P>
</TD>
<TD>
<P>Steroids</P>
</TD>
<TD>
<P>Mean =</P>
</TD>
<TD>
<P>SD =</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Control</P>
</TD>
<TD>
<P>Mean =</P>
</TD>
<TD>
<P>SD =</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>30. Primary outcome measure:</P>
</TD>
<TD>
<P>..............................................</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>31. Main outcomes</P>
</TD>
<TD>
<P>Steroids (n of mean)</P>
</TD>
<TD>
<P>Steroids (n-total of SD)</P>
</TD>
<TD>
<P>Control (n or mean)</P>
</TD>
<TD>
<P>Control (n-total or SD)</P>
</TD>
<TD>
<P>Time to follow-up (days)</P>
</TD>
</TR>
<TR>
<TD>
<P>Mortality (n)</P>
</TD>
<TD>
<P>......</P>
</TD>
<TD>
<P>......</P>
</TD>
<TD>
<P>......</P>
</TD>
<TD>
<P>......</P>
</TD>
<TD>
<P>......</P>
</TD>
</TR>
<TR>
<TD>
<P>AMI (n)</P>
</TD>
<TD>
<P>......</P>
</TD>
<TD>
<P>......</P>
</TD>
<TD>
<P>......</P>
</TD>
<TD>
<P>......</P>
</TD>
<TD>
<P>......</P>
</TD>
</TR>
<TR>
<TD>
<P>Pulmonary complications:</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>- ............................................................................ (n)</P>
</TD>
<TD>
<P>......</P>
</TD>
<TD>
<P>......</P>
</TD>
<TD>
<P>......</P>
</TD>
<TD>
<P>......</P>
</TD>
<TD>
<P>......</P>
</TD>
</TR>
<TR>
<TD>
<P>- ............................................................................ (n)</P>
</TD>
<TD>
<P>......</P>
</TD>
<TD>
<P>......</P>
</TD>
<TD>
<P>......</P>
</TD>
<TD>
<P>......</P>
</TD>
<TD>
<P>......</P>
</TD>
</TR>
<TR>
<TD>
<P>Duration of postoperative ventilation (min; mean + SD)</P>
</TD>
<TD>
<P>......</P>
</TD>
<TD>
<P>......</P>
</TD>
<TD>
<P>......</P>
</TD>
<TD>
<P>......</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Length of stay in ICU (hrs; mean + SD)</P>
</TD>
<TD>
<P>......</P>
</TD>
<TD>
<P>......</P>
</TD>
<TD>
<P>......</P>
</TD>
<TD>
<P>......</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Postoperative transfusion requirement (n)</P>
</TD>
<TD>
<P>......</P>
</TD>
<TD>
<P>......</P>
</TD>
<TD>
<P>......</P>
</TD>
<TD>
<P>......</P>
</TD>
<TD>
<P>......</P>
</TD>
</TR>
<TR>
<TD>
<P>Postoperative inotrope use (n)</P>
</TD>
<TD>
<P>......</P>
</TD>
<TD>
<P>......</P>
</TD>
<TD>
<P>......</P>
</TD>
<TD>
<P>......</P>
</TD>
<TD>
<P>......</P>
</TD>
</TR>
<TR>
<TD>
<P>32. Main conclusions</P>
</TD>
<TD>
<P>...............................................</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>...............................................</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>...............................................</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>33. Remarks</P>
</TD>
<TD>
<P>...............................................</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>...............................................</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>...............................................</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>...............................................</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>...............................................</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<SUBSECTION>
<HEADING LEVEL="6">Footnotes</HEADING>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2011-03-31 16:04:53 +0530" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2010-03-22 18:17:19 +0530" MODIFIED_BY="[Empty name]">Detailed Study Characteristics</TITLE>
<APPENDIX_BODY MODIFIED="2011-03-31 16:04:53 +0530" MODIFIED_BY="[Empty name]">
<TABLE COLS="13" ROWS="55">
<TR>
<TD VALIGN="TOP">
<P>
<B>Author</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Year of publication</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Enrolment</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Blinding</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Study size </B>
<BR/>
<B>(number of patients)</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Type of corticosteroid</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>HC equivalent dosage</B>
<BR/>
<B>(total administered amount)</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Total  HC equivalent dose given, considering  average weight 70 kg,  </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Period of treatment</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Time to follow up</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Mean Age (steroids/placebo)</B>
<BR/>
<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Surgery type</B>
<BR/>
<B>CABG (C), Valve (V)</B>
<BR/>
<B>or complex</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Remarks </B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Weis</P>
</TD>
<TD>
<P>2009</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>36</P>
</TD>
<TD>
<P>HC</P>
</TD>
<TD>
<P>550 mg</P>
</TD>
<TD>
<P>550 mg</P>
</TD>
<TD>
<P>4 days</P>
</TD>
<TD>
<P>28 days</P>
</TD>
<TD>
<P>67/69</P>
</TD>
<TD>
<P>High risk CPB</P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>Sobiesky</P>
</TD>
<TD>
<P>2008</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>28</P>
</TD>
<TD>
<P>DX</P>
</TD>
<TD>
<P>2667 mg</P>
</TD>
<TD>
<P>2667 mg</P>
</TD>
<TD>
<P>once</P>
</TD>
<TD>
<P>72 hr</P>
</TD>
<TD>
<P>62/65</P>
</TD>
<TD>
<P>C</P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>Halonen</P>
</TD>
<TD>
<P>2007</P>
</TD>
<TD>
<P>08/05-06/06</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>241</P>
</TD>
<TD>
<P>HC</P>
</TD>
<TD>
<P>400 mg</P>
</TD>
<TD>
<P>400 mg</P>
</TD>
<TD>
<P>3 days</P>
</TD>
<TD>
<P>ICU-stay</P>
</TD>
<TD>
<P>64/66</P>
</TD>
<TD>
<P>C and/or V</P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>Yared</P>
</TD>
<TD>
<P>2007</P>
</TD>
<TD>
<P>10/00-07/01</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>71</P>
</TD>
<TD>
<P>DX</P>
</TD>
<TD>
<P>16 mg/kg</P>
</TD>
<TD>
<P>1120 mg</P>
</TD>
<TD>
<P>once</P>
</TD>
<TD>
<P>Hosp-stay</P>
</TD>
<TD>
<P>69/74</P>
</TD>
<TD>
<P>C and/or V</P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>Sano</P>
</TD>
<TD>
<P>2006</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P>HC</P>
</TD>
<TD>
<P>100 mg/kg</P>
</TD>
<TD>
<P>7000 mg</P>
</TD>
<TD>
<P>surgery</P>
</TD>
<TD>
<P>Hosp-stay</P>
</TD>
<TD>
<P>64/61</P>
</TD>
<TD>
<P>C or V</P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>Enc</P>
</TD>
<TD>
<P>2006</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>MP</P>
</TD>
<TD>
<P>125 mg/kg</P>
</TD>
<TD>
<P>8750 mg</P>
</TD>
<TD>
<P>once</P>
</TD>
<TD>
<P>Hosp-stay</P>
</TD>
<TD>
<P>60/57</P>
</TD>
<TD>
<P>C (3VD)</P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>Whitlock</P>
</TD>
<TD>
<P>2006</P>
</TD>
<TD>
<P>04/04-02/05</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P>MP</P>
</TD>
<TD>
<P>2500 mg</P>
</TD>
<TD>
<P>2500 mg</P>
</TD>
<TD>
<P>surgery</P>
</TD>
<TD>
<P>Hosp-stay</P>
</TD>
<TD>
<P>67/66</P>
</TD>
<TD>
<P>C/V/complex</P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>Weis</P>
</TD>
<TD>
<P>2006</P>
</TD>
<TD>
<P>09/02-09/03</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>36</P>
</TD>
<TD>
<P>HC</P>
</TD>
<TD>
<P>550 mg</P>
</TD>
<TD>
<P>550 mg</P>
</TD>
<TD>
<P>4 days</P>
</TD>
<TD>
<P>Hosp-stay</P>
</TD>
<TD>
<P>68/69</P>
</TD>
<TD>
<P>High risk CPB</P>
</TD>
<TD>
<P>8 lost to Follow up</P>
</TD>
</TR>
<TR>
<TD>
<P>Prasongsukam</P>
</TD>
<TD>
<P>2005</P>
</TD>
<TD>
<P>08/00-02/01</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>86</P>
</TD>
<TD>
<P>MP/DX</P>
</TD>
<TD>
<P>5427 mg</P>
</TD>
<TD>
<P>5427 mg</P>
</TD>
<TD>
<P>24 hr</P>
</TD>
<TD>
<P>Hosp-stay</P>
</TD>
<TD>
<P>67/62</P>
</TD>
<TD>
<P>C</P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>Bingol</P>
</TD>
<TD>
<P>2005</P>
</TD>
<TD>
<P>01/00-01/03</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>P</P>
</TD>
<TD>
<P>1600 mg</P>
</TD>
<TD>
<P>1600 mg</P>
</TD>
<TD>
<P>&gt;10 days</P>
</TD>
<TD>
<P>3 months</P>
</TD>
<TD>
<P>64/64</P>
</TD>
<TD>
<P>C + other</P>
</TD>
<TD>
<P>COPD-patients</P>
</TD>
</TR>
<TR>
<TD>
<P>Rubens</P>
</TD>
<TD>
<P>2005</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>68</P>
</TD>
<TD>
<P>MP</P>
</TD>
<TD>
<P>5000 mg</P>
</TD>
<TD>
<P>5000 mg</P>
</TD>
<TD>
<P>once</P>
</TD>
<TD>
<P>Hosp-stay</P>
</TD>
<TD>
<P>56/54</P>
</TD>
<TD>
<P>C</P>
</TD>
<TD>
<P>3 excl: before surgery</P>
</TD>
</TR>
<TR>
<TD>
<P>Loef<BR/>Morariu </P>
</TD>
<TD>
<P>2005<BR/>2004</P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>DX</P>
</TD>
<TD>
<P>40 mg/kg</P>
</TD>
<TD>
<P>2800 mg</P>
</TD>
<TD>
<P>surgery</P>
</TD>
<TD>
<P>Hosp-stay</P>
</TD>
<TD>
<P>68/60</P>
</TD>
<TD>
<P>C</P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>Celik</P>
</TD>
<TD>
<P>2004</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P>MP</P>
</TD>
<TD>
<P>900 mg/kg</P>
</TD>
<TD>
<P>63000 mg</P>
</TD>
<TD>
<P>24 hr</P>
</TD>
<TD>
<P>Hosp-stay</P>
</TD>
<TD>
<P>60/62</P>
</TD>
<TD>
<P>C</P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>Oliver</P>
</TD>
<TD>
<P>2004</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>125</P>
</TD>
<TD>
<P>MP/DX</P>
</TD>
<TD>
<P>5427 mg</P>
</TD>
<TD>
<P>5427 mg</P>
</TD>
<TD>
<P>24 hr</P>
</TD>
<TD>
<P>ICU-stay</P>
</TD>
<TD>
<P>64/62</P>
</TD>
<TD>
<P>C and/or V</P>
</TD>
<TD>
<P>3 excl:<BR/>- retrosternal mass<BR/>- lateral thoracotomy<BR/>- surgery cancelled</P>
</TD>
</TR>
<TR>
<TD>
<P>Volk</P>
</TD>
<TD>
<P>2003</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>24</P>
</TD>
<TD>
<P>MP</P>
</TD>
<TD>
<P>75 mg/kg</P>
</TD>
<TD>
<P>5250 mg</P>
</TD>
<TD>
<P>once</P>
</TD>
<TD>
<P>Hosp-stay</P>
</TD>
<TD>
<P>65/60</P>
</TD>
<TD>
<P>C</P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>Halvorsen</P>
</TD>
<TD>
<P>2003</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>300</P>
</TD>
<TD>
<P>DX</P>
</TD>
<TD>
<P>213 mg</P>
</TD>
<TD>
<P>213 mg</P>
</TD>
<TD>
<P>once</P>
</TD>
<TD>
<P>ICU-stay</P>
</TD>
<TD>
<P>63/64</P>
</TD>
<TD>
<P>C</P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>Giomarelli</P>
</TD>
<TD>
<P>2003</P>
</TD>
<TD>
<P>01/02-04/02</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>MP</P>
</TD>
<TD>
<P>3750 mg</P>
</TD>
<TD>
<P>3750 mg</P>
</TD>
<TD>
<P>24 hr</P>
</TD>
<TD>
<P>Hosp-stay</P>
</TD>
<TD>
<P>63/65</P>
</TD>
<TD>
<P>C</P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>Abd. El-Hakeem</P>
</TD>
<TD>
<P>2003</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>46</P>
</TD>
<TD>
<P>DX</P>
</TD>
<TD>
<P>2667 mg</P>
</TD>
<TD>
<P>2667 mg</P>
</TD>
<TD>
<P>once</P>
</TD>
<TD>
<P>ICU-stay</P>
</TD>
<TD>
<P>36/35</P>
</TD>
<TD>
<P>V</P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>Abd. El-Hakeem</P>
</TD>
<TD>
<P>2003</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>DX</P>
</TD>
<TD>
<P>2667 mg</P>
</TD>
<TD>
<P>2667 mg</P>
</TD>
<TD>
<P>once</P>
</TD>
<TD>
<P>ICU stay</P>
</TD>
<TD>
<P>35/36</P>
</TD>
<TD>
<P>V</P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>El Azab</P>
</TD>
<TD>
<P>2002</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>18</P>
</TD>
<TD>
<P>DX</P>
</TD>
<TD>
<P>2667 mg</P>
</TD>
<TD>
<P>2667 mg</P>
</TD>
<TD>
<P>once</P>
</TD>
<TD>
<P>Hosp-stay</P>
</TD>
<TD>
<P>63/63</P>
</TD>
<TD>
<P>C</P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>Fillinger</P>
</TD>
<TD>
<P>2002</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>MP</P>
</TD>
<TD>
<P>81 mg/kg</P>
</TD>
<TD>
<P>5670 mg</P>
</TD>
<TD>
<P>24 hr</P>
</TD>
<TD>
<P>Hosp-stay</P>
</TD>
<TD>
<P>61/70</P>
</TD>
<TD>
<P>C</P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>Von Spiegel<BR/>Von Spiegel</P>
</TD>
<TD>
<P>2002<BR/>2001</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>DX</P>
</TD>
<TD>
<P>27 mg/kg</P>
</TD>
<TD>
<P>1867 mg</P>
</TD>
<TD>
<P>once</P>
</TD>
<TD>
<P>20 hr</P>
</TD>
<TD>
<P>63/67</P>
</TD>
<TD>
<P>C</P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>Chaney</P>
</TD>
<TD>
<P>2001</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>90</P>
</TD>
<TD>
<P>MP</P>
</TD>
<TD>
<P>300 mg/kg<BR/>150 mg/kg</P>
</TD>
<TD>
<P>21000 mg<BR/>10500 mg</P>
</TD>
<TD>
<P>surgery</P>
</TD>
<TD>
<P>Hosp-stay</P>
</TD>
<TD>
<P>67-62/<BR/>67</P>
</TD>
<TD>
<P>C</P>
</TD>
<TD>
<P>2 excl:<BR/>study violation</P>
</TD>
</TR>
<TR>
<TD>
<P>Volk</P>
</TD>
<TD>
<P>2001</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>26</P>
</TD>
<TD>
<P>MP</P>
</TD>
<TD>
<P>75 mg/kg</P>
</TD>
<TD>
<P>5250 mg</P>
</TD>
<TD>
<P>once</P>
</TD>
<TD>
<P>Hosp-stay</P>
</TD>
<TD>
<P>65/61</P>
</TD>
<TD>
<P>C</P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>Yared<BR/>Yared</P>
</TD>
<TD>
<P>2000<BR/>1998</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>236</P>
</TD>
<TD>
<P>DX</P>
</TD>
<TD>
<P>16 mg/kg</P>
</TD>
<TD>
<P>1120 mg</P>
</TD>
<TD>
<P>once</P>
</TD>
<TD>
<P>Hosp-stay</P>
</TD>
<TD>
<P>63/63</P>
</TD>
<TD>
<P>C and/or V</P>
</TD>
<TD>
<P>20 excl:<BR/>study violation (17), bleeding (3)</P>
</TD>
</TR>
<TR>
<TD>
<P>Tassani</P>
</TD>
<TD>
<P>1999</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>52</P>
</TD>
<TD>
<P>MP</P>
</TD>
<TD>
<P>5000 mg</P>
</TD>
<TD>
<P>5000 mg</P>
</TD>
<TD>
<P>once</P>
</TD>
<TD>
<P>Hosp-stay</P>
</TD>
<TD>
<P>unclear</P>
</TD>
<TD>
<P>C</P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>Wan</P>
</TD>
<TD>
<P>1999</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>MP</P>
</TD>
<TD>
<P>150 mg/kg</P>
</TD>
<TD>
<P>10500 mg</P>
</TD>
<TD>
<P>once</P>
</TD>
<TD>
<P>Hosp-stay</P>
</TD>
<TD>
<P>65/65</P>
</TD>
<TD>
<P>C and/or V</P>
</TD>
<TD>
<P>65 excl:<BR/>CPB time too long</P>
</TD>
</TR>
<TR>
<TD>
<P>Yilmaz</P>
</TD>
<TD>
<P>1999</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>MP</P>
</TD>
<TD>
<P>5 mg/kg</P>
</TD>
<TD>
<P>350 mg</P>
</TD>
<TD>
<P>once</P>
</TD>
<TD>
<P>Hosp-stay</P>
</TD>
<TD>
<P>50/55</P>
</TD>
<TD>
<P>C</P>
</TD>
<TD>
<P>5 excl:<BR/>transfusion (3)<BR/>glucose (2)</P>
</TD>
</TR>
<TR>
<TD>
<P>Chaney<BR/>Chaney</P>
</TD>
<TD>
<P>1999<BR/>1998</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P>MP</P>
</TD>
<TD>
<P>150 mg/kg</P>
</TD>
<TD>
<P>10500 mg</P>
</TD>
<TD>
<P>once</P>
</TD>
<TD>
<P>Hosp-stay</P>
</TD>
<TD>
<P>66/67</P>
</TD>
<TD>
<P>C</P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>Mayumi</P>
</TD>
<TD>
<P>1997</P>
</TD>
<TD>
<P>12/93-07/94</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>24</P>
</TD>
<TD>
<P>MP</P>
</TD>
<TD>
<P>100 mg/kg</P>
</TD>
<TD>
<P>70000 mg</P>
</TD>
<TD>
<P>once</P>
</TD>
<TD>
<P>7 days</P>
</TD>
<TD>
<P>53/54</P>
</TD>
<TD>
<P>V</P>
</TD>
<TD>
<P>3 excl:<BR/>IABP (1)<BR/>Transfusion (2)</P>
</TD>
</TR>
<TR>
<TD>
<P>Engelman</P>
</TD>
<TD>
<P>1995</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>19</P>
</TD>
<TD>
<P>MP/DX</P>
</TD>
<TD>
<P>5427 mg</P>
</TD>
<TD>
<P>5427 mg</P>
</TD>
<TD>
<P>24 hr</P>
</TD>
<TD>
<P>Hosp-stay</P>
</TD>
<TD>
<P>60/68</P>
</TD>
<TD>
<P>C</P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>Jansen</P>
</TD>
<TD>
<P>1991</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>25</P>
</TD>
<TD>
<P>DX</P>
</TD>
<TD>
<P>27 mg/kg</P>
</TD>
<TD>
<P>1867  mg</P>
</TD>
<TD>
<P>once</P>
</TD>
<TD>
<P>Hosp-stay</P>
</TD>
<TD>
<P>64/61</P>
</TD>
<TD>
<P>C</P>
</TD>
<TD>
<P>3 excl:<BR/>steroids in placebo group</P>
</TD>
</TR>
<TR>
<TD>
<P>Ferries</P>
</TD>
<TD>
<P>1987<BR/>1984</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>80</P>
</TD>
<TD>
<P>MP</P>
</TD>
<TD>
<P>150 mg/kg</P>
</TD>
<TD>
<P>10500 mg</P>
</TD>
<TD>
<P>once</P>
</TD>
<TD>
<P>24 hr</P>
</TD>
<TD>
<P>60/60<BR/>58/58</P>
</TD>
<TD>
<P>C/V/complex</P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>Morton</P>
</TD>
<TD>
<P>1976</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>95</P>
</TD>
<TD>
<P>MP</P>
</TD>
<TD>
<P>150 mg/kg</P>
</TD>
<TD>
<P>10500 mg</P>
</TD>
<TD>
<P>once</P>
</TD>
<TD>
<P>&gt; 30 days</P>
</TD>
<TD>
<P>unclear</P>
</TD>
<TD>
<P>C</P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>Amr</P>
</TD>
<TD>
<P>2009</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>100</P>
</TD>
<TD>
<P>DX</P>
</TD>
<TD>
<P>40 mg/kg</P>
</TD>
<TD>
<P>2800 mg</P>
</TD>
<TD>
<P>24 hr</P>
</TD>
<TD>
<P>Hosp-stay</P>
</TD>
<TD>
<P>68/67</P>
</TD>
<TD>
<P>C</P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>Demir</P>
</TD>
<TD>
<P>2009</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>MP</P>
</TD>
<TD>
<P>5000 mg</P>
</TD>
<TD>
<P>5000 mg</P>
</TD>
<TD>
<P>once</P>
</TD>
<TD>
<P>Hosp-stay</P>
</TD>
<TD>
<P>62/62</P>
</TD>
<TD>
<P>C</P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>Starobin</P>
</TD>
<TD>
<P>2007</P>
</TD>
<TD>
<P>02/04-01/05</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>90</P>
</TD>
<TD>
<P>BetaM</P>
</TD>
<TD>
<P>215 mg</P>
</TD>
<TD>
<P>215 mg</P>
</TD>
<TD>
<P>2-6 weeks</P>
</TD>
<TD>
<P>2 weeks</P>
</TD>
<TD>
<P>68/66</P>
</TD>
<TD>
<P>C</P>
</TD>
<TD>
<P> COPD-patients</P>
</TD>
</TR>
<TR>
<TD>
<P>Liakopoulos</P>
</TD>
<TD>
<P>2007</P>
</TD>
<TD>
<P>11/03-07/04</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>78</P>
</TD>
<TD>
<P>MP</P>
</TD>
<TD>
<P>75 mg/kg</P>
</TD>
<TD>
<P>5250 mg</P>
</TD>
<TD>
<P>once</P>
</TD>
<TD>
<P>Hosp-stay</P>
</TD>
<TD>
<P>67/66</P>
</TD>
<TD>
<P>C</P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>McBride</P>
</TD>
<TD>
<P>2004</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>36</P>
</TD>
<TD>
<P>MP</P>
</TD>
<TD>
<P>150 mg/kg</P>
</TD>
<TD>
<P>10500 mg</P>
</TD>
<TD>
<P>once</P>
</TD>
<TD>
<P>72 hr</P>
</TD>
<TD>
<P>63/30</P>
</TD>
<TD>
<P>C</P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>Bourbon</P>
</TD>
<TD>
<P>2004</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>49</P>
</TD>
<TD>
<P>MP</P>
</TD>
<TD>
<P>25 mg/kg<BR/>50 mg/kg</P>
</TD>
<TD>
<P>1750 mg<BR/>3500 mg</P>
</TD>
<TD>
<P>once</P>
</TD>
<TD>
<P>24 hr</P>
</TD>
<TD>
<P>62-60/<BR/>62</P>
</TD>
<TD>
<P>C</P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>Kilger<BR/>Schelling</P>
</TD>
<TD>
<P>2004<BR/>2003</P>
</TD>
<TD>
<P>12/99-12/00</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>91</P>
</TD>
<TD>
<P>HC</P>
</TD>
<TD>
<P>550 mg</P>
</TD>
<TD>
<P>550 mg</P>
</TD>
<TD>
<P>4 days</P>
</TD>
<TD>
<P>6 months</P>
</TD>
<TD>
<P>70/69</P>
</TD>
<TD>
<P>C and/or V</P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>Kilger</P>
</TD>
<TD>
<P>2003</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>80</P>
</TD>
<TD>
<P>HC</P>
</TD>
<TD>
<P>550 mg</P>
</TD>
<TD>
<P>550 mg</P>
</TD>
<TD>
<P>4 days</P>
</TD>
<TD>
<P>Hosp-stay</P>
</TD>
<TD>
<P>unclear</P>
</TD>
<TD>
<P>High risk CPB</P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>Sano</P>
</TD>
<TD>
<P>2003</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>HC</P>
</TD>
<TD>
<P>50 mg/kg</P>
</TD>
<TD>
<P>3500 mg</P>
</TD>
<TD>
<P>once</P>
</TD>
<TD>
<P>7 days</P>
</TD>
<TD>
<P>64/61</P>
</TD>
<TD>
<P>C and/or V</P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>Turkoz</P>
</TD>
<TD>
<P>2001</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>MP</P>
</TD>
<TD>
<P>150 mg/kg</P>
</TD>
<TD>
<P>10500 mg</P>
</TD>
<TD>
<P>once</P>
</TD>
<TD>
<P>24 hr</P>
</TD>
<TD>
<P>58/64</P>
</TD>
<TD>
<P>C</P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>Schurr</P>
</TD>
<TD>
<P>2001</P>
</TD>
<TD>
<P>08/99-11/00</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>50</P>
</TD>
<TD>
<P>MP</P>
</TD>
<TD>
<P>50 mg/kg</P>
</TD>
<TD>
<P>3500 mg</P>
</TD>
<TD>
<P>once</P>
</TD>
<TD>
<P>Hosp-stay</P>
</TD>
<TD>
<P>64/61</P>
</TD>
<TD>
<P>C</P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>Rumalla</P>
</TD>
<TD>
<P>2001</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>13</P>
</TD>
<TD>
<P>MP</P>
</TD>
<TD>
<P>5000 mg</P>
</TD>
<TD>
<P>5000 mg</P>
</TD>
<TD>
<P>once</P>
</TD>
<TD>
<P>6 months</P>
</TD>
<TD>
<P>63/61</P>
</TD>
<TD>
<P>C</P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>Harig<BR/>Harig</P>
</TD>
<TD>
<P>2001<BR/>1999</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>PR</P>
</TD>
<TD>
<P>1000 mg<BR/>500 mg</P>
</TD>
<TD>
<P>1000 mg</P>
<P>500 mg</P>
</TD>
<TD>
<P>surgery<BR/>once</P>
</TD>
<TD>
<P>30 days</P>
</TD>
<TD>
<P>63/61<BR/>65/61</P>
</TD>
<TD>
<P>C</P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>Toft</P>
</TD>
<TD>
<P>1997</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>16</P>
</TD>
<TD>
<P>MP</P>
</TD>
<TD>
<P>150 mg/kg</P>
</TD>
<TD>
<P>10500 mg</P>
</TD>
<TD>
<P>once</P>
</TD>
<TD>
<P>Hosp-stay</P>
</TD>
<TD>
<P>63/64</P>
</TD>
<TD>
<P>C</P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>Coetzer</P>
</TD>
<TD>
<P>1996</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>295</P>
</TD>
<TD>
<P>MP</P>
</TD>
<TD>
<P>150 mg/kg</P>
</TD>
<TD>
<P>10500 mg</P>
</TD>
<TD>
<P>once</P>
</TD>
<TD>
<P>&gt; 30 days</P>
</TD>
<TD>
<P>unclear</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>Andersen</P>
</TD>
<TD>
<P>1989</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>16</P>
</TD>
<TD>
<P>MP</P>
</TD>
<TD>
<P>150 mg/kg</P>
</TD>
<TD>
<P>10500 mg</P>
</TD>
<TD>
<P>once</P>
</TD>
<TD>
<P>7 days</P>
</TD>
<TD>
<P>58 all</P>
</TD>
<TD>
<P>C</P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>Cavarocchi</P>
</TD>
<TD>
<P>1986</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>61</P>
</TD>
<TD>
<P>MP</P>
</TD>
<TD>
<P>150 mg/kg</P>
</TD>
<TD>
<P>10500 mg</P>
</TD>
<TD>
<P>once</P>
</TD>
<TD>
<P>24 hr</P>
</TD>
<TD>
<P>62/64</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>Boscoe</P>
</TD>
<TD>
<P>1983</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>34</P>
</TD>
<TD>
<P>MP</P>
</TD>
<TD>
<P>300 mg/kg</P>
</TD>
<TD>
<P>21000 mg</P>
</TD>
<TD>
<P>surgery</P>
</TD>
<TD>
<P>24 hr</P>
</TD>
<TD>
<P>41-75/<BR/>38-71</P>
</TD>
<TD>
<P>C or V</P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>Codd</P>
</TD>
<TD>
<P>1977</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>150</P>
</TD>
<TD>
<P>MP</P>
</TD>
<TD>
<P>10000 mg</P>
</TD>
<TD>
<P>10000 mg</P>
</TD>
<TD>
<P>once</P>
</TD>
<TD>
<P>5 days</P>
</TD>
<TD>
<P>53/51</P>
</TD>
<TD>
<P>C</P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>Rao</P>
</TD>
<TD>
<P>1977</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>150</P>
</TD>
<TD>
<P>MP</P>
</TD>
<TD>
<P>5000 mg</P>
</TD>
<TD>
<P>5000 mg</P>
</TD>
<TD>
<P>once</P>
</TD>
<TD>
<P>Hosp-stay</P>
</TD>
<TD>
<P>unclear</P>
</TD>
<TD>
<P>C</P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
</TABLE>
<P>HC: Hydrocortisone, MP: Methylprednisolone, DX: Dexamethasone; PR: Prednisone, BetaM: Betamethasone</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2011-01-12 08:48:58 +0530" MODIFIED_BY="Joey Kwong" NO="5">
<TITLE MODIFIED="2010-01-25 14:00:36 +0530" MODIFIED_BY="[Empty name]">Reported study endpoints</TITLE>
<APPENDIX_BODY MODIFIED="2011-01-12 08:48:58 +0530" MODIFIED_BY="Joey Kwong">
<P>
<LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>
<I>a. Reported study endpoints</I> </P>
<TABLE COLS="19" ROWS="55">
<TR>
<TD VALIGN="TOP">
<P>
<B>Author</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Year of publication</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Mortality</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Cardiac complications</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Pulmonary complications</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Re-intubation</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Intubation time</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>LOS ICU</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>LOS hospital</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Renal failure</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Neurologic complications</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Atrial fibrillation</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Gastro-intedstinal complications</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Infections</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Inotrope use</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Transfusion</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Re-thoracotomy</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Biomarker</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>No major complications</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Weis</P>
</TD>
<TD VALIGN="TOP">
<P>2009</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X*</P>
</TD>
<TD VALIGN="TOP">
<P>X*</P>
</TD>
<TD VALIGN="TOP">
<P>X*</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X*c</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Sobiesky</P>
</TD>
<TD VALIGN="TOP">
<P>2008</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Halonen</P>
</TD>
<TD VALIGN="TOP">
<P>2007</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Yared</P>
</TD>
<TD VALIGN="TOP">
<P>2007</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X*</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Sano</P>
</TD>
<TD VALIGN="TOP">
<P>2006</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Enc</P>
</TD>
<TD VALIGN="TOP">
<P>2006</P>
</TD>
<TD VALIGN="TOP">
<P>
<I> </I>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<I> </I>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<I> </I>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Whitlock</P>
</TD>
<TD VALIGN="TOP">
<P>2006</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X*</P>
</TD>
<TD VALIGN="TOP">
<P>X*</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>Xc</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Weis</P>
</TD>
<TD VALIGN="TOP">
<P>2006</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X*</P>
</TD>
<TD VALIGN="TOP">
<P>X*</P>
</TD>
<TD VALIGN="TOP">
<P>X*</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Prasongsukam</P>
</TD>
<TD VALIGN="TOP">
<P>2005</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Bingol</P>
</TD>
<TD VALIGN="TOP">
<P>2005</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Rubens</P>
</TD>
<TD VALIGN="TOP">
<P>2005</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X*</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Loef</P>
<P>Morariu </P>
</TD>
<TD VALIGN="TOP">
<P>2005</P>
<P>2004</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>Xc</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Celik</P>
</TD>
<TD VALIGN="TOP">
<P>2004</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>Xc</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Oliver</P>
</TD>
<TD VALIGN="TOP">
<P>2004</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Volk</P>
</TD>
<TD VALIGN="TOP">
<P>2003</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>Xc</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Halvorsen</P>
</TD>
<TD VALIGN="TOP">
<P>2003</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X*</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Giomarelli</P>
</TD>
<TD VALIGN="TOP">
<P>2003</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Abd. El-Hakeem</P>
</TD>
<TD VALIGN="TOP">
<P>2003</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>
<I> </I>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<I> </I>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Abd. El-Hakeem</P>
</TD>
<TD VALIGN="TOP">
<P>2003</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>Xc</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>El Azab</P>
</TD>
<TD VALIGN="TOP">
<P>2002</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>
<I> </I>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<I> </I>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Fillinger</P>
</TD>
<TD VALIGN="TOP">
<P>2002</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Von Spiegel</P>
<P>Von Spiegel</P>
</TD>
<TD VALIGN="TOP">
<P>2002</P>
<P>2001</P>
</TD>
<TD VALIGN="TOP">
<P>
<I>X</I>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Chaney</P>
</TD>
<TD VALIGN="TOP">
<P>2001</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Volk</P>
</TD>
<TD VALIGN="TOP">
<P>2001</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Yared</P>
<P>Yared</P>
</TD>
<TD VALIGN="TOP">
<P>2000</P>
<P>1998</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X*</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Tassani</P>
</TD>
<TD VALIGN="TOP">
<P>1999</P>
</TD>
<TD VALIGN="TOP">
<P>
<I> </I>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<I> </I>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<I> </I>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>
<I> </I>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Wan</P>
</TD>
<TD VALIGN="TOP">
<P>1999</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Yilmaz</P>
</TD>
<TD VALIGN="TOP">
<P>1999</P>
</TD>
<TD VALIGN="TOP">
<P>
<I> </I>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Chaney</P>
<P>Chaney</P>
</TD>
<TD VALIGN="TOP">
<P>1999</P>
<P>1998</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Mayumi</P>
</TD>
<TD VALIGN="TOP">
<P>1997</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Engelman</P>
</TD>
<TD VALIGN="TOP">
<P>1995</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Jansen</P>
</TD>
<TD VALIGN="TOP">
<P>1991</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Ferries</P>
</TD>
<TD VALIGN="TOP">
<P>1987</P>
<P>1984</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Morton</P>
</TD>
<TD VALIGN="TOP">
<P>1976</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Amr</P>
</TD>
<TD VALIGN="TOP">
<P>2009</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Demir</P>
</TD>
<TD VALIGN="TOP">
<P>2009</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X*c</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Starobin</P>
</TD>
<TD VALIGN="TOP">
<P>2007</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X*</P>
</TD>
<TD VALIGN="TOP">
<P>X*</P>
</TD>
<TD VALIGN="TOP">
<P>X*</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Liakopoulos</P>
</TD>
<TD VALIGN="TOP">
<P>2007</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>McBride</P>
</TD>
<TD VALIGN="TOP">
<P>2004</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X*</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Bourbon</P>
</TD>
<TD VALIGN="TOP">
<P>2004</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>
<I> </I>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<I> </I>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X*</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Kilger</P>
<P>Schelling</P>
</TD>
<TD VALIGN="TOP">
<P>2004</P>
<P>2003</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X*</P>
</TD>
<TD VALIGN="TOP">
<P>X*</P>
</TD>
<TD VALIGN="TOP">
<P>X*</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>Xc</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Kilger</P>
</TD>
<TD VALIGN="TOP">
<P>2003</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X*</P>
</TD>
<TD VALIGN="TOP">
<P>X*</P>
</TD>
<TD VALIGN="TOP">
<P>X*</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>Xc</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Sano-2</P>
</TD>
<TD VALIGN="TOP">
<P>2003</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>
<I> </I>
</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Turkoz</P>
</TD>
<TD VALIGN="TOP">
<P>2001</P>
</TD>
<TD VALIGN="TOP">
<P>
<I> </I>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<I> </I>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<I> </I>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>Xc</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Schurr</P>
</TD>
<TD VALIGN="TOP">
<P>2001</P>
</TD>
<TD VALIGN="TOP">
<P>
<I> </I>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<I> </I>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<I> </I>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>
<I>X</I>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Rumalla</P>
</TD>
<TD VALIGN="TOP">
<P>2001</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Harig</P>
<P>Harig</P>
</TD>
<TD VALIGN="TOP">
<P>2001</P>
<P>1999</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Toft</P>
</TD>
<TD VALIGN="TOP">
<P>1997</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Coetzer</P>
</TD>
<TD VALIGN="TOP">
<P>1996</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Andersen</P>
</TD>
<TD VALIGN="TOP">
<P>1989</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>
<I> </I>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<I> </I>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Cavarocchi</P>
</TD>
<TD VALIGN="TOP">
<P>1986</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X*</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Boscoe</P>
</TD>
<TD VALIGN="TOP">
<P>1983</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Codd</P>
</TD>
<TD VALIGN="TOP">
<P>1977</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Rao</P>
</TD>
<TD VALIGN="TOP">
<P>1977</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
</TABLE>
<P/>
<P>X*: Only Median or Ranges ane mentioned, these studies were not included in analysis.</P>
<P>Xc: Number of transfusions, continuous variable.</P>
<P>
<I>
<BR/>
</I>
</P>
<P>
<LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>
<I>b. Different definitions of outcome measures used by authors </I>
</P>
<P> </P>
<TABLE COLS="1" ROWS="7">
<TR>
<TD VALIGN="TOP">
<P>
<I>Mortality:</I>
</P>
<P>
<BR/>Deductive conclusion no complications, no mortality:<BR/>
<LINK REF="STD-Oliver-2004" TYPE="STUDY">Oliver 2004</LINK>, Abd. El-Hakeem 2. 2003, <LINK REF="STD-Engelman-1995" TYPE="STUDY">Engelman 1995</LINK>, Jansen 1991, <LINK REF="STD-Demir-2009" TYPE="STUDY">Demir 2009</LINK>, <LINK REF="STD-Toft-1997" TYPE="STUDY">Toft 1997</LINK>
</P>
<P>Mortality mentioned, but unclear in which group:<BR/>
<LINK REF="STD-Morton-1976" TYPE="STUDY">Morton 1976</LINK>, <LINK REF="STD-Cavarocchi-1986" TYPE="STUDY">Cavarocchi 1986</LINK>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<I>Myocardial complication:</I>
</P>
<P>
<I> </I>
</P>
<P>Infarct:<BR/>
<LINK REF="STD-Halonen-2007" TYPE="STUDY">Halonen 2007</LINK>: (ECG diagnosis) , <LINK REF="STD-Whitlock-2006" TYPE="STUDY">Whitlock 2006</LINK> (nfd), Halvorsen (nfd), <LINK REF="STD-Giomarelli-2003" TYPE="STUDY">Giomarelli 2003</LINK> (nfd), <LINK REF="STD-Rao-1977" TYPE="STUDY">Rao 1977</LINK> (nfd), <LINK REF="STD-Amr-2009" TYPE="STUDY">Amr 2009</LINK> (nfd) <LINK REF="STD-Rubens-2005" TYPE="STUDY">Rubens 2005</LINK> (ECG diagnosis). <LINK REF="STD-Celik-2004" TYPE="STUDY">Celik 2004</LINK> (CK-MB and ECG diagnosis), <LINK REF="STD-Volk-2003" TYPE="STUDY">Volk 2003</LINK> (nfd), <LINK REF="STD-Chaney-2001" TYPE="STUDY">Chaney 2001</LINK> (ECG diagnosis), Yared 2000, (assist device), Chaney 99/98 (CK-MB), <LINK REF="STD-Morton-1976" TYPE="STUDY">Morton 1976</LINK> (CPK-LDH), Mc Bride 2007 (nfd), <LINK REF="STD-Codd-1977" TYPE="STUDY">Codd 1977</LINK> (ECG diagnosis)</P>
<P>Cardiac Compromise:<BR/>
<LINK REF="STD-Oliver-2004" TYPE="STUDY">Oliver 2004</LINK> (nfd)</P>
<P>Unclear:<BR/>
<LINK REF="STD-Yared-2007" TYPE="STUDY">Yared 2007</LINK>,</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<I>Pulmonary complications: </I>
</P>
<P>
<I> </I>
</P>
<P>Unclear:<BR/>
<LINK REF="STD-Yared-2007" TYPE="STUDY">Yared 2007</LINK>, <LINK REF="STD-Giomarelli-2003" TYPE="STUDY">Giomarelli 2003</LINK>,</P>
<P>Pneumonia:<BR/>
<LINK REF="STD-Weis-2009" TYPE="STUDY">Weis 2009</LINK>, <LINK REF="STD-Whitlock-2006" TYPE="STUDY">Whitlock 2006</LINK>, <LINK REF="STD-Halvorsen-2003" TYPE="STUDY">Halvorsen 2003</LINK>, <LINK REF="STD-Starobin-2007" TYPE="STUDY">Starobin 2007</LINK>, <LINK REF="STD-Liakopoulos-2007" TYPE="STUDY">Liakopoulos 2007</LINK>, <LINK REF="STD-Sano-2003" TYPE="STUDY">Sano 2003</LINK>, <LINK REF="STD-Toft-1997" TYPE="STUDY">Toft 1997</LINK>
</P>
<P>Embolism                                                <BR/>
<LINK REF="STD-Rao-1977" TYPE="STUDY">Rao 1977</LINK>
</P>
<P>Pulmonary function:                               <BR/>
<LINK REF="STD-Sano-2006" TYPE="STUDY">Sano 2006</LINK>
</P>
<P>Any pulmonary complication:                <BR/>Oliver 2007, <LINK REF="STD-Starobin-2007" TYPE="STUDY">Starobin 2007</LINK>
</P>
<P>Prolonged Ventilation:            <BR/>
<LINK REF="STD-Morton-1976" TYPE="STUDY">Morton 1976</LINK>
</P>
<P>Pleural effusion:                      <BR/>
<LINK REF="STD-Bingol-2005" TYPE="STUDY">Bingol 2005</LINK>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
<P>
<I>Renal Failure:</I>
</P>
<P>
<I> </I>
</P>
<P>Unclear:                  <BR/>Sobiesky 2008, <LINK REF="STD-Yared-2007" TYPE="STUDY">Yared 2007</LINK>, <LINK REF="STD-Giomarelli-2003" TYPE="STUDY">Giomarelli 2003</LINK>, <LINK REF="STD-Starobin-2007" TYPE="STUDY">Starobin 2007</LINK>, <LINK REF="STD-Sano-2006" TYPE="STUDY">Sano 2006</LINK>,</P>
<P>New dialysis:           <BR/>
<LINK REF="STD-Weis-2009" TYPE="STUDY">Weis 2009</LINK>, <LINK REF="STD-Whitlock-2006" TYPE="STUDY">Whitlock 2006</LINK>, Yared 00-98 (or oliguria), <LINK REF="STD-Demir-2009" TYPE="STUDY">Demir 2009</LINK>, Liakopoulos (or creatinine &gt; 2,0 mg/dl)</P>
<P>Creatinine:              <BR/>
<LINK REF="STD-Prasongsukarn-2005" TYPE="STUDY">Prasongsukarn 2005</LINK> (increased)</P>
<P>Oliguria:                  <BR/>
<LINK REF="STD-Toft-1997" TYPE="STUDY">Toft 1997</LINK>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<I>Gastro-intestinal complication: </I>
</P>
<P>
<I> </I>
</P>
<P>Ulcer/Bleeding/Perforation:<BR/>
<LINK REF="STD-Whitlock-2006" TYPE="STUDY">Whitlock 2006</LINK>, <LINK REF="STD-Halvorsen-2003" TYPE="STUDY">Halvorsen 2003</LINK>, <LINK REF="STD-Amr-2009" TYPE="STUDY">Amr 2009</LINK>, Prasonsukarn 2005, <LINK REF="STD-Chaney-2001" TYPE="STUDY">Chaney 2001</LINK>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<I>Infections: </I>
</P>
<P>
<I> </I>
</P>
<P>Mediastinitis:          <BR/>
<LINK REF="STD-Weis-2009" TYPE="STUDY">Weis 2009</LINK>, <LINK REF="STD-Halonen-2007" TYPE="STUDY">Halonen 2007</LINK>, Yared 98/00, <LINK REF="STD-Yilmaz-1999" TYPE="STUDY">Yilmaz 1999</LINK>,</P>
<P>Woundinfections:    <BR/>
<LINK REF="STD-Weis-2009" TYPE="STUDY">Weis 2009</LINK>, <LINK REF="STD-Halonen-2007" TYPE="STUDY">Halonen 2007</LINK>, <LINK REF="STD-Whitlock-2006" TYPE="STUDY">Whitlock 2006</LINK>, <LINK REF="STD-Bingol-2005" TYPE="STUDY">Bingol 2005</LINK>, <LINK REF="STD-Halvorsen-2003" TYPE="STUDY">Halvorsen 2003</LINK>, <LINK REF="STD-Amr-2009" TYPE="STUDY">Amr 2009</LINK>, <LINK REF="STD-Starobin-2007" TYPE="STUDY">Starobin 2007</LINK>, <LINK REF="STD-Prasongsukarn-2005" TYPE="STUDY">Prasongsukarn 2005</LINK>, <LINK REF="STD-Mayumi-1997" TYPE="STUDY">Mayumi 1997</LINK>,</P>
<P>Pneumonia:             <BR/>
<LINK REF="STD-Weis-2009" TYPE="STUDY">Weis 2009</LINK>, <LINK REF="STD-Whitlock-2006" TYPE="STUDY">Whitlock 2006</LINK>, <LINK REF="STD-Halvorsen-2003" TYPE="STUDY">Halvorsen 2003</LINK>, <LINK REF="STD-Prasongsukarn-2005" TYPE="STUDY">Prasongsukarn 2005</LINK>, <LINK REF="STD-Starobin-2007" TYPE="STUDY">Starobin 2007</LINK>, <LINK REF="STD-Liakopoulos-2007" TYPE="STUDY">Liakopoulos 2007</LINK>, <LINK REF="STD-Toft-1997" TYPE="STUDY">Toft 1997</LINK>
</P>
<P>Other Infection:      <BR/>
<LINK REF="STD-Weis-2009" TYPE="STUDY">Weis 2009</LINK>, <LINK REF="STD-Whitlock-2006" TYPE="STUDY">Whitlock 2006</LINK>, <LINK REF="STD-Halvorsen-2003" TYPE="STUDY">Halvorsen 2003</LINK>, <LINK REF="STD-Amr-2009" TYPE="STUDY">Amr 2009</LINK>, <LINK REF="STD-Starobin-2007" TYPE="STUDY">Starobin 2007</LINK>, <LINK REF="STD-Prasongsukarn-2005" TYPE="STUDY">Prasongsukarn 2005</LINK>, Yared 98/00, <LINK REF="STD-Andersen-1989" TYPE="STUDY">Andersen 1989</LINK>
</P>
<P>Antibiotic therapy:<BR/>Jansen 1991</P>
<P>Unclear:                  <BR/>
<LINK REF="STD-Yared-2007" TYPE="STUDY">Yared 2007</LINK>, <LINK REF="STD-Rao-1977" TYPE="STUDY">Rao 1977</LINK>, <LINK REF="STD-Demir-2009" TYPE="STUDY">Demir 2009</LINK>, <LINK REF="STD-Rubens-2005" TYPE="STUDY">Rubens 2005</LINK>, <LINK REF="STD-Rumalla-2001" TYPE="STUDY">Rumalla 2001</LINK>,</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<I>Neurological complications: </I>
</P>
<P>
<I> </I>
</P>
<P>Stroke:    <BR/>Sobiesky 2008, <LINK REF="STD-Halonen-2007" TYPE="STUDY">Halonen 2007</LINK>, <LINK REF="STD-Whitlock-2006" TYPE="STUDY">Whitlock 2006</LINK>, <LINK REF="STD-Giomarelli-2003" TYPE="STUDY">Giomarelli 2003</LINK>, <LINK REF="STD-Rao-1977" TYPE="STUDY">Rao 1977</LINK>, <LINK REF="STD-Amr-2009" TYPE="STUDY">Amr 2009</LINK>, <LINK REF="STD-Starobin-2007" TYPE="STUDY">Starobin 2007</LINK>, <LINK REF="STD-Oliver-2004" TYPE="STUDY">Oliver 2004</LINK> (clinically and CT), <LINK REF="STD-Chaney-2001" TYPE="STUDY">Chaney 2001</LINK>, Yared 98/00, Chaney 98/99, <LINK REF="STD-Rumalla-2001" TYPE="STUDY">Rumalla 2001</LINK>
</P>
<P>Unclear:  <BR/>
<LINK REF="STD-Yared-2007" TYPE="STUDY">Yared 2007</LINK>, <LINK REF="STD-Demir-2009" TYPE="STUDY">Demir 2009</LINK>
</P>
</TD>
</TR>
</TABLE>
<P> </P>
<P> </P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>